Page last updated: 2024-11-04

niacinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Niacinamide, also known as nicotinamide, is a form of vitamin B3. It is a key component in many cellular processes, including DNA repair, energy production, and cell signaling. Niacinamide is synthesized from nicotinic acid, which is found in many foods, including meat, poultry, fish, and legumes. It can also be produced by the body from tryptophan, an amino acid. Niacinamide has a wide range of potential health benefits, including reducing inflammation, improving skin health, and protecting against sun damage. It is also being studied for its potential to prevent and treat certain types of cancer. The importance of niacinamide lies in its crucial role in maintaining cellular health and its ability to support various bodily functions. Its wide range of potential health benefits and its role in cellular processes make it a subject of ongoing research.'

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID936
CHEMBL ID1140
CHEBI ID17154
SCHEMBL ID2926
SCHEMBL ID6278767
SCHEMBL ID19978192
MeSH IDM0014833

Synonyms (349)

Synonym
EN300-15612
HMS3394M21
AB00373895-13
niamide
beta-pyridinecarboxamide
MLS000069714 ,
smr000058212
CHEBI:17154 ,
nicotinamid
nicotinsaeureamid
nsc-27452
nsc27452
AC-907/25014114
niacin - vitamin b3
SGCUT00176
D00036
nicotinamide (jp17/inn)
niacinamide (usp)
nsc 13128
nicotinamidum [inn-latin]
nikotinsaeureamid [german]
nicotinsaureamid [german]
nicotinamida [inn-spanish]
dea no. 1405
niacinamide [usan]
nicotine amide
nicotylamidum
vitamin b (van)
einecs 202-713-4
niavit pp
nicotinic amide
pelmin
nicamindon
nicobion
nicota
pelmine
nicotamide
nicovitina
nandervit-n
.beta.-pyridinecarboxamide
vi-nicotyl
nikotinamid
NAM ,
witamina pp
nicosan 2
inovitan pp
niko-tamin
nicogen
nicotinsaureamid
pyridine, 3-carbamoyl-
nicotol
nicamina
vitamin b
amide pp
nicomidol
3-pyridinecarboxamide
hansamid
savacotyl
nicovitol
aminicotin
niocinamide
austrovit pp
nicotine acid amide
endobion
3-carbamoylpyridine
nicotililamido
factor pp
pp-faktor
nicozymin
nicasir
nicosylamide
nicotilamide
niozymin
benicot
nicofort
wln: t6nj cvz
pelonin amide
niacevit
amixicotyn
pyridine-3-carboxylic acid amide
nikotinsaeureamid
nsc13128
dipegyl
delonin amide
nicovel
nicotylamide
nsc-13128
3-pyridinecarboxylic acid amide
nicovit
pyridine-3-carboxamide
mediatric
amid kyseliny nikotinove [czech]
amnicotin
ccris 1901
hsdb 1237
m-(aminocarbonyl)pyridine
inchi=1/c6h6n2o/c7-6(9)5-2-1-3-8-4-5/h1-4h,(h2,7,9
papulex
ai3-02906
vitamin pp
niacinamide ,
C00153
98-92-0
acid amide
nicotinamide
nicotinic acid amide
niacinamide, meets usp testing specifications
nicotinamide, >=98% (hplc), powder
TO_000073
nicotinamide, bioreagent, suitable for cell culture, suitable for insect cell culture
nicotinamide, niacin, vitamin b3
DB02701
1YC5
NCGC00093354-04
NCGC00093354-03
MOLMAP_000061
3 pyridinecarboxamide
chembl1140 ,
bdbm27507
nicotinamide, >=99.5% (hplc)
A186B02E-6C70-4E54-9739-79398D439AAA
HMS2052M21
niacotinamide
HMS2090B05
HMS2093H03
BMSE000281
niacinamid
niacin (as niacinamide)
nicotinamidum
N0078
A845925
NCGC00093354-05
NCGC00093354-06
cas-98-92-0
dtxsid2020929 ,
dtxcid00929
tox21_302776
NCGC00256432-01
tox21_201716
NCGC00259265-01
STL163867
nsc759115
nsc-759115
MLS001424246
pharmakon1600-01505397
tox21_111202
AKOS005715850
HMS2236J03
CCG-101149
FT-0672696
unii-25x51i8rd4
niacinamide [usp]
nicotinamida
25x51i8rd4 ,
nicotinamide [inn]
ec 202-713-4
amid kyseliny nikotinove
FT-0631517
NCGC00093354-09
niacinamide [vandf]
nicotinamide [jan]
niacinamide [inci]
nicotinamidum [hpus]
niacinamide component of tpn
niacinamide [usp monograph]
nicotinamide [who-ip]
niacinamide [hsdb]
niacinamide [fcc]
niacinamide [usp-rs]
nicotinamide [mart.]
tpn component niacinamide
niacinamide [ii]
nicotinamide [ep impurity]
nicotinamide [mi]
nicotinamidum [who-ip latin]
nicotinamide [who-dd]
niacin (as niacinamide) [vandf]
nicotinamide [ep monograph]
niacinamide [orange book]
S1899
nicotinamide-(amide-15n)
HMS3370F21
HY-B0150
CS-1968
NC00399
SCHEMBL2926
tox21_111202_1
Z33546463
nicotin-amide
3-(aminocarbonyl)pyridine
Q-201470
SCHEMBL6278767
mediatric (salt/mix)
nictoamide
dipigyl
b-pyridinecarboxamide
vi-noctyl
3-amidopyridine
nicotinamide, british pharmacopoeia (bp) reference standard
SCHEMBL19978192
AB00373895_16
AB00373895_15
OPERA_ID_775
mfcd00006395
F2173-0513
nicotinamide, >=98.5% (hplc)
nicotinamide, tested according to ph.eur.
sr-01000721872
SR-01000721872-4
SR-01000721872-3
SR-01000721872-5
nicotinamide (niacinamide), analytical standard
niacinamide, united states pharmacopeia (usp) reference standard
HMS3655M20
nicotinamide, european pharmacopoeia (ep) reference standard
niacinamide, pharmaceutical secondary standard; certified reference material
nicotinamide, puriss., 99.0-101.0%
nicotinamide, vetec(tm) reagent grade, >=98%
nicotinamide 1.0 mg/ml in methanol
SBI-0206826.P001
HMS3713B22
vitamin b3 amide
SW197779-3
BCP07322
niacinamide;nicotinic acid amide;vitamin b3; vitamin pp
nicotinamide (vitamin b3)
FT-0773644
nicotinamide,(s)
nicotinamide 10 microg/ml in acetonitrile
AS-13845
Q192423
niacinamide;nicotinic acid amide;vitamin b3
HMS3884A16
SB74497
nicotinamide 100 microg/ml in methanol
SY024804
BN166252
CS-0694823
HY-B0150R
nicotinamide (standard)
dr. gloderm tabrx whitening
ultra whitening ample
nicotinamide (mart.)
pyridine-3-carboxylamide
toas rejuvenation
by selected hyaluron day serum
caviall wrinkle-free powertox
the skin house vital bright toner
cellpium double essence toner
shieldlife whitening ion mask
nicotinamide (ep monograph)
fresh mandarin aromatherapy mask27g
nicotinamidum (inn-latin)
cellexosome hr
dpc whitening booster mask
derma pella cleanser for sensitive and dry skin
miracle laser skin mist
an adc sp intensive moisture essence
the skin house vital bright eyecream
dr. cellmo
ultra whitening first essence
cellexosome sb
ginseng whitening
dr. color effect red
lebody lab renewal dual effect idebenone serum
the hayan cherry blossom brightening essence
karatica i m cure
intomedi hr peptide
pellagra-preventing factor
sferangs vita c capsulebooster
royal ginsenglotion
nyaam nyaam skin reborn serum
niacinamide (usp-rs)
brightuning peptide ampoule
the skin house vital brightserum
daily whitening care sheet mask
arilac brightening mask sheet pack
niacinamide face mask
derma pella facial cleanser for normal skin
cosmepure brightening calming toner
evecode thread lifting mask pack
tania purecream
cellpium premiumex hybrid essence
nicotinamida (inn-spanish)
aape continuous renewal mask
niacinamide (usp monograph)
arocell x belle j super power cell ampoule
cellpium premiumex hybrid toner
ala-c snail cell reparing essence
cellexosome he hr
the skin house vital brightcream
nicosedine
niveola p.h.c 3d festival mask pack
dr. gloderm time to whitening mask
celonia cm
lebody lab renewal dual effect peptide serum
royal ginseng essence
the skin house vital bright emulsion
fantastic lightcream
ultra v aqua shine mask
moistie pure essence
nicotinamidum (latin)
cellpium real mask pack
costem cell 5 n
dermahan the whitening moisturizing mask
juveheal w ampoule
primerose snail hydro essence
pahaba control
dpc aura booster mask
papa recipe bombee brightening honey mask pack
vita c bright serum
dr cellinme skin care ampoule
nyaam nyaam vita serum
mizon enjoy vital up time whitening mask
miracle moisturizer essence
a11ha01
vita c bright toner
vita c bright eyecream
rgo hydration toner
edge cutimal cat whitening mask
ultra whitening
mustus daily harvest squeeze tone up mask pack
niacinamide (ii)
aape skin ampoule
dr cellinme mask sheet
aape nutrient facial toner
royal ginseng toner
revital perfecting dual ampoule
aplin spot remover
siseundeusi luminant mask pack step2(whitening)
the skin house vital brightemulsion
brextem s
nicotinamide (ep impurity)
derladie herbalextract bodysolution mist
cosmepure brightening calming
aplin spot all kill
cellbn milky tone-upcream
nicamid
ni-nicotyl
nyaam nyaam peptide serum
royal ginsengcream
cellpium super richness ampoule
dr.althea power whitening glutathione
tania pure essence
bk cell 5days of secret snow whitening
vita c brightcream
arocell time reverse k i t
j9 ultra advanced intensive scalp serum v2
skin project ya cooling celluven mask

Research Excerpts

Overview

Niacinamide is a stable and water-soluble form of vitamin B3, a valuable and versatile cosmetic ingredient, which is well absorbed and tolerated by the skin.

ExcerptReferenceRelevance
"Niacinamide is a stable and water-soluble form of vitamin B3, a valuable and versatile cosmetic ingredient, which is well absorbed and tolerated by the skin. "( The protective effect of niacinamide on CHO AA8 cell line against ultraviolet radiation in the context of main cytoskeletal proteins.
Adamczyk, I; Gagat, M; Grzanka, A; Hałas-Wiśniewska, M; Izdebska, M; Kwiatkowska, I; Lewandowska, I, 2018
)
2.23
"Niacinamide is a well-tolerated and safe substance often used in cosmetics."( Niacinamide - mechanisms of action and its topical use in dermatology.
Kreft, D; Wohlrab, J, 2014
)
2.57
"Niacinamide is a well-known cosmetic ingredient that has been used traditionally for multiple skin benefits."( Niacinamide leave-on formulation provides long-lasting protection against bacteria in vivo.
Chakrabortty, A; Iyer, V; Majumdar, A; Mallemalla, P; Mathapathi, MS; Tiwari, JK; Vora, S, 2017
)
2.62
"Niacinamide (NAC) is a compound of B complex."( Niacinamide mitigated the acute lung injury induced by phorbol myristate acetate in isolated rat's lungs.
Chen, HI; Hsieh, NK; Lin, CC; Liou, HL, 2012
)
2.54
"Niacinamide seems to be a reasonably safe drug that, even at relatively high doses, is associated with a low incidence of side effects."( Response of generalized granuloma annulare to high-dose niacinamide.
Ma, A; Medenica, M, 1983
)
1.23
"Niacinamide is a possible candidate."( The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
Bissett, DL; Boissy, RE; Chhoa, M; Greatens, A; Hakozaki, T; Hillebrand, GG; Matsubara, A; Minwalla, L; Miyamoto, K; Zhuang, J, 2002
)
1.4

Effects

Niacinamide (NIA) has been widely used in cosmetic and personal care formulations for several skin conditions. It has been suggested to impact hair biology via stimulation of VEGF synthesis.

ExcerptReferenceRelevance
"Niacinamide has been verified in treating almost every skin disorder, viz. "( Cosmeceutical Aptitudes of Niacinamide: A Review.
Madaan, P; Malik, DS; Sikka, P, 2021
)
2.36
"Niacinamide has been suggested to impact hair biology via stimulation of VEGF synthesis. "( Topical niacinamide does not stimulate hair growth based on the existing body of evidence.
Davis, MG; Hartman, SM; Oblong, JE; Peplow, AW, 2020
)
2.44
"Niacinamide (NIA) has been widely used in cosmetic and personal care formulations for several skin conditions. "( Topical delivery of niacinamide: Influence of neat solvents.
Iliopoulos, F; Lane, ME; Lucas, RA; Monjur Al Hossain, ASM; Moore, DJ; Sil, BC, 2020
)
2.32

Treatment

Niacinamide treatment group experienced an average 0.7 +/- 0.9 mg/dL decrease in plasma phosphorus. Treatment with acetazolamide decreased TmP/GFR and serum phosphate, paralleled by a decrease in serum C-terminus FGF23.

ExcerptReferenceRelevance
"The niacinamide treatment group experienced an average 0.7 +/- 0.9 mg/dL decrease in plasma phosphorus and the placebo-treated group experienced an average 0.4 +/- 0.8 mg/dL increase."( The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.
Cheng, SC; Coyne, DW; Delmez, JA; Young, DO,
)
0.94
"Niacinamide-treated birds did not differ from either Trp-treated or control-treated birds, and no decreases in aggression were seen in birds with elevated blood niacin levels."( Decreases in aggression in tryptophan-supplemented broiler breeder males are not due to increases in blood niacin levels.
Mench, JA; Shea-Moore, MM; Thomas, OP, 1996
)
1.02
"Treatment with niacinamide in mice also provided protection from skin infections by enhancing AMPs."( Niacinamide leave-on formulation provides long-lasting protection against bacteria in vivo.
Chakrabortty, A; Iyer, V; Majumdar, A; Mallemalla, P; Mathapathi, MS; Tiwari, JK; Vora, S, 2017
)
2.24
"Treatment with niacinamide and acetazolamide decreased TmP/GFR and serum phosphate, which was paralleled by a decrease in serum C-terminus FGF23."( A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Brahim, J; Collins, MT; Dumitrescu, CE; Farrow, EG; Hart, TC; Kelly, MH; Khosravi, A; Murphey, MD; Nathan, MH; White, KE, 2009
)
0.69
"Treatment with niacinamide (nicotinamide), may have been of benefit since all problems were resolved within three months of ingestion."( Accidental ingestion of Vacor rodenticide: the symptoms and sequelae in a 25-month-old child.
Johnson, D; Kubic, P; Levitt, C, 1980
)
0.6

Toxicity

ExcerptReferenceRelevance
" In view of the inclusion of nicotinic acid, nicotinamide, salicylic acid, and phenylbutazone in this correlation between toxicity and 7-14C-nicotinamide mobilization, it is not necessary that the formation of compounds analogous to the nicotinamide dinucleotides plays a significant role in the toxic manifestations of the nicotinamide analogs."( Drug-biomolecule interactions: drug toxicity and vitamin coenzyme depletion.
Ahmad, N; Bederka, JP; Davitiyananda, D; Moses, ML, 1975
)
0.25
"The aim was to evaluate the effective and safe dosage for intracoronary administration of nicorandil (2-nicotinamidoethyl nitrate) in dogs."( Determination of effective and safe dose for intracoronary administration of nicorandil in dogs.
Ishikawa, S; Kojima, S; Mori, H; Ohsawa, K, 1990
)
0.28
" Larger doses of the agent showed adverse effects depending on the dosages."( Determination of effective and safe dose for intracoronary administration of nicorandil in dogs.
Ishikawa, S; Kojima, S; Mori, H; Ohsawa, K, 1990
)
0.28
"Human epidermal keratinocytes in culture were studied to evaluate their usefulness in demonstrating toxic events following exposure to sulfur mustard."( The use of human epidermal keratinocytes in culture as a model for studying the biochemical mechanisms of sulfur mustard toxicity.
Chan, P; Gross, CL; Meier, HL; Smith, WJ, 1990
)
0.28
"Deoxyadenosine has been implicated as the toxic metabolite causing profound lymphopenia in immunodeficient children with a genetic deficiency of adenosine deaminase (ADA), and in adults treated with the potent ADA inhibitor deoxycoformycin."( Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.
Carrera, CJ; Carson, DA; Kubota, M; Seto, S; Wasson, DB, 1985
)
0.27
" For the four B-cell toxic agents tested, an increase in medium glucose following any of these treatments reduced the percent of dead cells."( Pancreatic B cells possess defense mechanisms against cell-specific toxicity.
Pipeleers, D; Van de Winkel, M, 1986
)
0.27
" Thus, the mechanisms by which nicotinamide and thymidine protect against the toxic effects of STZ or ALX appear different."( Mechanisms of nicotinamide and thymidine protection from alloxan and streptozocin toxicity.
Forbes, PM; Hall, CR; LeDoux, SP; Patton, NJ; Wilson, GL, 1988
)
0.27
" The aim was to establish the pharmacokinetic profiles and their reproducibility during repeated administration, the maximum tolerated dose with fractionated radiotherapy, whether such a dose achieves sufficiently high plasma levels for radiosensitization, the optimal time interval between nicotinamide and irradiation, and toxic side effects."( Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity.
Dennis, MF; Hall, DW; Hoskin, PJ; Rojas, A; Saunders, MI; Stratford, MR, 1995
)
0.29
" The most often reported adverse event was headache, which was responsible for most of the study withdrawals due to clinical intolerance (9."( Nicorandil safety in the long-term treatment of coronary heart disease.
Darmon, JY; Witchitz, S, 1995
)
0.29
" Adverse events usually occurred early in the course of treatment."( Safety profile of an anti-anginal agent with potassium channel opening activity: an overview.
Roland, E, 1993
)
0.29
" It is our conclusion that radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable side effects."( Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Kaanders, JH; Marres, HA; Pop, LA; van Daal, WA; van der Kogel, AJ; van der Maazen, RW, 1995
)
0.29
" These results indicate that dilatation of the epicardial coronary artery was achieved with intracoronary nicorandil in a dose-dependent manner (up to 1 mg over 1 min) without any adverse effects in man, and the dilatory effect on coronary resistance vessels was of short duration."( Effective and safe dose of intracoronary nicorandil in man.
Fujita, M; Igawa, A; Inouc, H; Miwa, K; Yamanishi, K, 1995
)
0.29
" That a lesion of the inferior olive almost completely prevents the neurotoxicity demonstrates that ibogaine is not directly toxic to Purkinje cells, but that the toxicity is indirect and dependent on integrity of the olivocerebellar projection."( The olivocerebellar projection mediates ibogaine-induced degeneration of Purkinje cells: a model of indirect, trans-synaptic excitotoxicity.
Molliver, ME; O'Hearn, E, 1997
)
0.3
" This increase was significantly greater in striatum and coincided with the greater vulnerability of this brain region to the toxic effects of METH."( Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum.
Douglas, AJ; Lust, WD; Stephans, SE; Whittingham, TS; Yamamoto, BK, 1998
)
0.3
" We have developed a mouse model to demonstrate the toxic effects of methotrexate: mice were given 50 mg/kg acetaminophen, which itself has no effect on the liver."( Nicotinamide and methionine reduce the liver toxic effect of methotrexate.
Bache, K; Hauschild, A; Kröger, H; Krüger, D; Ohde, M; Thefeldt, W; Voigt, WP, 1999
)
0.3
" High-dose nicotinamide should still, however, be considered as a drug with toxic potential at adult doses in excess of 3 gm/day and unsupervised use should be discouraged."( Safety of high-dose nicotinamide: a review.
Bingley, PJ; Douek, IF; Gale, EA; Gillmor, HA; Knip, M; McLean, AE; Moore, WP, 2000
)
0.31
" The toxic effect of some beta-cells toxins like streptozotocin (used to produce animal models of IDDM) has been associated with the oxidative stress due to enhanced DNA repair and NAD depletion in damaged beta-cells."( The optimum dose of nicotinamide for protection of pancreatic beta-cells against the cytotoxic effect of streptozotocin in albino rat.
Hassan, N; Janjua, MZ,
)
0.13
" The most frequently reported adverse events over multiple cycles were gastrointestinal (75%), dermatologic (71%), constitutional (68%), pain (64%), or hepatic (61%) related."( Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D, 2005
)
0.33
" BAY 43-9006 was well tolerated, with mild to moderate toxicities; only six patients discontinued study therapy due to adverse events."( Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Cihon, F; Hirte, HW; Hotte, SJ; Lathia, C; Moore, M; Oza, A; Petrenciuc, O; Schwartz, B; Siu, L, 2005
)
0.33
" While Niacinamide is more toxic than Niacin in acute toxicity studies, both are relatively non-toxic."( Final report of the safety assessment of niacinamide and niacin.
, 2005
)
1.05
"Zinc neurotoxicity has been demonstrated in ischemic, seizure, hypoglycemic, and trauma-induced neuronal death where Zn(2+) is thought to be synaptically released and taken up in neighbouring neurons, reaching toxic concentrations."( Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway.
Cai, AL; Sheline, CT; Zipfel, GJ, 2006
)
0.33
" Sorafenib was generally well tolerated; most adverse events were mild to moderate in severity up to the defined maximum-tolerated dose of 400 mg twice daily (bid)."( Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Awada, A; Clark, JW; Eder, JP; Hendlisz, A; Hirte, HW; Lenz, HJ; Moore, MJ; Richly, H; Schwartz, B; Strumberg, D, 2007
)
0.34
"Advances in understanding the role of vascular endothelial growth factor (VEGF) in normal physiology are giving insight into the basis of adverse effects attributed to the use of VEGF inhibitors in clinical oncology."( Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Kamba, T; McDonald, DM, 2007
)
0.34
" The most frequent adverse events were fatigue (55%), diarrhea (51%), nausea (44%), and hypertension (42%)."( Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Bass, MB; Benjamin, R; Chang, DD; Herbst, RS; Koutsoukos, A; Kurzrock, R; Mulay, M; Ng, C; Polverino, A; Purdom, M; Rosen, LS; Silverman, J; Sun, YN; Van Vugt, A; Wiezorek, JS; Xu, RY, 2007
)
0.34
" In the current article, the significance of adverse events and their management in RCC patients is reviewed in order to guide the clinical oncologist through patient surveillance and treatment of adverse events."( Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Fiedler, W; Grünwald, V; Heinzer, H, 2007
)
0.34
" The tolerability of an agent is important in long-term treatment, and a predictable and manageable side-effect profile is advantageous."( Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Hutson, TE, 2007
)
0.34
" The most frequently occurring drug-related adverse events (any grade) were elevated lipase (56%), hand-foot skin reaction (55%), alopecia (39%), increased amylase (38%), rash/desquamation (37%), and diarrhea (34%)."( Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T, 2007
)
0.34
" We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy."( Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC, 2007
)
0.34
"Sorafenib in combination with other agents was generally well tolerated, and most adverse events were mild to moderate in severity."( Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Awada, A; Takimoto, CH, 2008
)
0.35
" The most common Grade 3/4 adverse events experienced on thalidomide monotherapy were venous thrombosis (3."( Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.
Claflin, JE; Crean, S; Lahn, M; Linz, H; Noel, JK; Ranganathan, G, 2008
)
0.35
" Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension."( Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E, 2007
)
0.34
"Sorafenib induces frequent cutaneous adverse events, some of which may lead to a dose reduction."( Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J, 2008
)
0.35
" Adverse events included hypertension, hand-foot syndrome, diarrhea, transaminitis, and fatigue."( Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ, 2008
)
0.35
" Congestive heart failure is a less common but serious side effect that warrants treatment discontinuation."( Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ, 2008
)
0.35
" Sixteen patients (62%) experienced motesanib-related adverse events, most commonly lethargy (n=6), diarrhoea (n=4), fatigue (n=3), headache (n=3), and nausea (n=3)."( Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
Lipton, L; McCoy, S; McGreivy, J; Price, TJ; Rosenthal, MA; Sun, YN, 2008
)
0.35
" The most frequently reported grade 3/4 drug-related adverse events in the 149 assessable patients treated with sorafenib were hand-foot skin reaction (HFSR; 16 patients [10."( Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Burock, K; Chen, Z; Cheng, AL; Feng, J; Guan, Z; Kang, YK; Kim, JS; Liang, H; Liu, J; Luo, R; Pan, H; Qin, S; Sun, Y; Tak, WY; Tsao, CJ; Voliotis, D; Wang, J; Xu, J; Yang, TS; Ye, S; Zou, J, 2009
)
0.35
"Despite their inherent selectivity, targeted therapies such as tyrosine kinase inhibitors (TKIs) can cause unusual adverse effects."( Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F, 2009
)
0.35
" Adverse events at 16 months after cross over were similar to those previously reported."( Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Anderson, S; Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Gore, M; Hofilena, G; Hutson, TE; Lathia, C; Negrier, S; Oudard, S; Pena, C; Rolland, F; Shan, M; Stadler, WM; Staehler, M; Szczylik, C, 2009
)
0.35
"Multitargeted kinase inhibitors are associated with a significant risk of various cutaneous adverse events."( Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC, 2009
)
0.35
" The most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%)."( Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Bastholt, L; Daumerie, C; Droz, JP; Elisei, R; Eschenberg, MJ; Jarzab, B; Juan, T; Locati, LD; Martins, RG; Pacini, F; Schlumberger, MJ; Sherman, SI; Stepan, DE; Sun, YN; Wirth, LJ, 2009
)
0.35
" With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair."( Adverse effects of anticancer agents that target the VEGF pathway.
Chen, HX; Cleck, JN, 2009
)
0.35
"Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing."( Rapid development of hypertension by sorafenib: toxicity or target?
Atkins, MB; Humphreys, BD, 2009
)
0.35
" This article presents a case study to illustrate side-effect management strategies for patients receiving MKIs for the treatment of advanced renal cell carcinoma."( Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Wood, LS, 2009
)
0.35
" Common drug-related adverse events, including fatigue, hand-foot skin reaction, rash or gastrointestinal disturbances, were manageable, reversible and generally low grade."( Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C, 2011
)
0.37
" Despite its inherent selectivity, sorafenib can cause unusual adverse events whose the management represents a challenge for oncologists."( Toxicity of sorafenib: clinical and molecular aspects.
Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B, 2010
)
0.36
"The clinical aspect of sorafenib-induced adverse events and the molecular basis behind this toxicity are discussed."( Toxicity of sorafenib: clinical and molecular aspects.
Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B, 2010
)
0.36
" Unlike some first-generation anti-cancer therapies, sorafenib is generally associated with moderate and manageable adverse events."( Managing adverse events associated with sorafenib in renal cell carcinoma.
Edmonds, K; Spencer-Shaw, A,
)
0.13
"The most common grade > or =2 drug-related adverse events were hand-foot skin reaction (18%), rash (14%), hypertension (12%), and fatigue (11%)."( Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; George, JR; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C, 2010
)
0.36
" Incidence rates of adverse events were significantly higher with sorafenib than with placebo."( Experience with sorafenib and adverse event management.
Bellmunt, J; Eisen, T; Fishman, M; Quinn, D, 2011
)
0.37
" Clinicians have changed their practice and are faced with a number of new adverse events."( [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Boyle, H; Fléchon, A; Négrier, S, 2010
)
0.36
" Strict monitoring of treatment-related adverse effects must be conducted in order to allow the early detection of cardiovascular toxicities and their prompt medication."( Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Brandes, AA; Franceschi, E; Girardi, F, 2010
)
0.36
" In conclusion, in daily practice sorafenib is safe and disease stabilization can be achieved in the majority of patients."( Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
Bechstein, WO; Engels, K; Gog, C; Herrmann, E; Lubomierski, N; Trojan, J; Vogl, TJ; Welker, MW; Zeuzem, S, 2010
)
0.36
" Sorafenib was well tolerated, and no adverse events were noticed."( Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Aucejo, F; Kim, R; Menon, N, 2011
)
0.37
" The most commonly reported treatment-related adverse events of any grade were diarrhoea (74%), rash/desquamation (51%), hand-foot skin reaction (49%), alopecia (39%), and fatigue (38%)."( Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Anderson, S; Bellmunt, J; Bukowski, R; Eisen, T; Escudier, B; Hutson, TE; Nadel, A; Porta, C; Staehler, M; Szczylik, C, 2010
)
0.36
" The most common grade ≥3 adverse events included rash/desquamation (5% in both groups), hand-foot skin reaction (8% in those aged ≥70 years vs."( Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C, 2010
)
0.36
" The most common adverse events were rash and diarrhoea."( Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK, 2010
)
0.36
" The most common motesanib treatment-related grade 3 adverse events included hypertension (23%), fatigue (9%), and diarrhea (5%)."( Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Baker, L; Benjamin, RS; Blay, JY; Bui, BN; Duyster, J; Hartmann, JT; McCoy, S; Reichardt, P; Rosen, LS; Schöffski, P; Schuetze, S; Skubitz, K; Stepan, DE; Sun, YN; Van Oosterom, A, 2011
)
0.37
" The most frequently reported adverse events were elevated transaminases, hypophosphatemia, fatigue, anorexia, diarrhoea, nausea, rash and palmar-plantar erythrodysaesthesia."( A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Burger, DM; Desar, IM; Timmer-Bonte, JN; van der Graaf, WT; van Herpen, CM, 2010
)
0.36
" Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)."( Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011
)
0.37
" The rapid introduction of novel treatment options into clinical practice within a relatively short time frame has created some new challenges pertaining to adverse event (AE) management in patients with advanced RCC."( Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud, A, 2011
)
0.37
" Data were collected on adverse events (AEs), treatment modifications (discontinuations, interruptions, dose changes), and reasons for these modifications."( Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C, 2011
)
0.37
" Rates of adverse events (AEs) and treatment modifications were analyzed; reasons for treatment modifications were examined."( Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST, 2012
)
0.38
" Commonest adverse events included hand-foot syndrome, other skin toxicities, diarrhoea and alopecia."( Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Ahmed, M; Barbachano, Y; Harrington, KJ; Hickey, J; Marais, R; Newbold, KL; Nutting, CM; Riddell, A; Viros, A, 2011
)
0.37
" In order to maximize the benefit of sorafenib and other investigational agents for patients with advanced disease, effective interventions have been designed to mitigate their associated adverse events, such as hand-foot skin reactions and hypertension."( Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Abou-Alfa, GK; Gish, RG; Tong, MJ, 2010
)
0.36
" Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors."( Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A, 2011
)
0.37
"As a group of European nurses familiar with treating patients with renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) using targeted/chemo- therapies, we aimed to review strategies for managing adverse events (AEs) associated with one targeted therapy, sorafenib."( Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A, 2012
)
0.38
" The majority of adverse events (AEs) were Grade 1-2 in severity."( Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S, 2011
)
0.37
" Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors."( Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y, 2011
)
0.37
" Predictivity for adverse outcomes in mammalian prenatal developmental toxicity studies used ToxRefDB and other sources of information, including Stemina Biomarker Discovery's predictive DevTox® model trained on 23 pharmaceutical agents of known developmental toxicity and differing potency."( Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics.
Cezar, GG; Conard, KR; Dix, DJ; Donley, EL; Fontaine, BR; Kleinstreuer, NC; Knudsen, TB; Palmer, JA; Smith, AM; Weir-Hauptman, AM; West, PR, 2011
)
0.37
" The most common severe adverse event probably related to sorafenib was diarrhea (12."( Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M, 2012
)
0.38
"Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs."( Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A, 2012
)
0.38
" The tumor-bearing survival time, adverse effect and toxicity associated with sorafenib were compared between the 3 groups."( [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J, 2011
)
0.37
" No significant difference was found in adverse effects associated with Sorafenib between groups A and C (P<0."( [Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J, 2011
)
0.37
" Adverse events, overall survival and time to progression were recorded."( Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S, 2011
)
0.37
"6 months), frequency of adverse events and discontinuation of sorafenib were not correlated with Child-Pugh class."( Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S, 2011
)
0.37
"While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events."( [Dermatologic side effects induced by new angiogenesis inhibitors].
Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V, 2011
)
0.37
" Treatment outcomes and related adverse events (AEs) were compared."( The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).
Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, RW; Poon, R; Tang, YF; Wong, H; Yao, TJ; Yau, T, 2011
)
0.37
" This has raised challenges in the management of adverse events (AEs) associated with the six targeted agents approved in RCC-sorafenib, sunitinib, pazopanib, bevacizumab (in combination with interferon alpha), temsirolimus, and everolimus."( Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S, 2012
)
0.38
" Their baseline characteristics, radiologic response, adverse events, and survival status were assessed."( Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C, 2012
)
0.38
"The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and South Korea - confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC)."( Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J, 2012
)
0.38
" The most common grade 3/4 adverse events were hand-foot skin reaction, diarrhoea and fatigue, the incidence of which was similar between subgroups."( Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J, 2012
)
0.38
"Most common adverse events (AEs) (grade 3-5) included neutropenia (89%), leucopaenia (81%), hand-foot skin reaction (30%) and fatigue (30%)."( Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M, 2012
)
0.38
" Treatment-emergent adverse events were generally mild and included fatigue, nausea, vomiting, and chills."( Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M, 2012
)
0.38
"Ganitumab up to 12 mg/kg was well tolerated, without adverse effects on pharmacokinetics in combination with either sorafenib, panitumumab, erlotinib, or gemcitabine."( Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M, 2012
)
0.38
" The commonest grade 3/4 adverse events were hand-foot syndrome (13."( The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T, 2012
)
0.38
" If acute toxicity testing at the saturation limit yields no adverse effects, further testing should not normally be required; the toxicity value of the endpoints should be considered as the saturation limit and adverse classification should not be required."( Aquatic toxicity tests with substances that are poorly soluble in water and consequences for environmental risk assessment.
Hamitou, M; Rufli, H; Salinas, ER; Weltje, L; Weyman, GS, 2012
)
0.38
"4% of patients experienced mild adverse events (grade 1 or 2), the most frequent were gastrointestinal and dermatological."( Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2012
)
0.38
"This report describes a positive experience of adverse event (AE) management of a multidisciplinary clinical team and 18 patients with late-stage renal cell carcinoma and hepatocellular carcinoma attending the Day Hospital Unit of the 'Centro Catanese di Oncologia Humanitas' (Italy) over a 2-year period."( Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM, 2012
)
0.38
"A retrospective, registry-based analysis to assess the outcomes of metastatic renal cell cancer (mRCC) patients treated with sunitinib and sorafenib who developed dermatologic adverse events was performed."( Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R, 2012
)
0.38
"The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC."( Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012
)
0.38
" The most common grade 3/4 adverse events included diarrhea, hand-foot skin reaction, and fatigue; the incidence of which did not differ appreciably among subgroups."( Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D, 2012
)
0.38
" 6m2 groups, grade 3-4 adverse events were observed in 64."( [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K, 2012
)
0.38
" The most common adverse events were fatigue (62."( Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
Díaz-Rubio, E; Ladero, JM; Manzano, A; Puente, J; Sastre, J; Zugazagoitia, J, 2013
)
0.39
" Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%."( High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012
)
0.38
" The overall incidence of treatment-related adverse events was 68."( [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF, 2012
)
0.38
"To investigate the clinic predictors of efficacy and adverse events of sorafenib in treating with advanced hepatocellular carcinoma (HCC) patients."( [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P, 2012
)
0.38
" The common adverse events were hand-foot syndrome (64."( [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P, 2012
)
0.38
" Dose reduction because of adverse events or intolerance was required in 91% of patients after 26 ± 11 days from the start of treatment."( Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013
)
0.39
" No differences in the frequency of grade 3 adverse events among different Child-Pugh classes were reported."( Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B, 2012
)
0.38
" The most frequent adverse events leading to discontinuation of sorafenib treatment were liver dysfunction (n = 8), hand-foot skin reaction (n = 7), and diarrhea (n = 4)."( Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y, 2013
)
0.39
"This study showed that sorafenib was safe and useful in Japanese patients with advanced HCC."( Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y, 2013
)
0.39
"This is the first reported case of sorafenib exposure associated fatal toxicity in the adjuvant setting and highlights the unpredictable adverse effects of novel adjuvant therapies."( Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Collier, J; Eisen, T; Fairfax, BP; Kaplan, R; Macaulay, VM; Meade, AM; Pratap, S; Protheroe, A; Ritchie, AW; Roberts, IS, 2012
)
0.38
" In two randomized trials, sorafenib was reported to be safe without a significant impact on quality of life (QoL)."( Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.
Brunello, F; Brunocilla, PR; Cantamessa, A; Carucci, P; Castiglione, A; Ciccone, G; Gaia, S; Rizzetto, M; Rolle, E, 2013
)
0.39
"Early prediction of tumour response and major adverse events (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) is essential for maximizing the clinical benefits of sorafenib."( Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K, 2013
)
0.39
" Clinical outcomes and treatment-related adverse events (AEs) were compared between younger (< 70 years) and older (≥ 70 years) patients."( Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R, 2013
)
0.39
" In conclusion, after using other VEGF inhibitor such as sunitinib, sorafenib is active and safe for the treatment of patients with advanced or metastatic RCC."( Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
Afonso, FJ; Anido, U; Antón-Aparicio, L; Fernández-Calvo, O; Lázaro, M; León, L; Ramos, M; Vázquez-Estévez, S, 2013
)
0.39
"5 mg/mL of the substances tested in any cell type examined, no toxic effects were found."( [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Eibl, K; Haritoglou, C; Kampik, A; Kernt, M; König, S; Langer, J; Liegl, RG; Siedlecki, J; Thiele, S, 2013
)
0.39
" The common all-causality adverse events (all grades) in Japanese patients were dysphonia (68%), hypertension (64%), hand-foot syndrome (64%) and diarrhea (56%) for axitinib, and hand-foot syndrome (86%), hypertension (62%) and diarrhea (52%) for sorafenib."( Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H, 2013
)
0.39
" The adverse vascular effects of Sorafenib may be due to the inhibition of the proliferation of vascular endothelial muscle cells."( Cardiovascular toxicity and sorafenib: a case report.
Cortejoso, L; García-Lledó, J; Giménez-Manzorro, A; Matilla-Peña, A; Salcedo-Plaza, M; Sanjurjo-Sáez, M; Tenorio Núñez, M,
)
0.13
"No adverse effect of preoperative administration of sorafenib was observed during and immediately after liver resection for HCC."( Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P, 2013
)
0.39
"Sorafenib can be well tolerated and safe in patients with recurrent HCC following LT and may be associated with a modest survival benefit."( Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Aucejo, F; Balci, B; El-Gazzaz, G; Estfan, B; Kim, R; Narayanan Menon, KV; Pelley, R; Romero-Marrero, C; Waghray, A,
)
0.13
" Adverse reactions with Sorafenib were observed in 41."( [Study on the usage, effectiveness, and toxicity associated to treatment with sorafenib].
Camañas-Troyano, C; Catalá-Pizarro, RM; Moriel-Sánchez, M,
)
0.13
" Sorafenib may be associated with the occurrence of adverse events, mainly gastrointestinal and cutaneous, requiring dose adjustment and treatment withdrawal in some cases."( [Study on the usage, effectiveness, and toxicity associated to treatment with sorafenib].
Camañas-Troyano, C; Catalá-Pizarro, RM; Moriel-Sánchez, M,
)
0.13
" The most common adverse events related to sorafenib in group T + S group and S group alone were hand foot skin reaction, diarrhea and alopecia."( [The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma].
Fan, WZ; Huang, YH; Li, JP; Wang, Y; Yang, JY; Zhang, YQ, 2013
)
0.39
"Skin toxicities that are common adverse reactions in advanced HCC patients treated with sorafenib may be used as surrogate markers for clinical benefit."( Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Lee, YJ; Shin, SY, 2013
)
0.39
" The most common adverse event was skin toxicity (67 %), followed by gastrointestinal symptoms (26 %), hypertension (22 %), fatigue (19 %), hematological toxicity (10 %), and hemorrhage (6 %)."( Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment.
Ishizuka, O; Nishizawa, O; Suzuki, H; Suzuki, T; Ueno, M, 2014
)
0.4
"Sorafenib has various adverse events that can cause treatment discontinuation or dose reduction."( Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014
)
0.4
"Hand-foot skin reaction (HFSR) was the most common adverse event among RCC (76 %) and HCC (66 %) patients."( Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T, 2014
)
0.4
" Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction."( Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J, 2014
)
0.4
" The most common (≥10% patients) treatment-emergent adverse events were gemcitabine-related thrombocytopenia (40%) followed by sorafenib-related hand-foot skin reaction and anorexia (33% each)."( Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Ahmad, S; Khattak, J; Murad, S; Naqi, N, 2014
)
0.4
" The side effect rates indicate that the drug was tolerated well."( Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N, 2013
)
0.39
" Adverse events led to temporary SORA discontinuation in 2 patients (28."( Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Bargellini, I; Bartolozzi, C; Campani, D; Carrai, P; Cioni, D; Crocetti, L; De Simone, P; Della Pina, C; Filipponi, F; Ghinolfi, D; Lencioni, R; Leonardi, G; Pezzati, D; Pollina, L,
)
0.13
"Although sorafenib improves survival in patients with hepatocellular carcinoma (HCC), doses have to be reduced in quite a few patients because of adverse events."( Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O, 2014
)
0.4
" Although 6 patients exhibited DLT, the cause of the adverse event was HFSR in all cases."( Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O, 2014
)
0.4
"The results of the present study indicated that intra-patient sorafenib dose re-escalations were safe and tolerable."( Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O, 2014
)
0.4
" Sorafenib-related adverse events (AEs) that commonly occur across these tumor types include hand-foot skin reaction (HSFR), rash, upper and lower gastrointestinal (GI) distress (ie, diarrhea), fatigue, and hypertension."( Management of sorafenib-related adverse events: a clinician's perspective.
Brose, MS; Frenette, CT; Keefe, SM; Stein, SM, 2014
)
0.4
" Grade 1 and 2 adverse events (AEs) that commonly occur during treatment (ie, dermatologic manifestations, diarrhea, fatigue, and hypertension) should be proactively managed."( Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Grande, C; Walko, CM, 2014
)
0.4
" Different degree of adverse drug reactions (ADRs) occurred in 9 patients but all were at grade 3 or lower."( [Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K, 2014
)
0.4
"The combination of sorafenib and TACE is an effective and safe treatment for HCC."( [Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K, 2014
)
0.4
" Majority of sorafenib adverse events appear within the first 60 days of treatment and studies correlating them with outcome are needed."( Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Ayuso, C; Bruix, J; Darnell, A; Forner, A; LLarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2014
)
0.4
" All but one patient presented at least one adverse event (median time to appearance 56 days)."( Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Ayuso, C; Bruix, J; Darnell, A; Forner, A; LLarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2014
)
0.4
"Development of dermatologic adverse events within 60 days of sorafenib initiation is associated with better survival."( Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Ayuso, C; Bruix, J; Darnell, A; Forner, A; LLarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F, 2014
)
0.4
" In silico toxicity predictions showed that two photoproducts are potentially more toxic than the parent compound considering oral rat LD50 while five photoproducts may induce mutagenic toxicity."( UV-visible degradation of boscalid--structural characterization of photoproducts and potential toxicity using in silico tests.
Bouchonnet, S; Bourcier, S; Clavaguera, C; Jaber, F; Kinani, A; Lassalle, Y; Rifai, A; Souissi, Y, 2014
)
0.4
" Response rates, incidence of adverse events, actuarial disease-free survival, and overall survival (OS) were estimated."( Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA, 2014
)
0.4
"As new antiangiogenic therapies have been introduced and added to the therapeutic arsenal against various types of cancer, previously unknown adverse effects have been detected."( Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Ara, M; Pastushenko, E, 2014
)
0.4
"Nicotinamide was generally well tolerated; the main adverse event was nausea, which in most cases was mild, dose-related, and resolved spontaneously or after dose reduction, use of antinausea drugs, or both."( Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Athanasopoulos, S; Chan, PK; Festenstein, R; Giunti, P; Huson, L; Law, PP; Leiper, J; Libri, V; Loyse, N; Mauri, M; Mohammad, T; Natisvili, T; Parkinson, MH; Piper, S; Ramesh, A; Tam, KT; Yandim, C, 2014
)
0.4
" The most frequently reported grade 3/4 treatment-related adverse events included thrombocytopenia 33%, neutropenia 16% and hand-foot skin reaction 13%."( Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S, 2014
)
0.4
" The most frequently reported drug-related adverse events (AEs) were hand-foot syndrome (57."( Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J, 2014
)
0.4
"Hand-foot skin reaction is a most common multi-kinase inhibitor-related adverse event."( Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).
Bito, T; Hirai, M; Hirano, T; Kume, M; Makimoto, H; Mizumoto, A; Mukai, A; Nakagawa, T; Nishigori, C; Nishimura, K; Uda, A; Yamamoto, K; Yamashita, K, 2014
)
0.4
" Grade 3 or greater sorafenib-related adverse events included fatigue, hypertension, diarrhea, oral mucositis, rash and HFSR."( Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Guo, DH; Pei, F; Si, HY; Tang, ZH; Wang, DX; Wang, WL; Xiao, BK; Xie, TT; Zhang, XY; Zhu, M, 2014
)
0.4
" Most frequent drug-related adverse events were diarrhea, rash, aspartate aminotransferase elevation, vomiting, and nausea."( A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH, 2014
)
0.4
" Frequent dose modifications due to grade 3 adverse events may have contributed to limited treatment effect."( A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH, 2014
)
0.4
" The adverse events (AEs), overall survival (OS), time to progression (TTP), and prognostic factors were analysed."( Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M, 2014
)
0.4
"Sorafenib is associated with adverse cardiac effects, including left ventricular dysfunction."( Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B, 2015
)
0.42
" Common adverse events (AEs) were also studied."( Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L, 2015
)
0.42
"Inhibition of the vascular endothelial growth factor receptor (VEGFR) with tyrosine kinase inhibitors (TKIs) is associated with cutaneous adverse effects that increase patient morbidity."( Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Cowen, EW; Massey, PR; Okman, JS; Wilkerson, J, 2015
)
0.42
" Adverse events were abstracted, with results presented in both fixed and random effects models."( Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Cowen, EW; Massey, PR; Okman, JS; Wilkerson, J, 2015
)
0.42
" The most common side effect was hand-foot skin reaction."( Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Gong, W; Liu, DJ; Liu, J; Sun, P; Xu, YT; Yu, GS; Zheng, SZ, 2014
)
0.4
" Reduction of the major metabolite SRF-Nox back to SRF may mediate decreased cellular viability and contribute to adverse reactions in some individuals."( Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
Gillani, TB; Murray, M; Rawling, T, 2015
)
0.42
" Although sorafenib has demonstrated many benefits in patients, the adverse effects cannot be ignored."( The adverse effects of sorafenib in patients with advanced cancers.
Gao, ZH; Li, Y; Qu, XJ, 2015
)
0.42
" The related adverse events and survival benefits were compared between the two groups."( Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015
)
0.42
"Sorafenib combined with TACE was equally well tolerated in both age groups, and grade 3 or 4 adverse events were similarly observed in 54."( Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015
)
0.42
" ASP015K was generally well tolerated, with no serious adverse events (AEs) reported."( A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
Akinlade, B; Ball, G; Catlin, M; Krueger, JG; Papp, K; Pariser, D; Wierz, G; Zeiher, B, 2015
)
0.42
"Treatment with small molecule tyrosine kinase inhibitors (TKIs) has improved survival in many cancers, yet has been associated with an increased risk of adverse events."( Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A, 2015
)
0.42
"Frequency of sorafenib-related adverse events was almost similar between Child-Pugh score 5, 6, and 7 patients."( Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O, 2015
)
0.42
" Overall, adverse event rates were generally similar between the treatment arms."( SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U, 2015
)
0.42
" The most common treatment-emergent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, and decreased appetite."( Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Austin, T; Beckman, RA; Cheng, AL; Greenberg, J; He, AR; Hung, CH; Izumi, N; Kang, YK; Kudo, M; Lim, HY; Ryoo, BY; Sheen, IS; Shiratori, S; Wang, Q, 2015
)
0.42
"0% of discontinued patients) were due to adverse events."( A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T, 2015
)
0.42
" Ocular toxicity was assessed and handled according to the Common Terminology Criteria for Adverse Events."( Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Alessio, G; Guida, M; Niro, A; Recchimurzo, N; Sborgia, L; Strippoli, S, 2015
)
0.42
"Ocular adverse events appeared early in the treatment."( Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Alessio, G; Guida, M; Niro, A; Recchimurzo, N; Sborgia, L; Strippoli, S, 2015
)
0.42
" Severe adverse events (AEs) or poor compliance was observed in 64 (36."( Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Chung, J; Hong, SH; Joo, KJ; Kim, CS; Kim, S; Kim, SH; Kim, TN; Kwak, C; Kwon, TG; Lee, SE; Nam, BH; Seo, IY; Seo, SI; Song, K, 2015
)
0.42
" However, some studies have been stopped owing to the development of severe adverse events."( Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H, 2015
)
0.42
" Sorafenib was administered at a dose of 400 mg twice daily, and continued until disease progression, at which point the dose was increased to 600 or 800 mg twice daily, or the onset of an intolerable adverse drug event (ADE) that required dose reduction or temporary suspension of treatment."( Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Fang, D; Guo, G; Huang, L; Li, X; Song, Y; Yu, X; Zhang, C; Zhang, X; Zhou, L, 2015
)
0.42
"Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies."( Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F, 2015
)
0.42
"Several adverse events (AEs) are known to be commonly observed during treatment with different tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC) patients."( Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Fujisawa, M; Harada, K; Imai, S; Miyake, H, 2016
)
0.43
"Several adverse events (AEs) commonly observed during treatment with different tyrosine kinase inhibitors (TKIs)."( Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Fujisawa, M; Harada, K; Imai, S; Miyake, H, 2016
)
0.43
" The major adverse events associated with the NAM therapy were diarrhea, flushing and nausea."( Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
El Borolossy, R; El Hakim, I; El Wakeel, LM; Sabri, N, 2016
)
0.43
" The incidence of cardiovascular adverse events, including congestive heart failure and cardiomyopathy (CHF/CM), acute myocardial infarction (AMI), stroke, and cardiovascular deaths, was examined through December 2010."( Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C, 2016
)
0.43
"The aim of the study is to evaluate the relationship between the adverse events and efficacy of sorafenib in patients with metastatic renal cell carcinoma (mRCC), with a purpose to guide the judgment of efficacy in sorafenib treatment."( The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y, 2015
)
0.42
" The total incidence of treatment-emergent adverse events (TEAEs) was similar between the placebo (64."( Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Ishikura, H; Iwasaki, M; Kaneko, Y; Saeki, S; Takeuchi, T; Tanaka, Y, 2016
)
0.43
"The use of multikinase inhibitors (MKI) in oncology, such as sorafenib, is associated with a cutaneous adverse event called hand-foot skin reaction (HFSR), in which sites of pressure or friction become inflamed and painful, thus significantly impacting quality of life."( Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
Baker, SD; Chen, T; Du, G; Gibson, AA; Hu, S; Inaba, H; Maitland, ML; Mascara, GP; Ong, SS; Orwick, SJ; Sparreboom, A; Vasilyeva, A; Vogel, P; Zimmerman, EI, 2016
)
0.43
" Adverse events (AE) occurred in nine (75%) patients."( Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR, 2016
)
0.43
"Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma."( Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016
)
0.43
"A total of 73/140 patients with advanced hepatocellular carcinoma receiving sorafenib developed relevant adverse events (grade ≥2) and were managed with a tolerable-adverse-event-protocol consisting of a drug stepwise dose reduction adjusted on patient's tolerability."( Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016
)
0.43
" The tolerable-adverse-event-protocol group experienced a more favourable outcome with respect to the minor adverse event group as for disease control rate (78% vs."( Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016
)
0.43
"In patients with advanced hepatocellular carcinoma, sorafenib dose adjustments based on inducing tolerability of relevant adverse events prolong drug exposure and maximize survival."( Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C, 2016
)
0.43
" Outcomes of interest were progression-free survival, objective response rate (ORR), overall survival, discontinuation of treatment due to adverse events (DAE) and occurrence of specific toxicities."( Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A, 2016
)
0.43
" Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events (AEs) and efficacy were recorded at follow-up."( Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J, 2016
)
0.43
"Tyrosine kinase inhibitors (TKIs) provide more effective targeted treatments for cancer, but are subject to a variety of adverse effects, such as hypothyroidism."( Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B, 2016
)
0.43
" The reported frequency of adverse events (AEs) and serious AEs was comparable in both treatment arms."( A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
Bazin, I; Bondarenko, I; Ciuleanu, T; Deptala, A; Ding, M; Egger, J; Fox, NL; Giantonio, B; Gribbin, M; Humphreys, R; Kalyani, RN; Lungulescu, D; Miron, L; Rodriguez-Torres, M; Sun, W; Wissel, P, 2016
)
0.43
"The purpose of the present study was to investigate whether genetic variants that influence angiogenesis and sorafenib pharmacokinetics are associated with clinical outcomes and toxic effects in advanced renal cell carcinoma patients treated with this drug."( The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
Cai, H; Cao, Q; Chen, J; Chu, H; Cui, L; Dong, B; Huang, Y; Ji, J; Jiang, M; Ju, X; Li, P; Li, X; Liu, F; Qin, C; Shao, P; Sun, L; Sun, X; Wang, J; Wang, M; Wang, S; Wang, X; Wu, B; Ye, D; Yin, C; Zhang, H; Zhang, Z; Zhao, H; Zhou, H; Zhou, L; Zhu, J; Zou, Q, 2016
)
0.43
" However, adverse effects common to the tyrosine kinase inhibitor class occur at a noticeably higher rate with sorafenib use in thyroid cancer patients."( Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016
)
0.43
"To provide an overview of the adverse effect profile of sorafenib in differentiated thyroid cancer and summarizes the literature regarding the frequency and etiology of selected adverse effects, with particular emphasis on the hand-foot skin reaction."( Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016
)
0.43
" Publications dealing with sorafenib and any of its common adverse effects were considered; this included randomized trials, observational studies, case reports or case series, and pertinent review articles."( Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016
)
0.43
"The DECISION trial of sorafenib in patients with differentiated thyroid cancer demonstrated significantly higher rates of common adverse effects, most notably hand-foot skin reaction, diarrhea, and hypertension, compared with sorafenib experience in renal or hepatocellular cancer."( Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016
)
0.43
"There is a distinct increase in the rate of occurrence of adverse effects of sorafenib when used in differentiated thyroid cancer compared with renal and hepatocellular cancer."( Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016
)
0.43
" Most common adverse events were hand-foot skin reaction and thrombocytopenia which were manageable."( Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X, 2016
)
0.43
" Of note, 24 patients started sorafenib at reduced dose; 6 of 36 patients (17%) required dose reduction due to adverse events (AEs)."( Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Bersanelli, M; Buti, S; Castagneto, B; Di Meglio, G; Leonetti, A; Masini, C; Pellegrino, B, 2016
)
0.43
" Data on patient demographic characteristics, treatment status, clinical outcome, and adverse events (AEs) were collected."( Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T, 2016
)
0.43
" The most common drug-related adverse events (DRAE) were hand-foot skin reaction (51."( Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T, 2016
)
0.43
"The purpose of our study was to test the hypothesis that sorafenib-related dermatologic adverse events (AEs) as an early biomarker can predict the long-term outcomes following the combination therapy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S)."( Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y, 2016
)
0.43
" The most common drug-related adverse events (AEs) included hand-foot skin reaction (47."( Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Furuse, J; Ikeda, M; Ito, Y; Izumi, N; Kadoya, M; Kokudo, N; Kudo, M; Numata, K; Okusaka, T; Takayama, T; Yamashita, S, 2016
)
0.43
" The radioembolization group also experienced fewer severe adverse effects."( Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M, 2016
)
0.43
"3%) had at least one grade 3 or 4 adverse reaction and 12 patients (41."( Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
Delcambre, C; Dutriaux, C; Heutte, N; Joly, F; Lesimple, T; Mouriaux, F; Neidhart-Berard, EM; Parienti, JJ; Penel, N; Peyro Saint Paul, L; Pham, AD; Piperno-Neumann, S; Servois, V; Thyss, A, 2016
)
0.43
" The hazard ratio (HR) or risk ratio (RR) with 95% confidence intervals (95%CIs) for time to progression (TTP), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and the incidence of treatment-related adverse events (AEs) were pooled using a fixed or random effect model in STATA 12."( Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Lv, L; Mei, ZC; Zeng, J, 2016
)
0.43
" In addition, the combination therapy increases the adverse events which usually disturb the treatment progress and should be increased attention."( Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Lv, L; Mei, ZC; Zeng, J, 2016
)
0.43
" The development of in vivo tools to study OATP1A/1B functions has greatly advanced our mechanistic understanding of their functional role in drug pharmacokinetics, and their implications for therapeutic efficacy and toxic side effects of anticancer and other drug treatments."( The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Durmus, S; Schinkel, AH; van Hoppe, S, 2016
)
0.43
"The mRECIST and dermatologic adverse events (AEs) can be used to assess the patient response to transarterial chemoembolization (TACE) and/or sorafenib for hepatocellular carcinoma (HCC)."( mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Bai, W; Cai, H; Fan, D; Han, G; Liu, L; Niu, J; Wang, E; Wang, W; Xia, D; Xia, J; Yang, M; Yin, Z; Zhang, L; Zhang, Z; Zhao, Y, 2017
)
0.46
"The combination of GBE (240mg QD) and standard dose sorafenib (400mg BID) is safe and tolerable among patients with advanced HCC."( Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016
)
0.43
" There are concerns about the increased risk of serious adverse events (SAEs) and fatal adverse events (FAEs) with sorafenib."( Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Ando, M; Ando, Y; Gyawali, B; Honda, K; Shimokata, T, 2017
)
0.46
" The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)."( Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017
)
0.46
"To systematically review relevant literature comparing the oncological outcomes and adverse events of different systemic therapies for patients with metastatic non-ccRCC."( A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A, 2017
)
0.46
" Sunitinib was associated with more Grade 3-4 adverse events than everolimus, although this was not statistically significant."( A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A, 2017
)
0.46
" Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect."( Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M, 2017
)
0.46
" Common adverse events included HFS (68."( Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria.
Agrawal, A; Chandrasekharan, A; Goel, A; Joshi, A; Menon, S; Noronha, V; Patil, VM; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A,
)
0.13
" Safety and efficacy variables were evaluated using National Cancer Institute-Common Toxicity Criteria for Adverse Events and Response Evaluation Criteria in Solid Tumors criteria."( In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
Chen, L; Huang, J; Liu, J; Mai, H; Mei, GH; Qu, H; Qu, N; Xu, X; Zhang, Y, 2017
)
0.46
"Osteonecrosis of the jaw (ONJ) is a rare treatment related side effect that was firstly described in 2002 through a case report in metastatic bone cancer patient treated with bisphosphonates (BPs) therapy."( Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P, 2017
)
0.46
" A detailed clinical trial should be performed to further evaluate the efficacy or adverse effects of the LDXGT formulation in combination with sorafenib in humans."( Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.
Cheng, YY; Ting, CT; Tsai, TH, 2017
)
0.46
" Primary outcomes were overall survival (OS), progression-free survival (PFS), adverse events (AEs), and QoL (SF-36 scores), and secondary outcomes were associations of clinical characteristics with QoL."( Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L, 2017
)
0.46
"Hand-foot skin reaction is recognized as one of the most common adverse events related to multiple tyrosine kinase inhibitors, but an effective prevention method has not been identified."( Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib.
Bito, T; Hirai, M; Hirano, T; Ishida, T; Kaku, K; Kume, M; Makimoto, H; Nakagawa, T; Nishigori, C; Nishioka, T; Shichiri, H; Yamamoto, K; Yano, I, 2017
)
0.46
" Secondary outcomes were overall response rate (ORR) and sorafenib-related adverse events (AEs)."( The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L, 2017
)
0.46
" The rates of grade III-IV adverse events in sorafenib and TACE + sorafenib groups were 29."( The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L, 2017
)
0.46
" In the safety population, at least one serious adverse event was reported in 174 (77%) of 226 patients in the SIRT group and in 176 (82%) of 216 in the sorafenib group."( Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V, 2017
)
0.46
" The overall incidence of adverse events was 93."( The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Matsumura, T; Matsushima, H; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y; Yoshitomi, M, 2018
)
0.48
"To analyse ophthalmological adverse events associated with mitogen-activated protein kinase kinase (MEK) inhibition with pimasertib treatment for metastatic cutaneous melanoma (CM)."( Pimasertib-associated ophthalmological adverse events.
Boon, CJF; Jager, MJ; Kruit, WHJ; Luyten, GPM; van Dijk, EHC; Vingerling, JR, 2018
)
0.48
"Patients with metastatic CM who are treated with the MEK inhibitor pimasertib are at high risk of development of ocular adverse events including serous retinopathy and possibly RVO, stressing the need of adequate ophthalmological follow-up including OCT during administration of pimasertib, despite the fact that SRF generally does not lead to ophthalmological complaints."( Pimasertib-associated ophthalmological adverse events.
Boon, CJF; Jager, MJ; Kruit, WHJ; Luyten, GPM; van Dijk, EHC; Vingerling, JR, 2018
)
0.48
" Approximately 50% of patients had at least one adverse event, and 6% had grade 3-4 adverse events."( Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J, 2018
)
0.48
" Prophylaxis for gastrointestinal adverse events may help to decrease dose interruptions or discontinuation."( Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J, 2018
)
0.48
" Acute toxicity testing in Wistar rats supported the safe administration of the nanoconjugate and established its localization in animal tissues by Perl's Prussian Blue reaction."( Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Asha, VV; Isaac, R; Jiji, SG; Philip, S; Praseetha, PK; Tom, G, 2018
)
0.48
" To investigate toxic effects and mechanisms of boscalid on freshwater algae Chlorella vulgaris (C."( Toxic effects of boscalid on the growth, photosynthesis, antioxidant system and metabolism of Chlorella vulgaris.
Cao, F; Li, C; Qi, S; Qian, L; Wang, C; Zhang, J; Zhao, F, 2018
)
0.48
" No serious adverse events due to NR supplementation were observed and safety blood tests were normal."( A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Brenner, C; Christensen, B; Dollerup, OL; Jessen, N; Møller, N; Ringgaard, S; Schmidt, MS; Stødkilde-Jørgensen, H; Sulek, K; Svart, M; Treebak, JT, 2018
)
0.48
"Evidence to date clearly indicates that nicotinamide is safe and effective for improving phosphorus metabolism in hemodialysis patients."( Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis.
Ma, T; Zhang, P; Zhang, Y, 2018
)
0.48
" The underlying mechanism of these adverse cardiac effects is largely unknown."( Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Becker, JR; Force, T; Galindo, CL; Glennon, MS; Gupte, M; Lal, H; Singh, AP; Umbarkar, P; Zhang, Q, 2019
)
0.51
" Its acute toxic effects on zebrafish and freshwater algae have been reported in our previous studies."( Toxic effects of boscalid in adult zebrafish (Danio rerio) on carbohydrate and lipid metabolism.
Chen, X; Qi, S; Qian, L; Wang, C; Wu, P; Zhang, J, 2019
)
0.51
"The major adverse effect associated with systemic administration of Fluconazole (FLZ), is hepatic toxicity."( Vitamin B combination reduces fluconazole toxicity in Wistar rats.
Al-Abbasi, FA; Anwar, F; Mushtaq, G; Sadath, S, 2019
)
0.51
" Secondary endpoints (assessed throughout) included ACR20, ACR50 and ACR70 response, changes from baseline in disease activity scores (DAS)28 and ACR core parameters, adverse events (AEs) and changes in clinical or laboratory measurements."( Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Akazawa, R; Chen, YH; Iwasaki, M; Izutsu, H; Kaneko, Y; Kawakami, A; Lee, SH; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Wei, JC; Yamada, E, 2019
)
0.51
" In this study, zebrafish served as an animal model to investigate the toxic effects and mechanisms of boscalid on aquatic vertebrates or higher animals."( Characterization of boscalid-induced oxidative stress and neurodevelopmental toxicity in zebrafish embryos.
Cao, Z; Liao, X; Liu, F; Lu, H; Meng, Y; Meng, Z; Su, M; Wang, H; Zhang, S; Zhou, L, 2020
)
0.56
" The difference in the number of patients with adverse events (AEs) among the intervention groups was not statistically significant."( Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Lee, YH; Song, GG, 2020
)
0.56
" Two subjects (one in the normal group and one in the mildly impaired group) each experienced a treatment-emergent adverse event (TEAE)."( Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Furihata, K; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sekino, H; Shibata, M; Shibata, T; Urae, A, 2020
)
0.56
" Treatment-emergent adverse events (TEAEs) were reported in 757/843 (89."( Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Chen, YH; Izutsu, H; Kaneko, Y; Kawakami, A; Nakashima, Y; Rokuda, M; Shiomi, T; Song, YW; Takeuchi, T; Tanaka, S; Tanaka, Y; Ushijima, S; Yamada, E, 2020
)
0.56
" Pharmacokinetic and pharmacodynamic parameters were assessed, and adverse events (AEs) monitored throughout."( Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Hatta, T; Kaneko, Y; Nishimura, T; Oda, K; Saito, M; Shibata, M; Toyoshima, J, 2020
)
0.56
" This study aimed to evaluate the impact of early adverse events (AEs) requiring sorafenib dose adjustment on survival outcomes of patients with advanced HCC."( Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
Hopkins, AM; Rowland, A; Ruanglertboon, W; Sorich, MJ, 2020
)
0.56
" No significant differences were observed in the incidence of serious adverse events after treatment with tofacitinib+MTX, peficitinib+MTX, adalimumab+MTX, or placebo+MTX."( Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee, YH; Song, GG, 2020
)
0.56
"In patients with RA with an inadequate response to DMARDs, tofacitinib 10 mg+MTX and peficitinib 150 mg+MTX were the most efficacious interventions and were not associated with a significant risk of serious adverse events."( Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee, YH; Song, GG, 2020
)
0.56
" However, the number of patients who experienced serious adverse events did not differ significantly between the JAK inhibitors, except for tofacitinib 5 mg, and placebo."( Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Gyu Song, G; Ho Lee, Y, 2020
)
0.56
" Although it is one of the most common fungicides in the aquatic environment, the potential adverse effects of boscalid on freshwater invertebrates still remain unclear."( Evaluation of boscalid toxicity on Daphnia magna by using antioxidant enzyme activities, the expression of genes related to antioxidant and detoxification systems, and life-history parameters.
Aksakal, FI, 2020
)
0.56
" Nevertheless, clinical utilization of CP is limited due to considerable adverse effects and toxicities."( Nicotinamide attenuates cyclophosphamide-induced hepatotoxicity in SD rats by reducing oxidative stress and apoptosis.
Jena, G; Khan, S; Patwa, J, 2020
)
0.56
" In contrast to a previously published safety assessment using a different synthetic NR (NIAGEN), whose no-observed-adverse-effect-level (NOAEL) was reported to be 300 mg/kg/d, there were no adverse changes in clinical pathology parameters and no notable macroscopic or microscopic findings or treatment-related effects at similar doses."( Safety Assessment of High-Purity, Synthetic Nicotinamide Riboside (NR-E) in a 90-Day Repeated Dose Oral Toxicity Study, With a 28-Day Recovery Arm.
Chen, J; Dellinger, RW; Guarente, L; Holmes, HE; Marinescu, AG; Mendes, O; Morris, M,
)
0.13
" Given HQ's side effects and potential controversy over its long-term use from prior animal studies, there is a consumer demand for non-HQ topical formulations that provide similar efficacy, but with a reduced adverse reaction profile to HQ."( Evaluating the Safety and Efficacy of a Topical Formulation Containing Epidermal Growth Factor, Tranexamic Acid, Vitamin C, Arbutin, Niacinamide and Other Ingredients as Hydroquinone 4% Alternatives to Improve Hyperpigmentation: A Prospective, Randomized,
Kalasho, BD; Minokadeh, A; Pletzer, V; Shemirani, NL; Waldman, AR; Zhang-Nunes, S; Zoumalan, CI; Zoumalan, RA,
)
0.34
" Incidence rates per 100 patient-years (PY) of adverse events (AEs) of special interest were calculated."( A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Fukuda, M; Izutsu, H; Kaneko, Y; Kato, D; Rokuda, M; Takeuchi, T; Tanaka, Y, 2021
)
0.62
" Several transformation products of boscalid and fenbuconazole were estimated to be significantly more orally toxic than their parent residues."( Hazard assessment using an in-silico toxicity assessment of the transformation products of boscalid, pyraclostrobin, fenbuconazole and glyphosate generated by exposure to an advanced oxidative process.
Prosser, RS; Skanes, B; Warriner, K, 2021
)
0.62
"Treatment-related adverse events included fatigue and nausea in the monotherapy arm (13% for each), hypothyroidism (30%) in the ramucirumab arm, diarrhea (54%) in the abemaciclib arm, and nausea (25%) in the merestinib arm."( Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Bang, YJ; Bendell, J; Carlsen, M; Chow, KH; Chung, HC; de Miguel, MJ; Gandhi, L; Italiano, A; Lin, CC; Patnaik, A; Schmidt, S; Su, WC; Szpurka, AM; Vangerow, B; Xu, X; Yap, TA; Yu, D; Zhao, Y, 2021
)
0.62
"The leaching rates, dissipation dynamics, and residue levels of flonicamid and its metabolites in tea leaves during processing and transferring were investigated to validate the safe risk in tea and transfer behavior using high performance liquid chromatography-tandem mass spectrometry with a convenient pretreatment method."( Dissipation, Processing, Leaching, and Safety Evaluation of Flonicamid and Its Metabolites in Tea.
Chen, Y; Hu, D; Liu, X; Lu, P; Yang, Y; Zhang, Q; Zhang, S, 2020
)
0.56
"The risk of long-term and short-term dietary intake of flonicamid was safe in tea infusions with the risk quotient (RQ) values <1 for the Chinese consumer."( Dissipation, Processing, Leaching, and Safety Evaluation of Flonicamid and Its Metabolites in Tea.
Chen, Y; Hu, D; Liu, X; Lu, P; Yang, Y; Zhang, Q; Zhang, S, 2020
)
0.56
" There were no significant differences between Groups A and B with respect to the incidence of adverse events or treatment discontinuation because of toxicity."( Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
Braghiroli, MI; da Fonseca, LG; Hoff, PM; Marta, GN; Moura, F; Sabbaga, J, 2021
)
0.62
" Overall survival, recurrence-free survival, and recurrence rates were analyzed, and adverse events were reviewed."( A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L, 2021
)
0.62
" The primary adverse events were hand-foot skin reaction, fatigue, and diarrhea of mild-to-moderate severity, whereas grade 4 adverse events were rare (< 1%)."( A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L, 2021
)
0.62
" Incidence rates per 100 patient-years of adverse events of special interest were calculated, and Cox proportional hazard analysis was conducted."( Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.
Fukuda, M; Kaneko, Y; Kato, D; Miyatake, D; Takeuchi, T; Tanaka, Y, 2022
)
0.72
" During the observation period, no patient had any serious adverse events or side effects associated with taking the drug."( [The result of prospective randomized study CITADEL - the efficacy and safety of drug cytoflavin in postcovid rehabilitation].
Bairova, KI; Petrikeeva, AE; Putilina, MV; Shabalina, NI; Teplova, NV, 2021
)
0.62
" Secondary outcomes were basal cell carcinomas (BCCs); cSCCs; actinic keratoses; melanomas; digestive, cutaneous, and biochemical adverse effects (AEs)."( Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
Fortin, PR; Mainville, L; Smilga, AS,
)
0.13
"Cutaneous immune-related adverse events (irAEs) occur in more than one-third of patients treated with immune checkpoint inhibitors; they are often the first clinical manifestation, although they may occur months after initiation of therapy."( Cutaneous immune-related adverse events and photodamaged skin in patients with metastatic melanoma: could nicotinamide be useful?
Colombo, J; Covarelli, P; De Giorgi, V; Doni, L; Silvestri, F; Stanganelli, I; Trane, L; Venturi, F; Zuccaro, B, 2022
)
0.72
" Adverse events (AEs) and serious AEs were reported in 91."( Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T, 2022
)
0.72
" The incidence of treatment-related adverse events (AEs) was also assessed."( The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Guo, L; Jiang, X; Wang, L; Zhang, L, 2022
)
0.72
" Objective response rate (ORR), PFS, disease control rate (DCR) and OS were calculated to assess the antitumor response and the treatment-related adverse events to the safety."( Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM, 2022
)
0.72
" Grade 3 or more treatment-related adverse events (TRAEs) occurred significantly less in patients in the RT + PD1 group than the TACE plus sorafenib group (29."( Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM, 2022
)
0.72
" No other adverse effects of treatment were reported by patients during the study period."( Evaluation of safety and efficacy of topical 4% nicotinamide in treatment of psoriasis; among a representative sample of Egyptians (an analytical observational study).
El-Khalawany, M; Elsheikh, M; Kadah, AS; Nouh, AH; Said, M, 2022
)
0.72
" In this study we sought to understand the temporal characteristics of treatment related adverse events (TRAEs) and frequency and timing of the dose modifications."( Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB, 2022
)
0.72
" Thus, this study aimed to observe the potential cardiovascular-related side effect after co-exposure to ASC and PON using zebrafish as an animal model."( Investigating Potential Cardiovascular Toxicity of Two Anti-Leukemia Drugs of Asciminib and Ponatinib in Zebrafish Embryos.
Alos, HC; Audira, G; Aventurado, CA; Hsiao, CD; Lai, YH; Lim, KH; Lin, HC; Roldan, MJM; Saputra, F; Tsai, GJ; Vasquez, RD, 2022
)
0.72
"Lenvatinib is safe and effective for advanced HCC in patients with Child-Pugh A, even with high tumor burden."( A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Atsukawa, M; Azemoto, R; Haga, Y; Ikeda, M; Inaba, Y; Inoue, M; Ito, K; Itobayashi, E; Itoh, Y; Itokawa, N; Kanogawa, N; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Maruta, S; Moriguchi, M; Morimoto, N; Nakamoto, S; Nakamura, K; Nakamura, M; Ogasawara, S; Okabe, S; Okubo, T; Ooka, Y; Seko, Y; Shiko, Y; Suzuki, E; Takatsuka, H; Watanabe, S, 2023
)
0.91
" The secondary endpoint was the occurrence of treatment-related adverse events in the two groups of patients."( Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
Liang, B; Lu, H; Xia, X; Zheng, C, 2023
)
0.91
" The primary outcome was safety, defined as the frequency of moderate and severe adverse events."( NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Af Geijerstam, SA; Berven, H; Dölle, C; Haugarvoll, K; Kverneng, S; Sheard, E; Skeie, GO; Søgnen, M; Tzoulis, C, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" On average, the Cmax then is approximately 300 ng/ml, which is achieved rapidly within 30 min after drug intake."( Pharmacokinetic profile of nicorandil in humans: an overview.
Frydman, A, 1992
)
0.28
" No significant difference was noted in any of the other pharmacokinetic parameters examined in the three groups, not even on comparing values obtained on the first and last days of treatment."( Pharmacokinetics of nicorandil in patients with normal and impaired renal function.
Molinaro, M; Regazzi, MB; Rondanelli, R; Salvadeo, A; Sartirana, E; Segagni, S; Villa, G, 1992
)
0.28
" The utility of the method is demonstrated in a dog pharmacokinetic study in which a 5-mg intravenous dose was compared to a 10-mg oral solution dose in six beagle dogs."( Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs.
Lewis, RC; Schwende, FJ, 1990
)
0.28
" Pharmacokinetic parameters were calculated model-independent."( Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man.
Cautreels, W; Escourrou, J; Garriot, P; Mery, D; Necciari, J, 1985
)
0.27
" The aim was to establish the pharmacokinetic profiles and their reproducibility during repeated administration, the maximum tolerated dose with fractionated radiotherapy, whether such a dose achieves sufficiently high plasma levels for radiosensitization, the optimal time interval between nicotinamide and irradiation, and toxic side effects."( Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity.
Dennis, MF; Hall, DW; Hoskin, PJ; Rojas, A; Saunders, MI; Stratford, MR, 1995
)
0.29
"The pharmacokinetic properties of nicotinamide and its tolerance were studied in seven patients affected by glioblastoma multiforme and treated with two fractions per day of radiation therapy."( Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme.
Caciagli, PG; Cartei, F; Danesi, R; Ducci, F; Fatigante, L; Laddaga, M; Tacca, M, 1994
)
0.29
" Nicorandil plasma concentrations increased disproportionately with dose, but nicorandil elimination obeyed apparent monoexponential kinetics, and the apparent half-life (t1/2) increased with dose."( A modified product inhibition model describes the nonlinear pharmacokinetics of nicorandil in rats.
Bachert, EL; Chung, SJ; Fung, HL; Li, ZW; Zhao, L, 1994
)
0.29
" The elimination half-life and AUC were also found to increase with drug dose, although these increases were non-linear."( Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy.
Dennis, IF; Honess, DJ; Horsman, MR; Høyer, M; Overgaard, J, 1993
)
0.29
" Neither the peak concentration nor the area under the concentration/time curve (AUC) of nicotinamide, nor the main metabolites of nicotinamide appeared to correlate with the incidence of toxicity."( Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy.
Dennis, MF; Hodgkiss, RJ; Hoskin, PJ; Rojas, A; Saunders, MI; Stratford, MR, 1996
)
0.29
"Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer."( Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998
)
0.3
" The peak plasma concentration was achieved at 1 h in only 54% of the pharmacokinetic profiles, but at this time 92% of the profiles had already exceeded the target concentration of 700 nmol/ml, the level required in the mouse for tumour radiosensitization."( Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998
)
0.3
" Blood samples were obtained over a 6-week period to assess pharmacokinetics, immunogenicity, and the pharmacodynamic effects on leukocytes and TNF-alpha."( Product equivalence study comparing the tolerability, pharmacokinetics, and pharmacodynamics of various human immunoglobulin-G formulations.
Andresen, I; Bolli, R; Kovarik, JM; Spycher, M, 2000
)
0.31
" time and pharmacokinetic parameters of tryptamide were calculated."( Pharmacokinetics of tryptamide following oral and intraperitoneal administration in rats.
Szumiło, H, 1990
)
0.28
" Thus, this method has been validated and can be applied for the drug monitoring or pharmacokinetic studies of BAY 43-9006 in small volumes of serum samples."( Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
Afify, S; Högger, P; Rapp, UR, 2004
)
0.32
" Pharmacokinetic sampling was performed in all patients; preliminary tumor response was also assessed."( Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D, 2005
)
0.33
" Pharmacokinetic profiles of BAY 43-9006 in plasma were determined during the first treatment cycle."( Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D, 2005
)
0.33
" Consistent with its observed half-life of approximately 27 h, BAY 43-9, 006 accumulated on multiple dosing."( Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Cihon, F; Hirte, HW; Hotte, SJ; Lathia, C; Moore, M; Oza, A; Petrenciuc, O; Schwartz, B; Siu, L, 2005
)
0.33
" This phase I, open-label, nonrandomized, noncontrolled, single-arm, dose escalation study was done to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, effect on biomarkers, and tumor response with BAY 43-9006 in 19 patients with advanced, refractory solid tumors."( Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D, 2005
)
0.33
" Pharmacokinetic analysis showed early absorption followed by delayed secondary peaks and slow terminal elimination."( Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D, 2005
)
0.33
"We previously reported a flow cytometry technique to monitor pharmacodynamic effects of the raf kinase inhibitor BAY 43-9006 based on the ability of phorbol ester (PMA) to phosphorylate extracellular-regulated kinase (ERK) in peripheral blood (Chow et al."( Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Chow, S; Hedley, D; Tong, FK, 2006
)
0.33
" In this article, we describe the application of flow cytometry to the pharmacodynamic monitoring of molecular-targeted agents in leukemia patients."( Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
Chow, S; Goolsby, C; Hedley, DW; Shankey, TV, 2008
)
0.35
" Patients were randomized to receive a single oral dose of ketoconazole 400 mg either on day 8 (Sequence 1; n = 7) or day 15 (Sequence 2; n = 7), while pharmacokinetic samples were collected."( Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Chen, L; Heath, EI; Ingram, M; Lorusso, P; Malburg, L; McGreivy, J; Melara, R; Pilat, MJ; Sun, YN; Wiezorek, J; Yan, L, 2008
)
0.35
" We conducted a randomized trial to investigate dynamic contrast magnetic resonance imaging (DCE-MRI) as a pharmacodynamic biomarker."( Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C, 2008
)
0.35
"IAUC(90) and K(trans) are pharmacodynamic biomarkers for sorafenib, but variability is high and magnitude of effect is less than previously reported."( Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C, 2008
)
0.35
" In conclusion, treatment with motesanib plus gemcitabine was well tolerated, with adverse event and pharmacokinetic profiles similar to that observed in monotherapy studies."( Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
Lipton, L; McCoy, S; McGreivy, J; Price, TJ; Rosenthal, MA; Sun, YN, 2008
)
0.35
" Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment, in children, additional interactions studies and studies on the relative or absolute bioavailability."( Clinical pharmacokinetics of tyrosine kinase inhibitors.
Gelderblom, H; Guchelaar, HJ; van Erp, NP, 2009
)
0.35
" The results of this study also showed that this combination therapy had encouraging antitumor activity and was not associated with relevant pharmacokinetic interaction in Japanese NSCLC patients."( Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S, 2010
)
0.36
"The aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic and pharmacodynamic markers with clinical outcome."( Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ, 2010
)
0.36
" Clinical and pharmacodynamic activity was observed in kidney cancer and melanoma."( Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN, 2010
)
0.36
" Dose recommendations for these patients are not available because pharmacokinetic data are missing."( Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Bode-Böger, SM; Luley, C; Martens-Lobenhoffer, J; Reiche, I; Tröger, U; Westphal, S, 2011
)
0.37
"Ten dialysis patients and eight patients with CKD were enrolled in a prospective, three-period, open-label pharmacokinetic study."( Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Bode-Böger, SM; Luley, C; Martens-Lobenhoffer, J; Reiche, I; Tröger, U; Westphal, S, 2011
)
0.37
" These compounds display optimal pharmacokinetic properties that warrant further in vivo investigations."( Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Davies, L; Hedley, D; Kirk, R; Lopes, F; Manne, HA; Marais, R; Ménard, D; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Ogilvie, LM; Preece, N; Springer, CJ; Suijkerbuijk, BM; Whittaker, S; Zambon, A, 2010
)
0.36
" This report discusses a clinically relevant pharmacokinetic CYP3A4 drug-drug interaction between sorafenib and felodipine in an 80-year-old Caucasian patient with HCC."( Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M, 2011
)
0.37
" The current phase I study investigates the effects of sorafenib on the pharmacokinetic (PK) profile of dacarbazine and its metabolite 5-amino-imidazole-4-carboxamide (AIC)."( Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011
)
0.37
" The method was sensitive, specific, precise, accurate and suitable for bioequivalence and pharmacokinetic studies."( Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Damaramadugu, R; Inamadugu, JK; Mullangi, R; Ponneri, V, 2010
)
0.36
" Motesanib concentrations were fitted to a 2-compartment population pharmacokinetic model."( Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Bruno, R; Claret, L; Kuchimanchi, M; Lu, JF; Melara, R; Sun, YN; Sutjandra, L, 2010
)
0.36
" Based on the overall toxicity profile and pharmacokinetic parameters, the recommended phase 2 doses were therefore sorafenib 400 mg bid and capecitabine 850 mg/m(2) bid, as scheduled above."( Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011
)
0.37
" Pharmacokinetic analyses were performed on day 1 without sorafenib and day 28 after steady-state sorafenib exposure; sorafenib pharmacokinetics were evaluated on day 28."( Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L, 2011
)
0.37
"We investigated the safety and feasibility of sorafenib in patients with end-stage renal disease undergoing hemodialysis by examining the influence of pharmacokinetic parameters to their benefit and also the occurrence of drug-related adverse events of sorafenib."( Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K, 2011
)
0.37
" The pharmacokinetic study was performed after a steady state was reached with 200 mg twice daily in six patients."( Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K, 2011
)
0.37
" In the pharmacokinetic study, the geometric mean of maximum concentration and area under the curve from 0 to 10 h of plasma concentration were similar on the day of hemodialysis and the day off hemodialysis."( Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K, 2011
)
0.37
" The validated method was successfully applied to a pharmacokinetic study after per os administration of nicorandil in rats."( Simultaneous quantitation of nicorandil and its denitrated metabolite in plasma by LC-MS/MS: application for a pharmacokinetic study.
Araujo, DP; Bastos, LF; César, IC; Coelho, Mde M; de Fátima, Â; Godin, AM; Guidine, PA; Pianetti, GA, 2011
)
0.37
" Pharmacokinetic analyses suggest sorafenib and metabolite exposure correlate with OS and DLTs."( Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M, 2013
)
0.39
"Sorafenib displays major interpatient pharmacokinetic variability."( Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Billemont, B; Blanchet, B; Boudou-Rouquette, P; Cabanes, L; Coriat, R; Franck, N; Goldwasser, F; Mir, O; Ropert, S; Tod, M, 2012
)
0.38
"We analyzed the severity and kinetics of sorafenib-induced toxicities in unselected consecutive patients with cancer, as well as their relationship with biological, clinical, and pharmacokinetic parameters."( Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Billemont, B; Blanchet, B; Boudou-Rouquette, P; Cabanes, L; Coriat, R; Franck, N; Goldwasser, F; Mir, O; Ropert, S; Tod, M, 2012
)
0.38
"Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib."( Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Avril, MF; Billemont, B; Blanchet, B; Coriat, R; Franck, N; Goldwasser, F; Lebbe, C; Mir, O; Pécuchet, N; Tod, M; Viguier, M, 2012
)
0.38
" The pharmacokinetic processes of sorafenib solution and lyophilized injection of S-SLN in vivo were in accordance with the two-compartment and one-compartment models, respectively."( Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles.
Yan, SJ; Zhang, FM; Zhang, H, 2012
)
0.38
" Monitoring long-term toxicities such as effects on growth and obtaining additional pharmacokinetic data were of importance due to the young age and long duration of therapy seen in previous phase I trials in children with NF1."( Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Balis, FM; Choyke, PL; Dombi, E; Fox, E; Jayaprakash, N; Kim, A; Korf, B; Martin, S; Muradyan, N; Reddy, A; Tepas, K; Turkbey, B; Widemann, BC; Wolters, P, 2013
)
0.39
" Erlotinib and sorafenib have significant pharmacokinetic interactions that may negatively impact the efficacy of the combination regimen."( NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013
)
0.39
" This study assessed the pharmacokinetics (PK) of everolimus and sorafenib alone and in combination in plasma and tissues, developed physiologically based pharmacokinetic (PBPK) models in mice, and assessed the possibility of PK drug interactions."( Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Fetterly, GJ; Hylander, BH; Jusko, WJ; Ma, WW; Pawaskar, DK; Repasky, EA; Straubinger, RM, 2013
)
0.39
" These studies provide the basis for pharmacodynamic evaluation of these drugs in patient-derived primary pancreatic adenocarcinomas explants."( Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Fetterly, GJ; Hylander, BH; Jusko, WJ; Ma, WW; Pawaskar, DK; Repasky, EA; Straubinger, RM, 2013
)
0.39
" However, there is little information about the pharmacokinetic interaction of sorafenib."( Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013
)
0.39
" Recently developed pharmacokinetic models could explain this phenomenon."( Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E, 2013
)
0.39
"The purpose of this study is to investigate the effect of exenatide on glycemic control following two administration routes in a streptozotocin/nicotinamide (STZ/NA)-induced diabetic rat model, and to develop a pharmacodynamic model to better understand the disease progression and the action of exenatide in this experimental system."( Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats.
Chen, T; Kagan, L; Mager, DE, 2013
)
0.39
" In this paper, the pharmacokinetic characteristics (absorption, distribution, metabolism and excretion) and drug-drug interactions of the approved TKIs are reviewed."( [Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Ding, JF; Zhong, DF, 2013
)
0.39
"Coamorphous ATC-NIC has improved physicochemical and pharmacokinetic properties as compared to ATC."( Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.
Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A, 2013
)
0.39
" Pharmacokinetic parameters of nicorandil and its isomers, as well as the plasma concentrations of the corresponding denitrated metabolites and also nicotinamide and nitrite were determined."( Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
Almeida, MO; Araujo, DP; César, IC; Coelho, MM; de Fátima, A; Dutra, MM; Godin, AM; Machado, RR; Menezes, RR; Oliveira, FC; Pianetti, GA; Santos, DA; Santos, JR, 2014
)
0.4
"To define the safety, efficacy, and pharmacogenetic and pharmacodynamic effects of sorafenib with gemcitabine-based chemoradiotherapy (CRT) in locally advanced pancreatic cancer."( Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ, 2014
)
0.4
" Pharmacodynamic analysis included serum VEGF and soluble VEGF receptor-1 and VEGF receptor-2 performed at baseline, C1D15 and C2D1."( Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J, 2014
)
0.4
" Plasma levels of refametinib, refametinib metabolite M17, and sorafenib were measured for pharmacokinetic assessments."( A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT, 2016
)
0.43
" Refametinib was readily absorbed following oral administration (plasma half-life of ∼16 hours at the MTD), and pharmacokinetic parameters displayed near-dose proportionality, with less than 2-fold accumulation after multiple dosing."( A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT, 2016
)
0.43
" Population pharmacokinetic (POPPK) modeling of motesanib and M4, an active metabolite, was performed to assess sources of variability in cancer patients."( Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients.
Gosselin, NH; Hsu, CP; Lu, JF; Mouksassi, MS, 2015
)
0.42
"Accompanied by significant improvements of modeling techniques and computational methods in medical sciences, the last thirty years saw the flourishing of pharmacokinetic models for applications in the pharmacometric field."( Innovations and Improvements in Pharmacokinetic Models Based on Physiology.
Abbiati, RA; Manca, D, 2017
)
0.46
" Four major points are detailed: (i) the mathematical formulation of the model, which allows modulating its complexity as a function of the administration route and active principle; (ii) a dedicated parameter of the PBPK model quantifies the drugprotein binding, which affects the active principle distribution; (iii) the gall bladder compartment and the bile enterohepatic circulation process; (iv) the coupling of the pharmacokinetic and pharmacodynamic models to produce an overall understanding of the drug effects on mammalian body."( Innovations and Improvements in Pharmacokinetic Models Based on Physiology.
Abbiati, RA; Manca, D, 2017
)
0.46
" The effects of verapamil, an inhibitor of the efflux pump P-gp, on the pharmacokinetic profile of peficitinib were assessed in this open-label, single-center, single-sequence, crossover drug-interaction study."( The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Fisniku, O; Garg, JP; Han, D; Howieson, C; Keirns, J; Wojtkowski, T; Zhu, T, 2017
)
0.46
" The aim of this study is to investigate the pharmacokinetic mechanism of drug-drug interactions of sorafenib including interacting with hepatoprotective formulation, Long-Dan-Xie-Gan-Tang formulation (LDXGT) and with two cytochrome P450 3A4 (CYP3A4) inhibitors, grapefruit juice and ketoconazole."( Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.
Cheng, YY; Ting, CT; Tsai, TH, 2017
)
0.46
" Blood samples were collected prior to administration and up to 72 h post-dose for pharmacokinetic assessment."( Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
Furihata, K; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sekino, H; Shibata, M; Shibata, T; Urae, A, 2020
)
0.56
" The impact of hepatic impairment on the peficitinib pharmacokinetic (PK) and safety profile was investigated in non-RA subjects (n = 24) in an open-label, parallel-group, multicenter comparative study in Japan."( Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Furihata, K; Inoue, K; Ito, T; Kaneko, Y; Katashima, M; Miyatake, D; Nishimura, T; Oda, K; Sakaki, M; Shibata, T; Toyoshima, J; Uchida, N; Urae, A, 2020
)
0.56
" Pharmacokinetic and pharmacodynamic parameters were assessed, and adverse events (AEs) monitored throughout."( Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
Hatta, T; Kaneko, Y; Nishimura, T; Oda, K; Saito, M; Shibata, M; Toyoshima, J, 2020
)
0.56
" Samples for pharmacokinetic analysis were collected before dose and ≤72 hours after dose."( The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
Kambayashi, A; Kaneko, Y; Kiyota, T; Nishimura, T; Oda, K; Shibata, M; Toyoshima, J, 2021
)
0.62
" Trigonelline and N-methylpyridinium absorption curves and 24-h urinary excretion reflect the daily consumption of different servings of coffee or CBPCC, showing also significant differences in main pharmacokinetic parameters."( Absorption, Pharmacokinetics, and Urinary Excretion of Pyridines After Consumption of Coffee and Cocoa-Based Products Containing Coffee in a Repeated Dose, Crossover Human Intervention Study.
Antonini, M; Bonadonna, R; Bresciani, L; Brighenti, F; Dei Cas, A; Del Rio, D; Martini, D; Mena, P; Rosi, A; Tassotti, M, 2020
)
0.56
" Pharmacokinetic values peaked at day-7 and progressively declined until day-60."( Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Brunet, M; Corominas, J; da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Millán, O; Reig, M; Samper, E; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F, 2020
)
0.56
" This report describes the findings from 2 phase 1 studies assessing the pharmacokinetic (PK) profile of a single dose of asciminib (40 mg) in individuals with impaired renal function (based on absolute glomerular filtration rate; NCT03605277) or impaired hepatic function (based on Child-Pugh classification; NCT02857868)."( Pharmacokinetics of Asciminib in Individuals With Hepatic or Renal Impairment.
Aimone, P; Allepuz, A; Hoch, M; Hourcade-Potelleret, F; Quinlan, M; Sato, M; Sengupta, T; Zack, J, 2021
)
0.62
" These results demonstrate that RJX-P and RJX-B are bioequivalent relative to their pharmacodynamic effects on tissue SOD and ascorbic acid levels."( Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX).
Orhan, C; Ozercan, IH; Powell, J; Sahin, E; Sahin, K; Uckun, FM; Volk, M, 2021
)
0.62
" This study aimed to describe pharmacokinetic (PK) properties of asciminib and to identify clinically relevant covariates impacting its exposure."( Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Combes, FP; Ho, YY; Hoch, M; Li, YF; Lorenzo, S; Sy, SKB, 2022
)
0.72

Compound-Compound Interactions

We evaluated the effect of topical post-laser treatment with adipocyte-derived stem cell-containing medium (ADSC-CM) in combination with niacinamide through a double-blind, randomized, vehicle-controlled study.

ExcerptReferenceRelevance
"On a model of transplantable albeolar-mucous RS cancer it is shown that hydrocortisone, desoxycorticosteonre-acetate (DOCA), cyanocobalamine used in combination with folic and nicotinic acids does not lower the cytostatic activity of thiophosphamide and in a number cases even potentiates its action."( [Effect of corticosteroids, vitamins and their combination with thiophosphamide on the indicators of carbohydrate and electrolyte metabolism of animals with experimental tumors].
Butov, VI; Dunaev, VV,
)
0.13
"Minimum bactericidal concentrations of salicylate, nicotinaldehyde singly, and in combination with nicotinic acid, or nicotinamide were determined for Staphylococcus aureus 79 and 80, and Escherichia coli 95, at inocula of 10(7)--10(2)."( The sensitivity of Staphylococcus aureus 79 and 80, and Escherichia coli 95 to sodium salicylate, nicotinaldehyde singly, and in combination with nicotinic acid or nicotinamide.
Kaplan, D, 1979
)
0.26
" The purpose of this study was to examine the effects of PENTO alone or in combination with NA (PENTO + NA) on the oxygenation and radio-response of FSaII murine fibrosarcomas of mice."( Increases in tumor response by pentoxifylline alone or in combination with nicotinamide.
Kim, JH; Lee, I; Levitt, SH; Song, CW, 1992
)
0.28
" Administration of nicotinamide in combination with ziksorin or phenobarbital enhanced the enzyme-inducing effects of the latter."( [Effect of nicotinic acid, nicotinamide and its combination with ziksorin and phenobarbital on the UDP glucuronyl transferase activity of the hepatic endoplasmic reticulum in the rat].
Bushma, MI; Legon'kova, LF; Lukienko, PI,
)
0.13
"Between March 1991 and October 1993, 49 patients with inoperable head and neck carcinoma were randomly assigned to receive either radiation therapy alone (group A) or radiotherapy combined with simultaneous application of Mitomycin C and Bleomycin (group B)."( Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report.
Budihna, M; Furlan, L; Lesnicar, H; Rudolf, Z; Smid, L; Soba, E; Zakotnik, B; Zargi, M, 1995
)
0.29
" In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)."( Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas.
de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995
)
0.29
" PTX alone or in combination with NA is potentially useful to radiosensitize tumours."( Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline.
Lee, I; Levitt, SH; Song, CW, 1993
)
0.29
" The purpose in this paper is to investigate the possibility of selective radiosensitization of tumors by reduced dose rate irradiation in combination with carbogen inhalation."( Middle dose rate irradiation in combination with carbogen inhalation selectively and more markedly increases the responses of SCCVII tumors.
Akaboshi, M; Akuta, K; Masunaga, S; Ono, K, 1994
)
0.29
"0 Gy/min) in combination with carbogen inhalation."( Middle dose rate irradiation in combination with carbogen inhalation selectively and more markedly increases the responses of SCCVII tumors.
Akaboshi, M; Akuta, K; Masunaga, S; Ono, K, 1994
)
0.29
" The method is based on solid phase extraction in combination with ion-paired reversed phase high performance liquid chromatography."( Simultaneous determination of nicotinic acid and its two metabolites in human plasma using solid-phase extraction in combination with high performance liquid chromatography.
Miyauchi, Y; Nakamura, T; Sano, N, 1993
)
0.29
"15 when radiation was combined with carbogen and/or nicotinamide."( Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice.
Buchegger, F; Coucke, PA; Mirimanoff, RO; Sun, LQ, 2001
)
0.31
" A next group of 87 patients received 60 mg/kg nicotinamide in combination with domperidone."( Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
Bussink, J; Folkes, LK; Kaanders, JH; Stratford, MR; van der Kogel, AJ, 2002
)
0.31
" If nicotinamide was given in combination with domperidone, 86% of the patients continued the nicotinamide medication until the end of the treatment period."( Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
Bussink, J; Folkes, LK; Kaanders, JH; Stratford, MR; van der Kogel, AJ, 2002
)
0.31
" In phase I studies, sorafenib demonstrated single-agent activity in patients with advanced solid tumors and was successfully combined with oxaliplatin in preclinical studies."( Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Brendel, E; Christensen, O; Henning, BF; Hilger, RA; Hofstra, E; Kupsch, P; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R; Wiesemann, K, 2005
)
0.33
"Continuous oral sorafenib 400 mg twice daily was safely combined with oxaliplatin without detectable drug interactions and showed preliminary antitumor activity in this phase I study."( Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Brendel, E; Christensen, O; Henning, BF; Hilger, RA; Hofstra, E; Kupsch, P; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R; Wiesemann, K, 2005
)
0.33
" Sorafenib demonstrated single-agent activity in Phase I studies, and was tolerated and inhibited tumor growth in combination with doxorubicin in preclinical studies."( Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Brendel, E; Christensen, O; Flashar, C; Grubert, M; Henning, BF; Hilger, RA; Kupsch, P; Ludwig, M; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R, 2006
)
0.33
"Intravenous (iv) vinorelbine and interperitoneal (ip) cisplatin were administered intermittently (q4d x 3) in combination with sorafenib administered orally (po) once daily for 9 days starting on the same day as the standard agent."( Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X, 2007
)
0.34
" As discussed in this mini-review, the clinical potency of sorafenib as a single agent or in combination with other antitumor agents is being evaluated in several ongoing clinical trials in patients with renal carcinoma."( Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
Bukowski, RM; Reddy, GK, 2006
)
0.33
" In this article, we examined the anti-leukemic effects of two distinct histone deacetylase (HDAC1 and Sir2) inhibitors, sodium phenyl butyrate (PB) and vitamin B3, respectively, on human promyelocytic leukemia cells HL-60, using HDACIs alone and in combination with all trans retinoic acid (RA)."( Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells.
Magnusson, KE; Merzvinskyte, R; Navakauskiene, R; Savickiene, J; Treigyte, G, 2006
)
0.33
" There were no drug-drug interactions and the recommended dose for future studies is sorafenib 400 mg twice daily plus IFN 9 MIU."( Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E, 2007
)
0.34
"Clinical trials showing longer survival when chemotherapy is combined with antiangiogenic agents (AAs) have led to growing interest in designing combined modality protocols that exploit abnormalities in tumor vasculature."( Design of clinical trials of radiation combined with antiangiogenic therapy.
Senan, S; Smit, EF, 2007
)
0.34
" Potential drug-drug interactions and the relationship between pharmacokinetics and toxicity were also assessed."( Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C, 2007
)
0.34
"Sorafenib combined with gefitinib is well tolerated, with promising efficacy in patients with advanced non-small cell lung cancer."( Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C, 2007
)
0.34
"To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinoma cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or the novel anticancer agents sorafenib or bortezomib."( Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007
)
0.34
" Furthermore, additive anti-neoplastic effects were observed when MS-275 treatment was combined with gemcitabine or doxorubicin, while combination with the multi-kinase inhibitor sorafenib or the proteasome inhibitor bortezomib resulted in overadditive anti-neoplastic effects."( Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007
)
0.34
"The growth of human cholangiocarcinoma cells can be potently inhibited by MS-275 alone or in combination with conventional cytostatic drugs or new, targeted anticancer agents."( Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007
)
0.34
" Sorafenib has demonstrated preclinical and clinical activity against several tumor types, as a monotherapy and in combination with other anti-cancer agents."( Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Awada, A; Takimoto, CH, 2008
)
0.35
"This review summarizes the safety, pharmacokinetics, and anti-tumor activity of sorafenib combined with other targeted agents or cytotoxics from a series of Phase I/II trials in approximately 600 patients with advanced solid tumors."( Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Awada, A; Takimoto, CH, 2008
)
0.35
"Sorafenib in combination with other agents was generally well tolerated, and most adverse events were mild to moderate in severity."( Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Awada, A; Takimoto, CH, 2008
)
0.35
"To investigate the inhibitory effect of sorafenib in combination with arsenic trioxide (As2O3) on hepatocellular carcinoma cells and explore the mechanisms of the synergetic antitumor effects of the two agents."( [Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Cui, YZ; Luo, RC; Wu, J; Zhang, H, 2008
)
0.35
"This study evaluated the safety, maximum tolerated dose, pharmacokinetics, and antitumor activity of sorafenib, a multikinase inhibitor, combined with paclitaxel and carboplatin in patients with solid tumors."( A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Albertini, MR; Brose, MS; Elder, D; Flaherty, KT; Hingorani, SR; Jacobetz, MA; Lathia, C; Liu, G; O'Dwyer, PJ; Petrenciuc, O; Redlinger, M; Schiller, J; Schuchter, LM; Tuveson, DA; Van Belle, PA; Weber, BL; Xia, C, 2008
)
0.35
" This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo."( Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008
)
0.35
"Xenograft of a highly metastatic human HCC tumor (LCI-D20) was used to evaluate primary tumor growth and lung metastasis after treatment with rapamycin alone or in combination with sorafenib."( Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008
)
0.35
"Rapamycin, alone and in combination with sorafenib, strongly inhibited primary tumor growth and lung metastases in LCI-D20 model."( Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J, 2008
)
0.35
"The aim of this open-label phase 1b study was to assess the safety and pharmacokinetics of motesanib in combination with gemcitabine in patients with advanced solid tumours."( Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
Lipton, L; McCoy, S; McGreivy, J; Price, TJ; Rosenthal, MA; Sun, YN, 2008
)
0.35
" The purpose of this study was to evaluate the antitumor efficacy of IL-2 combined with sorafenib in three different murine renal cancer models using Renca cells."( Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T, 2009
)
0.35
"When rhIL-2 was combined with sorafenib, the antitumor efficacy was significantly augmented in comparison with either rhIL-2 or sorafenib alone in all the models."( Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T, 2009
)
0.35
" This study was to evaluate the schedule-dependent effect of sorafenib in combination with paclitaxel (TAX) on human hepatocellular carcinoma cell BEL-7402, and explore the underlying mechanism."( [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
Li, M; Li, N; Wu, T; Zhang, Y, 2009
)
0.35
" This phase I trial was conducted to evaluate drug safety and pharmacokinetics as well as tumor response of sorafenib in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)."( Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S, 2010
)
0.36
"The present study confirmed that sorafenib at 400 mg once daily in combination with carboplatin AUC 5 mg min mL(-1) and paclitaxel 200 mg/m(2) is feasible in Japanese patients with advanced NSCLC."( Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S, 2010
)
0.36
"Treatment with motesanib was tolerable when combined with carboplatin/paclitaxel and/or panitumumab, with little effect on motesanib pharmacokinetics at the 125-mg once daily dose level."( Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Blumenschein, GR; Gladish, G; McGreivy, J; O'Rourke, T; Parson, M; Reckamp, K; Sandler, A; Stephenson, GJ; Sun, YN; Ye, Y, 2010
)
0.36
"This phase Ib study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AMG 102, a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in combination with bevacizumab or motesanib in patients with advanced solid tumors."( A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Anderson, A; Beaupre, DM; Deng, H; Leitch, IM; Oliner, KS; Park, DJ; Rosen, PJ; Shubhakar, P; Sweeney, CJ; Yee, LK; Zhu, M, 2010
)
0.36
"AMG 102 in combination with bevacizumab was well tolerated."( A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Anderson, A; Beaupre, DM; Deng, H; Leitch, IM; Oliner, KS; Park, DJ; Rosen, PJ; Shubhakar, P; Sweeney, CJ; Yee, LK; Zhu, M, 2010
)
0.36
"The aim of this study was to investigate the effect of sorafenib combined with daunorubicin on leukemic k562 cell line."( [Effect of sorafenib combined with daunorubicin on K562 cell line].
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ, 2010
)
0.36
"A phase I trial escalating doses of sorafenib in combination with fixed doses of PE (Arm A) or CbP (Arm B) was performed using a 3-patient cohort design to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT); DLT were assessed in the first cycle."( A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM, 2011
)
0.37
"The MTD of sorafenib was 200 mg BID continuously in combination with carboplatin (AUC of 5) and pemetrexed 500 mg/m² every 3 weeks."( A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM, 2011
)
0.37
" The role of combination with other chemotherapy drugs in advanced cholangiocarcinoma still needs to be defined."( Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun, W; Tao, Y,
)
0.13
"After lower dosage of sorafenib was used as a combination with hepatic arterial infusion chemotherapy, size of hepatic lesions and level CA19-9 of peripheral blood count were decreased, without any damage to the hepatic function, except for temporary skin hyperkeratosis as well as vomit."( Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun, W; Tao, Y,
)
0.13
"So far as in our patient, the application of sorafenib combination with other agents through hepatic arterial infusion chemotherapy may be an effective way for cholangiocarcinoma, but the definite mechanism has to be confirmed by methods of molecular biology."( Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun, W; Tao, Y,
)
0.13
" Sorafenib, not alone but in combination with ABT-737, efficiently induced apoptosis in hepatoma cells."( The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T, 2010
)
0.36
"Bcl-xL inactivation by ABT-737 in combination with sorafenib was found to be safe and effective for anti-HCC therapy in preclinical models."( The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T, 2010
)
0.36
" The in vitro migration of H1299 cells, which expressed high levels of both VEGF ligands and receptors, was inhibited by treatment with sorafenib, and this effect was significantly increased by the combination with anti-EGFR drugs."( Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D, 2010
)
0.36
"Sorafenib, a multikinase inhibitor of Raf and several growth factor receptors, is under investigation in combination with dacarbazine, a commonly used chemotherapeutic agent for the treatment of many cancers."( Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC, 2011
)
0.37
"To evaluate (125)I seed brachytherapy combined with sorafenib in the treatment of patients with multiple lung metastases after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC)."( Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W, 2010
)
0.36
"From July 2006 to December 2009, eight patients with multiple lung metastases after OLT for HCC underwent (125)I brachytherapy combined with sorafenib, and laboratory and radiologic examinations were performed before and after the treatment."( Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W, 2010
)
0.36
"(125)I brachytherapy combined with sorafenib is safe, feasible and promising approach in the treatment of patients with multiple lung metastases after OLT for HCC, but large-scale randomized clinical trials are necessary for confirmation."( Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W, 2010
)
0.36
"To provide more evidence sources to the standard treatment for patients with advanced hepatocellular carcinoma, the writer analyze patients' time to progression (TTP) and overall survival (OS) after patients receiving transcatheter arterial chemoembolization (TACE) combined with sorafenib as a treatment of advanced hepatocellular carcinoma (HCC); observe the healing effect embolization combined with anti-angiogenic treatment for advanced hepatocellular carcinoma; and also analyze treatment of security."( [Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
Hu, BS; Huang, GM; Huang, JW; Li, Y; Lu, LG; Shao, PJ; Wei, ZG; Zhang, L, 2010
)
0.36
"It is unknown whether sorafenib can be combined with transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma."( Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010
)
0.36
"Twenty-one patients were screened and 14 received sorafenib combined with TACE."( Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010
)
0.36
"Continuous administration of sorafenib at a dose of 400 mg bid combined with TACE was tolerable."( Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z, 2010
)
0.36
" The relative low doses at the MTD, in combination with the PK results, do not warrant further development of this combination."( A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Burger, DM; Desar, IM; Timmer-Bonte, JN; van der Graaf, WT; van Herpen, CM, 2010
)
0.36
"To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)."( [Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH, 2010
)
0.36
" The aim of this multicenter, randomized phase II study was to evaluate clinical activity and safety of sorafenib in combination with erlotinib or gemcitabine in unselected untreated elderly patients with non-small-cell lung cancer (NSCLC)."( Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G, 2011
)
0.37
"After 2 weeks of IFN-alone treatment, eligible patients received 28-day cycles of continuous sorafenib 200 mg (Cohort 1) or 400 mg (Cohorts 2 and 3) twice daily combined with intramuscular IFN 6 (Cohorts 1 and 2) or 9 (Cohort 3) million international units (MIU) three times a week."( Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
Fujii, H; Fukino, K; Hamamoto, Y; Hashine, K; Niwakawa, M; Sumiyoshi, Y; Tanigawa, T; Yamaguchi, R, 2012
)
0.38
"Sorafenib administered in combination with IFN was well tolerated, with promising results in efficacy."( Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
Fujii, H; Fukino, K; Hamamoto, Y; Hashine, K; Niwakawa, M; Sumiyoshi, Y; Tanigawa, T; Yamaguchi, R, 2012
)
0.38
"To explore the safety and efficacy of sorafenib in combination with chemotherapy for the treatment of FLT3 positive acute myeloid leukemia (AML), to highlight the impact of FLT3 mutations and targeting therapy on response of AML."( [Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review].
Li, QH; Liu, BC; Liu, KQ; Mi, YC; Wang, JX; Wei, H; Wei, SN; Zhou, CL, 2011
)
0.37
"Sirolimus can be safely combined with sorafenib or sunitinib."( Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K, 2011
)
0.37
"Sorafenib in combination with cytarabine resulted in strong anti-AML activity in vitro and in vivo."( Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S, 2011
)
0.37
"This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery."( Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N, 2011
)
0.37
"To investigate the in vitro inhibitory effects of DC(dendritic cell)-CIK (cytokine-induced killer cell) cocultured cells combined with sorafenib against hepatocellular carcinoma cell line BEL27402."( [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
He, JT; Zhang, D, 2011
)
0.37
" The cytotoxicity of DC-CIK cocultured cells (DC-CIK) combined with sorafenib against BEL-7402 cells was determined by CCK8 kit."( [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
He, JT; Zhang, D, 2011
)
0.37
"DC-CIK cocultured cells combined with sorafenib can inhibit the growth of hepatocellular carcinoma cell line BEL-7402 in vitro."( [In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
He, JT; Zhang, D, 2011
)
0.37
" This study investigated the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with gemcitabine and cisplatin."( Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M, 2012
)
0.38
" No clinically relevant pharmacokinetic drug-drug interaction between sorafenib, cisplatin, and gemcitabine was detected."( Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M, 2012
)
0.38
"Sorafenib as continuous oral treatment in combination with gemcitabine and cisplatin demonstrated an acceptable safety profile."( Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M, 2012
)
0.38
"To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia."( Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011
)
0.37
"Sorafenib in combination with clofarabine and cytarabine is tolerable and shows activity in relapsed/refractory pediatric AML."( Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011
)
0.37
"The objective of this trial was to evaluate the clinical effects of sorafenib, a multi-targeted kinase inhibitor, in combination with androgen receptor blockade in patients with castration-resistant prostate cancer."( A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E, 2012
)
0.38
" Sorafenib 400 mg twice daily was administered with bicalutamide 50 mg once daily on a 28-day cycle."( A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E, 2012
)
0.38
"This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD) or twice daily (BID) in combination with erlotinib and gemcitabine in patients with solid tumors."( Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S, 2011
)
0.37
"Patients received weekly intravenous gemcitabine (1000 mg/m2) and erlotinib (100 mg QD) alone (control cohort) or in combination with motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD; cohorts 1-4); or erlotinib (150 mg QD) in combination with motesanib (100 or 125 mg QD; cohorts 5 and 6)."( Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S, 2011
)
0.37
" The MTD of motesanib in combination with gemcitabine and erlotinib was 100 mg QD."( Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S, 2011
)
0.37
" Motesanib 125 mg QD was tolerable only in combination with erlotinib alone."( Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S, 2011
)
0.37
" Here, we evaluated the effect of the dual PI3K/mTOR inhibitor NVP-BEZ235, in combination with the multikinase inhibitor sorafenib on renal cancer cell proliferation and survival in vitro as well as on tumor growth in vivo."( Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L, 2011
)
0.37
" The anticancer efficacy of NVP-BEZ235 alone, or in combination with sorafenib, was also evaluated on RCC xenografts in nude mice."( Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L, 2011
)
0.37
" The antitumor efficacy of NVP-BEZ235 in combination with sorafenib was superior to NVP-BEZ235 or sorafenib alone."( Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L, 2011
)
0.37
" The protocol involved sorafenib 400 mg twice per day combined with DEB-TACE."( Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Bhagat, N; Cosgrove, D; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK, 2011
)
0.37
" Recent clinical trials have assessed the efficacy and safety of the multikinase inhibitor sorafenib in combination with common treatments for advanced breast cancer."( Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.
Gomez, P; Lacouture, ME, 2011
)
0.37
"To investigate the safety of transarterial chemoembolisation (TACE) in combination with sorafenib in patients with hepatocellular carcinoma (HCC)."( Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W, 2012
)
0.38
"These findings do not support use of an intensive, high-dose doxorubicin-based TACE regimen in combination with sorafenib in this study population."( Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W, 2012
)
0.38
"• Transarterial chemoembolisation (TACE) is widely used in patients with hepatocellular carcinoma (HCC) • Various antiangiogenic and other agents have been used to augment this treatment • We tested lipiodol-TACE with bilirubin-adjusted doxorubicin dosing in combination with sorafenib • This trial was stopped prematurely because of safety reasons • Our safety results do not support the combination of sorafenib with this TACE regimen."( Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W, 2012
)
0.38
"This dose escalation, uncontrolled phase I study evaluated the tolerability, pharmacokinetics (PK), and antitumor activity of oral sorafenib 100, 200, or 400 mg twice daily (bid, continuous regimen) in combination with 5-fluorouracil/leucovorin (5-FU/LCV, intravenous infusion or bolus) in patients with advanced, solid tumors."( Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S, 2012
)
0.38
" Owing to these reasons and the potential of sorafenib to synergize with other anticancer therapies, its combination with other targeted agents and chemotherapy has been widely explored with promising results."( Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
Ibrahim, N; Walsh, WR; Yang, JL; Yu, Y, 2012
)
0.38
"This phase 1b dose-escalation study assessed safety, tolerability, and pharmacokinetics of ganitumab, a fully human monoclonal antibody against the insulin-like growth factor 1 (IGF1) receptor, combined with targeted agents or cytotoxic chemotherapy in patients with advanced solid tumors."( Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M, 2012
)
0.38
" every 2 weeks) combined with either sorafenib 400 mg twice daily, panitumumab 6 mg/kg every 2 weeks, erlotinib 150 mg once daily, or gemcitabine 1,000 mg/m(2) on days 1, 8, and 15 of each 4-week cycle."( Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M, 2012
)
0.38
"Ganitumab up to 12 mg/kg appeared well tolerated combined with sorafenib, panitumumab, erlotinib, or gemcitabine."( Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M, 2012
)
0.38
"Ganitumab up to 12 mg/kg was well tolerated, without adverse effects on pharmacokinetics in combination with either sorafenib, panitumumab, erlotinib, or gemcitabine."( Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M, 2012
)
0.38
"We performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)."( Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012
)
0.38
"Three-weekly docetaxel and prednisone could be combined with sorafenib at 400 mg BID on days 1-21 without reaching MTD."( Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012
)
0.38
" We investigated the antitumor activity of motesanib, a selective antagonist of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, platelet-derived growth factor receptor, and Kit, alone and combined with chemotherapy in five human NSCLC xenograft models (A549, Calu-6, NCI-H358, NCI-H1299, and NCI-H1650) containing diverse genetic mutations."( Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B, 2012
)
0.38
" When combined with cisplatin, motesanib significantly inhibited the growth of Calu-6, NCI-H358, and NCI-H1650 tumor xenografts compared with either single agent alone (P < 0."( Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B, 2012
)
0.38
"These data demonstrate that motesanib had antitumor activity against five different human NSCLC xenograft models containing diverse genetic mutations, and that it had enhanced activity when combined with cisplatin or docetaxel."( Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
Coxon, A; Kaufman, S; Polverino, A; Saffran, D; Schmidt, J; Starnes, C; Sweet, H; Wang, H; Weishuhn, D; Xu, M; Ziegler, B, 2012
)
0.38
" Drug-drug interactions are frequently undesirable and may lead to increased toxicity and mortality."( Prediction of transporter-mediated drug-drug interactions using endogenous compounds.
Fromm, MF, 2012
)
0.38
"We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)."( Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013
)
0.39
" This phase II study was conducted by the SWOG cooperative group to evaluate the efficacy of sorafenib in combination with carboplatin and paclitaxel (CP) in metastatic uveal melanoma."( Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS, 2012
)
0.38
" NMRI mice bearing subcutaneous HUH6-derived tumours were treated with sorafenib alone or in combination with cisplatin."( Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW, 2013
)
0.39
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer."( [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
He, ZY; Hua, XD, 2012
)
0.38
"Sorafenib combined with MCT and TACE can improve the disease control rate and prolong the survival in patients with recurrent HCC."( [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
He, ZY; Hua, XD, 2012
)
0.38
"This prospective non-randomized controlled trial aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) vs TACE alone for the treatment of patients with unresectable intermediate or advanced hepatocellular carcinoma."( Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y, 2013
)
0.39
"Patients were treated with everolimus 10 mg daily in combination with sorafenib (dose level 1: 200 mg twice daily; dose level 2: 200 mg per morning, 400 mg per evening) using standard phase I dose escalation design."( Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E, 2013
)
0.39
" Sorafenib 200 mg twice daily in combination with everolimus 10 mg daily was established as the MTD."( Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E, 2013
)
0.39
"Data on the efficacy and safety of sorafenib in combination with transarterial chemoembolization (TACE) in patients with advanced hepatocellular carcinoma (HCC) are lacking."( Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y, 2013
)
0.39
"Sorafenib in combination with TACE should be considered a safe and effective therapy for advanced HCC."( Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y, 2013
)
0.39
"Based upon preclinical evidence for improved antitumor activity in combination, this phase I study investigated the maximum-tolerated dose (MTD), safety, activity, pharmacokinetics (PK), and biomarkers of the mammalian target of rapamycin inhibitor, temsirolimus, combined with sorafenib in hepatocellular carcinoma (HCC)."( Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM, 2013
)
0.39
" The purpose of this phase I study was to evaluate the safety, pharmacokinetics, and preliminary efficacy of sorafenib in combination with S-1 plus CDDP."( A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y, 2014
)
0.4
" Pharmacokinetic analysis showed no significant differences in the exposures of sorafenib when administered alone or in combination with S-1 and CDDP."( A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y, 2014
)
0.4
") or placebo, combined with mFOLFOX6 (oxaliplatin 85 mg/m(2); levo-leucovorin 200 mg/m(2); fluorouracil 400 mg/m(2) bolus and 2400 mg/m(2) continuous infusion) every 14 days."( Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013
)
0.39
" These results do not support further development of sorafenib in combination with mFOLFOX6 in molecularly unselected patients with mCRC."( Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013
)
0.39
"To evaluate the effectiveness and safety of sorafenib combined with transarterial chemoembolization (TACE) in patients with advanced primary hepatocellular carcinoma."( Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.
Chen, L; Cui, HZ; Dai, GH; Shi, Y,
)
0.13
"Sorafenib combined with TACE is a safe and effective treatment of advanced primary hepatocellular carcinoma."( Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.
Chen, L; Cui, HZ; Dai, GH; Shi, Y,
)
0.13
" Anti-proliferative effects of sorafenib were evidenced by (1)H MRS and (18)F-FLT PET after 2 days of treatment with sorafenib, with no additional effect of the combination with radiation therapy, results that are in agreement with Ki67 staining."( Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging.
Bol, A; Bouzin, C; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karmani, L; Karroum, O; Kengen, J; Labar, D; Levêque, P; Magat, J; Mignion, L,
)
0.13
" To assess the anti-tumor effect of sorafenib and the synergistic effect of sorafenib combined with 5-Fu by measuring the tumor weight and number of lung metastases."( [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Shen, HJ; Wang, YH; Xu, J, 2013
)
0.39
" Sorafenib, in combination with ionizing radiation, induced the accumulation of tumor cells in the G2-M phase and delayed the repair of DNA damage caused by ionizing radiation."( Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
Ha, H; Jeong, JH; Jeong, YK; Kim, EH; Kim, MS; Kim, W; Lee, JY,
)
0.13
"We provide a scientific rationale for the use of sorafenib in combination with radiotherapy in colorectal cancer."( Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
Ha, H; Jeong, JH; Jeong, YK; Kim, EH; Kim, MS; Kim, W; Lee, JY,
)
0.13
" In this study, we investigated the synergistic antitumour activity of sorafenib in combination with tetrandrine."( Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Gong, K; Li, J; Li, W; Liu, T; Mei, L; Wan, J; Yu, C, 2013
)
0.39
"This was a two-part investigation that included the in vitro effects of sorafenib in combination with tetrandrine on cancer cells and the in vivo antitumour efficacy of this drug combination on tumour xenografts in nude mice."( Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Gong, K; Li, J; Li, W; Liu, T; Mei, L; Wan, J; Yu, C, 2013
)
0.39
"To compare the time to progression (TTP) and overall survival (OS) in patients with advanced-stage hepatocellular carcinoma (HCC) who are undergoing sorafenib treatment combined with transarterial chemoembolization (TACE) versus sorafenib monotherapy."( Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM, 2013
)
0.39
" Patients are stratified by hormone-receptor status, geographic region, and prior metastatic chemotherapy status and randomized (1:1) to capecitabine (1000 mg/m2 orally twice daily (BID), days 1 to 14 of 21) in combination with sorafenib (orally BID, days 1 to 21, total dose 600 mg/day) or matching placebo."( A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M, 2013
)
0.39
" To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy."( Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma.
Cha, J; Han, KH; Kim, JW; Lee, IJ; Seong, J, 2013
)
0.39
" This phase I study was designed to determine the maximum tolerated dose (MTD) of everolimus given with sorafenib 400mg twice daily in patients with advanced HCC of Child-Pugh class A liver function who were naive to systemic therapy."( Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Brandt, U; Bruix, J; Chen, LT; Finn, RS; Gomez-Martin, C; Kang, YK; Kim, TY; Klümpen, HJ; Kunz, T; Paquet, T; Poon, RT; Rodriguez-Lope, C; Sellami, D; Yau, T, 2013
)
0.39
"The purpose of this study is to assess clinical efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) on patients with unresectable hepatocellular carcinoma (HCC)."( Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB, 2013
)
0.39
"The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species."( Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013
)
0.39
" Synergistic effects in combination with sorafenib were shown in Huh-7, Hep3B xenografts, and MH3924A allografts."( Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013
)
0.39
"BAY 86-9766 shows potent single-agent antitumor activity and acts synergistically in combination with sorafenib in preclinical HCC models."( Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013
)
0.39
" This study evaluated the efficacy and safety of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation in the treatment of hepatocellular carcinomas larger than 5 cm."( Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ, 2013
)
0.39
"5 cm) treated with sorafenib after transcatheter arterial chemoembolization combined with radiofrequency ablation between 2007 and 2011 was reviewed."( Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ, 2013
)
0.39
"Sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation is a promising approach to the treatment of large, unresectable hepatocellular carcinomas."( Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ, 2013
)
0.39
" Sorafenib combined with transarterial chemoembolization is a novel treatment approach for advanced HCC."( Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.
Chen, MS; Gao, HJ; Xu, L; Zhang, YJ, 2014
)
0.4
" In addition, the MHCCLM3 cells were less sensitive to 5-FU when administrated in combination with sorafenib, as evidenced by the half inhibitory concentration (IC50) significantly increasing from (102."( [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Deng, LF; Jia, QA; Li, JH; Ren, ZG; Shen, HJ; Sun, XJ; Wang, YH, 2013
)
0.39
" Together our findings indicate that valproate which act as inhibitor of cell proliferation and inducer of apoptosis in human cancer MIAPaca2 cells when used in combination with nicotinamide makes it a potentially good candidate for new anticancer drug development."( Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Ahmadian, S; Jafary, H; Soleimani, M, 2014
)
0.4
"This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (EOC)."( Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014
)
0.4
"Sorafenib, alone or in combination with carboplatin and paclitaxel, has activity in patients with platinum-sensitive EOC."( Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014
)
0.4
"To determine the safety and efficacy of transarterial chemoembolization (TACE) combined with sorafenib (hereafter, TACE-sorafenib) in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT)."( Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K, 2014
)
0.4
" Finally, this study demonstrated that MPT0B271 in combination with erlotinib significantly inhibits the growth of the human non-small cell lung cancer A549 cells as compared with erlotinib treatment alone, both in vitro and in vivo."( Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Chang, JY; Hsiao, CJ; Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC, 2014
)
0.4
"This study aimed to determine the recommended dose of capecitabine combined with peginterferon α-2a (Phase I) and evaluate its safety and efficacy for sorafenib-refractory advanced hepatocellular carcinoma (Phase II)."( A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014
)
0.4
"Capecitabine at 2000 mg/(m(2)∙day) combined with peginterferon α-2a (90 μg/week) exhibited moderate, albeit manageable, toxicity and was declared as the recommended phase II dose."( A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014
)
0.4
" This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma."( Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014
)
0.4
"Patients were treated with RT (60 Gy in 2 Gy fractions) combined with TMZ 75 mg m(-2) daily, and Sb administered at three dose levels (200 mg daily, 200 mg BID, and 400 mg BID) starting on day 8 of RT."( Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014
)
0.4
"Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas."( Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014
)
0.4
"The aim of this study was to investigate the prognostic significance of blood NLR in patients with intermediate-advanced hepatocellular carcinoma (HCC) who received transcatheter arterial embolization (TAE) combined with Sorafenib."( Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
Mu, H; Song, TQ; Wang, M; Wei, K; Zhang, W, 2014
)
0.4
"The purpose of the present study was to compare the efficacies of transarterial chemoembolization (TACE) combined with sorafenib versus TACE monotherapy for treating patients with advanced hepatocellular carcinoma (HCC)."( Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z, 2014
)
0.4
"To retrospectively analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of patients with intermediate-advanced hepatocellular carcinoma (HCC) and assess the prognostic impact of baseline characteristics."( Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Luo, J; Shao, G; Zheng, J, 2014
)
0.4
"Patients with intermediate-advanced HCC received TACE combined with sorafenib in this Phase 2 clinical trial."( Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Luo, J; Shao, G; Zheng, J, 2014
)
0.4
"TACE in combination with sorafenib might have acceptable safety and efficiency in the treatment of intermediate-advanced HCC."( Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Luo, J; Shao, G; Zheng, J, 2014
)
0.4
" The purpose of this study is to investigate the effect of HBO in combination with sorafenib on hepatoma cells."( Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF, 2014
)
0.4
"Hepatoma cell lines (BEL-7402 and SK-Hep1) were treated with HBO at 2 atmosphere absolute pressure for 80 min per day or combined with sorafenib or cisplatin."( Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF, 2014
)
0.4
"Although HBO, sorafenib or cisplatin alone could inhibit growth of hepatoma cells, HBO combined with sorafenib or cisplatin resulted in much greater synergistic growth inhibition (cell proliferation and colony formation) in hepatoma cells."( Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF, 2014
)
0.4
"We show for the first time that HBO combined with sorafenib results in synergistic growth inhibition and apoptosis in hepatoma cells, suggesting a potential application of HBO combined with sorafenib in HCC patients."( Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF, 2014
)
0.4
"Eligible patients were randomly assigned in a 2:1 ratio to receive AEG35156 (300 mg weekly intravenous infusion) in combination with sorafenib (400 mg twice daily orally) or sorafenib alone."( Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC, 2016
)
0.43
"AEG35156 in combination with sorafenib showed additional activity in terms of ORR and was well tolerated."( Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC, 2016
)
0.43
"Sorafenib in combination with Transarterial chemoembolization (TACE) is increasingly used in patients with unresectable hepatocellular carcinoma (HCC), but the current evidence is still controversial."( Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Bai, M; Han, GH; Yang, M; Yuan, JQ, 2014
)
0.4
" We conducted studies using a TKI (sunitinib or sorafenib) in combination with recombinant vaccines in two murine tumor models: colon carcinoma (MC38-CEA) and breast cancer (4T1)."( Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Coplin, MA; Donahue, RN; Farsaci, B; Grenga, I; Hodge, JW; Lepone, LM; Molinolo, AA, 2014
)
0.4
" The urinary glucose excretion was drastically elevated in the dapagliflozin group, but the combination with mitiglinide suppressed it about 50%."( Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Maruyama, K; Mori, Y; Ojima, K; Yaguchi, A; Yokoyama, A, 2015
)
0.42
"This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients with advanced solid tumors."( Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Adjei, AA; Chai, F; Dy, GK; Goff, L; Lamar, M; Ma, WW; Martell, R; Means-Powell, JA; Puzanov, I; Saif, MW; Santoro, A; Savage, RE; Schwartz, B; Simonelli, M; Sosman, J; Zucali, P, 2015
)
0.42
" Entinostat 10 mg orally once every 2 weeks in combination with sorafenib 400 mg orally twice daily, representing full single agent doses of each drug was identified as the recommended phase 2 dose (RP2D)."( A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y, 2015
)
0.42
"This study was aimed to investigate the therapeutic potential of coenzyme Q10 and its combination with metformin on streptozotocin (STZ)-nicotinamide-induced diabetic nephropathy (DN)."( Effect of coenzyme Q10 alone and its combination with metformin on streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
Balaraman, R; Maheshwari, RA; Sen, AK; Seth, AK,
)
0.13
"These data on the metformin-trimethoprim interaction support the potential utility of N(1)-methylnicotinamide as an endogenous probe for renal drug-drug interactions with involvement of renal cation transporters."( N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Auge, D; Fromm, MF; Hoier, E; Maas, R; Mieth, M; Müller, F; Pontones, CA; Renner, B; Zolk, O, 2015
)
0.42
" Moreover, imetelstat alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC functional ability, as shown by decreased mammosphere counts and invasive potential."( The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Herbert, BS; Koziel, JE, 2015
)
0.42
" The aim of present study is to explore the efficacy and safety of sorafenib combined with RFA therapy for the patients with medium-sized HCC."( Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M, 2015
)
0.42
"Sorafenib combined with RFA significantly decreased recurrence rates and prolonged the survival time of medium-sized HCC patients."( Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M, 2015
)
0.42
"This retrospective study was carried out to compare the outcomes between elderly (≥70 years of age) and nonelderly patients (<70 years of age) with advanced hepatocellular carcinoma (HCC) who received sorafenib combined with transarterial chemoembolization (TACE)."( Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015
)
0.42
"Sorafenib combined with TACE was equally well tolerated in both age groups, and grade 3 or 4 adverse events were similarly observed in 54."( Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015
)
0.42
"Sorafenib combined with TACE may be well tolerated and effective in elderly patients with advanced HCC."( Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z, 2015
)
0.42
"We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib."( [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014
)
0.4
" PR-104 monotherapy elicited significant reductions in growth of Hep3B and HepG2 xenografts, and the combination with sorafenib was significantly active in all 4 xenograft models."( Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR, 2015
)
0.42
" This study investigated the efficacy of perifosine alone and in combination with sorafenib in a transgenic mouse model of HCC."( Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015
)
0.42
" The transgenic mice were treated with perifosine alone and in combination with sorafenib to evaluate efficacy of drugs on tumor growth and survival."( Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015
)
0.42
"Treatment with perifosine for 5 weeks, alone and in combination with sorafenib, strongly inhibited tumor growth and increased survival."( Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015
)
0.42
"The preclinical effect that current study showed represents a strong rationale for clinical trials using perifosine alone and in combination with sorafenib in the treatment of HCC patients."( Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW, 2015
)
0.42
" We aimed to assess the safety, tolerance, pharmacokinetics and clinical activity of S-1 combined with sorafenib in patients with mRCC."( Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y, 2015
)
0.42
" S-1 was administered orally at 60, 80, 100 or 120 mg/day on days 1-28 of a 42-day cycle in combination with sorafenib (400 or 800 mg/day), given daily with dose adjustment."( Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y, 2015
)
0.42
"To investigate the safety and feasibility of sorafenib neoadjuvant therapy combined with retroperitoneoscopic radical nephrectomy (RRN) in treating T2 large renal cell carcinoma (RCC)."( Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
Gao, ZL; Lin, CH; Liu, QZ; Men, CP; Wang, J; Wang, K; Wu, JT; Yu, SQ; Yuan, HJ, 2015
)
0.42
" Here we provide models of human hepatocellular carcinoma (HCC), the most common form of primary liver cancer, in vitro and in vivo to evaluate the efficacy of NFC alone and in combination with sorafenib, a kinase inhibitor approved for treatment of HCC."( A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF, 2015
)
0.42
" This phase I trial sought to determine the maximum tolerable dose (MTD) of bevacizumab and sorafenib combined with standard cytotoxic therapy for advanced gastrointestinal (GI) cancers."( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016
)
0.43
"A standard 3 + 3 trial design utilized 3 escalating sorafenib dose levels: (1) 200 mg daily, days 3-7, 10-14; (2) 200 mg twice daily, days 3-6, 10-13; and (3) 200 mg twice daily, days 3-7, 10-14 combined with standard dose FOLFIRI (5-fluouracil, leucovorin, and irinotecan) and bevacizumab (5 mg/kg), repeated every 14 days."( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016
)
0.43
" The MTD was determined to be dose level 2: sorafenib 200 mg twice daily, days 3-6, 10-13 combined with FOLFIRI and bevacizumab at standard doses."( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016
)
0.43
"The MTD of this regimen is sorafenib 200 mg twice daily, days 3-6, 10-13 combined with standard doses of FOLFIRI and bevacizumab."( Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J, 2016
)
0.43
" The goal of this study was to elucidate the antitumor effect of the flavonoid, fisetin, combined with the multikinase inhibitor, sorafenib, against human cervical cancer cells in vitro and in vivo."( Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF, 2016
)
0.43
" Subsequently, it was combined with sorafenib."( Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A, 2016
)
0.43
"To investigate the anticancer effect and its mechanism of SN-38 combined with sorafenib on hepatocellular cancer cell lines HepG-2 and BEL-7402."( [Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z, 2015
)
0.42
"SRB colorimetry showed the synergistic anticancer activities of SN-38 combined with sorafenib, with a combination index of <0."( [Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z, 2015
)
0.42
"This meta-analysis aimed to analyze the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)."( Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH, 2016
)
0.43
"TACE combined with sorafenib has potential efficacy for HCC."( Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH, 2016
)
0.43
"This retrospective cohort study aimed to evaluate the prognostic value of the alpha-fetoprotein (AFP) response in advanced-stage hepatocellular carcinoma (HCC) patients treated with sorafenib combined with transarterial chemoembolization."( The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; He, C; Jia, J; Liu, L; Niu, J; Xia, J; Yang, M; Yin, Z; Yuan, J; Zhang, L; Zhao, Y, 2016
)
0.43
" Given their synergistic activity in combination, we conducted a phase II study to determine the clinical activity of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)."( A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS, 2016
)
0.43
"Sorafenib combined with erlotinib is well-tolerated with manageable toxicity and appears to be effective against advanced NSCLC with one or two prior line of systemic treatment (NCT00801385)."( A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS, 2016
)
0.43
"In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29)."( Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells.
Altun, A; Ataseven, H; Kaya, TT; Koyluoglu, G; Turgut, NH, 2016
)
0.43
"To study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3(+) relapsed and refractory acute myeloid leukemia (FLT3(+) RR-AML)."( [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016
)
0.43
"Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency."( [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016
)
0.43
"We evaluated radiotherapy using helical tomotherapy (HT) combined with sorafenib for treatment of pulmonary metastases from hepatocellular carcinoma (HCC)."( Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S, 2016
)
0.43
" This phase I study investigated the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK) and biomarker correlates of selumetinib combined with sorafenib in patients with advanced hepatocellular carcinoma (HCC)."( A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP, 2016
)
0.43
" Selumetinib exposures in combination with sorafenib were comparable to other monotherapy studies."( A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP, 2016
)
0.43
"The MTD of selumetinib was 75 mg daily when combined with sorafenib 400 mg twice a day in CP ≤7 HCC."( A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP, 2016
)
0.43
"This study was designed to evaluate the tolerability and effectiveness of GBE combined with sorafenib in patients with advanced HCC."( Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016
)
0.43
"Patients with advanced HCC were treated with increasing doses of GBE in combination with sorafenib."( Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016
)
0.43
" Compared with previous study, the toxicities of the combination therapy were similar with those observed in sorafenib monotherapy, GBE in combination with sorafenib slightly improved OS."( Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C, 2016
)
0.43
" In the S/P arm, patients were treated orally with sorafenib continuous dosing at two dose levels (DL1: 200 mg twice daily and DL2: 400 mg twice daily) combined with plitidepsin (1."( Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M, 2017
)
0.46
"To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA)."( Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A, 2017
)
0.46
"In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 weeks with satisfactory tolerability."( Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Cardiel, MH; Codding, C; Garg, JP; Genovese, MC; Greenwald, M; Kivitz, AJ; Shay, K; Wang, A; Wang, X; Zubrzycka-Sienkiewicz, A, 2017
)
0.46
" A phase I study evaluated the combination with sorafenib in HCC."( Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Abou-Alfa, GK; Agajanov, T; Beylergil, V; Boisserie, F; Carrasquilo, JA; Chen, YC; Cheng, AL; Di Laurenzio, L; Frenette, C; Gansukh, B; Hsu, CH; Larson, SM; Lee, R; Lin, ZZ; Lyashchenko, SK; Ma, J; Maki, Y; Morikawa, H; O'Donoghue, J; O'Neil, B; Ohishi, N; Ohtomo, T; Pandit-Taskar, N; Ruan, S; Schwartz, L; Shao, YY; Smith-Jones, PM; Tanaka, T; Wan, P; Yen, CJ, 2017
)
0.46
" The maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of pimasertib in combination with temsirolimus, safety and pharmacokinetics (PK) were investigated."( Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Fu, S; Guo, W; Janku, F; Kurzrock, R; Mita, A; Mita, M; Naing, A; Natale, R; Piha-Paul, SA; Zhao, C, 2017
)
0.46
" The aim of this study is to investigate the pharmacokinetic mechanism of drug-drug interactions of sorafenib including interacting with hepatoprotective formulation, Long-Dan-Xie-Gan-Tang formulation (LDXGT) and with two cytochrome P450 3A4 (CYP3A4) inhibitors, grapefruit juice and ketoconazole."( Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.
Cheng, YY; Ting, CT; Tsai, TH, 2017
)
0.46
" Patients were randomised 1:1 by computerised minimisation algorithm to continuous oral sorafenib (400 mg twice-daily) or matching placebo combined with TACE using drug-eluting beads (DEB-TACE), which was given via the hepatic artery 2-5 weeks after randomisation and according to radiological response and patient tolerance thereafter."( Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A, 2017
)
0.46
" Alternative systemic therapies need to be assessed in combination with TACE to improve patient outcomes."( Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A, 2017
)
0.46
" However, as with other drugs, sorafenib has its limitations, and various clinical trials have been conducted to develop novel molecular targeted agents for use alone or in combination with existing locoregional therapies."( Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Arizumi, T; Kudo, M, 2017
)
0.46
"Purpose To retrospectively investigate the safety and efficacy of sorafenib combined with transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) in the treatment of recurrent hepatocellular carcinoma (rHCC) with portal vein tumor thrombosis, extrahepatic metastases (advanced hepatocellular carcinoma), or both after initial hepatectomy."( Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X, 2018
)
0.48
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)."( Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018
)
0.48
" In conclusion, the results revealed a synergistic anti-hepatoma effect of bufalin combined with sorafenib via affecting the tumor vascular microenvironment by targeting mTOR/VEGF signaling."( Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Chi, H; Meng, Z; Wang, H; Zhang, C, 2018
)
0.48
"To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT)."( [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X, 2018
)
0.48
" The hepatic cancer cell lines Hep3b and HepG2 were treated with Sora alone or in combination with NPCs in concomitant, sequential, and inverted sequential regimens."( Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
Abaza, MSI; Al-Attiyah, RJ; Bahman, AA; Khoushiash, SI, 2018
)
0.48
" We retrospectively analyzed the clinical efficacy between SU/SO combined with DC-CIK and SU/SO monotherapy in treating renal cell carcinoma (RCC) patients with metastasis after radical nephrectomy."( Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL, 2018
)
0.48
"All patients (n = 34) with postoperative mRCC in our hospital from January 2009 to January 2014 were received either SU/SO monotherapy (Group 1, n = 15) or in combination with DC-CIK (Group 2, n = 19)."( Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL, 2018
)
0.48
" No significant drug-drug interactions were observed."( A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
de Jonge, M; de Weger, VA; Demers, B; Deutsch, E; Goodstal, S; Hsu, K; Langenberg, MHG; Lolkema, M; Macé, S; Schellens, JHM; Thomas, K; Tuffal, G; Varga, A, 2019
)
0.51
" These initial results were compared to results after eight weeks of treatment with sunscreen in combination with niacinamide, retinoic acid, or placebo."( DNA Methyltransferases in Malar Melasma and Their Modification by Sunscreen in Combination with 4% Niacinamide, 0.05% Retinoic Acid, or Placebo.
Campuzano-García, AE; Castanedo-Cázares, JP; Cortés-García, JD; Fuentes-Ahumada, C; Hernández-Blanco, D; Torres-Alvarez, B, 2019
)
0.94
"To investigate the short-term efficacy of sorafenib combined with vascular endothelial growth factor (VEGF) inhibitor in the treatment of renal cell carcinoma (RCC)."( Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma.
Liu, X; Qin, J; Wang, Q,
)
0.13
"Sorafenib combined with Avastin can significantly improve the immune function, reduce the expression level of VEGF, improve the QoL, prolong the survival and obtain satisfactory short-term efficacy in RCC patients, which has important application value in the clinical treatment of RCC."( Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma.
Liu, X; Qin, J; Wang, Q,
)
0.13
" In an open-label, drug-drug interaction study, 24 healthy volunteers received a single dose of metformin 750 mg on Days 1 and 10, and a single dose of peficitinib 150 mg on Days 3 and 5-11."( A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Kaneko, Y; Nishimura, T; Oda, K; Shibata, M; Toyoshima, J, 2020
)
0.56
"The objective of this study was to investigate potential drug-drug interactions of peficitinib with methotrexate and the short-term safety of coadministration."( Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Akinlade, B; Cao, Y; Chindalore, V; Moy, S; Sawamoto, T; Valluri, U; Zhang, W; Zhu, T, 2020
)
0.56
"We evaluated the effect of topical post-laser treatment with adipocyte-derived stem cell-containing medium (ADSC-CM) in combination with niacinamide through a double-blind, randomized, vehicle-controlled study."( Randomized controlled study for the anti-aging effect of human adipocyte-derived mesenchymal stem cell media combined with niacinamide after laser therapy.
Chung, KB; Kim, J; Kim, S; Lee, JH; Lee, YI, 2021
)
1.03
"We demonstrated that post-laser topical application of ADSC-CM in combination with niacinamide has anti-aging effect on skin."( Randomized controlled study for the anti-aging effect of human adipocyte-derived mesenchymal stem cell media combined with niacinamide after laser therapy.
Chung, KB; Kim, J; Kim, S; Lee, JH; Lee, YI, 2021
)
1.05
"This phase Ia/Ib PACT study evaluated the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of a new programmed cell death ligand 1 (PD-L1) inhibitor, LY3300054, as monotherapy or in combination with ramucirumab, abemaciclib, or merestinib (a type II MET kinase inhibitor) in patients with advanced, refractory solid tumors (NCT02791334)."( Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Bang, YJ; Bendell, J; Carlsen, M; Chow, KH; Chung, HC; de Miguel, MJ; Gandhi, L; Italiano, A; Lin, CC; Patnaik, A; Schmidt, S; Su, WC; Szpurka, AM; Vangerow, B; Xu, X; Yap, TA; Yu, D; Zhao, Y, 2021
)
0.62
"The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC)."( Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.
Cao, G; Han, Y; Liu, B; Liu, Z; Shi, Q; Sun, B; Wang, J; Xu, H; Xu, L; Yan, D; Zhi, W; Zou, Y, 2021
)
0.62
"The present study provides real-world evidence indicating that regorafenib combined with TACE was beneficial and tolerable in patients with unresectable HCC."( Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.
Cao, G; Han, Y; Liu, B; Liu, Z; Shi, Q; Sun, B; Wang, J; Xu, H; Xu, L; Yan, D; Zhi, W; Zou, Y, 2021
)
0.62
" In conclusion, this work clearly revealed a potential synthetic lethality effect for I combined with sorafenib, and will probably offer a new strategy at least for breast cancer treatment."( Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Guan, XY; Li, GB; Ma, X; Song, C; Wang, HL; Yang, LL; Yu, YM, 2022
)
0.72
" Here, we studied the efficacy of a new generation of allosteric AKT inhibitor, vevorisertib, alone or in combination with sorafenib."( Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A, 2022
)
0.72
"To observe the effect of niacinamide-containing body emollients combined with a cleansing gel on the clinical symptoms of mild atopic dermatitis (AD) in adults."( A single-center, randomized, controlled study on the efficacy of niacinamide-containing body emollients combined with cleansing gel in the treatment of mild atopic dermatitis.
Wang, J; Wang, SS; Zhu, JR, 2023
)
1.45

Bioavailability

Niacinamide is a stable and water-soluble form of vitamin B3. It is well absorbed and tolerated by the skin. This antiviral activity of LL37 is enhanced by the hydrotropic action of niacinamic.

ExcerptReferenceRelevance
" Thus, it easily enters the systemic blood flow, resulting in almost complete bioavailability (75-100%)."( Pharmacokinetic profile of nicorandil in humans: an overview.
Frydman, A, 1992
)
0.28
"To evaluate the bioavailability of 4 different formulations of nicorandil, 10 mg and 20 mg (Bracco) versus 10 mg ang 20 mg (Merck), we have carried out a study involving 24 young healthy volunteers."( [The bioavailability of nicorandil after oral administration of a single dose of 10 or 20 mg preparations].
Buggia, I; Iacona, I; Molinaro, M; Regazzi, MB; Rondanelli, R; Villani, P; Zoia, C, 1992
)
0.28
" The bioavailability of an investigational drug in cynomolgus monkeys could be enhanced sevenfold by inclusion complexation with 2-HP-beta-CD."( Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs.
Albers, E; Müller, BW, 1991
)
0.28
" The absolute bioavailability of nicorandil in dogs in this study was determined to be 84."( Determination of nicorandil in plasma using high-performance liquid chromatography with photoconductivity and ultraviolet detection. Application to pre-clinical pharmacokinetics in beagle dogs.
Lewis, RC; Schwende, FJ, 1990
)
0.28
" Bioavailability of niacin from roasted and boiled groundnuts was assessed in adult human subjects."( Bioavailability of niacin from processed groundnuts.
Chaturvedi, A; Geervani, P, 1986
)
0.27
" Bioavailability and/or biotransformation are the factors most likely to account for the differences observed between species, and between in vivo and in vitro studies for this long-acting antisecretory agent."( In vivo and in vitro effects of CM 57755, a new gastric antisecretory agent acting on histamine H2 receptors.
Aureggi, G; Bianchetti, A; Carminati, P; Lavezzo, A; Manzoni, L; Nisato, D, 1984
)
0.27
" Individual plasma nicorandil concentrations were variable and systemic bioavailability was reduced compared with values reported in healthy subjects."( Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain.
Arnold, JM; Hearron, AE; Jungbluth, GL; Kowey, PR; Luderer, JR; Wolf, DL, 1994
)
0.29
" In dogs the in vivo absorption rate was similar to the in vitro dissolution rate, but in humans it was only about half."( Preparation of controlled release granules of TA-5707F using enteric polymers and ethylcellulose, and their in vivo evaluation.
Maejima, T; Matsukawa, Y; Osawa, T; Yamakita, H, 1996
)
0.29
" The effective combinations (L-TC + DOX, NAC + DOX, NAC + DMTU, NAC + HMT, NC + DOX) combined agents, reducing the bioavailability of the mustard with compounds possibly acting on the consequences of alkylation."( Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations.
Baeza-Squiban, A; Calvet, J; Marano, F; Rappeneau, S, 2000
)
0.31
"Previous studies have demonstrated a relationship between hyperhomocysteinemia and endothelial dysfunction, reduced bioavailability of nitric oxide, elastinolysis and, vascular muscle cell proliferation."( Induction of oxidative stress by homocyst(e)ine impairs endothelial function.
Aru, GM; Mujumdar, VS; Tyagi, SC, 2001
)
0.31
" Solid dispersion capsule PNC1 (containing 1:5--drug-carrier ratio solid dispersion) and the corresponding physical mixture capsule PNC1A were used for bioavailability studies in healthy human volunteers."( Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Balasubramaniam, J; Kumar, MT; Pandit, JK; Verma, MM, 2003
)
0.32
" Accordingly, it is suitable for quality-control applications, drug monitoring, and bioavailability and bioequivalency studies."( Spectrofluorimetric determination of warfarin sodium by using N1-methylnicotinamide chloride as a fluorigenic agent.
El Barbary, RA; El Dawy, MA; Mabrouk, MM,
)
0.13
" The proposed method is simple, with low instrumentation requirements, suitable for quality control application, bioavailability and bioequivalency studies."( Spectrofluorimetric determination of drugs containing active methylene group using N1-methyl nicotinamide chloride as a fluorigenic agent.
El Barbary, RA; El Dawya, MA; Mabrouk, MM, 2006
)
0.33
" After approximately one month in vitro (DIV 25), the cultures were treated for immunocytochemistry to characterise neuronal phenotype with markers against the N-methyl-D-aspartate receptor subunit 1 (NR1), the dopamine pacemaker enzyme tyrosine hydroxylase (TH), and nitric oxide synthase (NOS), the enzyme regulating the bioavailability of NO."( Plasticity of the central nervous system (CNS) following perinatal asphyxia: does nicotinamide provide neuroprotection?
Bustamante, D; Goiny, M; Herrera-Marschitz, M; Klawitter, V; Morales, P, 2006
)
0.33
" A novel nicotinamide, AMG 706, was identified as a potent, orally bioavailable inhibitor of the VEGFR1/Flt1, VEGFR2/kinase domain receptor/Flk-1, VEGFR3/Flt4, platelet-derived growth factor receptor, and Kit receptors in preclinical models."( AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Alva, G; Bready, J; Cattley, R; Chen, D; Coxon, A; DeMelfi, T; Diaz, Z; Estrada, J; Gan, Y; Kaufman, S; Kendall, R; Kumar, G; Meyer, J; Montestruque, S; Neervannan, S; Patel, V; Polverino, A; Radinsky, R; Starnes, C; Talvenheimo, J; Tasker, A; Wang, L, 2006
)
0.33
"AMG 706 is an investigational, orally bioavailable inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and stem-cell factor receptor."( Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Bass, MB; Benjamin, R; Chang, DD; Herbst, RS; Koutsoukos, A; Kurzrock, R; Mulay, M; Ng, C; Polverino, A; Purdom, M; Rosen, LS; Silverman, J; Sun, YN; Van Vugt, A; Wiezorek, JS; Xu, RY, 2007
)
0.34
" Since both drugs are extensively metabolized, this study investigated the bioavailability and pharmacokinetics of their co-administration following single-dose administration."( The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Cefali, E; Menon, R; Tolbert, D, 2007
)
0.34
"Sorafenib is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal cell carcinoma (RCC)."( Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Bukowski, R; Dreicer, R; Elson, P; Garcia, J; Ioachimescu, AG; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L, 2008
)
0.35
" These findings establish bioavailability and potent effects of these nucleosides in stimulating the increase of NAD+ concentrations in mammalian cells."( Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells.
Chan, NY; Sauve, AA; Yang, T, 2007
)
0.34
" The pH-dependent release of PTX from HP micelles can be used to increase the bioavailability of PTX upon oral delivery."( Hydrotropic polymer micelles containing acrylic acid moieties for oral delivery of paclitaxel.
Acharya, G; Huh, KM; Kim, JY; Kim, S; Park, K, 2008
)
0.35
" Finally, we show that yeast nicotinic acid riboside utilization largely depends on uridine hydrolase and nicotinamide riboside kinase and that nicotinic acid riboside bioavailability is increased by ester modification."( Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism.
Belenky, P; Brenner, C; Christensen, KC; Gazzaniga, F; Pletnev, AA, 2009
)
0.35
"This study investigated the cytotoxicity and mechanism of action of AS703026, a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM)."( Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
Anderson, KC; Burger, P; Chauhan, D; Clark, A; Fulciniti, M; Goutopoulos, A; Hideshima, T; Kim, K; Kong, SY; Li, X; Munshi, NC; Nahar, S; Ogden, J; Podar, K; Rastelli, L; Richardson, P; Rumizen, MJ; Song, W; Tai, YT, 2010
)
0.36
" Oral bioavailability and preliminary evidence of activity make this compound an appealing choice for additional investigations."( Motesanib and advanced NSCLC: experiences and expectations.
Blumenschein, GR; Raghav, KP, 2011
)
0.37
" The formulations were optimized by orthogonal design (L(9)(3(4))) and their bioavailability were evaluated in rat, comparing to pH-sensitive Eudragit nanoparticles and suspension of sorafenib."( Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
Fan, JM; Jia, ZR; Liu, YO; Wang, XQ; Zhang, Q; Zhao, B, 2011
)
0.37
" The cocrystals outperformed QUE dihydrate with increases in bioavailability up to nearly 10-fold."( Cocrystals of quercetin with improved solubility and oral bioavailability.
Kavuru, P; Shytle, RD; Smith, AJ; Wojtas, L; Zaworotko, MJ, 2011
)
0.37
" Absolute bioavailability significantly dropped with increasing daily doses of sorafenib."( Saturable absorption of sorafenib in patients with solid tumors: a population model.
Abbas, H; Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Goldwasser, F; Harcouet, L; Hornecker, M; Mir, O; Ropert, S; Sassi, H; Taieb, F; Tod, M, 2012
)
0.38
" We examined both in vivo and in vitro whether the compound might induce vasorelaxation in human blood vessels through the improvement of nitric oxide (NO) bioavailability and a reduction of oxidative stress mediated by endothelial NO synthase (eNOS) function."( Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels.
Dobrucki, LW; Domagala, TB; Dropinski, J; Kalinowski, L; Kotula-Horowitz, K; Leszczynska-Wiloch, M; Polanski, S; Szczeklik, A; Szeffler, A; Wojciechowski, J; Wojnowski, L, 2012
)
0.38
" CF102 demonstrated good oral bioavailability and linear PK behavior."( CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM, 2013
)
0.39
" This could not be explained by in vitro measurements of drug properties and excellent bioavailability with low variability observed in preclinical species."( Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling.
Ding, X; He, M; Kulkarni, R; Patel, N; Zhang, X, 2013
)
0.39
" Previously, we reported on the development of LY2801653: a novel, orally bioavailable oncokinase inhibitor with MET as one of its targets."( Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Bi, C; Credille, KM; Donoho, GP; Manro, JR; Peek, VL; Walgren, RA; Wijsman, JA; Wu, W; Yan, L; Yan, SB, 2013
)
0.39
" Additional studies with nicotinamide riboside in models of Alzheimer's disease indicate bioavailability to brain and protective effects, likely by stimulation of brain NAD synthesis."( Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Chi, Y; Sauve, AA, 2013
)
0.39
" The amorphous form of ATC possesses higher solubility, dissolution rate, and bioavailability than its crystalline form."( Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.
Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A, 2013
)
0.39
" (1) More recently regorafenib (Stivarga) has been developed, which is a further fluorinated version of sorafenib with greater bioavailability and similar inhibitory properties against RAF-1/class III RTKs."( Multi-kinase inhibition in ovarian cancer.
Dent, P, 2014
)
0.4
" Herein, we report a lipid-coated nanodiamond (ND) system loading water-insoluble sorafenib (SND) to improve the bioavailability and efficacy on suppression of cancer metastasis."( The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Bao, X; Chen, J; He, X; Li, Y; Niu, B; Yu, H; Zhang, Z; Zhu, J, 2014
)
0.4
" Sublingually delivered NPs with nicotinamide exhibited high pharmacological availability (>100%) and bioavailability (>80%) at a dose of 5 IU/kg."( Insulin-loaded alginic acid nanoparticles for sublingual delivery.
Devarajan, PV; Patil, NH, 2016
)
0.43
"The purpose of this study was to investigate the effect of preparation methods on cocrystallization between baicalein (BE) and nicotinamide (NCT), their intermolecular interaction, and to demonstrate that BE-NCT cocrystal can achieve the simultaneous enhancement in solubility, dissolution, and oral bioavailability of BE."( Baicalein-nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability.
Gao, Y; Huang, Y; Shi, L; Zhang, B; Zhang, J, 2014
)
0.4
" These results suggest that SeMet may improve glucose tolerance in a NA/STZ-induced mild diabetic mouse model by increasing bioavailability in the pancreas."( Effects of administering sodium selenite, methylseleninic acid, and seleno-L-methionine on glucose tolerance in a streptozotocin/nicotinamide-induced diabetic mouse model.
Arakawa, T; Nakamuro, K; Ogino, H; Okuno, T; Sakazaki, F; Shimizu, R; Ueno, H, 2014
)
0.4
" The structural difference between sorafenib and t-CUPM significantly reduces inhibitory spectrum of kinases by this analogue, and pharmacokinetic characterization demonstrates a 20-fold better oral bioavailability of t-CUPM than sorafenib in mice."( Biological evaluation of a novel sorafenib analogue, t-CUPM.
Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Wecksler, AT; Weiss, RH; Wettersten, HI; Wu, J, 2015
)
0.42
" Noticeably, the in vitro and in vivo studies revealed that co-crystal 1 possesses improved dissolution rate and superior bioavailability on animal model."( Improving the dissolution and bioavailability of 6-mercaptopurine via co-crystallization with isonicotinamide.
Chen, C; Lin, Y; Mei, X; Pan, G; Wang, JR; Yu, X; Zhou, C, 2015
)
0.42
"Despite their strong role in human health, poor bioavailability of flavonoids limits their biological effects in vivo."( Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.
Rupasinghe, HV; Sudan, S, 2015
)
0.42
" However, the low bioavailability of resveratrol raises questions about whether the antidiabetic effects of oral resveratrol can act directly on these tissues."( Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network.
Baur, JA; Breen, DM; Côté, CD; Daljeet, M; Duca, FA; Filippi, BM; Lam, TK; Rasmussen, BA; Zadeh-Tahmasebi, M, 2015
)
0.42
" Starting from compound 1, oral bioavailability was improved by modifying metabolically unstable sites and reducing molecular weight."( Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
Funami, H; Igawa, Y; Iwaki, T; Kamiide, Y; Kanki, S; Koyama, M; Maruoka, H; Muto, T; Nagahira, A; Shibata, M; Takahashi, B, 2015
)
0.42
" However, the oral bioavailability of sorafenib tablet (Nexavar) is merely 38-49% relative to the oral solution, due to the low aqueous solubility of sorafenib and its relatively high daily dose."( Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
Chen, Y; Chen, Z; Li, Y; Liu, C; Lu, J; Qian, F; Wang, S; Wu, G, 2016
)
0.43
"Interaction energies between a family of 36 calix[n]arenes, their corresponding thia- analogues, and two commercially available second generation tyrosine kinase III inhibitors-Bosutinib and Sorafenib-were calculated through DFT methods at the B97D/6-31G(d,p) level of theory, based on Natural Population Analysis, for the in silico development of suitable drug carriers based on the aforementioned macrocycles which can increase their bioavailability and in turn their pharmaceutical efficiency."( A mixed DFT-MD methodology for the in silico development of drug releasing macrocycles. Calix and thia-calix[N]arenes as carriers for Bosutinib and Sorafenib.
Aguilar-Suárez, LE; Barroso-Flores, J; Galindo-Murillo, R, 2016
)
0.43
" In BRAF-mutant melanomas, orally bioavailable B-Raf inhibitors, such as vemurafenib, achieve dramatic responses initially, but this is followed by rapid emergence of resistance driven by numerous mechanisms and requiring second-generation treatment approaches."( B-Raf Inhibition in the Clinic: Present and Future.
Fiskus, W; Mitsiades, N, 2016
)
0.43
" In addtion, to improve their bioavailability and reduce their metabolism, we encapsulated sorafenib and nilotinib into styrene-co-maleic acid micelles."( A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
Archibald, M; Greish, K; Nehoff, H; Pritchard, T; Rosengren, RJ; Taurin, S, 2016
)
0.43
" In vivo pharmacokinetic result demonstrated that an extended circulation and bioavailability of DOX+SOR/iRGD NPs than free drugs."( iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Chan, HF; Chen, M; Hu, J; Liang, G; Skibba, M; Zhang, J, 2016
)
0.43
" LNS were used as nanocarriers for sorafenib owing to their desired features in increasing the solubility and dissolution velocity, improving the bioavailability of sorafenib."( In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N, 2016
)
0.43
" Moreover, 6 is orally bioavailable with a favorable in vivo pharmacokinetic profile."( Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.
Cho, NC; El-Damasy, AK; Keum, G; Nam, G; Pae, AN, 2016
)
0.43
"Pimasertib showed a favourable pharmacokinetic profile with high absolute bioavailability and a unique metabolic pathway (conjugation with phosphoethanolamine)."( Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
Johne, A; Massimini, G; Scheible, H; Udvaros, I; von Richter, O, 2016
)
0.43
" GBT1118 is a novel orally bioavailable small molecule that binds to hemoglobin and produces a concentration-dependent left shift of the oxygen-hemoglobin dissociation curve with subsequent increase in hemoglobin-oxygen affinity and arterial oxygen loading."( Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis.
Dufu, K; Geng, X; Hutchaleelaha, A; Lehrer-Graiwer, J; Li, CM; Li, Z; Oksenberg, D; Patel, MP; Vlahakis, N; Xu, Q, 2016
)
0.43
" Oral administration of NEN to mice significantly slowed growth of genetically induced liver tumors and patient-derived xenografts, whereas niclosamide did not, coinciding with the observed greater bioavailability of NEN compared with niclosamide."( Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B, 2017
)
0.46
"Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts."( Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS, 2017
)
0.46
" The nanocomplex enhanced bioavailability of hydrophobic drugs, efficient tumor cell targeting and exhibited pH-responsive function and sustained release profile."( Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G, 2017
)
0.46
"Minimal information is available on the oral bioavailability and liver-targeting properties of sorafenib solid lipid nanoparticles (SRF-SLNs) in rats."( Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
Sun, S; Wang, H; Xie, B; Yang, W; Yu, M, 2018
)
0.48
" aureus, (iii) larger oral absorption and bioavailability (2."( Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating.
Bolas-Fernandez, F; Dea-Ayuela, MA; Galiana, C; Healy, AM; Mugheirbi, NA; O'Connell, P; Serrano, DR; Walsh, D; Worku, ZA, 2018
)
0.48
" Despite being orally bioavailable in cancer patients, pimasertib undergoes faster clearance with a short elimination half-life."( Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
Srinivas, NR, 2018
)
0.48
"Niacinamide is a stable and water-soluble form of vitamin B3, a valuable and versatile cosmetic ingredient, which is well absorbed and tolerated by the skin."( The protective effect of niacinamide on CHO AA8 cell line against ultraviolet radiation in the context of main cytoskeletal proteins.
Adamczyk, I; Gagat, M; Grzanka, A; Hałas-Wiśniewska, M; Izdebska, M; Kwiatkowska, I; Lewandowska, I, 2018
)
2.23
" The current study evaluated the relative bioavailability of its 2 tablet variants, AAA and NXA, compared with the capsule CSF and assessed the impact of food in healthy participants in a 2-arm, randomized, open-label, 4-way crossover design."( Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2-Arm, Crossover, Randomized, Open-Label Study in Healthy Volunteers.
Kemp, C; Menssen, HD; Quinlan, M; Tian, X, 2019
)
0.51
" Here, we describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays."( Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
Amano, Y; Hamaguchi, H; Higashi, Y; Inoue, T; Ito, M; Moritomo, A; Nakai, K; Nakajima, Y; Nomura, N; Shirakami, S, 2018
)
0.48
" Zoledronic acid is a class III drug with poor oral bioavailability due to its poor permeability and low aqueous solubility; hence an attempt has been made to improve its solubility by co-crystallization technology."( Designing of Stable Co-crystals of Zoledronic Acid Using Suitable Coformers.
Badamane Sathyanarayana, M; Laxmi, P; Pai, A; Pai, G; Sg, V; Varma, A, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"012mg/ml 23oC) and low oral bioavailability (about 35-65% for a once 10mg dose)."( Dissolution rate enhancement of new co-crystals of ezetimibe with maleic acid and isonicotinamide.
Kai, S; Li Na, D; Ling, F; Man, Z; Wen, L; Xiao-Hui, Z; Yan-Jie, H; Yu-Zhen, Y, 2019
)
0.51
" The solubility, dissolution rate and bioavailability of gliclazide SGNCs were significantly improved compared to pure gliclazide."( Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
Bhattamisra, SK; Krishnamoorthy, R; Panda, BP; Patnaik, S; Seng, LB; Shivashekaregowda, NKH, 2019
)
0.51
" Thus, proving cocrystallization to be a potential solution to the solubility limited bioavailability problems of diacerein."( Cocrystals of diacerein: Towards the development of improved biopharmaceutical parameters.
Chadha, R; Chakraborti, S; Grewal, MK; Jindal, A; Tomar, S, 2020
)
0.56
" Peficitinib, an orally bioavailable inhibitor of the Janus kinase (JAK) receptor family, was approved in Japan in 2019 and Korea in 2020 for the treatment of RA."( Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Izutsu, H; Tanaka, Y, 2020
)
0.56
" This crucial role can be attributed to the gut microflora and its ability to shape human behavior and development by mediating the bioavailability of metabolites."( Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects.
Anton, E; Ciobica, A; Cojocariu, RO; Dhunna, N; Doroftei, B; Grab, D; Ilie, OD; Maftei, R; McKenna, J; Simionescu, G, 2020
)
0.56
" This technique could help in improving bioavailability of drug, hence reducing the need for high dosages and signifying a novel paradigm for future clinical applications."( Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy.
Khan, R; Kumar, A; Ray, E; Sharma, A; Shukla, R; Vaghasiya, K; Verma, RK, 2020
)
0.56
" Therefore, a metabolism inhibitor would be necessary to improve the oral bioavailability of emodin further."( Improved Solubility and Oral Absorption of Emodin-Nicotinamide Cocrystal Over Emodin with PVP as a Solubility Enhancer and Crystallization Inhibitor.
An, SH; Ban, E; Jung, BH; Kim, A; Park, B; Park, M; Yoon, NE, 2020
)
0.56
"Co-crystallization with NIC improved the solubility and dissolution profile and, hence, the bioavailability of the poorly water-soluble drug SIM."( Simvastatin-Nicotinamide Co-Crystals: Formation, Pharmaceutical Characterization and in vivo Profile.
Ahmad, M; Idrees, HA; Khan, FM, 2020
)
0.56
" We concluded that PD-CSNPs and PD ameliorate diabetic liver damage by modulating glucose transporter 2 expression, affecting the activity of carbohydrate metabolism enzymes, and suppressing oxidative stress and inflammation, PD-CSNPs being more efficient than PD, probably due to higher bioavailability and prolonged release."( Hepatoprotective Effects of Polydatin-Loaded Chitosan Nanoparticles in Diabetic Rats: Modulation of Glucose Metabolism, Oxidative Stress, and Inflammation Biomarkers.
Abd El-Hameed, AM; Abd El-Twab, SM; Abdel-Moneim, A; El-Shahawy, AAG; Yousef, AI, 2021
)
0.62
"To improve the solubility/dissolution rate of asenapine maleate and hence the bioavailability using the co-crystal approach."( Enhancement of the Solubility of Asenapine Maleate Through the Preparation of Co-Crystals.
Al-Nimry, SS; Khanfar, MS, 2022
)
0.72
"Co-crystals with improved solubility/dissolution rate of asenapine maleate were prepared successfully and were expected to enhance the bioavailability of the drug."( Enhancement of the Solubility of Asenapine Maleate Through the Preparation of Co-Crystals.
Al-Nimry, SS; Khanfar, MS, 2022
)
0.72
" The model allows one to describe on a mechanistic basis why the percutaneous absorption rate of NA is approximately 60-fold lower than that of its lower melting, more lipophilic analog, MN."( Modeling the Percutaneous Absorption of Solvent-deposited Solids Over a Wide Dose Range.
Jaworska, J; Kasting, GB; Tonnis, K; Xu, L; Yu, F, 2022
)
0.72
"This study aimed to improve the in vitro dissolution, permeability and oral bioavailability of adefovir dipivoxil (ADD) by cocrystal technology and clarify the important role of coformer selection on the cocrystal's properties."( Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals.
Gao, Y; Li, L; Ma, K; Pang, Z; Qian, S; Wei, Y; Zhang, J; Zheng, D, 2021
)
0.62
"Coformer selection had an important role on cocrystal's properties, and cocrystallization of ADD with a suitable coformer was an effective approach to enhance both dissolution and bioavailability of ADD."( Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals.
Gao, Y; Li, L; Ma, K; Pang, Z; Qian, S; Wei, Y; Zhang, J; Zheng, D, 2021
)
0.62
"Lenalidomide (LDM), widely used for the treatment of transfusion-dependent anaemia, has low oral bioavailability due to its poor aqueous solubility."( Novel pharmaceutical cocrystal of lenalidomide with nicotinamide: Structural design, evaluation, and thermal phase transition study.
Wang, L; Yan, Y; Zhang, X; Zhou, X, 2022
)
0.72
" Finally, we evaluated the bioavailability of NRTOCl by studying its digestibility in simulated intestinal fluid."( Synthesis, Stability, and Bioavailability of Nicotinamide Riboside Trioleate Chloride.
Abbaspourrad, A; Enayati, M; Khazdooz, L; Lin, T; Madarshahian, S; Mosleh, I; Ufheil, G; Wooster, TJ; Yan, B; Zarei, A, 2021
)
0.62
" And the pharmacokinetic results showed that AZL-NA cocrystal could significantly improve the bioavailability of AZL."( Azilsartan-nicotinamide cocrystal: Preparation, characterization and in vitro / vivo evaluation.
Geng, X; Jin, T; Xiao, Y; Zhu, X, 2022
)
0.72
"To overcome the low bioavailability of lipophilic free thymoquinone (TQ), this study aims to evaluate a novel oral formula of TQ-loaded chitosan nanoparticles (TQ-CsNPs) for the effective treatment of diabetes."( Therapeutic significance of thymoquinone-loaded chitosan nanoparticles on streptozotocin/nicotinamide-induced diabetic rats: In vitro and in vivo functional analysis.
Abdel-Moneim, A; El-Shahawy, AAG; Eldin, ZE; Hosni, A; Hussien, M; Zanaty, MI, 2022
)
0.72
"Recently, coamorphization and cocrystal technologies are of particular interest in the pharmaceutical industry due to their ability to improve the solubility/dissolution and bioavailability of poorly water-soluble drugs, while the coamorphous system often tends to convert into the stable crystalline form usually crystalline physical mixture of each component during formulation preparation or storage."( Mechanistic Study on Transformation of Coamorphous Baicalein-Nicotinamide to Its Cocrystal Form.
Cao, W; Ding, F; Gao, Y; Li, A; Pang, Z; Qian, S; Wang, N; Wang, R; Wei, Y; Zhang, J, 2023
)
0.91
" Due to its beneficial effects and to the evidence of the reduction of NAD bioavailability with aging, researchers are seeking ways to replenish the cellular NAD pool, by administrating its precursors (NAM and NR), believing that it will reduce the RGC vulnerability to external stressors, such as increased IOP."( The use of Nicotinamide and Nicotinamide riboside as an adjunct therapy in the treatment of glaucoma.
Costa, VP; Goulart Nacácio E Silva, S; Occhiutto, ML, 2023
)
0.91
" The results highlight that the ELT obtained tremendous improvements in water solubility and bioavailability after cocrystal formation."( First cocrystal of esculetin: Simultaneously optimized in vitro/vivo properties and antioxidant effect.
Han, CB; Li, JY; Li, YT; Liu, F; Sun, WJ; Tong, SY; Wang, JH; Wang, XK, 2023
)
0.91
" This antiviral activity of LL37 is enhanced by the hydrotropic action of niacinamide, which may increase the bioavailability of the AMP."( Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruption.
Ajnabi, J; Bhatt, T; Dam, B; Dias, PM; Ghatlia, N; Gulzar, SE; Jamora, C; Kataria, S; Khedkar, SU; Lall, S; Majumdar, A; Pandey, S; Raut, J; Sundaramurthy, V; Vemula, PK; Waskar, M, 2023
)
2.58

Dosage Studied

Niacinamide cannot stimulate VEGF synthesis across a broad dose-response range. Study was to assess the feasibility of extemporaneous compounding of slow-release oral dosage form of niac inamide.

ExcerptRelevanceReference
" Probit analysis of the cleft-palate response to dose of different genotypes revealed a family of linear and parallel dose-response curves."( 6-Aminonicotinamide-induced cleft palate in the mouse: the nature of the difference between the A/J and C57Bl/6J strains in frequency of response and its genetic basis.
Biddle, FG, 1977
)
0.26
" Recommendations are offered with respect to dosage of the vitamins and duration of their administration in order to assist in correcting vitamin deficiency revealed."( [Vitamin B1, PP and C allowances of weight lifters and their requirements during training and competition periods].
Kononenko, AI; Podorozhnyi, PG,
)
0.13
" Hemodynamic responses occurred within 5 min of dosing and terminated within 240 min."( Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Giles, TD; Hearron, AE; Karalis, DG; Mohrland, JS; Pina, IL; Porter, RS; Quiroz, AC; Roffidal, L; Wolf, DL; Zaleski, R, 1992
)
0.28
" After 3 weeks, the dosage could be doubled according to clinical criteria."( Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study.
Bucx, JJ; Henneman, JA; Hugenholtz, PG; Kelder, JC; Kerker, JP; Meeter, K; Tijssen, JG, 1992
)
0.28
" There was no biostatistical agreement between the two methods in estimating cardiovascular function either before or after dosing (ZCG estimated substantially larger SV, CO and lower TPR)."( Agreement and reproducibility of the estimates of cardiovascular function by impedance cardiography and M-mode echocardiography in healthy subjects.
Belz, GG; Butzer, R; de Mey, C; Matthews, J; Schroeter, V, 1992
)
0.28
" Phentolamine, antazoline, tolazoline, and midaglizole also shifted the dose-response curve for nicorandil to the right in the dose range of 1-100 microM."( Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein.
Ichihara, K; Nagasaka, M; Okumura, K, 1992
)
0.28
" The dose-response curves for AZT and probenecid, an organic anion inhibitor, revealed IC50 values of 225 and 15 microM, respectively."( Interaction of 3'-azido-3'-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles.
Griffiths, DA; Hall, SD; Sokol, PP, 1991
)
0.28
" In conclusion, whereas nicorandil possesses a dilatory action on both large and small coronary arteries, in a clinical setting, with a daily dosage of 15-30 mg, part of the beneficial effects of nicorandil may be the result of a dilation of the large coronary arteries and may be due to the fact that a coronary steal phenomenon does not occur after nicorandil administration."( Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs.
Hashimoto, K; Kinoshita, M; Ohbayashi, Y, 1991
)
0.28
" Niaprazine at a daily dosage of 1 mg/kg body weight or placebo at random was administered to a selected group of 36 children (aged from 6 months to 6 years) suffering from frequent nighttime waking or inability to fall asleep."( The effect of niaprazine on some common sleep disorders in children. A double-blind clinical trial by means of continuous home-videorecorded sleep.
Cortesi, F; Giannotti, F; Ottaviano, S, 1991
)
0.28
" At 24 hours from dosing about 35% of the dose had been excreted as inorganic sulphate and 20."( The metabolism of thionicotinamide in the rat.
Ruse, MJ; Waring, RH, 1991
)
0.28
"The aim was to evaluate the effective and safe dosage for intracoronary administration of nicorandil (2-nicotinamidoethyl nitrate) in dogs."( Determination of effective and safe dose for intracoronary administration of nicorandil in dogs.
Ishikawa, S; Kojima, S; Mori, H; Ohsawa, K, 1990
)
0.28
" A dose-response curve was constructed for DQ-2556 inhibition of NMN transport in rat BBMV."( Effect of DQ-2556, a new cephalosporin, on organic ion transport in renal plasma membrane vesicles from the dog, rabbit and rat.
Sokol, PP, 1990
)
0.28
" Dose-response curves for the increase in coronary blood flow produced by nicorandil or cromakalim were shifted to the right in a parallel manner and to similar extents by glibenclamide given intravenously to support dogs."( Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Satoh, K; Taira, N; Yoneyama, F, 1990
)
0.28
" The recommended dosage is 20 drops three times daily, to be taken for 5 to 10 years following cancer surgery."( [GELUM oral-rd: blood pH regulator and oxygen activator. Documentation No.27].
Deplazes, G; Hauser, SP, 1990
)
0.28
" Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators."( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
Holzmann, S; Kukovetz, WR, 1987
)
0.27
" The dose-response curve of nifedipine was shifted parallel to the right by the infusion of Bay K 8644 and the dose-ratio was the greatest of the 4 drugs."( Differential antagonism by Bay K 8644 of vasodilator effects of nifedipine, diltiazem, nicorandil and nitroglycerin in dog femoral circulation.
Ishii, K; Sato, Y; Taira, N, 1988
)
0.27
"This report presents the findings of some studies on single intravenous and oral dosing performed in healthy volunteers to determine the pharmacokinetics and preliminary metabolism of nicorandil, a new vasodilator acting via increase of both membrane potassium conductance and intracellular cyclic guanosine monophosphate in vascular smooth muscle."( Pharmacokinetics of nicorandil.
Bouthier, J; Bruno, R; Caplain, H; Chapelle, P; Diekmann, H; Frydman, AM; Gaillard, C; Le Liboux, A; Thebault, JJ; Ungethuem, W, 1989
)
0.28
" Nicorandil administration produced a significant decrease in systolic and diastolic blood pressure, from 18 minutes after dosing which lasted up to the end of the study (i."( Effects of nicorandil on arterial and venous vessels of the forearm in systemic hypertension.
Bouthier, J; Chau, NP; Levenson, J; Roland, E; Simon, AC, 1989
)
0.28
" Maximal hemodynamic changes were observed 30 minutes after dosing and remained statistically significant at 3 hours."( Hemodynamic action of nicorandil in chronic congestive heart failure.
Bouthier, J; Dahan, M; Gourgon, R; Jaeger, P; Juliard, JM; Solal, AC, 1989
)
0.28
" NE- and KCI-induced dose-response relationships were differentially depressed by SG-75 (NE much greater than KCI) and NIF (KCI much greater than NE)."( Effects of 2-nicotinamidoethyl nitrate on agonist-sensitive Ca++ release and Ca++ entry in rabbit aorta.
Hester, RK, 1985
)
0.27
" Intravenous infusion of CM 57755 induced a parallel shift to the right of the dimaprit dose-response curve."( Inhibition of dimaprit- and pentagastrin-induced gastric acid secretion in cats by the new histamine H2 antagonist, CM 57755.
Bianchetti, A; Lavezzo, A; Manara, L; Manzoni, L, 1986
)
0.27
" Dose-response relations with regard to guanylate cyclase stimulation of organic nitrates and sodium nitrite were compared in the presence of cysteine and its closely related methylester."( Guanylate cyclase activation by organic nitrates is not mediated via nitrite.
Kukovetz, WR; Romanin, C, 1988
)
0.27
" Nor did their 14CO2 production differ after intraperitoneal dosing with [methylene-14C]tryptophan."( Leucine excess and niacin status in rats.
Carpenter, KJ; Cook, NE, 1987
)
0.27
" A dose-response curve for MPTP and its oxidized metabolite, MPP+, revealed IC50 values of 160 and 16 microM, respectively."( The neurotoxins 1-methyl-4-phenylpyridinium and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine are substrates for the organic cation transporter in renal brush border membrane vesicles.
Holohan, PD; Ross, CR; Sokol, PP, 1987
)
0.27
" Stimulation by ascorbate of the hexose monophosphate shunt of adherent neutrophils and augmentation by ascorbate of neutrophil mobility had comparable dose-response relationships, could be reversed by washing the cells, and were both suppressed by preincubation of the neutrophils with 6-aminonicotinamide, but not with the neutrophil-immobilizing factor."( Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid.
Austen, KF; Gigli, I; Goetzl, EJ; Wasserman, SI, 1974
)
0.25
" Damage was measured by alkaline elution 24 hrs after dosing with BOP."( Nicotinamide stimulates the repair of carcinogen-induced DNA damage in the hamster pancreas in vivo.
Lawson, T,
)
0.13
"Comparisons were made of the dose-response and time-course characteristics of nicotinamide (NIC) and its metabolite, N1-methylnicotinamide (MNIC), protection from alloxan-induced diabetes in mice."( Characteristics of nicotinamide and N1-methylnicotinamide protection from alloxan diabetes in mice.
Falany, J; Fischer, LJ; Fisher, R, 1983
)
0.27
"Studies on controlled release dosage forms were conducted by using waxy materials for a newly developed anti-allergy drug, 6-methyl-N-(1H-tetrazol-5-yl)-2-pyridinecarboxamide (TA-5707F), which is not maintained at an effective level in blood for a long duration."( Preparation of controlled release tablets of TA-5707F with wax matrix type and their in vivo evaluation in beagle dogs.
Maejima, T; Osawa, T; Yamakita, H, 1995
)
0.29
" To measure the dose-response kinetics of bolus injections of intracoronary nicorandil and to compare the vasodilatory response to nicorandil with that of intracoronary papaverine in humans, coronary blood flow velocity was measured in 30 patients using a 3Fr intravascular Doppler catheter."( Coronary microvascular response to intracoronary administration of nicorandil.
Hongo, M; Nakatsuka, T; Sekiguchi, M; Takenaka, H; Uchikawa, S; Watanabe, N, 1995
)
0.29
" Employing additional short term infusions, dose-response curves were obtained by giving nicorandil or glyceryl trinitrate at increasing dosages both in the preinfusion control state and 4 h after terminating the nicorandil infusion."( Long term increases in coronary arterial conductance during five day infusion of low dose nicorandil.
Bassenge, E; Fink, B; Huckstorf, C; Sommer, O, 1994
)
0.29
" However, at the higher dose there was a shift of the dose-response curve of both nicorandil and glyceryl trinitrate to the right, indicating some tolerance."( Long term increases in coronary arterial conductance during five day infusion of low dose nicorandil.
Bassenge, E; Fink, B; Huckstorf, C; Sommer, O, 1994
)
0.29
" In healthy volunteers and at this dosage (10 mg twice a day), cross tolerance between nicorandil and nitroglycerin does not occur."( Comparison of tolerance to intravenous nitroglycerin during nicorandil and intermittent nitroglycerin patch in healthy volunteers.
Billon, N; Funck-Brentano, C; Jaillon, P; Tabone, X, 1994
)
0.29
" The dose-response relation between ATP and the UDP-induced KATP-channel activity was shifted to the right in the presence of Mg2+ (2 mM)."( Regulation of ATP-sensitive K+ channels by ATP and nucleotide diphosphate in rabbit portal vein.
Kamouchi, M; Kitamura, K, 1994
)
0.29
"Two types of multiple controlled release dosage forms, hydroxypropylmethyl cellulose acetyl succinate (HPMC-AS) coated granules and double layer coated granules with HPMC-AS and ethyl cellulose (EC), were prepared for the newly developed antihistaminergic drug, TA-5707F, using a centrifugal fluidizing granulator."( Preparation of controlled release granules of TA-5707F using enteric polymers and ethylcellulose, and their in vivo evaluation.
Maejima, T; Matsukawa, Y; Osawa, T; Yamakita, H, 1996
)
0.29
" Particular attention was focused on the aspects of dose-response relationship, temperature sensitivity, and ischemic tolerance."( Effect of the potassium-channel opener nicorandil as an adjunct to cardioplegia on myocardial preservation in isolated rabbit hearts.
Sunamori, M; Wang, Y; Yoshida, T, 1996
)
0.29
" Prior exposure to FeSO4/H2O2 produced significant endothelial damage as reflected by the right-ward shift of the dose-response curve of bradykinin-induced endothelium-dependent relaxation."( Hydroxyl radical scavenging effect of nicaraven in myocardial and coronary endothelial preservation and reperfusion injury.
Alam, MS; Hashimoto, M; Ku, K; Masumura, S; Nakayama, K; Nosaka, S; Saitoh, Y; Tamura, K; Yamauchi, M, 1997
)
0.3
" When dosed orally JTV-506 (0."( Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs.
Aisaka, K; Hirata, Y, 1997
)
0.3
" Preincubation with the antithyroid drug methimazole, at concentrations ranging from 0-25 microM, prevented superoxide-induced fibroblast proliferation in a dose-response pattern."( Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy.
Bahn, RS; Barnes, S; Burch, HB; Lahiri, S, 1997
)
0.3
" At every dose level, rSO2 and BVI were determined, and the dose-response relationship was obtained."( [Effects of nicorandil on regional cerebral oxygen saturation].
Dohi, S; Kasuya, Y, 1997
)
0.3
" Nicorandil (3 mg/kg) given orally was rapidly absorbed, reaching the maximal plasma (approximately 2,600 ng/ml) and vascular concentrations (approximately 176 ng/g) at 15 min after the dosing and thereafter decreased rapidly."( Vascular levels and cGMP-increasing effects of nicorandil administered orally to rats.
Akima, M; Kamachi, S; Kitajima, S; Moriyasu, M; Sakai, K; Tanikawa, M, 1998
)
0.3
" Nicorandil (100 micrograms kg-1 bolus, 25 micrograms kg-1 min-1 infusion) was begun and a second dose-response study of isoflurane was obtained as before."( Cardiovascular effects of concomitant administration of isoflurane and nicorandil in dogs.
Bastien, O; Foëx, P; Pigott, D; Piriou, V; Ross, S; Trivin, F, 1998
)
0.3
" To examine the effect of supplementing energy metabolism on METH-induced dopamine content depletions, the striatum was perfused directly with decylubiquinone or nicotinamide to enhance the energetic capacity of the tissue during or after a neurotoxic dosing regimen of METH."( Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum.
Douglas, AJ; Lust, WD; Stephans, SE; Whittingham, TS; Yamamoto, BK, 1998
)
0.3
" As the result, the urinary excretion of Nam, N1-methyl-4-pyridone-3-carboxamide (4-Py), Nam + N1-methylnicotinamide (MNA) + N1-methyl-2-pyridone-5-carboxamide (2-Py) + 4-Py was lower in the CCl4-treated groups than in the non-treated group (control) regardless of the experimental period (1 mo and 2 mo) or dosing amount of CCl4 (0."( Tryptophan-niacin metabolism in liver cirrhosis rat caused by carbon tetrachloride.
Egashira, Y; Isagawa, A; Komine, T; Ohta, T; Sanada, H; Shibata, K; Yamada, E, 1999
)
0.3
" We evaluated the effects of hydroxyl radical scavenger AVS [(+/-)-N,N'-propylenedinicotinamide; Nicaraven] after experimental SAH on rodent behavioral deficits (employing a battery of well-characterized assessment tasks over a 2-day observation period) and blood-brain barrier (BBB) permeability changes two days after SAH (quantifying the microvascular alterations according to the extravasation of protein-bound Evans Blue using a spectrophotofluorimetric technique) in dose-response and time-window experiments."( Effects of the radical scavenger AVS on behavioral and BBB changes after experimental subarachnoid hemorrhage.
Costa, G; d'Avella, D; Germanò, A; Imperatore, C; Tomasello, F, 2000
)
0.31
" To estimate the N-methylation ability for azaheterocyclic amines in parkinsonian patient, nicotinamide was dosed with 100 mg to 26 parkinsonians and 20 controls consisted of 16 other neurogenic disease patients and 4 healthy volunteers."( N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test.
Aoyama, K; Fukushima, S; Hayase, N; Kobayashi, S; Matsubara, K; Ohta, S; Okada, K; Satomi, M; Shimizu, K; Shiono, H; Uezono, T; Yamaguchi, S, 2000
)
0.31
" However, the dosage and time of treatment require clarification."( Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.
Adams, JD; Chan, P; Chang, ML; Kem, S; Klaidman, LK; Sugawara, T; Yang, J, 2002
)
0.31
" The results suggest that early application of nicotinamide at a suitable dosage significantly ameliorates necrotic and apoptotic brain injury after focal ischemia-reperfusion."( Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.
Adams, JD; Chan, P; Chang, ML; Kem, S; Klaidman, LK; Sugawara, T; Yang, J, 2002
)
0.31
" Once daily oral dosing of BAY 43-9006 demonstrated broad-spectrum antitumor activity in colon, breast, and non-small-cell lung cancer xenograft models."( BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X, 2004
)
0.32
" However, a randomized, double-blind, placebo-controlled, multicenter trial showed that thioctic acid at an oral dosage of 800 mg/day for 4 months significantly improved cardiac autonomic neuropathy in type 2 diabetic patients."( The role of antioxidant micronutrients in the prevention of diabetic complications.
Bonnefont-Rousselot, D, 2004
)
0.32
"At the dosage used, calcitriol has a modest effect on residual pancreatic beta-cell function and only temporarily reduces the insulin dose."( The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI).
Anguissola, GB; Bizzarri, C; Cavallo, MG; Crinò, A; Di Stasio, E; Guglielmi, C; Manfrini, S; Matteoli, MC; Patera, IP; Pitocco, D; Pozzilli, P; Spera, S; Suraci, C; Visalli, N, 2006
)
0.33
"Oral administration of ML120B inhibited paw swelling in a dose-dependent manner (median effective dosage 12 mg/kg twice daily) and offered significant protection against arthritis-induced weight loss as well as cartilage and bone erosion."( IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Anderson, K; Chandra, S; DuPont, M; Gangurde, P; Harriman, G; Hepperle, M; Jaffee, B; Kujawa, J; Lane, J; Morgan, J; Ocain, T; Savinainen, A; Schopf, L; Siebert, E; Silva, M; Wen, D; Xu, Y, 2006
)
0.33
" In mechanism of action studies, using the 786-O and Renca RCC tumor models, the effect of sorafenib was assessed after dosing for 3 or 5 days in the SC models and 21 days in the SRC models."( Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D, 2007
)
0.34
" In the PLC/PRF/5 xenograft model, sorafenib tosylate dosed at 10 mg/kg inhibited tumor growth by 49%."( Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X, 2006
)
0.33
"Floating dosage forms enable the sustained delivery of drugs in the gastro-intestinal tract."( Sustained release of hydrophobic and hydrophilic drugs from a floating dosage form.
Boey, FY; Tang, YD; Venkatraman, SS; Wang, LW, 2007
)
0.34
" elegans), increased dosage of the gene encoding SIR-2."( The Caenorhabditis elegans nicotinamidase PNC-1 enhances survival.
Burgering, BM; Pellis-van Berkel, W; Schavemaker, JM; van der Horst, A, 2007
)
0.34
" Twelve healthy males were enrolled in an open-label, dose-rate escalation study and received 2000 mg niacin at 3 different dosing rates."( Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites.
Adams, MH; Cefali, EA; González, MA; Leu, JH; Menon, RM; Tolbert, DS, 2007
)
0.34
" These trials followed different treatment regimens (7 days on/7 days off, n = 19; 21 days on/7 days off, n = 44; 28 days on/7 days off, n = 41; or continuous dosing, n = 69) to establish the optimum dosing schedule."( Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Awada, A; Clark, JW; Eder, JP; Hendlisz, A; Hirte, HW; Lenz, HJ; Moore, MJ; Richly, H; Schwartz, B; Strumberg, D, 2007
)
0.34
" In conclusion, FT-Raman spectroscopy is a fast and valuable tool for a quantitative determination of the extents of incompatibility in solid dosage forms."( Compaction of lactose drug mixtures: quantification of the extent of incompatibility by FT-Raman spectroscopy.
Flemming, A; Picker-Freyer, KM, 2008
)
0.35
"The study design includes two different dosage arms and a placebo group with a total sample size of 150 patients and is powered to detect a modest reduction in the mean tumor size burden in the high-dose sorafenib arm compared with a slight increase in the placebo group."( Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM, 2007
)
0.34
") on a continuous dosing schedule."( Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T, 2007
)
0.34
" The authors highlight the case of a 51-year-old Caucasian woman treated for metastatic renal cell carcinoma who presented with well-defined tender erythematous callosities of the fingers and feet, following a dosage increase of sorafenib."( Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis, NI; Maroon, MS, 2008
)
0.35
" The rapidity and frequency of sorafenib dose reductions indicates that sorafenib at 200 mg twice daily with bevacizumab 5 mg/kg every 2 weeks may not be tolerable long term, and alternate sorafenib dosing schedules should be explored."( Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ, 2008
)
0.35
" However, this was accompanied by a grade 3 skin reaction, which improved as sorafenib dosage was gradually reduced."( Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Chen, CK; Chen, YJ; Hsieh, CH; Jeng, KS; Lin, CC; Lin, CP; Liu, CY; Shueng, PW; Tai, HC; Wang, CH, 2009
)
0.35
" Subsequently, the effects of a 1-week chronic daily dosing of DPP-IV inhibitors and sulfonylureas were investigated."( Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
Hayakawa, M; Matsuyama-Yokono, A; Nakano, R; Shibasaki, M; Shiraki, K; Someya, Y; Tahara, A, 2009
)
0.35
" Sorafenib dosed at 50 mg/kg and 100 mg/kg inhibited tumour growth by 85% and 96%, respectively."( Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Choo, SP; Chow, P; Chung, A; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Soo, KC; Thng, CH, 2009
)
0.35
") injection of 55 mg/kg STZ and a nicotinamide group (1g/kg/day) which were dosed orally for 3 days followed by (i."( Effect of nicotinamide on experimental induced diabetes.
Alenzi, FQ, 2009
)
0.35
" The safety and efficacy, and optimal dosing and timing of starting replacement therapy in patients affected by TKI-related hypothyroidism need accurate appraisal and should be evaluated prospectively in appropriately designed trials."( Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F, 2009
)
0.35
" These agents can increase wakefulness (W) in cats and rodents following acute administration, but their effects after repeat dosing have not been reported previously."( Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
Anaclet, C; Brown, SH; Buda, C; Feng, JQ; Franco, P; Guidon, G; Guo, RX; Lin, JS; Medhurst, AD; Parmentier, R; Roberts, JC; Sastre, JP; Upton, N; Zhang, M, 2009
)
0.35
" After twice daily dosing for 8 days, the effect of GSK189254 (10 mg x kg(-1)) on W in both Ox+/+ and Ox-/- mice was significantly reduced, while the effect on narcoleptic episodes in Ox-/- mice was significantly increased."( Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
Anaclet, C; Brown, SH; Buda, C; Feng, JQ; Franco, P; Guidon, G; Guo, RX; Lin, JS; Medhurst, AD; Parmentier, R; Roberts, JC; Sastre, JP; Upton, N; Zhang, M, 2009
)
0.35
" Moreover, the differential effects observed on W and narcoleptic episodes following repeat dosing could have important implications in clinical studies."( Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.
Anaclet, C; Brown, SH; Buda, C; Feng, JQ; Franco, P; Guidon, G; Guo, RX; Lin, JS; Medhurst, AD; Parmentier, R; Roberts, JC; Sastre, JP; Upton, N; Zhang, M, 2009
)
0.35
"MTT colorimetric assay was used to obtain the dose-response curve of sorafenib in BEL-7402/FU cells, and flow cytometry performed to assess the effect of sorafenib on Rho123 concentration in the cells."( [Sorafenib reverses multidrug resistance of hepatoma cells in vitro].
Cui, YZ; Huang, N; Li, AM; Lü, CW; Luo, RC; Wei, L; Yang, L; Zheng, DY; Zheng, H, 2009
)
0.35
" The results suggest that nicotinic acid in a dosage of 16."( Investigation of niacin on parameters of metabolism in a physiologic dose: randomized, double-blind clinical trial with three different dosages.
Reimann, J; Schön, C; Schweikart, J, 2009
)
0.35
" The medication dosed at 400 mg twice daily is both efficacious and safe in the treatment of metastatic renal cell carcinoma in Chinese patients."( Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Dai, B; Dong, B; Huang, Y; Lu, JJ; Shen, Y; Yao, X; Ye, D; Zhang, H; Zhang, S; Zhu, Y, 2009
)
0.35
" In light of the important role of NK cells in antitumor immunity, and because multiple approaches presently aim to combine PKI treatment with immunotherapeutic strategies, our data demonstrate that choice and dosing of the most suitable PKI in cancer treatment requires careful consideration."( The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
Baessler, T; Kampa, KM; Krusch, M; Mayer, F; Salih, HR; Salih, J; Schlicke, M, 2009
)
0.35
" In order to assess the safety of sorafenib in PAH, patients with advanced but stable disease on parenteral prostanoids (with or without oral sildenafil) were initiated on treatment at the lowest active dosage administered to cancer patients: 200 mg daily."( A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L, 2010
)
0.36
"Fifty patients with advanced HCC, Child-Pugh A or B, received sorafenib at a dosage of 800 mg/day for 28 days with a following week of rest and long-acting octreotide at a dose of 40 mg, administered every 28 days."( Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B, 2010
)
0.36
"Intermittent sorafenib dosing with bevacizumab has promising clinical activity and less sorafenib dose reduction and side effects, but does not ameliorate HFSR."( Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Annunziata, CM; Azad, N; Houston, N; Kohn, EC; Kotz, H; Lee, JM; Minasian, L; Sarosy, GA; Squires, J, 2010
)
0.36
" Together the present study clearly reflects that combined dosage of tetrahydrocurcumin and chlorogenic acid augments enzymic antioxidants with a concomitant decrease in lipid peroxidation and protects against streptozotocin-nicotinamide-induced type 2 diabetes in experimental rats."( Comparative and combined effect of chlorogenic acid and tetrahydrocurcumin on antioxidant disparities in chemical induced experimental diabetes.
Karthikesan, K; Menon, VP; Pari, L, 2010
)
0.36
" There is little information on the dosage adjustment of sorafenib for patients with end-stage renal failure."( Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Inui, K; Kamba, T; Mizuno, T; Nakamura, E; Ogawa, O; Shinsako, K; Terada, T; Watanabe, J, 2010
)
0.36
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."( Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011
)
0.37
"The dose cohorts consisted of fixed continuous oral dosing of 400 mg sorafenib twice daily, starting at 14 days before tanespimycin, which was administered intravenously at escalating doses (starting at 300 mg/m,(2) with 50 mg/m(2) increments), on days 1, 8, and 15 in a 28-day cycle."( Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN, 2010
)
0.36
"We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen."( A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M, 2010
)
0.36
" Additional data on plasma pharmacokinetics after oral dosing and the plasma free fraction gave a corresponding estimate of the free concentration of GSK189254 required to occupy 50% of the available receptor sites (EC(50)) (0."( Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET.
Ashworth, S; Comley, RA; Cunningham, VJ; Gee, AD; Gunn, RN; Lai, RY; Laruelle, M; Plisson, C; Rabiner, EA; Wilson, AA, 2010
)
0.36
" Key aspects of sorafenib pharmacology, dosing in the presence of organ dysfunction, toxicities and weaknesses of the research done so far are summarized."( Sorafenib: a clinical and pharmacologic review.
Fetterly, G; Iyer, R; Lugade, A; Thanavala, Y, 2010
)
0.36
" A dose-response trend existed for increasing concentrations of nicotinamide, but it was not significant."( Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.
Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010
)
0.36
"The relatively small patient numbers, relatively high placebo effect, and maximum in-life portion of only 12 weeks of dosing are weaknesses of the study."( Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.
Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010
)
0.36
" This should be relevant for dosing regiments to optimize the treatment with this promising anti-tumour drug."( Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
Fischer, JW; Grandoch, M; Rose, A; Rosenkranz, A; Rübben, H; vom Dorp, F; Weber, AA, 2010
)
0.36
" Dosing in both treatment phases was generally well tolerated with manageable toxicities and no requirement for dose reduction."( Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG, 2010
)
0.36
"After lower dosage of sorafenib was used as a combination with hepatic arterial infusion chemotherapy, size of hepatic lesions and level CA19-9 of peripheral blood count were decreased, without any damage to the hepatic function, except for temporary skin hyperkeratosis as well as vomit."( Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun, W; Tao, Y,
)
0.13
" Hence, dosing will play a critical role in clinical studies assessing the merits of NIC and TAU as diabetes-preventing agents."( Comparative study of the binding characteristics to and inhibitory potencies towards PARP and in vivo antidiabetogenic potencies of taurine, 3-aminobenzamide and nicotinamide.
Lau-Cam, CA; Pandya, KG; Patel, MR, 2010
)
0.36
" These combinations appear to be the most promising for in vivo pre-clinical studies, with a view to testing in melanoma patients as a continuous dosing strategy, due to the in vitro additive inhibitory effect on growth seen in both endothelial and cancer cells."( Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P, 2010
)
0.36
" In addition to basic therapy, 16 patients of the main group were treated with the antioxidant power-normalizing drug cytoflavin used in dosage 20 ml/day intravenous in drops from the 1st to 10th day and 2 tablets twice a day from the 11th to 35th day."( [Effect of early correction of energy and free-radical homeostasis on the clinical-morphological presentation of cerebral infarction].
Bolevich, SB; Fedin, AI; Goluzova, IuN; Iliukhina, OA; Men'shova, NI; Rumiantseva, SA; Silina, EV; Vasil'ev, IuD, 2010
)
0.36
" 3 patients remain on sorafenib, 2 at a reduced dosage (600 mg/d)."( Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
Frank-Raue, K; Ganten, M; Kreissl, MC; Raue, F, 2011
)
0.37
" The population pharmacokinetic/pharmacodynamic model provides a tool for predicting tumor response to the drug to support the dosing regimen of motesanib in thyroid cancer patients."( Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Bruno, R; Claret, L; Kuchimanchi, M; Lu, JF; Melara, R; Sun, YN; Sutjandra, L, 2010
)
0.36
" Dose-response simulations were performed in patients with differentiated thyroid cancer."( Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer.
Bruno, R; Claret, L; Lu, JF; Sun, YN, 2010
)
0.36
"The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome."( A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011
)
0.37
" This leads to the decrease in intrahepatic vascular resistance, but also to liver damage in the dosage we used."( Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J, 2011
)
0.37
" Although treatment-associated AEs are common, the majority of AEs reported during clinical trial experiences were grade 1 or 2 in severity and manageable with intervention in the form of supportive measures and/or dosage modification."( Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud, A, 2011
)
0.37
" This model can be used to simulate and explore alternative dosing regimens and to develop exposure-response relationships for sorafenib."( Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Dahut, WL; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Mould, DR; Venitz, J; Woo, S; Yarchoan, R, 2011
)
0.37
" However, it is very difficult to estimate sorafenib dosage because it is difficult to maintain stable administration and dosage intervals due to several side-effects."( One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Arai, Y; Imazu, T; Inoue, H; Kajikawa, J; Kawashima, A; Kinoshita, T; Nin, M; Nishimura, K; Nonomura, N; Takada, S; Takayama, H; Tanigawa, G; Tsujimura, A; Yasunaga, Y, 2011
)
0.37
" Cohort C explored an alternate schedule of 7-day on/7-day off flat dose capecitabine 1,000 mg BID with continuous dosing of sorafenib 400 mg BID."( A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA, 2012
)
0.38
" The rate of grade 3 HFSR is concerning and limits the feasibility of prolonged dosing of sorafenib with capecitabine 1,000 mg/m(2) on the 21-day schedule."( A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA, 2012
)
0.38
" Overexpression of Sas2-mediated H4K16 acetylation activity in wild-type cells led to increased rates of chromosome loss and synthetic dosage lethality in kinetochore mutants."( A role for histone H4K16 hypoacetylation in Saccharomyces cerevisiae kinetochore function.
Acuña, R; Au, WC; Basrai, MA; Choy, JS, 2011
)
0.37
" In the main group (n=61), the complex treatment included cytoflavin in dosage 2 ml/kg/day, intravenously during 5 days."( [Clinical-encephalographic evaluation of preterm children treated with cytoflavin during the first year of life].
Asmolova, GA; Degtiareva, MG; Grebennikova, OV; Rogatkina, SO; Serova, ND; Sigova, IuA; Volodin, NN, 2011
)
0.37
"Previous research has demonstrated considerable preclinical efficacy of nicotinamide (NAM; vitamin B(3)) in animal models of TBI with systemic dosing at 50 and 500 mg/kg yielding improvements on sensory, motor, cognitive and histological measures."( Continuous nicotinamide administration improves behavioral recovery and reduces lesion size following bilateral frontal controlled cortical impact injury.
Anderson, GD; Hoane, MR; Vonder Haar, C, 2011
)
0.37
" Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic spread of the tumor, radiologic response at month 2, and sorafenib dosing were independent predictors of shortened survival."( Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C, 2011
)
0.37
" For the patient with liver cirrhosis, who is receiving warfarin, PT-INR values might be elevated during the early period of sorafenib treatment dosage as for the increase in quantity."( [Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2011
)
0.37
" Simulations were done to compare different daily dosing regimens in a context of dose-escalation."( Saturable absorption of sorafenib in patients with solid tumors: a population model.
Abbas, H; Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Goldwasser, F; Harcouet, L; Hornecker, M; Mir, O; Ropert, S; Sassi, H; Taieb, F; Tod, M, 2012
)
0.38
"Fifteen hepatocellular carcinoma patients with Child-Pugh A cirrhosis, in whom sorafenib dosing remained unchanged from initiation of treatment to disease progression, were eligible for this analysis."( Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B, 2012
)
0.38
"A modification of the sorafenib dosing schedule involving higher dose intermittent treatment appeared to improve its efficacy in this xenograft model relative to conventional dosing."( High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Brown, V; Goldberg, SN; Mier, JW; Signoretti, S; Wang, X; Zhang, L, 2011
)
0.37
" In the in vitro study, sorafenib impaired the viability of H295R cells with dose-response and time-response relationships."( Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M, 2012
)
0.38
"• Transarterial chemoembolisation (TACE) is widely used in patients with hepatocellular carcinoma (HCC) • Various antiangiogenic and other agents have been used to augment this treatment • We tested lipiodol-TACE with bilirubin-adjusted doxorubicin dosing in combination with sorafenib • This trial was stopped prematurely because of safety reasons • Our safety results do not support the combination of sorafenib with this TACE regimen."( Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W, 2012
)
0.38
" Concomitant 5-FU/LCV resulted in no clinically relevant changes in the area under the plasma concentration-time curve in the dosing interval (AUC(0-12)) and maximum plasma concentration (C(max)) of sorafenib (100-400 mg bid) at steady state."( Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S, 2012
)
0.38
" They started on a reduced dose of sorafenib which increased to the standard dosage according to tolerance in each patient."( Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
Chang, HM; Kang, YK; Kim, JE; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Suh, DJ, 2012
)
0.38
" On the other hand, the optimal combination and dosage of these drugs, selection of the apropriate biomarker and better understanding of the conflicting role of PDGFR and FGFR signaling in angiogenesis remain future challenges."( [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Döme, B; Török, S, 2012
)
0.38
" Furthermore, the RAIN-Droplet model has facilitated the discovery of a novel pro-angiogenic capacity for sorafenib, which may impact the clinical application and dosing regimen of that drug."( RAIN-Droplet: a novel 3D in vitro angiogenesis model.
Dong, Z; Nör, JE; Zeitlin, BD, 2012
)
0.38
" Sorafenib dosing and adverse events (AEs) are collected throughout the study."( First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2012
)
0.38
" Variation in sorafenib dosing by specialty are also observed; Child-Pugh status did not appear to influence the starting dose of sorafenib."( First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2012
)
0.38
" In contrast, drug dosing had no effect on PFS."( Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Avril, MF; Billemont, B; Blanchet, B; Coriat, R; Franck, N; Goldwasser, F; Lebbe, C; Mir, O; Pécuchet, N; Tod, M; Viguier, M, 2012
)
0.38
" Patients received sorafenib 200 or 400 mg orally, twice daily, at 12 h intervals, on a continuous dosing schedule."( Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K, 2012
)
0.38
" However, it is unclear whether this dosage is tolerable for patients with a low body surface area(BSA)."( [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K, 2012
)
0.38
"Standard dosage seems intolerable for patients with low BSA, and results in poor prognosis."( [Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K, 2012
)
0.38
" The starting dose for the last 13 enrolled patients was 400 mg/day; in the absence of toxicity this dosage was gradually increased to 800 mg/day after 3 weeks ('ramp-up strategy')."( Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E, 2012
)
0.38
" Starting at a lower dosage may allow prolonged compliance to treatment and might be considered according to patient tolerance."( Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E, 2012
)
0.38
"Sorafenib or dasatinib displayed sigmoidal or saturation-type dose-response relationships for apoptosis induction, which were uniform or highly divergent, respectively, among individual CLL samples and therefore might complement each other in their clinical potential for CLL."( Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM, 2012
)
0.38
" In this cohort of liver transplant recipients side effects prevented full dosing of sorafenib and necessitated discontinuation of sorafenib in the majority of patients, yet antitumor efficacy seemed promising in combination with mTORi."( High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012
)
0.38
"Sorafenib, which is approved for treatment of HCC, has also shown promising antifibrotic activity, and therefore refinement of its dosing requirements and window of efficacy are important goals prior to antifibrotic clinical trials."( Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
Chou, H; Fiel, MI; Friedman, SL; Hong, F, 2013
)
0.39
" However, the newer targeted anticancer therapies have different pharmacokinetic (PK) and dosing characteristics compared with traditional cytotoxic drugs, making it possible to estimate the steady-state drug exposure with a single trough-level measurement."( Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S, 2012
)
0.38
" Patients received sorafenib orally 400 mg twice daily on a continuous dosing schedule with 6 weeks counting as a single cycle."( [Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P, 2012
)
0.38
" At the same dosage (2 g/kg), in comparison with nicotinamide, nicotinic acid was weaker in raising plasma N(1)-methylnicotinamide levels (0."( Excessive nicotinic acid increases methyl consumption and hydrogen peroxide generation in rats.
Cao, Y; Li, D; Li, SZ; Luo, N; Ma, Q; Shi, Q; Zhou, SS, 2013
)
0.39
" Once-daily dosing of ipragliflozin (0."( Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Noda, A; Qun, L; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M, 2012
)
0.38
"The purpose of this study was to assess the feasibility of extemporaneous compounding of slow-release oral dosage form of niacinamide and to evaluate its release kinetics."( Compounding of slow-release niacinamide capsules: feasibility and characterization.
Calija, B; Milić, J; Radojkovic, B,
)
0.63
" The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly."( Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012
)
0.38
" After 3 months of treatment with a maximum dosage of 400 mg/day sorafenib, there was an improvement in the patient's New York Heart Association (NYHA) functional class from IV to III."( Sorafenib is effective in the treatment of pulmonary veno-occlusive disease.
Fukuda, K; Kataoka, M; Satoh, T; Yanagisawa, R; Yoshino, H, 2012
)
0.38
" Sorafenib dosage was reduced in a third of patients, but this did not have an impact on progression-free survival (PFS) (p=0."( Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J, 2013
)
0.39
" continuous dosing in combination with dacarbazine, 300 mg/m(2) for three consecutive days every 21 days until disease progression or intolerable toxicity."( Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB, 2013
)
0.39
" These binding characteristics and the pharmacokinetic profile of AZD5213 indicate that high daytime and low night-time H3RO could be achieved following once daily oral dosing of AZD5213."( AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects.
Boström, E; Halldin, C; Jostell, KG; Jucaite, A; Nyberg, S; Segerdahl, M; Stenkrona, P; Takano, A, 2013
)
0.39
" The mean starting dose for patients who initiated on sorafenib (n = 16) was 725 mg and for temsirolimus (n = 15) was 25 mg: their study samples were insufficient for further, meaningful dosing analyses."( Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Borker, R; Fonseca, E; Hess, G, 2013
)
0.39
" The mice were randomized into seven groups: blank control (A), vehicle control (B), single liposome doxorubicin (C), single sorafenib group (D), liposome doxorubicin combined with low dose sorafenib group (E), combined group with medium dosage of sorafenib (F), combined group with high-dose of sorafenib(G)."( [Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice].
An, CM; Han, ZK; Li, ZJ; Ma, J; Tang, PZ; Wang, Z, 2012
)
0.38
" Liposome doxorubicin combined with medium dosage of sorafenib had a better therapeutic effect and less side effects."( [Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice].
An, CM; Han, ZK; Li, ZJ; Ma, J; Tang, PZ; Wang, Z, 2012
)
0.38
"Thirty-seven HCC patients were started on a reduced dosage of sorafenib, subsequently increased to the standard dosage."( Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K, 2013
)
0.39
" In every case, we recommend to start the selected targeted agents at standard dosage and to pursue therapy as long as possible because the control of disease should be the primary endpoint for the management of mRCC."( Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P, 2014
)
0.4
" The dosage of sorafenib was increased to 200 mg twice daily (20 mg/kg/day, 500 mg/m(2))."( Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Ewig, JM; Iyer, P; Mayer, JL, 2014
)
0.4
" The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated."( A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A, 2013
)
0.39
" Consequently, sorafenib dosage was reduced to 200 mg daily, and the oral mucositis was attenuated."( Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T, 2013
)
0.39
" The results suggested that microemulsion and multiple emulsion formulations could be new and alternative dosage forms for topical application of NA."( Investigation of different emulsion systems for dermal delivery of nicotinamide.
Özer, Ö; Tuncay, S,
)
0.13
" In addition, the dosing period was considered to be extended to focus on measures to take against the side effects of sorafenib within the early phase."( [Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma].
Hashida, T; Inokuma, T; Kanamori, K; Kitada, N; Konishi, A; Suginoshita, Y; Tanaka, S, 2013
)
0.39
"Therapy with sorafenib was initiated and continued at a reduced dosage of 400 mg⁄day in 66 of 99 patients, with 22 patients requiring further dose reduction."( In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM, 2013
)
0.39
" This dosing algorithm was designed to mitigate dermatologic and other toxicity, in addition to detailed guidelines for prophylactic and symptomatic treatment."( A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M, 2013
)
0.39
" Long-term treatment with reduced SO dosage and Synchro-Levels resulted in a sustained radiological and clinical response with normalization of α-fetoprotein levels."( Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Moroni, M; Zanlorenzi, L, 2013
)
0.39
"4%) patients treated with cytoflavin in dosage 20-40 ml daily intravenously in drops during 10 days in addition to standard treatment."( [Correction of energy homeostasis in the acute period of concomitant brain injury].
Beletskiĭ, AV; Nikonov, VV; Pavlenko, AIu, 2013
)
0.39
" We hypothesised that in the case of high-dosage nicorandil or after an increased dosage of nicorandil, nicotinic acid and nicotinamide (two main metabolites of nicorandil) cannot appropriately merge into the endogenous pool of nicotinamide adenine dinucleotide/phosphate, which leads to abnormal distribution of these metabolites in the body."( Role of nicotinic acid and nicotinamide in nicorandil-induced ulcerations: from hypothesis to demonstration.
Barbaud, A; Brouillard, C; Cuny, JF; Gauchotte, G; Jouzeau, JY; Petitpain, N; Scala-Bertola, J; Schmutz, JL; Trechot, P, 2015
)
0.42
" The intrinsic dissolution rate and solubility of ATC-NIC were determined along with plasma concentrations of ATC using HPLC after oral dosing in rats."( Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.
Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A, 2013
)
0.39
"The objective was to quantify the risk dynamics for the sorafenib-induced hand-foot syndrome (HFS) and to explore by simulations the dose-toxicity relationships according to different dosing regimens."( Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).
Blanchet, B; Boudou-Rouquette, P; Freyer, G; Goldwasser, F; Hénin, E; Thomas-Schoemann, A; Tod, M; Vidal, M, 2014
)
0.4
" Sorafenib dosing and adverse events (AEs) were collected at follow-up visits."( GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2014
)
0.4
" The incidence and nature of drug-related AEs were broadly similar across Child-Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population."( GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2014
)
0.4
"Consistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups."( GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK, 2014
)
0.4
" (4) Sorafenib is routinely dosed daily (400 mg BID) and 7 d after the start of dosing has a Cmax of ~21 μM with a nadir at 12 h of ~10 μM, and is a highly protein bound based on in vitro assays."( Multi-kinase inhibition in ovarian cancer.
Dent, P, 2014
)
0.4
" The VEGF signal inhibitors significantly elevated blood pressure (BP) in rats within a few days of the initiation of dosing, and levels recovered after dosing ended."( Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
Honda, M; Isobe, T; Komatsu, R; Kuramoto, S; Shindoh, H; Tabo, M, 2014
)
0.4
" donovani in the BALB/c mouse model of infection; dosing on days 7-11 with a 50 mg/kg oral dose of sunitinib, lapatinib or sorafenib reduced liver amastigote burdens by 41%, 36% and 30%, respectively, compared with untreated control mice."( Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Croft, SL; Sanderson, L; Yardley, V, 2014
)
0.4
" Sorafenib was dosed orally 400 mg twice daily until progression, except during CRT when it was escalated from 200 mg to 400 mg daily, and 400 mg twice daily."( Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ, 2014
)
0.4
" Phase 1 showed a dose-response relation for proportional change in frataxin protein concentration from baseline to 8 h post-dose, which increased with increasing dose (p=0·0004)."( Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Athanasopoulos, S; Chan, PK; Festenstein, R; Giunti, P; Huson, L; Law, PP; Leiper, J; Libri, V; Loyse, N; Mauri, M; Mohammad, T; Natisvili, T; Parkinson, MH; Piper, S; Ramesh, A; Tam, KT; Yandim, C, 2014
)
0.4
"8%) received at least one fully dosed cycle, 2 (11."( A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA, 2014
)
0.4
" Patients with histologically or clinically diagnosed HCC received TACE with interrupted dosing of sorafenib (sorafenib discontinued for 3 days before and 4-7 days after TACE)."( The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH, 2015
)
0.42
"The disturbance of lipid metabolism was induced by the introduction of exogenic cholesterol-in -oil emulsion in dosage 40 mg /kg of body mass during 20 days."( [The assessment of the effects of cytoflavin and cardioxipin on the emotional status of rats with dyslipidemia].
Antropova, NV; Kustikova, IN; Moiseeva, IIa; Rodina, OP; Vodop'ianova, OA, 2014
)
0.4
" At 13 weeks of age, ZF rats were dosed orally with dapagliflozin once daily up to the 22(nd) day."( Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Maruyama, K; Mori, Y; Ojima, K; Yaguchi, A; Yokoyama, A, 2015
)
0.42
" Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy."( Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS, 2014
)
0.4
"To investigate the role of sorafenib dosage escalation in Asian patients with metastatic renal cell carcinoma that had progressed after routine dosages."( A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2014
)
0.4
"Sorafenib dosage escalation to 600 or 800 mg twice a day was offered to 41 patients with metastatic renal cell carcinoma who had progressed on normal dosages."( A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2014
)
0.4
" The pre-escalation Karnofsky performance status, serum calcium concentration, neutrophil/lymphocyte ratio, PFS and the highest toxicity grade at the routine dosage were associated with a longer PFS in the dosage-escalation period."( A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2014
)
0.4
"Sorafenib dosage escalation was efficacious and tolerable in Asian patients."( A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP, 2014
)
0.4
" Thus, t-CUPM may have the potential to reduce the adverse events observed from the multikinase inhibitory properties and the large dosing regimens of sorafenib."( Biological evaluation of a novel sorafenib analogue, t-CUPM.
Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Wecksler, AT; Weiss, RH; Wettersten, HI; Wu, J, 2015
)
0.42
" (1) There were not significant differences between sorafenib concentrations in patients who tolerate the full dose versus patients with reduced dose due to toxicity; (2) the average sorafenib concentrations measured 3 h after the morning dosing were lower than those measured 12 h after the evening dosing (p = 0."( Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
Bazzica, M; Di Gion, P; Fucile, C; Lantieri, F; Marenco, S; Marini, V; Martelli, A; Mattioli, F; Picciotto, A; Pieri, G; Robbiano, L; Savarino, V; Stura, P; Zuccoli, ML, 2015
)
0.42
"Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C."( Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V, 2015
)
0.42
" We could show variability in plasma levels according to changes in dosage of TKIs or during treatment-free intervals."( [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P, 2015
)
0.42
" At maximum dosage and time (15 μM and 96 h), Sorafenib-loaded PLGA and HMC-coated liposomes killed 88."( Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH, 2015
)
0.42
" Child-Pugh status does not seem to influence the approach to sorafenib dosage or time to progression but does seem to be a strong prognostic factor for survival."( [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A, 2015
)
0.42
" Ongoing prospective controlled studies are needed to further define the dosing of sorafenib in the post-HSCT period and to determine the optimal context for this treatment approach."( Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A, 2015
)
0.42
" Five sequential ASP015K cohorts were enrolled, consisting of four twice-daily dosing groups (10, 25, 60, 100 mg) and one once-daily dosing group (50 mg) for 6 weeks."( A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
Akinlade, B; Ball, G; Catlin, M; Krueger, JG; Papp, K; Pariser, D; Wierz, G; Zeiher, B, 2015
)
0.42
" Indeed, histamine elicited a sigmoid dose-response curve for IP3 production, shifted to the right by chlorpheniramine maleate, and elicited a double bell-shaped curve for cAMP production, partially suppressed by the selective H2R, H3R and H4R antagonists when each added alone, and completely ablated when combined together."( Histamine receptor expression in human renal tubules: a comparative pharmacological evaluation.
Camussi, G; Chazot, PL; Grange, C; Lanzi, C; Moggio, A; Pini, A; Rosa, AC; Veglia, E, 2015
)
0.42
" Patients in the first group (experimental group), consisting of 32 patients, as part of combined therapy received ascorbic acid (5% solution twice a day in a recommended dosage of 20 ml/day for 20 days); the second group (37 patients) received 10 ml of cytoflavin intravenously by drop infusion twice a day for 10 days; the third group received cytoflavin for 20 days (from day 1 to day 10 - 20 ml a day, from day 11 to day 20 - 10 ml a day)."( [Performance evaluation of integrated cytoprotective therapy of different duration in patients with cerebral infarction].
Chichanovskaia, LV; Eliseev, EV; Kabaeva, EN; Kovalenko, AL; Lukin, DI; Nazarov, MV; Nedorostkova, TIu; Rumiantseva, SA; Silina, EV; Stupin, VA; Tsukurova, LA, 2015
)
0.42
" Rat biological samples collected after oral dosing of (14)C-labelled ASP015K were examined using a liquid chromatography-radiometric detector and mass spectrometer (LC-RAD/MS)."( Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans.
Nakada, N; Oda, K, 2015
)
0.42
" The objective of the model-based work would be the determination of the optimized doses and dosing schedules of everolimus and sorafenib, offering the maximization of the predicted modeled benefit/toxicity ratio in patients with solid tumors."( Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.
Barrois, C; Berger, F; Cassier, P; El-Madani, M; Freyer, G; Guitton, J; Hénin, E; Lachuer, J; Lefort, T; Rodriguez-Lafrasse, C; Slimane, K; Tod, M; Valette, PJ; You, B, 2015
)
0.42
"To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation."( Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Bodoky, G; Bronowicki, JP; Croitoru, A; Daniele, B; Mathurin, P; Papandreou, C; Ratziu, V; Serejo, F; Stål, P; Turnes, J, 2015
)
0.42
" In 5 patients with pronounced toxicity, we switched to an alternating dosing schedule with 1 month on/1 month off sorafenib."( Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A, 2015
)
0.42
" Firstly, formulations of indomethacin and nicotinamide in varying weight ratios were studied since novel tablet dosage forms containing multi-drugs are of industrial interest."( Comparison of pharmaceutical formulations: ATR-FTIR spectroscopic imaging to study drug-carrier interactions.
Biggart, GD; Clarke, GS; Ewing, AV; Hale, CR; Kazarian, SG, 2015
)
0.42
" Twenty-five subjects enrolled in the study were divided into two groups: patients with dosage reduced or withdrawn due to adverse effects (n = 8), and patients with dosage maintained for 1 month after initial administration (n = 17)."( Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
Hisamichi, K; Jin, Y; Kataoka, Y; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H, 2015
)
0.42
"To describe dosing patterns and to compare the drug costs per month spent in progression-free survival (PFS) among patients with advanced renal cell carcinoma (aRCC) treated with everolimus or axitinib following a first tyrosine kinase inhibitor (TKI)."( Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ, 2016
)
0.43
" Real-world dosing patterns were summarized."( Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ, 2016
)
0.43
" Pharmacokinetic analysis revealed that oral dosing of t-CUPM resulted in higher blood levels than that of sorafenib throughout the complete time course (48 h)."( Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y, 2016
)
0.43
" The overall dosing strategy was consistent in Chinese patients across Child-Pugh subgroups."( Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J, 2016
)
0.43
" The dosage was temporarily reduced in only two patients, and oral steroids were added in four."( Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM, 2016
)
0.43
"With the changed dosing schedule, this regimen was very well tolerated."( Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016
)
0.43
" Revised dosing still resulted in high toxicity."( Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG, 2016
)
0.43
" To date, this case had the shortest duration and the lowest dosage of sorafenib to have induced acute pancreatitis."( Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Cheng, KS; Chou, JW; Huang, CW, 2016
)
0.43
" Effects of race (Asian vs non-Asian) and dosing frequency were identified as statistically significant covariates on the CL/F of M4."( Population pharmacokinetic modeling of motesanib and its active metabolite, M4, in cancer patients.
Gosselin, NH; Hsu, CP; Lu, JF; Mouksassi, MS, 2015
)
0.42
" Baseline characteristics, renal function, survival, safety, and dosage were stratified according to baseline estimated glomerular filtration rate (eGFR): G1 (eGFR≥90), G2 (eGFR≥60-<90), G3a (eGFR≥45-<60), G3b (eGFR≥30-<45), G4 (eGFR≥15-<30), and G5 (eGFR<15)."( Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.
Adachi, M; Akaza, H; Ito, Y; Kabu, K; Oya, M; Tatsugami, K, 2016
)
0.43
" Because dosing delays and modifications were associated with the MTD, the recommended phase II dose was declared to be pemetrexed 500 mg/m2 every 14 days with oral sorafenib 400 mg given twice daily on days 1-5."( Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W, 2016
)
0.43
" Cohort B involved a modified schedule of sorafenib dosing on days 1-5 of each 14-day pemetrexed cycle."( Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W, 2016
)
0.43
" We detected a moderate dose-response in one clinically approved indication, hepatocellular carcinoma, but not in another approved malignancy, renal cell carcinoma, or when data were pooled across all malignancies tested."( Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy.
Fergusson, D; Henderson, VC; Kimmelman, J; MacKinnon, N; Mattina, J, 2016
)
0.43
" The patient was treated with gemcitabine as first line, with a resulting progressive disease after two months, and then with sorafenib at standard dosage in the second line setting."( Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P, 2016
)
0.43
" These data suggest that administration of NMN at a proper dosage has a strong protective effect against ischemic brain injury."( Nicotinamide mononucleotide inhibits post-ischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia.
Kristian, T; Long, A; Owens, K; Park, JH, 2016
)
0.43
"Patients received a median of five cycles of Aza (range, 2-9) and sorafenib with a median daily dosage of 750 mg (range 400-800) for 129 d (range, 61-221)."( Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T, 2017
)
0.46
" In the S/P arm, patients were treated orally with sorafenib continuous dosing at two dose levels (DL1: 200 mg twice daily and DL2: 400 mg twice daily) combined with plitidepsin (1."( Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M, 2017
)
0.46
"About 26 patients with solid tumors were treated in four different dosing schedules."( EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
Badary, OA; Barrois, C; Cassier, P; Colomban, O; El-Demerdash, E; El-Madani, M; El-Shenawy, SM; Freyer, G; Gagnieu, MC; Guitton, J; Hommel-Fontaine, J; Ibrahim, BM; Lefort, T; Maillet, D; Peron, J; Rodriguez-Lafrasse, C; Tod, M; Valette, PJ; You, B, 2017
)
0.46
" In addition to standard treatment, 36 patients received cytoflavin in the dosage of two tablets twice a day for 30 days."( [Pathogenetic aspects of the use of cytoflavine in the treatment of сhronic post-traumatic headache].
Iskra, DA,
)
0.13
" Furthermore, peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens."( A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
Chida, N; Higashi, Y; Inami, M; Inoue, T; Ito, M; Kuno, M; Morita, Y; Nakamura, K; Okuma, K; Shirakami, S; Yamagami, K; Yamazaki, S, 2017
)
0.46
" Structural modifications on lead compound 4a were explored with the aim of improving potency, physicochemical properties, and animal PK predictive of QD (once a day) dosing regimen in human."( Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.
Nakao, K; Nukui, S; Okumura, Y; Yamagishi, T, 2017
)
0.46
" Additional secondary endpoints are postprogression survival from time of symptomatic progression, duration of and response to each systemic treatment regimen and dosing of sorafenib throughout the treatment period."( Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M, 2017
)
0.46
"004) were associated with shorter OS compared to the presence of segmental PVI (or absence of macroscopic vascular invasion, MVI), full dosage of sorafenib and Child-Pugh class A, respectively."( Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY, 2017
)
0.46
"Details on study population, type and duration of treatment, dosage of vitamins, association with lipid-influencing drugs, length of follow-up, and incidence and type of adverse events were extracted."( Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation.
Gregori, D; Lamprecht, M; Minto, C; Vecchio, MG, 2017
)
0.46
" The absence of synergy in vivo highlighted the need to further optimize the dosing schedules of YM155 and sorafenib, as well as their routes of administration."( Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Go, ML; Huynh, H; Sim, MY; Yuen, JSP, 2017
)
0.46
" Cautious dosing using a sorafenib ramp up schedule might have contributed to negative results."( A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker, T; Göhler, T; Indorf, M; Nusch, A; Overkamp, F; Rösel, S; Sahlmann, J; Trarbach, T, 2017
)
0.46
" The primary end point was overall survival (OS) of patients who were prescribed standard starting dosage sorafenib (800 mg/d per os) versus that of patients who were prescribed reduced starting dose sorafenib (< 800 mg/d per os)."( Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
D'Addeo, K; Kaplan, DE; Mamtani, R; Mehta, R; Reiss, KA; Taddei, TH; Wileyto, EP; Yu, S, 2017
)
0.46
" All patients who received TACE and interrupted dosing of sorafenib for early or intermediate-stage HCC in Taiwan from 2009 to 2010 were recruited into the TACE and sorafenib group."( Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE, 2017
)
0.46
"With a high patient tolerance to an interrupted sorafenib dosing schedule, the combination of TACE with sorafenib was associated with improved overall survival in early-intermediate stage HCC when compared with treatment with TACE alone."( Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE, 2017
)
0.46
"The tyrosine kinase inhibitors sorafenib and imatinib are important in the treatment of a range of cancers but adverse effects in some patients necessitate dosage modifications."( Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Edwards, RJ; Ghassabian, S; Gillani, TB; Murray, M; Rawling, T, 2018
)
0.48
" We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite of NA by ∼80% at 2 h when dosed in mice orally at 50 mg/kg."( Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.
Anchan, NK; Bhamidipati, RK; Burri, RR; Chandrasekar, DV; Czech, J; Dhakshinamoorthy, S; Gosu, R; Hallur, MS; Kadnur, SV; Kannt, A; Kristam, R; Langer, T; Mane, VS; Marker, A; Mullangi, R; Murugesan, KR; Narasimhulu, LK; Putta, VPRK; Rajagopal, S; Rudolph, C; Ruf, S; Sarkar, S; Schreuder, H; Shaik, S; Singh, M; Suresh, J; Swamy, IN; Yura, T, 2018
)
0.48
"Thirty-six albino rats were divided into six groups: Control group; TAA group (IP injection with TAA at a dosage of 200 mg/Kg three times a week for two months); TAA + NA group (rats administered with NA at a dosage of 200 mg/kg daily besides TAA as in the control); TAA + VB2 group (rats administered with vitamin B2 at a dosage of 30 mg/kg daily besides injection with TAA); TAA + VC group (rats administered with vitamin C at a dosage of 200 mg/kg daily along with injection of TAA)."( Potential effects of the combination of nicotinamide, vitamin B2 and vitamin C on oxidative-mediated hepatotoxicity induced by thioacetamide.
Abdelmottaleb Moussa, SA; Al Tamimi, J; Alaamer, A; Alhazza, IM; Bashandy, SAE; Ebaid, H; Hassan, I, 2018
)
0.48
" Based on the review, it appeared that there was the need to identify the optimal dose and the dosing regimen of pimasertib to provide a balance between safety and efficacy when combined with approved therapies."( Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor.
Srinivas, NR, 2018
)
0.48
"Sorafenib has satisfactory efficacy and safety in Chinese Child-Pugh A and B patients with unresectable HCC using the recommended dosage of 800 mg/day, and the safety of sorafenib is not affected by liver function."( Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J, 2018
)
0.48
" The number of insects was counted before and 2, 3, 7 and 10 days after the application of pesticide in the test area within different dosage groups."( [Research on control effect of sulfoxaflor and flonicamid on Lonicera japonica].
Hou, SY; Li, JX; Wang, PS; Wang, YJ; Xue, J, 2018
)
0.48
" The nicotinamide dose-response experiment showed that relative blood flow measured by DCS increased following treatment with 500- and 1000-mg  /  kg nicotinamide."( Validation of diffuse correlation spectroscopy sensitivity to nicotinamide-induced blood flow elevation in the murine hindlimb using the fluorescent microsphere technique.
Bubel, TM; Choe, R; Han, S; Liu, Z; Proctor, AR; Ramirez, GA, 2018
)
0.48
" Adding the methylated vegetable oil adjuvant to fungicides would result in unprolonging half-life and acceptably low dietary exposure risk on strawberries, but lower dosage of fungicides were used."( Positive effects of an oil adjuvant on efficacy, dissipation and safety of pyrimethanil and boscalid on greenhouse strawberry.
Cang, T; Qi, P; Wang, Q; Wang, X; Wang, Z; Wu, S; Xu, X; Zhao, X, 2018
)
0.48
" The primary outcome was peficitinib dose-response at Week 8, with response assessed using Mayo score change from baseline."( Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Bertelsen, K; Feagan, BG; Johanns, J; Lichtenstein, GR; Marano, C; O'Brien, CD; Panes, J; Sandborn, WJ; Sands, BE; Strauss, R; Szapary, P; Vermeire, S; Yang, Z; Zhang, H, 2018
)
0.48
"The comparatively low recovery of NIA following in vitro mass-balance and permeation studies for pseudo-finite and finite dosing of the active compared with infinite dosing is attributed to chemical derivatisation of the molecule during skin penetration."( Use of LC-MS analysis to elucidate by-products of niacinamide transformation following in vitro skin permeation studies.
Lane, ME; Moore, DJ; Sil, BC, 2018
)
0.73
"In field experiments, assessment of herbicide selectivity and efficacy rarely takes advantage of dose-response regressions."( Assessing herbicide symptoms by using a logarithmic field sprayer.
Andreasen, C; Cunha, BRD; Nielsen, J; Rasmussen, J; Ritz, C; Streibig, JC, 2019
)
0.51
"Suitable nonlinear regression models are now available for fitting dose-response data from a logarithmic sprayer in field experiments."( Assessing herbicide symptoms by using a logarithmic field sprayer.
Andreasen, C; Cunha, BRD; Nielsen, J; Rasmussen, J; Ritz, C; Streibig, JC, 2019
)
0.51
"The dose escalation, confirmation, and expansion results support the dosing of merestinib at 120 mg once daily, based on acceptable exposure and safety at this dose."( First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W, 2019
)
0.51
" Sorafenib dosing was individualized, starting at 200 mg twice a day (BID), and titrated based on tolerability or toxicities until a tolerable dose was identified."( A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Baer, MR; Dezern, A; Duong, VH; Emadi, A; Gocke, C; Gojo, I; Greer, J; Jones, RJ; Karp, J; Levis, M; Pratz, KW; Rosner, G; Rudek, MA; Smith, BD; Wright, JJ; Zahurak, M, 2020
)
0.56
"5-fold the recommended dosage yield terminal residues, which are clearly lower than the maximum residue limit (MRL) established by China (MRL =5 mg."( Dissipation pattern and residual levels of boscalid in cucumber and soil using liquid chromatography-tandem mass spectrometry.
Abd El-Aty, AM; Gao, L; Hacımüftüoğlu, F; He, Y; Khan, M; Meng, M; She, Y; Wang, M; Yohannes, WK, 2020
)
0.56
" No previous study has, however, designated the time of TRP dosing to improve mood."( Effect of Tryptophan, Vitamin B
Akamatsu, Y; Hayashi, T; Moritani, T; Nishida, MM; Tsujita, N, 2019
)
0.51
" Testing in an in vitro VEGF synthesis assay, it was found that niacinamide cannot stimulate VEGF synthesis across a broad dose-response range."( Topical niacinamide does not stimulate hair growth based on the existing body of evidence.
Davis, MG; Hartman, SM; Oblong, JE; Peplow, AW, 2020
)
1.23
" The lack of standardized dosing and standardized outcome measures makes comparison across existing studies challenging, and the lack of adverse events reporting in the majority of studies limits analysis of supplement safety."( Dietary supplements in dermatology: A review of the evidence for zinc, biotin, vitamin D, nicotinamide, and Polypodium.
Kim, N; Thompson, KG, 2021
)
0.62
" Docking results proved the affinity of NAm to IFN-γ, which can affirm the increased levels of IFN-γ, IL-12p40 and TNF-α as well as reductions in IL-10 secretion with a dose-response effect, especially in the combination group."( The potential role of nicotinamide on Leishmania tropica: An assessment of inhibitory effect, cytokines gene expression and arginase profiling.
Babaei, Z; Bamorovat, M; Keyhani, A; Khosravi, A; Mostafavi, M; Mousavi, SM; Oliaee, RT; Salarkia, E; Sharifi, F; Sharifi, I; Tavakoly, R, 2020
)
0.56
" Serial blood samples were collected for methotrexate concentration after dosing on Days 1 (methotrexate alone) and 8 (methotrexate plus peficitinib) and for peficitinib concentration after dosing on Days 7 (peficitinib alone) and 8 (methotrexate plus peficitinib)."( Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Akinlade, B; Cao, Y; Chindalore, V; Moy, S; Sawamoto, T; Valluri, U; Zhang, W; Zhu, T, 2020
)
0.56
" Administration of peficitinib did not result in changes to methotrexate area under the concentration-time curve from time zero to infinity or maximum observed concentration following a methotrexate dose (15-25 mg), and there was no significant effect of methotrexate (15-25 mg) on peficitinib area under the concentration-time curve within a 12-hour dosing interval."( Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Akinlade, B; Cao, Y; Chindalore, V; Moy, S; Sawamoto, T; Valluri, U; Zhang, W; Zhu, T, 2020
)
0.56
" Consistent with this observation, VU0360172 could also enhance thalamic GAT-1 protein expression, depending on the dosing regimen."( Pharmacological activation of mGlu5 receptors with the positive allosteric modulator VU0360172, modulates thalamic GABAergic transmission.
Bruno, V; Cannella, M; Celli, R; Ciruela, F; Di Menna, L; Mascio, G; Ngomba, RT; Nicoletti, F; Pittaluga, A; Santolini, I; van Luijtelaar, G; Vergassola, M; Wall, MJ, 2020
)
0.56
" NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg."( Nicotinamide riboside with pterostilbene (NRPT) increases NAD
Dellinger, R; Guarente, LP; Parikh, SM; Rhee, EP; Simic, P; Vela Parada, XF, 2020
)
0.56
"Four dosing schedules of pimasertib (once daily [qd], 5 days on, 2 days off; qd, 15 days on, 6 days off; continuous qd; continuous twice daily [bid]) were evaluated in patients with advanced solid tumors."( Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Aftimos, P; Awada, A; Delord, JP; Dinulescu, M; Faivre, S; Gomez-Roca, C; Houédé, N; Italiano, A; Kefford, R; Kruse, V; Lebbé, C; Leijen, S; Lesimple, T; Massimini, G; Pages, C; Raymond, E; Rottey, S; Schellens, JHM; Scheuler, A, 2021
)
0.62
"5 h across dosing schedules, and the apparent terminal half-life was 5 h across qd dosing schedules."( Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Aftimos, P; Awada, A; Delord, JP; Dinulescu, M; Faivre, S; Gomez-Roca, C; Houédé, N; Italiano, A; Kefford, R; Kruse, V; Lebbé, C; Leijen, S; Lesimple, T; Massimini, G; Pages, C; Raymond, E; Rottey, S; Schellens, JHM; Scheuler, A, 2021
)
0.62
"Based on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedule and the RP2D was defined as 60 mg bid."( Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Aftimos, P; Awada, A; Delord, JP; Dinulescu, M; Faivre, S; Gomez-Roca, C; Houédé, N; Italiano, A; Kefford, R; Kruse, V; Lebbé, C; Leijen, S; Lesimple, T; Massimini, G; Pages, C; Raymond, E; Rottey, S; Schellens, JHM; Scheuler, A, 2021
)
0.62
" However, nicotinamide offers cellular protection in a specific concentration range, with dosing outside of this range leading to detrimental effects."( Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders.
Maiese, K, 2021
)
0.62
"The mechanical properties of powders determine the ease of manufacture and ultimately the quality of the oral solid dosage forms."( Modulation of the powder properties of lamotrigine by crystal forms.
Kavanagh, ON; Sun, CC; Walker, GM; Wang, C, 2021
)
0.62
" Therefore, we designed this updated network meta-analysis to further establish the optimal dosage of peficitinib in treating RA."( The optimal dosage of pefcitinib for the treatment of active rheumatoid arthritis: A protocol for an updated network meta-analysis.
Chen, C; Sun, C; Zhou, Y, 2021
)
0.62
" Other adverse events, dosing and outcome data were collected during a homogeneous protocolled follow-up."( Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M, 2021
)
0.62
" The data showed that SMN salt cocrystals combine the advantages of salt and cocrystals and show potential for dosage form development."( New Sodium Mefenamate - Nicotinamide Multicomponent Crystal Development to Modulate Solubility and Dissolution: Preparation, Structural, and Performance Study.
Fisandra, F; Horikawa, A; Nugrahani, I; Uekusa, H, 2021
)
0.62
"The study was able to progress through all 4 dosing levels of sorafenib by the accrual of 40 patients."( Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S, 2022
)
0.72
" Second, the binding of asciminib decreases the binding free energies of nilotinib by ∼3 and ∼7 kcal/mol for the wildtype and T315I-mutated protein, respectively, suggesting the possibility of reducing nilotinib dosage and lowering risk of developing resistance in the treatment of CML."( Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
Amiri, W; Friedman, R; Lindahl, E; Oruganti, B; Rahimullah, R; Yang, J, 2022
)
0.72
"5) after allogeneic HSCT with a median daily dosage of 400 mg (range: 200-800) orally, and lasted a median of 11."( Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F, 2022
)
0.72
" The soil microbial function in the boscalid treatment were simulated at the recommended dosage and two-fold recommended dosage but showed an inhibition-recovery-stimulation trend at the five-fold recommended dosage with an increase in treatment frequency."( Deciphering the diversity, composition, function, and network complexity of the soil microbial community after repeated exposure to a fungicide boscalid.
Chen, G; Han, L; Kong, X; Liu, X; Nie, J; Wang, Q; Xu, K; Xu, M, 2022
)
0.72
" So it is imperative to find the drugs that can both reduce the dosage and enhance the antifungal efficacy of AmB."( Nicotinamide potentiates amphotericin B activity against
Cao, Y; Liao, Z; Shen, J; Yan, Y; Zhu, Z, 2022
)
0.72
" Here we assessed CBD dose-response effects in the Genetically Epilepsy Prone Rats (GEPR-3) strain, which exhibits two types of epileptic seizures, brainstem-dependent generalized tonic-clonic seizures and limbic seizures."( Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain.
Campos-Rodriguez, C; Forcelli, PA; Garcia-Cairasco, N; Lazarini-Lopes, W; N'Gouemo, P, 2023
)
0.91
" Therefore, two different dose-response studies were performed, one for generalized tonic-clonic seizures and the other for limbic seizures."( Cannabidiol attenuates generalized tonic-clonic and suppresses limbic seizures in the genetically epilepsy-prone rats (GEPR-3) strain.
Campos-Rodriguez, C; Forcelli, PA; Garcia-Cairasco, N; Lazarini-Lopes, W; N'Gouemo, P, 2023
)
0.91
" Our goal was to exploit the food supplements to mimic the topical antivirals' functions but circumventing their severe side effects, which has limited the necessary dosage needed to exhibit the desired antiviral activity."( Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19.
Aghamohammadi, M; França, TCC; Goncalves, AS; LaPlante, SR; Shahdousti, P; Sirouspour, M, 2022
)
0.72
" The academic EVESOR trial (NCT01932177) was designed to assess alternative doses and intermittent dosing schedules of EVE and SOR combination therapy to improve the benefit-risk ratio for patients with solid tumors."( Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B, 2023
)
0.91
"EVESOR is a multiparameter dose-escalation phase I trial investigating different doses and dosing schedules, with the final objective of generating data for modeling and simulation."( Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B, 2023
)
0.91
"The objective was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics and progression-free survival (PFS) based on data from EVESOR trial in patients with solid tumors treated with everolimus and sorafenib combination therapy and to simulate alternative dosing schedules for sorafenib."( A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Augu-Denechere, D; Bonnin, N; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Péron, J; Puszkiel, A; Rousset, P; Tartas, S; Tod, M; Trillet-Lenoir, V; You, B, 2023
)
0.91
"Everolimus (5-10 mg once daily, qd) and sorafenib (200-400 mg twice daily, bid) were administered according to four different dosing schedules in 43 solid tumor patients."( A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Augu-Denechere, D; Bonnin, N; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Péron, J; Puszkiel, A; Rousset, P; Tartas, S; Tod, M; Trillet-Lenoir, V; You, B, 2023
)
0.91
"Cytoflavin therapy at a dosage of 2 tablets 2 times a day for 25 days can be recommended as part of complex therapy for patients with DE and a COVID-19."( [Evaluation of the effectiveness of the drug Cytoflavin in patients with dyscirculatory encephalopathy who have undergone a new coronavirus infection].
Belova, LA; Dolgova, DR; Kruglova, LR; Kuvayskaya, AA; Mashin, VV; Plaksina, TD; Sukhikh, SS, 2023
)
0.91
"The dosage was reduced from 1000 to 500 mg due to gastrointestinal symptoms in the run-in phase."( Oral Nicotinamide for Actinic Keratosis Prevention in Kidney Transplant Recipients: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial.
Bostom, A; Cho, E; George-Washburn, EA; Gohh, R; Hashemi, KB; Robinson-Bostom, L; Walker, J; Weinstock, MA; Zhang, H, 2023
)
0.91
" Diabetic conditions were induced by administering streptozotocin at a dosage of 45 mg/kg body weight and nicotinamide at a dosage of 110 mg/kg body weight through intraperitoneal injection."( Antihyperglycemic activity of 14-deoxy, 11, 12-didehydro andrographolide on streptozotocin-nicotinamide induced type 2 diabetic rats.
Guru, A; Issac, PK; Kamaraj, N; Velumani, K, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (376 Items)

ItemProcessFrequency
Plant-based foods and beveragescore-ingredient1,092
Plant-based foodscore-ingredient1,047
Cereals and potatoescore-ingredient1,024
Cereals and their productscore-ingredient1,022
Beveragescore-ingredient780
Snackscore-ingredient322
Breakfast cerealscore-ingredient287
Breakfastscore-ingredient287
Sweet snackscore-ingredient274
Biscuits and cakescore-ingredient244
Carbonated drinkscore-ingredient242
Sodascore-ingredient235
Waterscore-ingredient203
Cakescore-ingredient166
Energy drinkscore-ingredient134
Extruded cerealscore-ingredient107
Dried productscore-ingredient98
Dried products to be rehydratedcore-ingredient97
Dehydrated beveragescore-ingredient96
Biscuitscore-ingredient72
Cereal flakescore-ingredient69
Flakescore-ingredient69
Corn flakescore-ingredient62
Extruded flakescore-ingredient62
Cereal barscore-ingredient52
Sweetened beveragescore-ingredient50
Barscore-ingredient50
Plant-based beveragescore-ingredient47
Beverages and beverages preparationscore-ingredient40
Frozen foodscore-ingredient36
Energy drink without sugar and with artificial sweetenerscore-ingredient35
Mealscore-ingredient34
Artificially sweetened beveragescore-ingredient33
Cereal grainscore-ingredient28
Seedscore-ingredient28
en:corn-flakescore-ingredient27
Cooking helperscore-ingredient26
Dessert mixescore-ingredient23
Aliments et boissons à base de végétauxcore-ingredient22
Baking Mixescore-ingredient21
Pastry helperscore-ingredient21
Aliments d'origine végétalecore-ingredient21
Cake mixescore-ingredient20
Céréales et pommes de terrecore-ingredient20
Céréales et dérivéscore-ingredient19
Energy drink with sugarcore-ingredient19
Céréales pour petit-déjeunercore-ingredient17
Petit-déjeunerscore-ingredient17
Meatscore-ingredient16
Meats and their productscore-ingredient16
Vegetable fatscore-ingredient16
Fatscore-ingredient16
Dietary drink for sportcore-ingredient14
Toasted oatscore-ingredient13
Honey nut toasted oatscore-ingredient13
Avenacore-ingredient13
Oatcore-ingredient13
Pie doughcore-ingredient12
en:Plant-based foods and beveragescore-ingredient12
Rice dishescore-ingredient12
Iced teascore-ingredient12
Tea-based beveragescore-ingredient12
en:Cereals and their productscore-ingredient11
en:Cereals and potatoescore-ingredient11
en:Plant-based foodscore-ingredient11
Dairiescore-ingredient11
Vitamin waterscore-ingredient11
Ricescore-ingredient10
Boissonscore-ingredient10
Fruit-based beveragescore-ingredient9
Frosted corn flakescore-ingredient9
en:open-beauty-factscore-ingredient9
Soupscore-ingredient9
Frozen meatscore-ingredient8
Dessertscore-ingredient8
en:Breakfast cerealscore-ingredient8
en:Breakfastscore-ingredient8
en:artificially-sweetened-beveragescore-ingredient8
Confectioneriescore-ingredient8
Dietary supplementscore-ingredient8
Dairy drinkscore-ingredient7
Legumes and their productscore-ingredient7
en:breakfast-cerealscore-ingredient7
en:sweetened-beveragescore-ingredient7
Flavored waterscore-ingredient6
Carbonated waterscore-ingredient6
Juices and nectarscore-ingredient5
Sweetenerscore-ingredient5
Baby foodscore-ingredient5
Pastascore-ingredient5
en:Beveragescore-ingredient5
Instant beveragescore-ingredient5
Cocoa and its productscore-ingredient5
Pancake mixescore-ingredient5
Frozen dessertscore-ingredient5
Peanut butterscore-ingredient5
Nut butterscore-ingredient5
Legume butterscore-ingredient5
Oilseed pureescore-ingredient5
Plant-based spreadscore-ingredient5
Nuts and their productscore-ingredient5
Spreadscore-ingredient5
Hot beveragescore-ingredient5
Diet beveragescore-ingredient5
Puffed grainscore-ingredient5
Coffee-drinks-with-milkcore-ingredient5
Coffee drinkscore-ingredient5
Pastriescore-ingredient4
Prepared meatscore-ingredient4
Porridgecore-ingredient4
Pasta dishescore-ingredient4
Lemonadecore-ingredient4
Cocoa and chocolate powderscore-ingredient4
Milk substitutescore-ingredient4
Dairy substitutescore-ingredient4
Cereals with fruitscore-ingredient4
Teascore-ingredient4
Crackerscore-ingredient4
Appetizerscore-ingredient4
Salty snackscore-ingredient4
Puffed cerealscore-ingredient4
Canned soupscore-ingredient4
Canned mealscore-ingredient4
Canned foodscore-ingredient4
Non-alcoholic beveragescore-ingredient4
Non food productscore-ingredient4
Rolled flakescore-ingredient3
Sandwichescore-ingredient3
Chocolate powderscore-ingredient3
Cereal flakes with fruitscore-ingredient3
en:flakescore-ingredient3
Meat alternativescore-ingredient3
Puffed ricecore-ingredient3
Boissons énergisantescore-ingredient3
Simple syrupscore-ingredient3
Syrupscore-ingredient3
en:Sweetened beveragescore-ingredient3
Condimentscore-ingredient3
Vitaminscore-ingredient3
Chocolate croissantcore-ingredient3
Fruit juicescore-ingredient2
Sugarscore-ingredient2
Breakfast cereals fortified with vitamins and chemical elementscore-ingredient2
cerealcore-ingredient2
Iced teas with lemonadecore-ingredient2
Frozen seafoodcore-ingredient2
Seafoodcore-ingredient2
Fruit nectarscore-ingredient2
Gritscore-ingredient2
Breadscore-ingredient2
en:extruded-cerealscore-ingredient2
Meal replacementscore-ingredient2
Cereal flourscore-ingredient2
Flourscore-ingredient2
Yogurtscore-ingredient2
Fermented dairy dessertscore-ingredient2
Dairy dessertscore-ingredient2
Fermented milk productscore-ingredient2
Fermented foodscore-ingredient2
Sausagescore-ingredient2
Long grain ricescore-ingredient2
Vegetarian pattiescore-ingredient2
Céréales souffléescore-ingredient2
Grains souffléescore-ingredient2
Legume-based drinkscore-ingredient2
Plant-based milk alternativescore-ingredient2
Corn-flakescore-ingredient2
Flocons extrudéscore-ingredient2
Céréales extrudéescore-ingredient2
Flocons de céréalescore-ingredient2
Floconscore-ingredient2
Boisson énergisante non sucrée avec édulcorantscore-ingredient2
Boissons et préparations de boissonscore-ingredient2
Spring waterscore-ingredient2
Maple syrupscore-ingredient2
White ricescore-ingredient2
Water enhancercore-ingredient2
energycore-ingredient2
Licensed productscore-ingredient2
Groceriescore-ingredient2
gazeusescore-ingredient2
Unsweetened beveragescore-ingredient2
Open Beauty Factscore-ingredient2
Boissons avec sucre ajoutécore-ingredient2
sans sucre ajoutécore-ingredient2
Beverages with orangecore-ingredient1
Cereal with raisinscore-ingredient1
Rolled oatscore-ingredient1
Pizza Crustcore-ingredient1
Carbonatedcore-ingredient1
Plain porridgecore-ingredient1
en:Extruded cerealscore-ingredient1
Productos sin glutencore-ingredient1
en:Flavored waterscore-ingredient1
en:Carbonated waterscore-ingredient1
en:Spring waterscore-ingredient1
en:Waterscore-ingredient1
en:Carbonated drinkscore-ingredient1
Flavored sparkling waterscore-ingredient1
en:dehydrated-beveragescore-ingredient1
Plant-based milk alcore-ingredient1
Corn semolinascore-ingredient1
fr:préparation pancakecore-ingredient1
fr:préparation gaufrescore-ingredient1
Préparations pour pâtisseriescore-ingredient1
de:Pfannkuchenmischungcore-ingredient1
en:cake-mixescore-ingredient1
Crispbreadscore-ingredient1
en:rolled-flakescore-ingredient1
Porridge with fruitscore-ingredient1
Mixed cereal flakescore-ingredient1
en:Cooking helperscore-ingredient1
Cereales en granocore-ingredient1
Cereales para el desayunocore-ingredient1
Cereales y derivadoscore-ingredient1
Semillascore-ingredient1
Cereales y patatascore-ingredient1
Desayunoscore-ingredient1
Alimentos de origen vegetalcore-ingredient1
Alimentos y bebidas de origen vegetalcore-ingredient1
Freeze-dried foodscore-ingredient1
Rolled wheat flakescore-ingredient1
Black teascore-ingredient1
Creamercore-ingredient1
Muesliscore-ingredient1
Cereal branscore-ingredient1
Wheat flourscore-ingredient1
Electrolyte-drink-mixcore-ingredient1
Jasmine ricecore-ingredient1
Indica ricescore-ingredient1
Aromatic ricescore-ingredient1
Sweet chocolate mixcore-ingredient1
fr:poudre-chocolat-canadacore-ingredient1
Gruau d'avoinecore-ingredient1
Gruaucore-ingredient1
Vegan pattiescore-ingredient1
fr:110core-ingredient1
Breakfast cereals rich in fibrecore-ingredient1
Soy-based drinkscore-ingredient1
Cereal flakes with fruitcore-ingredient1
Mélanges de céréales souffléscore-ingredient1
Baby oat cerealcore-ingredient1
Smoothiescore-ingredient1
Boissons à base de végétauxcore-ingredient1
en:energy-drink-with-sugarcore-ingredient1
en:energy-drinkscore-ingredient1
Long Jing green teascore-ingredient1
Chinese green teascore-ingredient1
Green teascore-ingredient1
en:Boissons énergisantescore-ingredient1
en:Boissons édulcoréescore-ingredient1
en:Boissons sans sucre ajoutécore-ingredient1
en:Boissons gazeusescore-ingredient1
en:Boissons avec sucre ajoutécore-ingredient1
en:Boissonscore-ingredient1
édulcoréescore-ingredient1
Muffins mixcore-ingredient1
Chicken sandwichescore-ingredient1
Poultry sandwichescore-ingredient1
Jelly beanscore-ingredient1
Gummi candiescore-ingredient1
Candiescore-ingredient1
Pizzascore-ingredient1
Pizzas pies and quichescore-ingredient1
Stewscore-ingredient1
Apple cereal barscore-ingredient1
Fruits cereal barscore-ingredient1
Peach nectarscore-ingredient1
en:Cereal grainscore-ingredient1
en:Seedscore-ingredient1
Flavored antioxidant beveragecore-ingredient1
Biscuits and cakes Cakescore-ingredient1
en:Smoothiescore-ingredient1
en:Plant-based beveragescore-ingredient1
Low-fat yogurtscore-ingredient1
Suero en polvocore-ingredient1
Polvos de proteínacore-ingredient1
Suplementos de culturismocore-ingredient1
Suplementos dietéticoscore-ingredient1
Lácteoscore-ingredient1
en:bodybuilding-supplementscore-ingredient1
Oat-flakescore-ingredient1
Fruit and plant-milk beveragecore-ingredient1
en:vitaminscore-ingredient1
sweetened shredded wheat cerealcore-ingredient1
en:Energy drinkscore-ingredient1
Flavorscore-ingredient1
Food additivescore-ingredient1
Coffeescore-ingredient1
Drink mixcore-ingredient1
en:sodascore-ingredient1
Power Drinkcore-ingredient1
Meat analogues from soy or wheat proteinscore-ingredient1
Meat analoguescore-ingredient1
Céréales au chcore-ingredient1
Céréales au chocolat pour petit-déjeuner équilibrécore-ingredient1
Céréales au chocolatcore-ingredient1
Céréales pour petit déjeuner riches en fibrescore-ingredient1
Bread crumbscore-ingredient1
Proteincore-ingredient1
Puffed wheatcore-ingredient1
Open Products Factscore-ingredient1
Chocolate chip cookiescore-ingredient1
Drop cookiescore-ingredient1
Chocolate biscuitscore-ingredient1
Snacks and desserts for babiescore-ingredient1
Spicescore-ingredient1
Super B-Complexcore-ingredient1
Vitamin-bcore-ingredient1
Vit-bcore-ingredient1
Nutritional-supplementcore-ingredient1
B-complexcore-ingredient1
en:flavored-waterscore-ingredient1
Flavored bottled watercore-ingredient1
Eau vitaminécore-ingredient1
Protein powderscore-ingredient1
Bodybuilding supplementscore-ingredient1
Corncore-ingredient1
Whole Graincore-ingredient1
Rice productcore-ingredient1
Boissons sans sucre ajoutécore-ingredient1
Refrigerated plant-based foodscore-ingredient1
Refrigerated foodscore-ingredient1
Frozen plant-based foodscore-ingredient1
Zero sugarcore-ingredient1
No sugarcore-ingredient1
No artificial colourscore-ingredient1
Low caloriescore-ingredient1
High caffeinecore-ingredient1
B-vitaminscore-ingredient1
drinkcore-ingredient1
hot cerealcore-ingredient1
instant cerealcore-ingredient1
Sweet pastries and piescore-ingredient1
Viennoiseriescore-ingredient1
Tea bagscore-ingredient1
Aloe Vera drinkscore-ingredient1
Milkscore-ingredient1
Plasticcore-ingredient1
Still fruit soft drink with reduced sugar and with 10-50% of fruit juicecore-ingredient1
Still fruit soft drinkscore-ingredient1
Proposed-for-deletioncore-ingredient1
Emptycore-ingredient1
en:cereal-flakescore-ingredient1
Chicken nuggetscore-ingredient1
Breaded chickencore-ingredient1
Poultry nuggetscore-ingredient1
Cooked chickencore-ingredient1
Chicken preparationscore-ingredient1
Cooked poultriescore-ingredient1
Chickenscore-ingredient1
Breaded productscore-ingredient1
Poultriescore-ingredient1
Meat preparationscore-ingredient1
Chicken and its productscore-ingredient1
Nutritional Supplementcore-ingredient1
Multi-Vitamincore-ingredient1
Vegetarian mealcore-ingredient1
Meal kitscore-ingredient1
Kosteusrasvacore-ingredient1
Aurinkorasvacore-ingredient1
Rasvacore-ingredient1
bg:Шампоаниcore-ingredient1
énergisantescore-ingredient1
Enhaned watercore-ingredient1
Dried mealscore-ingredient1
Skincarecore-ingredient1
Salmon skinscore-ingredient1
health drinkcore-ingredient1
digestive enzymescore-ingredient1
Carbonated Sodascore-ingredient1
Flavoured milkscore-ingredient1
Chapelurecore-ingredient1
Painscore-ingredient1
Farines sans levurecore-ingredient1
Farinescore-ingredient1

Roles (13)

RoleDescription
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitorAn EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of a NAD(+) ADP-ribosyltransferase (EC 2.4.2.30).
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
cofactorAn organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
EC 3.5.1.98 (histone deacetylase) inhibitorAn EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).
anti-inflammatory agentAny compound that has anti-inflammatory effects.
Sir2 inhibitorAn EC 3.5.1.98 (histone deacetylase) inhibitor that interferes with the action of Sir2.
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyridinecarboxamideA member of the class of pyridines that is a substituted pyridine in which at least one of the substituents is a carboxamide or N-substituted caraboxamide group.
pyridine alkaloid
vitamin B3Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (102)

PathwayProteinsCompounds
Organelle biogenesis and maintenance23216
Mitochondrial biogenesis668
Transcriptional activation of mitochondrial biogenesis357
Metabolism14961108
Metabolism of vitamins and cofactors146155
Metabolism of water-soluble vitamins and cofactors102114
Nicotinate metabolism2243
Nicotinamide salvaging1030
DNA Repair25547
Base Excision Repair3523
Resolution of Abasic Sites (AP sites)257
Resolution of AP sites via the multiple-nucleotide patch replacement pathway156
POLB-Dependent Long Patch Base Excision Repair66
DNA Double-Strand Break Repair10313
Homology Directed Repair839
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)799
Processing of DNA double-strand break ends518
HDR through MMEJ (alt-NHEJ)104
Nucleotide Excision Repair847
Global Genome Nucleotide Excision Repair (GG-NER)587
DNA Damage Recognition in GG-NER242
Signaling Pathways1269117
Signaling by TGFB family members847
Signaling by TGF-beta Receptor Complex677
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer326
Downregulation of SMAD2/3:SMAD4 transcriptional activity176
Signaling by WNT14820
TCF dependent signaling in response to WNT1049
Degradation of AXIN472
Intracellular signaling by second messengers12614
PI3K/AKT Signaling1138
PTEN Regulation776
Regulation of PTEN stability and activity525
Cellular responses to stimuli48356
Cellular responses to stress46954
Cellular response to heat stress709
Regulation of HSF1-mediated heat shock response577
Cell Cycle53831
Cell Cycle, Mitotic41031
M Phase27921
Mitotic Metaphase and Anaphase15812
FOXO-mediated transcription607
Regulation of FOXO transcriptional activity by acetylation85
Mitotic Anaphase15712
Nuclear Envelope (NE) Reassembly5110
Initiation of Nuclear Envelope (NE) Reformation147
Nicotinate and Nicotinamide Metabolism1434
NAD Salvage620
NAD Metabolism1435
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
N-Ribosyl-nicotinamide + Orthophosphate = Nicotinamide + D-Ribose 1-phosphate ( Nicotinate and Nicotinamide metabolism )13
Nicotinamide D-ribonucleotide + Pyrophosphate = Nicotinamide + D-5-Phospho-ribosyl 1-diphosphate ( Nicotinate and Nicotinamide metabolism )14
Disease1278231
Infectious disease89579
Uptake and actions of bacterial toxins389
Uptake and function of diphtheria toxin73
Gene expression (Transcription)90249
RNA Polymerase II Transcription72842
Generic Transcription Pathway60839
thiazole component of thiamine diphosphate biosynthesis III09
Epigenetic regulation of gene expression11717
Negative epigenetic regulation of rRNA expression456
SIRT1 negatively regulates rRNA expression95
superpathway of thiamine diphosphate biosynthesis III (eukaryotes)324
NAD biosynthesis III (from nicotinamide)07
pyridine nucleotide cycling (plants)322
thiazole biosynthesis III (eukaryotes)09
Infection with Mycobacterium tuberculosis7442
Escape of Mtb from the phagocyte15
Phagocyte cell death caused by cytosolic Mtb15
NAD+ Signalling Pathway (Cancer)1012
NAD+ Signalling and Aging1110
NAD salvage pathway V (PNC V cycle)017
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
SARS-CoV Infections28229
SARS-CoV-1 Infection11422
Translation of Structural Proteins1114
Maturation of nucleoprotein45
SARS-CoV-1 Infection6019
SARS-CoV-2 Infection7720
SARS-CoV-2 Infection19527
NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence19
Late SARS-CoV-2 Infection Events3418
Bacterial Infection Pathways12347
Viral Infection Pathways72739
8p23.1 copy number variation syndrome013
NAD salvage47
NAD biosynthesis III (from nicotinamide)310
pyridine nucleotide cycling (plants)022
aldoxime degradation49
superpathway of thiamine diphosphate biosynthesis III (eukaryotes)1225
tRNA splicing I712
thiazole biosynthesis III (eukaryotes)29
NAD salvage pathway I (PNC VI cycle)420
superpathway of NAD biosynthesis in eukaryotes1135
NAD salvage pathway V (PNC V cycle)421
superpathway of thiamin diphosphate biosynthesis III (eukaryotes)2541
tRNA splicing812
nicotinamide riboside salvage pathway II15
NAD salvage pathway1121
pyridine nucleotide cycling017
NAD salvage pathway I018
NAD biosynthesis III47
NAD salvage pathway I017
Folic acid network070
Differentiation pathway012
Selenium micronutrient network095
Pluripotent stem cell differentiation pathway011
NAD+ metabolism014
NAD+ biosynthetic pathways014

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00250.003245.467312,589.2998AID2517
GLI family zinc finger 3Homo sapiens (human)Potency25.83900.000714.592883.7951AID1259369; AID1259392
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.68320.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency53.43170.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency31.99990.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency53.43170.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency26.60110.375827.485161.6524AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.10800.000229.305416,493.5996AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency28.95250.000723.06741,258.9301AID743085
activating transcription factor 6Homo sapiens (human)Potency26.02580.143427.612159.8106AID1159516
Caspase-7Cricetulus griseus (Chinese hamster)Potency81.59910.006723.496068.5896AID1346980
caspase-3Cricetulus griseus (Chinese hamster)Potency81.59910.006723.496068.5896AID1346980
gemininHomo sapiens (human)Potency6.51310.004611.374133.4983AID624296
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency16.89660.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency16.89660.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, NAD-dependent deacetylaseThermotoga maritimaIC50 (µMol)1,000.00001,000.00001,000.00001,000.0000AID977608
Poly [ADP-ribose] polymerase 2Mus musculus (house mouse)IC50 (µMol)129.52450.01901.69169.8100AID1798811
NAD-dependent histone deacetylase SIR2Saccharomyces cerevisiae S288CIC50 (µMol)50.00008.80008.80008.8000AID1317154
Coagulation factor VIIHomo sapiens (human)Ki8,000.00000.00021.55669.0000AID1201284
Poly [ADP-ribose] polymerase 1Homo sapiens (human)IC50 (µMol)187.00700.00020.81239.8100AID1204000; AID1248040; AID162395; AID1798811; AID492548; AID739045
Cytochrome P450 3A5Homo sapiens (human)IC50 (µMol)40.00000.00330.70736.2000AID1371062
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)IC50 (µMol)3.30000.00051.33138.0000AID266504
Protein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)IC50 (µMol)15.00002.40006.40979.0000AID1734010
NAD(+) hydrolase SARM1Homo sapiens (human)IC50 (µMol)43.80003.20004.90008.7000AID1622849
NAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)IC50 (µMol)28.22140.50003.848110.0000AID1167212; AID1176357; AID1196156; AID1280434; AID1509494; AID1509501; AID1509507; AID1526040; AID1633283; AID274367; AID281694; AID320392; AID441073; AID712590
NAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)IC50 (µMol)130.95000.00601.62509.0000AID1167211; AID1196154; AID1280433; AID1317153; AID1371030; AID1371063; AID1509508; AID268179; AID441072; AID455742; AID712589; AID722019
NAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)IC50 (µMol)78.45710.85005.430010.0000AID1167213; AID1509510; AID1599759; AID1633285; AID441074; AID674941; AID712588
NAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)IC50 (µMol)58.20000.10003.38006.6000AID1194531; AID1777544; AID712587
NAD-dependent protein deacetylase Schistosoma mansoniIC50 (µMol)221.55001.90001.90001.9000AID1526036; AID1526038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (313)

Processvia Protein(s)Taxonomy
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrion organizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA metabolic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of protein localizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to oxidative stressPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein modification processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
telomere maintenancePoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
apoptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to gamma radiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
carbohydrate biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein autoprocessingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
macrophage differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of DNA-templated transcription, elongationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to insulin stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to UVPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of circadian sleep/wake cycle, non-REM sleepPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of catalytic activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of mitochondrial depolarizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of SMAD protein signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of necroptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein localization to chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to zinc ionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
replication fork reversalPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of cGAS/STING signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of protein localization to nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of single strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to aldosteronePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of adipose tissue developmentPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to amyloid-betaPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of myofibroblast differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of base-excision repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to nerve growth factor stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ATP generation from poly-ADP-D-ribosePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of ATP biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A5Homo sapiens (human)
steroid metabolic processCytochrome P450 3A5Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A5Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A5Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A5Homo sapiens (human)
retinol metabolic processCytochrome P450 3A5Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A5Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A5Homo sapiens (human)
oxidative demethylationCytochrome P450 3A5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
negative regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
signal transductionNAD(+) hydrolase SARM1Homo sapiens (human)
nervous system developmentNAD(+) hydrolase SARM1Homo sapiens (human)
response to glucoseNAD(+) hydrolase SARM1Homo sapiens (human)
NAD catabolic processNAD(+) hydrolase SARM1Homo sapiens (human)
cell differentiationNAD(+) hydrolase SARM1Homo sapiens (human)
negative regulation of MyD88-independent toll-like receptor signaling pathwayNAD(+) hydrolase SARM1Homo sapiens (human)
regulation of neuron apoptotic processNAD(+) hydrolase SARM1Homo sapiens (human)
innate immune responseNAD(+) hydrolase SARM1Homo sapiens (human)
response to axon injuryNAD(+) hydrolase SARM1Homo sapiens (human)
regulation of dendrite morphogenesisNAD(+) hydrolase SARM1Homo sapiens (human)
nervous system processNAD(+) hydrolase SARM1Homo sapiens (human)
protein localization to mitochondrionNAD(+) hydrolase SARM1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic nuclear membrane reassemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of exit from mitosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of autophagyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of peptidyl-threonine phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
substantia nigra developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelination in peripheral nervous systemNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of myelinationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to oxidative stressNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of DNA bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular lipid catabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
innate immune responseNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of fatty acid biosynthetic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of meiotic nuclear divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of striated muscle tissue developmentNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
regulation of cell cycleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
response to redox stateNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of cell divisionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of attachment of spindle microtubules to kinetochoreNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to caloric restrictionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of oligodendrocyte progenitor proliferationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cellular response to epinephrine stimulusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of execution phase of apoptosisNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
positive regulation of oocyte maturationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of satellite cell differentiationNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
base-excision repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
determination of adult lifespanNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
response to UVNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
retrotransposon silencingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid metabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
subtelomeric heterochromatin formationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of telomere maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IINAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
ketone biosynthetic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein import into nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
glucose homeostasisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of circadian rhythmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
post-translational protein modificationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of gene expression, epigeneticNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glycolytic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of glucose importNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein export from nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of fibroblast proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein secretionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of lipid catabolic processNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein delipidationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
cardiac muscle cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of cold-induced thermogenesisNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of protein localization to chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell population maintenanceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of chondrocyte proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
regulation of protein localization to plasma membraneNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of blood vessel branchingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein localization to site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell proliferationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of stem cell differentiationNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
single strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA synthesis involved in DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ovulation from ovarian follicleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular glucose homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of protein phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endothelial cell proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adaptive immune responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin organizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
triglyceride mobilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA damage responseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to oxidative stressNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
spermatogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of mitotic cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
muscle organ developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of centrosome duplicationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cholesterol effluxNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of lipid storageNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of glucose metabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macroautophagyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein ubiquitinationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
macrophage differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of prostaglandin biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatin formationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein destabilizationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of TOR signalingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of endodeoxyribonuclease activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to insulinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
circadian regulation of gene expressionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
leptin-mediated signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of smooth muscle cell apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intracellular triglyceride homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cell population proliferationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to glucose starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphorylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
behavioral response to starvationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cholesterol homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of neuron apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
response to leptinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of MHC class II biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of gluconeogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of DNA repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of angiogenesisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cell cycleNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of transcription by glucoseNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
white fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of helicase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of smooth muscle cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
maintenance of nucleus locationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fatty acid homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage cytokine productionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hydrogen peroxideNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of bile acid biosynthetic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
UV-damage excision repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to tumor necrosis factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to hypoxiaNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to ionizing radiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of protein serine/threonine kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of brown fat cell differentiationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
stress-induced premature senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
energy homeostasisNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein depropionylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA repair-dependent chromatin remodelingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
regulation of cellular response to heatNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of signal transduction by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of protein acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of adipose tissue developmentNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cellular response to leukemia inhibitory factorNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of macrophage apoptotic processNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular response to testosterone stimulusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of peptidyl-lysine acetylationNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
negative regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of cellular senescenceNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
positive regulation of double-strand break repairNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
chromatin remodelingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
aerobic respirationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of insulin secretionNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
peptidyl-lysine deacetylationNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of superoxide dismutase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of catalase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
positive regulation of ceramide biosynthetic processNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deacetylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrion organizationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
regulation of ketone biosynthetic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
response to nutrient levelsNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine demalonylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
peptidyl-lysine desuccinylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein deglutarylationNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
epigenetic regulation of gene expressionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (99)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatin bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein kinase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear estrogen receptor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ubiquitin protein ligase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
identical protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein homodimerization activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
histone deacetylase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
R-SMAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator activator activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-tyrosine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-histidine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BS6 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H3S10 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
monooxygenase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 3A5Homo sapiens (human)
protein bindingCytochrome P450 3A5Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A5Homo sapiens (human)
oxygen bindingCytochrome P450 3A5Homo sapiens (human)
heme bindingCytochrome P450 3A5Homo sapiens (human)
aromatase activityCytochrome P450 3A5Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
transcription corepressor activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+ bindingProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
NAD+ nucleosidase activityNAD(+) hydrolase SARM1Homo sapiens (human)
protein bindingNAD(+) hydrolase SARM1Homo sapiens (human)
signaling adaptor activityNAD(+) hydrolase SARM1Homo sapiens (human)
NADP+ nucleosidase activityNAD(+) hydrolase SARM1Homo sapiens (human)
NAD+ nucleotidase, cyclic ADP-ribose generatingNAD(+) hydrolase SARM1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone acetyltransferase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
histone deacetylase bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
tubulin deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
ubiquitin bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
transcription factor bindingNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
damaged DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleotidyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatin DNA bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleosome bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
protein homodimerization activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K18 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein-arginine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
DNA damage sensor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent histone H3K56 deacetylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein demyristoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD-dependent protein depalmitoylase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
TORC2 complex bindingNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
p53 bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription coactivator activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
transcription corepressor activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear receptor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
identical protein bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
HLH domain bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
bHLH transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
metal ion bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitogen-activated protein kinase bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
lysine-acetylated histone bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein-propionyllysine depropionylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
DNA-binding transcription factor bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H4K12 deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
histone H3K deacetylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD-dependent histone decrotonylase activityNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
keratin filament bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
promoter-specific chromatin bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
enzyme bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
sequence-specific DNA bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD-dependent histone deacetylase activityNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
NAD+ ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
zinc ion bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD-dependent protein lysine deacetylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-malonyllysine demalonylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-succinyllysine desuccinylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
protein-glutaryllysine deglutarylase activityNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
NAD+ bindingNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (70)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear replication forkPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
membranePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-containing complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-DNA complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A5Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A5Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP15Homo sapiens (human)
cytoplasmNAD(+) hydrolase SARM1Homo sapiens (human)
mitochondrionNAD(+) hydrolase SARM1Homo sapiens (human)
mitochondrial outer membraneNAD(+) hydrolase SARM1Homo sapiens (human)
cytosolNAD(+) hydrolase SARM1Homo sapiens (human)
microtubuleNAD(+) hydrolase SARM1Homo sapiens (human)
cell surfaceNAD(+) hydrolase SARM1Homo sapiens (human)
axonNAD(+) hydrolase SARM1Homo sapiens (human)
dendriteNAD(+) hydrolase SARM1Homo sapiens (human)
synapseNAD(+) hydrolase SARM1Homo sapiens (human)
protein-containing complexNAD(+) hydrolase SARM1Homo sapiens (human)
dendriteNAD(+) hydrolase SARM1Homo sapiens (human)
chromosome, telomeric regionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrosomeNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
centrioleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
microtubuleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
plasma membraneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
growth coneNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
midbodyNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranodal junctionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
paranode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perikaryonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
myelin sheathNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
lateral loopNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
Schmidt-Lanterman incisureNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
juxtaparanode region of axonNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
perinuclear region of cytoplasmNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
mitotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
meiotic spindleNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
glial cell projectionNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-2Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
pericentric heterochromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
endoplasmic reticulumNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of double-strand breakNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
site of DNA damageNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
intracellular membrane-bounded organelleNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromosome, subtelomeric regionNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-6Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
ESC/E(Z) complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
fibrillar centerNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear envelopeNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleolusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
cytosolNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
PML bodyNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
eNoSc complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
euchromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
chromatin silencing complexNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
rDNA heterochromatinNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nuclear inner membraneNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleoplasmNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
protein-containing complexNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
nucleusNAD-dependent protein deacetylase sirtuin-3, mitochondrialHomo sapiens (human)
nucleusNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrionNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
cytosolNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
mitochondrial matrixNAD-dependent protein deacylase sirtuin-5, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (239)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID266504Inhibition of Wistar rat brain FAAH2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
AID1489147Cytotoxicity against HUVEC assessed as reduction in cell viability after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs.
AID1268052Inhibition of human recombinant SIRT1 deacetylase activity using Arg-His-Lys-Lys(epsilon-acetyl)-AMC as substrate incubated for 45 mins by fluorescence analysis2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD(+)/NADH Ratio and SIRT1.
AID1742974Inhibition of recombinant human SIRT5 at 50 uM using flour de lys succinyl as substrate in presence of NAD+ by fluorometric assay relative to control2020European journal of medicinal chemistry, Nov-15, Volume: 206Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
AID1526054Inhibition of human sirtuin 3 at 500 uM relative to control2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID415908Increase in serine palmitoyltransferase 2 mRNA expression in human HaCaT cells by RT-PCR relative to untreated control2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Lithospermic acid derivatives from Lithospermum erythrorhizon increased expression of serine palmitoyltransferase in human HaCaT cells.
AID455755Inhibition of human SIRT3 by fluorogenic assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID1599759Inhibition of human recombinant sirtuin 3 using fluoro-lysine sirtuin 2 deacetylase substrate measured after 45 mins by fluorimetry assay2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1219590Drug metabolism in human liver microsomes assessed as antibody-mediated reduction in CYP2E1-mediated nicotinamide N-oxide formation at 2 mM by HPLC analysis relative to control2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID266506Selectivity for Wistar rat MGL-like activity over FAAH2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
AID674946Reduction in ATP level in human SK-MEL-28 cells at 100 uM maintained in Locke's solution after 24 hrs by luciferase-based assay in absence of GF and glucose2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID269133Inhibition of Escherichia coli KPR at 11 mM2006Journal of medicinal chemistry, Aug-10, Volume: 49, Issue:16
Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods.
AID1742976Inhibition of recombinant human SIRT2 (25 to 389 residues) expressed in Escherichia coli BL21(DE3) at 50 uM using ZMAL as substrate incubated for 4 hrs in presence of NAD+ followed by incubation with trypsin for 20 mins by trypsin-coupled assay based homo2020European journal of medicinal chemistry, Nov-15, Volume: 206Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID674935Inhibition of human SIRT3 expressed in Escherichia coli assessed as enzyme activity using Z-MAL as substrate at 1 mM after 6 hrs by fluorescence assay2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID1219598Drug metabolism in human liver microsomes assessed as CYP2B6-mediated nicotinamide N-oxide formation by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1489151Antiangiogenic activity in HUVEC assessed as inhibition of tube formation on matrigel at 12.5 ug/ml after 24 hrs by Mayer's hematoxylin staining based light microscopy relative to control2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs.
AID1219594Drug metabolism in human liver microsomes assessed as CYP2E1-mediated nicotinamide N-oxide formation preincubated for 5 mins at 45 degC after 30 mins by HPLC analysis in absence of NADPH2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1371031Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as growth inhibition after 24 hrs by measuring incorporation of [3H]-hypoxanthine by liquid scintillation counting method2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1489148Cytotoxicity against HUVEC assessed as reduction in cell viability up to 12.5 ug/ml after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs.
AID1371062Inhibition of N-terminal His6-tagged recombinant Leishmania infantum SIR2RP1 expressed in Escherichia coli in presence of NAD+ by fluorimetric method2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID671801Upregulation of SPTLCB2 mRNA expression in neonatal human foreskin keratinocytes at 10 uM after 4 days relative to vehicle treated control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Improvement by sodium dl-α-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels.
AID1509507Inhibition of recombinant human SIRT2 deacylation activity using Fluor de Lys Sirt2 as substrate measured at 5 mins interval for 30 mins in presence of NAD+ by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID1917589Modulation of human Sirt3 (118 to 399 residues) deacetylation activity under steady state assessed as substrate deacetylation at 1 uM and incubated for 30 mins using FdL2 (QPKKAc-AMC) peptide substrate in presence of NAD+ by fluorescence-based assay relat2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Discovery of novel compounds as potent activators of Sirt3.
AID441073Inhibition of human recombinant SIRT2 after 60 mins by fluorimetric analysis2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
AID671794Increase in ceramide content in human skin at 2% administered topically after 4 weeks relative to vehicle treated control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Improvement by sodium dl-α-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels.
AID1167213Inhibition of catalytically active human SIRT3 (102 to 399 amino acids) expressed in Escherichia coli BL21 (DE3) cells using fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled peptide by fluorescence assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1633283Inhibition of recombinant human N-terminal His6-tagged/SUMO-fused SIRT2 (38 to 356 residues) expressed in Escherichia coli BL21 assessed as reduction in deacetylase activity using acetylated H3K9 as substrate preincubated for 15 mins followed by substrate2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1139154Drug level in Swiss mouse plasma treated with ortho-nicorandil at 100 mg/kg, po after 10 hrs by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID274368Inhibition of human SIRT1 at 50 uM2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID1777544Inhibition of human recombinant SIRT5 assessed as inhibition of substrate desuccinylation using Fluor de Lys-Succinyl green peptide as substrate in presence of NAD+ measured by fluorometric assay2021Bioorganic & medicinal chemistry, 09-01, Volume: 45Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.
AID441074Inhibition of human recombinant SIRT3 after 60 mins by fluorimetric analysis2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
AID1371066Antileishmanial activity against amastigote stage of Leishmania infantum MHOM/MA671TMAP263 expressing luciferase after 72 hrs by luciferase assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID674937Inhibition of human SIRT2 assessed as enzyme activity using Fluor-de-Lys as substrate at 1 mM by fluorometry2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID1526042Inhibition of human sirutin 2 assessed as inhibition of susbtrate demyristoylation at 20 uM using (Z)-(Myr)-Lys-AMC as substrate relative to control2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1440185Activation of SIRT1 in Alzheimer's disease patient serum assessed as increase in deacetylation of SIRT1 substrate peptide at 5 mM preincubated for 1 hr followed by substrate addition measured after 1 hr by fluorescence spectroscopic method2017European journal of medicinal chemistry, Feb-15, Volume: 127Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in cellular model of Alzheimer's disease.
AID281694Inhibition of human recombinant GST-tagged SIRT2 by histone deacetylase assay2004Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
An in silico approach to discovering novel inhibitors of human sirtuin type 2.
AID1219599Drug metabolism in human liver microsomes assessed as chlorzoxazone-mediated reduction of CYP2E1-mediated nicotinamide N-oxide formation at 2 mM by HPLC analysis relative to control2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1167212Inhibition of full length human SIRT2 expressed in Escherichia coli BL21 (DE3) cells using fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled peptide by fluorescence assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1509501Inhibition of recombinant human SIRT2 demyristoylase activity using p53(Myr)-AMC as substrate measured after 3 hrs in presence of NAD+ and trypsin by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID1742977Inhibition of recombinant human SIRT3 (101 to 399 residues) expressed in Escherichia coli BL21(DE3) at 50 uM using ZMAL as substrate incubated for 4 hrs in presence of NAD+ followed by incubation with trypsin for 20 mins by trypsin-coupled assay based hom2020European journal of medicinal chemistry, Nov-15, Volume: 206Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
AID320392Inhibition of human recombinant Sirt2 expressed in Escherichia coli BL21 by fluorescent deacetylase assay2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode.
AID1202499Inhibition of SIRT6 (unknown origin) using (DABCYL)ISGASE(MyK)DIVHSE(EDANS)G substrate in presence of NAD followed by 1 hr incubation with trypsin by FRET assay2015European journal of medicinal chemistry, , Volume: 96A FRET-based assay for screening SIRT6 modulators.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1509519Inhibition of recombinant human SIRT3 (118 to 399 residues) demyristoylase activity expressed in Escherichia coli using p53(Myr)-AMC as substrate measured after 3 hrs in presence of NAD+ and trypsin by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID162395Inhibitory activity against Poly (ADP-ribose) polymerase 12003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries.
AID441075Selectivity ratio of IC50 for human recombinant SIRT2 to IC50 for human recombinant SIRT12009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
AID1526038Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells assessed as inhibition of substrate demyristoylation using (Z)-(Myr)-Lys-AMC as substrate2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1467207Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Alkaloids from aerial parts of Houttuynia cordata and their anti-inflammatory activity.
AID712589Inhibition of recombinant SIRT1 using ZMAL substrate after 4 hrs by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID674941Inhibition of human SIRT3 expressed in Escherichia coli using Z-MAL as substrate after 6 hrs by fluorescence assay2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID1202498Inhibition of SIRT1 (unknown origin) at 300 uM using (DABCYL)ISGASE(AcK)DIVHSE(EDANS)G substrate in presence of NAD followed by 1 hr incubation with trypsin by FRET assay2015European journal of medicinal chemistry, , Volume: 96A FRET-based assay for screening SIRT6 modulators.
AID1509535Inhibition of recombinant human N-terminal polyhis-tagged SIRT6 (1 to 355 residues) defatty-acylase activity expressed in Escherichia coli using SFP3 as substrate measured for 3460 sec in presence of NAD+ by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID1498673Inhibition of human SIRT3 expressed in Escherichia coli BL21 at 250 uM using H3K9AcWW as substrate preincubated for 15 mins followed by substrate addition measured after 1 hr by HPLC analysis relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
The mimics of N
AID1489149Cytotoxicity against HUVEC assessed as reduction in cell viability at 100 ug/ml after 24 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
Chemical constituents from the rare mushroom Calvatia nipponica inhibit the promotion of angiogenesis in HUVECs.
AID674938Inhibition of human SIRT3 expressed in Escherichia coli assessed as enzyme activity using Z-MAL as substrate at 100 uM after 6 hrs by fluorescence assay2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID1139153Drug level in Swiss mouse plasma treated with para-nicorandil at 100 mg/kg, po after 10 hrs by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID274367Inhibition of human recombinant SIRT22006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1204000Inhibition of PARP1 (unknown origin)2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
AID1526075Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(Pal)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID739045Inhibition of PARP1 (unknown origin)2013Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors.
AID1526069Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(But)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1202497Inhibition of SIRT6 (unknown origin) at 300 uM using (DABCYL)ISGASE(MyK)DIVHSE(EDANS)G substrate in presence of NAD followed by 1 hr incubation with trypsin by FRET assay2015European journal of medicinal chemistry, , Volume: 96A FRET-based assay for screening SIRT6 modulators.
AID1526071Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(Oct)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1176357Inhibition of human recombinant SIRT22015Bioorganic & medicinal chemistry, Jan-15, Volume: 23, Issue:2
Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1371030Inhibition of human SIRT12017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID712587Inhibition of SIRT5 using ZK(suc)A substrate after 1 hr by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID1196156Inhibition of human recombinant SIRT2 assessed as deacetylation of N-acetyl lysine residue in p53 (317 to 320) after 30 mins by luciferase-mediated luminescence assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Functionalized tetrahydro-1H-pyrido[4,3-b]indoles: a novel chemotype with Sirtuin 2 inhibitory activity.
AID1194532Inhibition of SIRT5 (unknown origin) at 30 uM using (DABCYL)ISGASE(SuK)DIVHSE(EDANS)G peptide substrate incubated for 1 hrs followed by 1 hr incubation with trypsin and nicotinamide by FRET-based assay2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1371070Antiparasitic activity against tachyzoite stage of Toxoplasma gondii2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID674936Inhibition of human SIRT1 assessed as enzyme activity using Fluor-de-Lys as substrate at 1 mM by fluorometry2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID492548Inhibition of PARP12010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.
AID1280434Inhibition of GST-tagged recombinant human SIRT2 using MPSDKTIGG as substrate by liquid scintillation counting analysis in presence of [3H]-acetic acid2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.
AID1498674Inhibition of human SIRT5 expressed in Escherichia coli BL21 at 250 uM using H3K9AcWW as substrate preincubated for 15 mins followed by substrate addition measured after 1 hr by HPLC analysis relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
The mimics of N
AID1917587Modulation of human Sirt3 (118 to 399 residues) deacetylation activity under steady state assessed as substrate deacetylation at 50 uM and incubated for 30 mins using FdL2 (QPKKAc-AMC) peptide substrate in presence of NAD+ by fluorescence-based assay rela2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Discovery of novel compounds as potent activators of Sirt3.
AID1509508Inhibition of recombinant human C-terminal His6-tagged SIRT1 (Met1 to Ser747 residues) defatty-acylase activity expressed in Escherichia coli using SFP3 as substrate measured at 5 mins interval for 60 mins in presence of NAD+ by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1219593Drug metabolism in human liver microsomes assessed as CYP2E1-mediated nicotinamide N-oxide formation after 30 mins by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1509494Inhibition of recombinant human SIRT2 defatty-acylase activity using SFP3 as substrate measured at 5 mins interval for 60 mins in presence of NAD+ by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID674945Effect on ATP level in human SK-MEL-28 cells maintained in medium containing GF and glucose at 100 uM after 24 hrs by luciferase-based assay2012European journal of medicinal chemistry, Sep, Volume: 55Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.
AID415910Increase in serine palmitoyltransferase protein expression in human HaCaT cells at 100 ug/mL by Western blot relative to untreated control2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Lithospermic acid derivatives from Lithospermum erythrorhizon increased expression of serine palmitoyltransferase in human HaCaT cells.
AID1139152Drug level in Swiss mouse plasma treated with nicorandil at 100 mg/kg, po after 10 hrs by LC-MS/MS analysis2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Synthesis, antinociceptive activity and pharmacokinetic profiles of nicorandil and its isomers.
AID1317154Non-competitive inhibition of recombinant yeast glutathione-S-transferase-tagged SIRT2 using acetylated histone as substrate measured after 30 mins by fluorimetric analysis2016European journal of medicinal chemistry, Aug-25, Volume: 119How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
AID1317153Non-competitive inhibition of recombinant human SIRT1 using acetylated histone as substrate measured after 30 mins by fluorimetric analysis2016European journal of medicinal chemistry, Aug-25, Volume: 119How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
AID1498681Inhibition of human N-terminal His6-SUMO-tagged SIRT2 (38 to 356 residues) expressed in Escherichia coli BL21 at 250 uM using H3K9AcWW as substrate preincubated for 15 mins followed by substrate addition measured after 1 hr by HPLC analysis relative to co2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
The mimics of N
AID1509515Inhibition of recombinant human C-terminal His6-tagged SIRT1 (Met1 to Ser747 residues) demyristoylase activity expressed in Escherichia coli using p53(Myr)-AMC as substrate measured after 3 hrs in presence of NAD+ and trypsin by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID1372697Inhibition of mushroom tyrosinase using tyrosine as substrate pretreated for 5 mins followed by substrate addition measured after 20 mins by ELISA2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Characterization of tyrosinase inhibitory constituents from the aerial parts of Humulus japonicus using LC-MS/MS coupled online assay.
AID1219591Drug metabolism in insect microsomes assessed as CYP2E1 (unknown origin)-mediated nicotinamide N-oxide formation after 30 mins by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID441072Inhibition of human recombinant SIRT1 after 60 mins by fluorimetric analysis2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
AID722019Inhibition of N-terminal His6-tagged SIRT1 coding region (156-664) (unknown origin) expressed in Escherichia coli BL21(DE3) using 31.25 uM ac-RHKKac-AMC and 750 uM NAD+ as substrate after 45 mins by fluorometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Identification of benzofuran-3-yl(phenyl)methanones as novel SIRT1 inhibitors: binding mode, inhibitory mechanism and biological action.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1371058Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi at 5 uM by Alamar Blue assay2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1498672Inhibition of human SIRT1 expressed in Escherichia coli BL21 at 250 uM using H3K9AcWW as substrate preincubated for 15 mins followed by substrate addition measured after 1 hr by HPLC analysis relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
The mimics of N
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1202728Induction of human ESC differentiation assessed as increase in microphthalmia-associated transcription factor expression measured over 8 weeks relative to total pigmented area2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Stemistry: the control of stem cells in situ using chemistry.
AID1526068Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of ZMAL2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1167211Inhibition of full length human SIRT1 expressed in Escherichia coli BL21 (DE3) cells using fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled peptide by fluorescence assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.
AID712590Inhibition of recombinant SIRT2 using ZMAL substrate after 4 hrs by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1321906Protection against focal cerebral ischemia in Wistar rat model of permanent MCAO assessed as reduction in infarction volume administered ip at 2 hrs post reperfusion measured 3 days post MCAO2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of novel hydrogen sulfide releasing nicotinic acid derivatives.
AID1370960Inhibition of SIRT1 (unknown origin) assessed as reduction in Fluor de Lys deacetylation at 10 to 20 uM incubated for 5 mins followed by substrate addition measured after 45 mins in presence of NAD/NADH by fluorescence assay2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
SIRT1 activator isolated from artificial gastric juice incubate of total saponins in stems and leaves of Panax ginseng.
AID268179Inhibition of human SIRT12006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
Nepsilon-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine Nepsilon-deacetylation.
AID1526053Inhibition of human sirtuin 1 at 500 uM relative to control2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1202727Induction of human ESC differentiation assessed as appearance of pigmented area measured over 8 weeks relative to control2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
Stemistry: the control of stem cells in situ using chemistry.
AID1633285Inhibition of human SIRT3 assessed as reduction in deacetylase activity using acetylated H3K9 as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by UV-HPLC analysis2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.
AID1219597Drug metabolism in human liver microsomes assessed as CYP2A6-mediated nicotinamide N-oxide formation by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID441076Selectivity ratio of IC50 for human recombinant SIRT3 to IC50 for human recombinant SIRT12009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.
AID671795Increase in ceramide content in human skin at 4% administered topically after 4 weeks relative to vehicle treated control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Improvement by sodium dl-α-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels.
AID1371063Inhibition of human SIRT1 in presence of NAD+ by fluorimetric method2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID1196154Inhibition of human recombinant SIRT1 assessed as deacetylation of N-acetyl lysine residue in p53 (317 to 320) after 30 mins by luciferase-mediated luminescence assay2015European journal of medicinal chemistry, Mar-06, Volume: 92Functionalized tetrahydro-1H-pyrido[4,3-b]indoles: a novel chemotype with Sirtuin 2 inhibitory activity.
AID1498675Inhibition of human SIRT6 (1 to 294 residues) expressed in Escherichia coli Rosetta (DE3) at 250 uM using H3K9AcWW as substrate preincubated for 15 mins followed by substrate addition measured after 1 hr by HPLC analysis relative to control2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
The mimics of N
AID712588Inhibition of recombinant SIRT3 using ZMAL substrate after 4 hrs by homogeneous fluorescence assay2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.
AID1526036Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells assessed as inhibition of substrate deacetylation using ZMAL as substrate2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1219592Drug metabolism in human liver microsomes assessed as CYP2E1-mediated nicotinamide N-oxide formation at 3 mM after 30 mins by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1201284Inhibition of human soluble tissue factor/factor VIIa expressed in Origami B (DE3) using D-Ile-Pro-Arg-pNA as substrate after 30 mins by spectrophotometric analysis2015Journal of medicinal chemistry, Mar-26, Volume: 58, Issue:6
Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening.
AID455741Inhibition of yeast Hst2 by fluorimetric assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID1526074Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(Myr)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1509510Inhibition of recombinant human SIRT3 (118 to 399 residues) defatty-acylase activity expressed in Escherichia coli using SFP3 as substrate measured at 5 mins interval for 60 mins in presence of NAD+ by fluorescence assay2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Development of Peptide-Based Sirtuin Defatty-Acylase Inhibitors Identified by the Fluorescence Probe, SFP3, That Can Efficiently Measure Defatty-Acylase Activity of Sirtuin.
AID671800Upregulation of SPTLCB1 mRNA expression in neonatal human foreskin keratinocytes at 10 uM after 4 days relative to vehicle treated control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Improvement by sodium dl-α-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels.
AID1526072Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(Dec)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1280433Inhibition of human SIRT1 using MPSDKTIGG as substrate by liquid scintillation counting analysis in presence of [3H]-acetic acid2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.
AID401477Displacement of [3H]diazepam from benzodiazepine receptor in rat cerebral cortex membrane
AID415753Increase in serine palmitoyltransferase 1 mRNA expression in human HaCaT cells by RT-PCR relative to untreated control2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Lithospermic acid derivatives from Lithospermum erythrorhizon increased expression of serine palmitoyltransferase in human HaCaT cells.
AID455742Inhibition of human full length SIRT1 expressed in DE3 cells by fluorimetric assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID1917588Modulation of human Sirt3 (118 to 399 residues) deacetylation activity under steady state assessed as substrate deacetylation at 10 uM and incubated for 30 mins using FdL2 (QPKKAc-AMC) peptide substrate in presence of NAD+ by fluorescence-based assay rela2022Bioorganic & medicinal chemistry, 11-01, Volume: 73Discovery of novel compounds as potent activators of Sirt3.
AID671797Increase in ceramide content in normal human keratinocytes at 1 to 30 uM after 6 days relative to vehicle treated control2012Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12
Improvement by sodium dl-α-tocopheryl-6-O-phosphate treatment of moisture-retaining ability in stratum corneum through increased ceramide levels.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1526070Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(Hex)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1194531Inhibition of human SIRT5 assessed as reduction in desuccinylase activity using KQTAR(SuK)STGGKA substrate2015Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8
A FRET-based assay for screening SIRT5 specific modulators.
AID1742975Inhibition of recombinant human SIRT1 (133 to 747 residues) expressed in Escherichia coli BL21(DE3) at 50 uM using ZMAL as substrate incubated for 4 hrs in presence of NAD+ followed by incubation with trypsin for 20 mins by trypsin-coupled assay based hom2020European journal of medicinal chemistry, Nov-15, Volume: 206Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
AID1202500Inhibition of SIRT6 (unknown origin) using AMC containing peptide substructure by fluorogenic assay2015European journal of medicinal chemistry, , Volume: 96A FRET-based assay for screening SIRT6 modulators.
AID722020Inhibition of N-terminal His6-tagged SIRT1 coding region (156-664) (unknown origin) expressed in Escherichia coli BL21(DE3) using 31.25 uM ac-RHKKac-AMC and 750 uM NAD+ as substrate at 100 uM after 45 mins by fluorometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Identification of benzofuran-3-yl(phenyl)methanones as novel SIRT1 inhibitors: binding mode, inhibitory mechanism and biological action.
AID1219595Drug metabolism in insect microsomes assessed as FMO3 (unknown origin)-mediated nicotinamide N-oxide formation after 30 mins by HPLC analysis2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID455754Inhibition of human SIRT2 by fluorogenic assay2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Identification and characterization of novel sirtuin inhibitor scaffolds.
AID443106Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 48 hrs by MTT assay relative to control in presence of nicotinamide2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry.
AID1526073Inhibition of recombinant Schistosoma mansoni sirtuin 2 (21 to 322 residues) expressed in Escherichia coli BL21(DE3) cells in presence of (Z)-(Lau)Lys-AMC2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1649763Binding affinity to 15N-labeled FKBP51 (1 to 140 residues) (unknown origin) expressed in Escherichia coli OD2N assessed as induction of chemical shift perturbations by two-dimensional 1H/15N HSQC NMR spectroscopy2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
AID724201Inhibition of Plasmodium falciparum NAD-dependent protein deacetylase Sir2A2013European journal of medicinal chemistry, Jan, Volume: 59Sirtuins as emerging anti-parasitic targets.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID1219596Drug metabolism in human liver microsomes assessed as diethyldithiocarbamate-mediated reduction of CYP2E1-mediated nicotinamide N-oxide formation at 2 mM by HPLC analysis relative to control2013Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID724202Inhibition of Leishmania infantum SIR2RP12013European journal of medicinal chemistry, Jan, Volume: 59Sirtuins as emerging anti-parasitic targets.
AID1526040Inhibition of human sirtuin 2 assessed as inhibition of substrate deacetylation using ZMAL as substrate2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from
AID1248040Inhibition of PARP1 (unknown origin)2015Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20
Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
AID1371029Inhibition of Plasmodium falciparum Sir2A2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2005Molecular cell, Mar-18, Volume: 17, Issue:6
Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802837Fluorimetric Assay from Article 10.1002/cbic.201600655: \\Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.\\2017Chembiochem : a European journal of chemical biology, 05-18, Volume: 18, Issue:10
Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.
AID1798811Scintillation Proximity Assay (SPA) from Article 10.1124/mol.108.048751: \\Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhib2008Molecular pharmacology, Dec, Volume: 74, Issue:6
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12,553)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903402 (27.10)18.7374
1990's1160 (9.24)18.2507
2000's1668 (13.29)29.6817
2010's5336 (42.51)24.3611
2020's987 (7.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 75.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index75.78 (24.57)
Research Supply Index9.58 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index277.28 (26.88)
Search Engine Supply Index3.95 (0.95)

This Compound (75.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,097 (8.20%)5.53%
Reviews1,231 (9.20%)6.00%
Case Studies728 (5.44%)4.05%
Observational35 (0.26%)0.25%
Other10,290 (76.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (249)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nicotinamide Riboside in Ulcerative Colitis [NCT05561738]40 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Evaluation of Efficacy and Safety of Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients [NCT03850886]Phase 261 participants (Actual)Interventional2019-01-15Completed
NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease [NCT03816020]30 participants (Actual)Interventional2019-03-09Completed
To Determine if the Cardiovascular Risk Indices Including Postprandial Hypertriglyceridaemia Are Modified Favourably by Nicotinic Acid (Niacin) in Patients With Polycystic Ovary Syndrome ( PCOS) [NCT01118598]Phase 434 participants (Actual)Interventional2010-06-30Completed
Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia [NCT01216956]24 participants (Actual)Interventional2006-09-30Completed
Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19 [NCT04751604]900 participants (Actual)Interventional2021-02-01Completed
Effect of Nicotinic Acid as add-on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine: A Randomized, Double-blind, Placebo-controlled Trial [NCT05846373]Phase 266 participants (Anticipated)Interventional2022-11-25Recruiting
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia [NCT03510884]Phase 3153 participants (Actual)Interventional2018-05-31Completed
Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS) [NCT01381354]Phase 138 participants (Actual)Interventional2010-10-31Completed
Effect of Nicotinamide Riboside and Pterostilbene Supplementation on Muscle Regeneration in Elderly Humans - A Randomized, Placebo-controlled, Clinical Trial [NCT03754842]32 participants (Actual)Interventional2019-02-12Completed
Pilot Study of Nicotinamide Mononucleotide Supplementation in Patients With Hypertension [NCT04903210]Phase 420 participants (Anticipated)Interventional2021-06-01Recruiting
Pilot Study of Preoperative Nicotinamide Riboside (Vitamin B3) Supplementation in Patients Undergoing Elective Left Ventricular Assist Device (LVAD) Implantation [NCT03727646]Early Phase 15 participants (Actual)Interventional2018-09-26Completed
Vitamin B3 as a Novel Mitochondrial Therapy for Obesity [NCT03951285]56 participants (Actual)Interventional2016-05-25Completed
Double-blind, Randomized, Placebo-controlled, Single-center, 2 Treatment, 3-way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy Subjects [NCT01258491]Phase 118 participants (Actual)Interventional2005-05-31Completed
A Randomized, Double-Blind, Crossover Study to Assess the Effects of Nicotinamide Riboside on Cognitive Function, Mood and Sleep in Older Adult Men and Women [NCT03562468]40 participants (Actual)Interventional2018-06-13Completed
Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC) [NCT04844528]Phase 286 participants (Anticipated)Interventional2021-08-05Recruiting
International, Multicenter, Randomized, Single Blind, Placebo-controlled Study of Efficacy and Safety of CITOFLAVIN® in the Acute Period of Head Injury in Adults [NCT04631484]Phase 3320 participants (Anticipated)Interventional2020-10-08Recruiting
Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia: A Multicenter Clinical Trial [NCT03626298]Phase 4125 participants (Actual)Interventional2016-08-01Completed
Improved Adipose Tissue Storage of Dietary Fatty Acids as a New Mechanism for the Rapid Remission of Hepatic and Cardiac Metabolic Dysfunction After Bariatric Surgery [NCT05934409]40 participants (Anticipated)Interventional2023-11-01Recruiting
Effect of β-nicotinamide Mononucleotide Intervention on Healthy Young Subjects With Acute Binge Drink: a Double-blinded, Randomized, Crossover Trial [NCT05882214]20 participants (Anticipated)Interventional2023-12-31Recruiting
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease [NCT05589766]Phase 280 participants (Anticipated)Interventional2023-01-23Recruiting
Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate, a Beta-2 Adrenergic Receptor Agonist [NCT05553184]12 participants (Actual)Interventional2022-07-05Completed
Quantifying Brown Adipose Tissue Thermogenesis in Type 2 Diabetes [NCT05092945]40 participants (Anticipated)Interventional2021-05-18Recruiting
Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients [NCT03635411]Phase 148 participants (Anticipated)Interventional2018-12-06Recruiting
Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease [NCT02140814]Phase 210 participants (Actual)Interventional2014-05-31Completed
Phase II Study of a Non-Steroidal Novel Treatment for Scalp Psoriasis [NCT01368887]Phase 2160 participants (Anticipated)Interventional2013-04-30Suspended(stopped due to Sponsor seeking additional financial support before starting the study)
Avaliação de Aceitabilidade dérmica, eficácia Hidratante, restauração da Barreira e equilíbrio da Microbiota da Pele atópica de um Produto Hidratante - Estudo Clínico, Instrumental e Subjetivo. [NCT05530707]49 participants (Actual)Interventional2022-09-05Completed
Carotid Plaque Characteristics by MRI in AIM-HIGH [NCT01178320]230 participants (Actual)Observational2008-03-31Completed
A Multicentre Double-blind Placebo-controlled Randomized Study of Efficacy and Safety of Cytoflavin®, Intravenous Administration and Enteric-coated Tablets, Used in Elderly Patients for Prevention of Cognitive Decline After Major Surgery [NCT03849664]Phase 3200 participants (Actual)Interventional2017-06-02Completed
Dose Finding Study of Nicotinamide in Hemodialysis Patients With Hyperphosphatemia [NCT01200784]Phase 2252 participants (Actual)Interventional2010-08-31Completed
The Effect of Exercise and Nicotinamide Riboside on Muscle Health and Insulin Resistance in Adult Survivors of Childhood Cancer With Prediabetes: A Pilot Feasibility Study [NCT05023993]20 participants (Anticipated)Interventional2022-06-23Recruiting
Pharmacodynamics and Tolerance Study of Nicotinamide Mononucleotide (NMN) Supplementation at 400 mg/Day [NCT04862338]17 participants (Actual)Interventional2021-04-26Completed
The Efficacy and Safety of a Mental Intervention Program vs. Usual Care and Nicotinamide Riboside (NR) vs. Placebo for Improving Health-related Quality of Life in Long Covid: A 2 x 2 Factorial Randomized Controlled Trial [NCT05703074]Phase 2310 participants (Anticipated)Interventional2023-01-30Recruiting
Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD+) for Treatment of Patients With Post-COVID-19 Syndrome (Long-COVID19) [NCT04604704]Phase 236 participants (Actual)Interventional2021-01-28Completed
Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy [NCT03642990]Phase 25 participants (Actual)Interventional2019-11-08Terminated(stopped due to Enrollment challenges)
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia [NCT04430517]Early Phase 150 participants (Anticipated)Interventional2022-03-02Recruiting
"A Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial of Efficacy and Safety of Remaxol®, a Solution for Intravenous Infusions Produced by STPF POLYSAN (Russia), in Patients With Mechanical Jaundice of Non-Malignant Origin" [NCT03418935]Phase 3342 participants (Actual)Interventional2017-04-03Completed
Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial) [NCT04112043]Phase 149 participants (Actual)Interventional2020-07-28Completed
A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors. [NCT04948333]Phase 3199 participants (Actual)Interventional2021-10-13Active, not recruiting
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease [NCT05617508]80 participants (Anticipated)Interventional2022-11-22Recruiting
Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial [NCT04910230]24 participants (Actual)Interventional2020-03-01Completed
A Phase I, Double-blind, Randomised, Placebo-controlled, Single-ascending and Multiple-ascending Dose Trial to Evaluate Safety and Pharmacokinetics of Oral Controlled-ileocolonic-release Nicotinamide (CICR-NAM) Compared to Immediate-release Nicotinamide a [NCT05258474]Phase 149 participants (Actual)Interventional2020-12-04Completed
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase With Addition of Lower Dose Tyrosine Kinas Inhibitors for Patients With Chronic Myeloid Leukemia Who do Not Achieve a Deep Molecular Remission [NCT05143840]Phase 28 participants (Anticipated)Interventional2022-04-22Recruiting
A Multi Center Two Part Study to Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults [NCT04823260]90 participants (Actual)Interventional2021-05-25Completed
Effect of Nicotinic Acid on Adipose Tissue Inflammation in Obese Subjects [NCT01083329]Phase 224 participants (Actual)Interventional2010-01-31Completed
The Quantitative Analysis of Clitoral Blood Before and After a Topically Applied Vasodilating Cream Using Sonographic Doppler Flow Plethysmography [NCT01085981]30 participants (Anticipated)Interventional2010-04-30Not yet recruiting
[NCT02300740]Early Phase 112 participants (Actual)Interventional2014-12-31Completed
Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in Friedreich's Ataxia [NCT01589809]Phase 240 participants (Anticipated)Interventional2012-06-30Active, not recruiting
Phase II Study of Nicotinamide in Early Onset Preeclampsia [NCT03419364]Phase 223 participants (Actual)Interventional2017-11-01Completed
Three-Day Dosing NAD + Study [NCT03707652]8 participants (Actual)Interventional2018-03-12Completed
Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults [NCT03821623]Phase 2118 participants (Anticipated)Interventional2019-05-10Recruiting
A Multicenter, Double-blind, Placebo-controlled, Randomized Trial of the Efficacy and Safety of Remaxol®, a Solution for Infusions Produced by STPF POLYSAN (Russia), in Patients With Malignant Mechanical Jaundice [NCT03416062]Phase 3240 participants (Actual)Interventional2017-04-03Completed
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase [NCT02890992]Phase 242 participants (Actual)Interventional2016-09-15Completed
NOPARK Open Label Extension Study [NCT05546567]400 participants (Anticipated)Interventional2022-09-28Recruiting
An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia [NCT03510715]Phase 318 participants (Actual)Interventional2018-08-31Completed
Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer [NCT01349088]Phase 1/Phase 20 participants (Actual)Interventional2013-12-31Withdrawn
A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia [NCT01294683]Phase 3977 participants (Actual)Interventional2011-02-04Terminated
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial [NCT05955924]Phase 3396 participants (Anticipated)Interventional2023-08-28Recruiting
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Hypercholesterolemia [NCT00769132]Phase 126 participants (Actual)Interventional2007-08-03Completed
Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy [NCT00715273]Phase 4217 participants (Actual)Interventional2001-05-01Completed
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study [NCT05695027]Phase 2/Phase 3188 participants (Anticipated)Interventional2023-03-14Recruiting
A Phase II, Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy of BASIS™ (Nicotinamide Riboside and Pterostilbene) Treatment for Kidney Protection in Patients Treated by Complex Aortic Aneurysm Repair and Aortic Arch Re [NCT04342975]Phase 2238 participants (Anticipated)Interventional2020-12-01Recruiting
An Open-Label, Definitive Bioequivalence Study to Compare the Pharmacokinetics of the Simvastatin, Nicotinic Acid, and MK0524 (Laropiprant) Components of a Formulation of MK0524B With That of Zocor™ and MK0524A Tablets [NCT00943124]Phase 1220 participants (Actual)Interventional2007-07-31Completed
Energy Metabolism in Neurodegenerative Diseases: A Randomized, Double Blind, Placebo-Controlled Clinical Pilot Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. [NCT00605930]20 participants (Actual)Interventional2004-04-30Completed
Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial of Efficacy and Safety of the Drug Cytoflavin®, Administered Intravenously Followed by Oral Intake, in Patients With Diabetic Polyneuropathy [NCT04649203]Phase 3216 participants (Actual)Interventional2020-11-25Completed
Alleviation by NIAGEN of Persistent Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors [NCT04112641]Phase 248 participants (Anticipated)Interventional2020-02-19Recruiting
Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma [NCT05790577]Phase 288 participants (Actual)Interventional2022-02-01Completed
A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients With Primary Hypercholesterolemia or Mixed Dyslipidem [NCT01335997]Phase 31,139 participants (Actual)Interventional2011-05-01Terminated(stopped due to Business Reasons)
Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D): Relative Contribution of Dietary vs Systemic Fatty Acids to Lean Tissue Fatty Acid Fluxes and Oxidative vs Non-oxidative Pathways [NCT02808182]50 participants (Actual)Interventional2017-01-17Completed
A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor [NCT02426086]Phase 2107 participants (Actual)Interventional2015-08-28Completed
The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism [NCT06162013]Phase 2330 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Effects of Nicotinamide Riboside (Vitamin B3) in Patients With Ataxia Telangiectasia. [NCT03962114]Phase 224 participants (Actual)Interventional2019-03-18Completed
A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes [NCT00485758]Phase 3796 participants (Actual)Interventional2007-07-31Completed
Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial [NCT00712049]Phase 4200 participants (Anticipated)Interventional2008-06-30Recruiting
Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients [NCT01011699]Phase 3176 participants (Actual)Interventional2010-01-31Terminated(stopped due to Financial problem)
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease: The NICE Trial [NCT03743636]Phase 390 participants (Actual)Interventional2018-10-01Completed
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients [NCT03685773]Phase 20 participants (Actual)Interventional2019-04-21Withdrawn(stopped due to "Permanently terminated due to COVID-19 given the poor vaccine penetrance in liver transplant recipients.~This is not a suspension of IRB approval.")
A Single-centre Trial to Investigate the Safety and Pharmacokinetics of Orally Administered Nicotinamide Mononucleotide (NMN, 400mg) Over 29 Days of Supplementation in Healthy Adults. [NCT04910061]24 participants (Actual)Interventional2021-08-05Completed
The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia [NCT02836184]Phase 445 participants (Anticipated)Interventional2016-07-31Recruiting
An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets [NCT00944645]Phase 1188 participants (Actual)Interventional2006-10-31Completed
Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study) [NCT00633698]Phase 3150 participants (Anticipated)Interventional2008-01-31Active, not recruiting
Comparison of the Effectiveness and Safety Between Moisturizing Cream Containing Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Hermatitis in Intensive Care Unit Nurses: a Double Blind Randomized Clinical Trial [NCT04218500]92 participants (Actual)Interventional2019-09-03Completed
A Randomized, Double-Blind, Placebo-Controlled, 4-Period, Crossover Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With Type 2 Diabetes [NCT00618995]Phase 126 participants (Actual)Interventional2007-08-31Completed
An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors [NCT00861419]Phase 188 participants (Anticipated)Interventional2005-12-31Completed
A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inh [NCT04925479]Phase 1/Phase 234 participants (Anticipated)Interventional2021-12-27Recruiting
Polyphenol Rich Aerosol as a Support for Cancer Patients in Minimizing Side Effects After a Radiation Therapy [NCT05994638]10 participants (Anticipated)Interventional2023-08-21Recruiting
Phase II Trial With Safety-Run-In of MEK Inhibitor MSC1936369B in Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies [NCT00957580]Phase 281 participants (Actual)Interventional2009-09-30Terminated(stopped due to The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1))
Pilot Study to Test the Safety and Efficacy of Metformin, Dasatinib, Rapamycin and Nutritional Supplements (Bio-quercetin; Bio-fisetin; Glucosamine; Nicotinamide Riboside; Trans-resveratrol) in Reducing Clinical Measures of Aging in Older Adults [NCT04994561]Phase 10 participants (Actual)Interventional2022-06-30Withdrawn(stopped due to Study was withdrawn)
Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies [NCT00691210]Phase 140 participants (Actual)Interventional2008-06-30Completed
Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury [NCT05958277]Phase 3300 participants (Actual)Interventional2021-06-01Completed
Randomized, Controlled Pilot Study of Niacinamide in Polycystic Kidney Disease [NCT02558595]Phase 236 participants (Actual)Interventional2015-09-22Completed
Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery [NCT00796887]Phase 228 participants (Actual)Interventional2009-04-30Completed
SENolytics to Improve Osteoporosis Therapy: a Randomised Controlled Clinical Trial The SENIOR Trial [NCT06018467]Phase 2120 participants (Anticipated)Interventional2023-09-06Recruiting
Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans [NCT02835664]15 participants (Actual)Interventional2016-12-31Completed
"Pharmacokinetic Study of Nicotinamide Riboside" [NCT02689882]Phase 18 participants (Actual)Interventional2015-11-30Completed
Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application [NCT02758990]16 participants (Actual)Interventional2016-03-31Terminated(stopped due to Recruiting and financial constraints)
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD [NCT04040959]Phase 2118 participants (Anticipated)Interventional2019-11-19Recruiting
The Role of Nicotinamide Riboside in Mitochondrial Biogenesis [NCT03432871]13 participants (Actual)Interventional2017-12-08Completed
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH [NCT00880178]324 participants (Actual)Observational2008-05-31Completed
SCH 465981: Assessment of Bi-Directional Interaction Between Components of Vytorin® (Ezetimibe and Simvastatin) and Niaspan® (Niacin Extended-Release Tablets) in Healthy Subjects [NCT00652431]Phase 118 participants (Actual)Interventional2007-05-31Completed
Effect of Adjunctive Use of Vitamin B3 and B9 on Myeloperoxidase Level in the GCF of Patients With Stage I and II Periodontitis, a Randomized, Parallel Group, Double Blinded, Placebo Controlled Study [NCT05435378]Early Phase 130 participants (Anticipated)Interventional2022-07-01Not yet recruiting
Effect of Nicotinamide Riboside on Myocardial and Skeletal Muscle Injury and Function in Patients With Metastatic Breast Cancer Receiving Anthracyclines [NCT05732051]Phase 260 participants (Anticipated)Interventional2023-03-16Recruiting
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults [NCT05517122]68 participants (Actual)Interventional2022-06-27Active, not recruiting
Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults [NCT02921659]Phase 1/Phase 230 participants (Actual)Interventional2015-04-30Completed
The Effect of Supplemental Adjuvants for Intracellular Nutrition and Treatment on Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration [NCT00893724]60 participants (Anticipated)Interventional2009-06-30Active, not recruiting
Phase I Open Label Trial of Pharmacokinetics and Safety of 99mTc Niacinamide Polyethylene Glycol Bicyclic RGD Peptide (99mTc-3PRGD2) Injection in Healthy Volunteers [NCT03974685]Phase 110 participants (Actual)Interventional2018-12-12Completed
Effect of Tredaptive on Serum Lipoproteins, Lipoproteins Metabolism, Oxidative Stress and HDL Antioxidant Function [NCT01054508]Phase 438 participants (Actual)Interventional2010-06-30Completed
Effect of Niacin On Fatty Acid Trapping [NCT01984073]Phase 126 participants (Actual)Interventional2012-12-31Completed
A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure [NCT01173471]Phase 250 participants (Actual)Interventional2010-12-31Completed
Role of Extended-release Niacin on Immune Activation in HIV-infected Patients Treated With Antiretroviral Therapy: a Proof-of-concept Study [NCT02018965]Phase 216 participants (Actual)Interventional2011-11-30Completed
A Multicenter, Double-blind, Placebo-controlled, Randomized Study of the Efficacy and Safety of Sequential Therapy With CYTOFLAVIN® (NTFF POLYSAN, Russia), Solution for Intravenous Infusion and Enteric-coated Tablets, in the Complex Rehabilitation of Pati [NCT05935787]Phase 3196 participants (Anticipated)Interventional2023-03-23Recruiting
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation &Amp;Amp;Amp;Amp; Metabolic Rate [NCT06044935]100 participants (Anticipated)Interventional2024-01-03Recruiting
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus [NCT06032923]Phase 1/Phase 278 participants (Anticipated)Interventional2024-01-03Not yet recruiting
Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease [NCT00580931]Phase 1/Phase 250 participants (Actual)Interventional2008-01-31Completed
The Benefits of Nicotinamide Riboside Upon Cognition and Sleep in Older Veterans [NCT05500170]50 participants (Anticipated)Interventional2023-04-04Recruiting
Efficacy of Nicotinamide on Retinal Ganglion Cell Functions in Glaucoma Patients : Clinical Trial, Cross-over Design, Double-blind, Placebo-control, Randomized, Single-center Study [NCT06078605]80 participants (Anticipated)Interventional2022-09-16Recruiting
A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Compare the Pharmacokinetic Profiles of Three Different Strengths of ASP015K Extended Release Formulation With ASP015K Immediate Release Formulation and to Evaluate Food Effect on Extended Re [NCT01686217]Phase 130 participants (Actual)Interventional2012-06-30Completed
Improved Skin Whitening Outcomes Associated With Nicotinamide Fortified Consumption in 30 to 50-Year-old Women, a Double Blind, Control and Randomized Study [NCT05696938]70 participants (Actual)Interventional2023-02-16Completed
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis [NCT04271735]29 participants (Actual)Interventional2020-08-26Completed
Mechanisms of Prediabetic States in Sleep Apnea [NCT04234217]300 participants (Anticipated)Interventional2019-11-26Recruiting
The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients [NCT00316472]Phase 140 participants Interventional2006-04-30Completed
[NCT02701127]Early Phase 155 participants (Actual)Interventional2016-03-31Completed
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia [NCT00961636]Phase 31,152 participants (Actual)Interventional2009-10-31Completed
A Multicenter, Randomized, Double-Blinded, Parallel-Design Study to Evaluate the Lipid-Altering Efficacy of 2 Formulations of MK0524A Compared to NIASPAN (TM) [NCT00533312]Phase 2407 participants (Actual)Interventional2005-04-30Completed
A Phase 1, Open-Label, 4-Way Crossover Regional Drug Absorption Study to Assess the Bioavailability of ASP015K in Healthy Subjects [NCT01430078]Phase 112 participants (Actual)Interventional2010-09-30Completed
A Double-blind, Double-dummy, Placebo-controlled, Incomplete Block, Two Period Crossover Study of the Histamine H3 Antagonist GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Central Sensitisation in Healthy Volunteers [NCT00387413]Phase 140 participants (Actual)Interventional2006-10-02Completed
Efficacy of Nicotinic Acid for VEGFR Inhibitor-Associated Hand-Foot Skin Reactions in Solid Tumor Patients: a Randomised Controlled Phase 2 Trial [NCT04242927]Phase 236 participants (Anticipated)Interventional2020-03-09Recruiting
Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet) [NCT02950441]Phase 212 participants (Anticipated)Interventional2016-06-30Recruiting
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients [NCT00508885]Phase 1/Phase 217 participants (Actual)Interventional2006-10-31Completed
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment [NCT04877522]Phase 4347 participants (Anticipated)Interventional2022-08-30Recruiting
A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma [NCT01242930]Phase 213 participants (Actual)Interventional2010-11-30Completed
The Effects of NAD on Brain Function and Cognition [NCT02942888]46 participants (Actual)Interventional2017-11-30Completed
Nicotinamide Riboside in Diabetic Polyneuropathy [NCT03685253]Phase 1/Phase 254 participants (Anticipated)Interventional2019-01-24Suspended(stopped due to pilot component of study completed)
Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients [NCT00536237]Phase 2154 participants (Actual)Interventional2004-08-31Completed
Regulation of Endogenous Glucose Production by Central KATP Channels [NCT03540758]Phase 260 participants (Anticipated)Interventional2018-08-01Recruiting
A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia [NCT03061474]Phase 246 participants (Actual)Interventional2017-07-12Completed
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis [NCT01959282]Phase 2219 participants (Actual)Interventional2013-11-15Completed
A Pilot Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation [NCT04332341]Early Phase 120 participants (Anticipated)Interventional2020-05-19Recruiting
A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients [NCT01992874]Phase 138 participants (Actual)Interventional2013-11-30Completed
Effects of NAD Restoration on Neurovascular Coupling in Community Dwelling Older Adults [NCT05483465]Phase 4214 participants (Anticipated)Interventional2023-05-03Recruiting
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure [NCT02961829]30 participants (Actual)Interventional2015-07-31Completed
Exercise Versus Extended-Release Niacin in Patients With Coronary Heart Disease and Low High-Density Lipoproteins (HDL) Cholesterol: Effect on Lipid Profile and Endothelial Function [NCT00298909]Phase 448 participants (Actual)Interventional2006-03-31Completed
The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults. [NCT05984550]Early Phase 110 participants (Anticipated)Interventional2023-08-31Not yet recruiting
Absorption and Digestion Kinetics of Human Metabolites [NCT05017428]5 participants (Actual)Interventional2021-04-08Completed
Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure [NCT04528004]Early Phase 140 participants (Anticipated)Interventional2020-09-26Recruiting
Postprandial Modulation of HDL Metabolism [NCT01803594]18 participants (Actual)Interventional2012-08-31Completed
An Open-Label, Randomized, Phase 1b Study Evaluating the Effect of Different Doses of AMG 706 on the Gallbladder in Subjects With Advanced Solid Tumors [NCT00448786]Phase 149 participants (Actual)Interventional2007-02-28Completed
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia [NCT03761511]Phase 2225 participants (Anticipated)Interventional2023-04-30Not yet recruiting
The Treatment of Acute Schizophrenia With High Dose Niacinmide Plus Ascorbate Plus Pyridoxine Plus Centrum Forte vs. Centrum Forte Only as an Add-On to Risperidone and Dietary Counseling [NCT00140166]Phase 455 participants (Anticipated)Interventional2005-07-31Completed
Multicenter Comparative Randomized Study to Assess Safety and Efficacy and Select the Optimal Dosage Regimen of REMAXA®, Enteric-coated Tablets, in Comparison With REMAXOL®, Solution for Infusions, in Patients With Intrahepatic Cholestasis Caused by Chron [NCT06183242]Phase 2/Phase 3414 participants (Anticipated)Interventional2023-05-27Recruiting
NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection [NCT04818216]Phase 228 participants (Actual)Interventional2021-06-11Completed
Shorter Recovery Time After Critical Illness [NCT04110028]Phase 1/Phase 257 participants (Actual)Interventional2019-10-01Completed
Efficacy and Safety of Topical Nicotinamide in Treatment of Discoid Lupus Erythematosus [NCT05362188]Early Phase 160 participants (Actual)Interventional2022-03-01Completed
A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection [NCT05175768]375 participants (Anticipated)Interventional2021-12-27Recruiting
A Pilot Study to Measure Plasma and Urinary Prostaglandin D2 Metabolites Evoked by Niacin [NCT01275300]9 participants (Actual)Interventional2007-07-31Completed
An Open-Label, Phase Ib Dose Escalation Trial of Oral Combination Therapy With MSC1936369B and SAR245409 in Subjects With Locally Advanced or Metastatic Solid Tumors [NCT01390818]Phase 1146 participants (Actual)Interventional2011-05-31Completed
SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers [NCT00194402]Phase 464 participants (Actual)Interventional2003-08-31Completed
Influence of Combined Therapy of Niacin and Statins on Stem Cell Mobilization and Inflammatory Parameters in Patients Suffering From Coronary Artery Disease - Randomized Clinical Study - [NCT00431145]Phase 280 participants Interventional2006-10-31Recruiting
A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study. Extension Protocol [NCT05095571]300 participants (Anticipated)Interventional2021-10-07Recruiting
A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study [NCT04562831]380 participants (Anticipated)Interventional2020-10-07Recruiting
Exploratory Study of Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome [NCT03789175]Phase 1/Phase 21 participants (Actual)Interventional2019-03-25Completed
A Double Blind, Randomized Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation [NCT01542138]Phase 428 participants (Actual)Interventional2011-07-31Completed
A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia [NCT01583647]Phase 110 participants (Actual)Interventional2012-06-30Terminated(stopped due to In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a significant increase in incidence of some types of non-fatal SAEs.)
A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer [NCT00033436]Phase 3330 participants (Anticipated)Interventional2000-10-31Completed
The Effects of Nicotinamide Riboside Supplementation on Nicotinamide Adenine Dinucleotide (NAD+/NADH) Ratio and Bioenergetics [NCT03151707]Phase 411 participants (Actual)Interventional2017-10-01Completed
Effect of NMN (Nicotinomide Mononucleotide) Supplementation on Cardiometabolic Function [NCT03151239]25 participants (Actual)Interventional2017-07-01Completed
The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial [NCT02303483]40 participants (Actual)Interventional2016-01-04Completed
Nicotinamide, an Inhibitor of PARP-1, for Preventing Delirium in Older Adults [NCT04725253]146 participants (Anticipated)Interventional2021-01-21Not yet recruiting
Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects [NCT00176020]Phase 118 participants InterventionalNot yet recruiting
NAPS: Niacin for Parkinsons Disease [NCT03808961]7 participants (Actual)Interventional2020-01-01Active, not recruiting
NR-SAFE: a Safety Study Investigating Treatment With High-dose Nicotinamide Riboside (NR) in Parkinson's Disease [NCT05344404]20 participants (Actual)Interventional2022-04-29Completed
"A Multicenter, Randomized, Double-Blind, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Coadministered MK0524B Tablets in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia" [NCT00269217]Phase 31,400 participants (Actual)Interventional2006-01-31Completed
The Low HDL On Six Weeks Statin Therapy (LOW) Study [NCT00238004]Phase 460 participants Interventional2005-11-30Active, not recruiting
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia [NCT00269204]Phase 31,620 participants (Actual)Interventional2005-12-31Completed
Intensive Tailored Exercise Training With NAD+ Precursor Supplementation to Improve Muscle Mass and Fitness in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors [NCT05194397]Phase 280 participants (Anticipated)Interventional2023-03-21Recruiting
Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans [NCT04691986]144 participants (Anticipated)Interventional2023-09-01Recruiting
Facial Skin Clinical and Microbial Profiling From Oral Probiotic Supplementation [NCT05597254]109 participants (Actual)Interventional2022-09-26Completed
Nutritional Support and Prophylaxis Doses of Azithromycin for Pregnant Women to Improve Birth Outcomes in the Peri-urban Slums of Karachi, Pakistan -a Randomized Controlled Trial [NCT04012177]1,884 participants (Actual)Interventional2019-07-22Active, not recruiting
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: A Pilot, Placebo-controlled, Randomized Trial [NCT03769285]Phase 2120 participants (Actual)Interventional2018-12-03Active, not recruiting
Evaluation of Topical Nicotinamide in Combination With Calcipotriol Compared With Calcipotriol Alone for the Treatment of Mild to Moderate Psoriasis. [NCT01763424]Phase 2/Phase 366 participants (Actual)Interventional2011-07-31Completed
The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE [NCT02258074]Phase 2205 participants (Actual)Interventional2015-03-31Completed
The Glaucoma Nicotinamide Trial - A Prospective, Randomized, Placebo-controlled, Double-masked Trial [NCT05275738]660 participants (Anticipated)Interventional2022-05-18Recruiting
Effects of Nicotinamide Riboside on Metabolism and Vascular Function [NCT03501433]16 participants (Actual)Interventional2018-02-01Completed
A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor MSC1936369B Given Orally to Subjects With Solid Tumours [NCT00982865]Phase 1182 participants (Actual)Interventional2007-12-31Completed
Non-interventional Prospective Observational Study of Efficacy and Safety of Cytoflavin in Combination With Reperfusion Compared to Treatment With Other Neuroprotective Drugs Used in Routine Clinical Practice in Patients With Cerebral Infarction [NCT05297851]200 participants (Actual)Observational2022-04-10Completed
Free Fatty Acids, Body Weight, and Growth Hormone Secretion in Children [NCT01237041]Phase 1/Phase 237 participants (Actual)Interventional2011-07-01Terminated(stopped due to Study Medication unavailable)
A Randomized, Double-blind, Parallel, Multicenter, Placebo-controlled, Prospective Study to Evaluate the Functionality of the Flushing ASsessment Tool (FAST) in Subjects Administered Niaspan® Plus Acetylsalicylic Acid (ASA), Niaspan® Plus ASA Placebo or N [NCT00630877]Phase 3276 participants (Actual)Interventional2008-02-29Completed
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression [NCT04670081]Phase 2144 participants (Actual)Interventional2021-06-10Active, not recruiting
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19 [NCT04407390]Phase 20 participants (Actual)Interventional2020-06-01Withdrawn(stopped due to No volunteers where recruited to this study. Other studies were prioritised over this at the time of enrollment.)
Phase I Dose Escalation Trial of MEK1/2 Inhibitor MSC1936369B Combined With Temsirolimus in Subjects With Advanced Solid Tumors [NCT01378377]Phase 133 participants (Actual)Interventional2011-05-27Terminated(stopped due to The trial was stopped due to the toxicities observed with the combination of pimasertib and temsirolimus.)
Oxidative Stress and Cardiovascular Denervation in Diabetes: An Interventional Trial [NCT00116207]Phase 344 participants (Actual)Interventional2000-01-31Completed
Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics, Pharmacodynamics & Safety of Escalating Doses of Basis (Nicotinamide Riboside and Pterostilbene) in Patients With Acute Kidney Injury (AKI) [NCT03176628]24 participants (Actual)Interventional2017-11-01Completed
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) Trial [NCT04750616]Phase 2304 participants (Anticipated)Interventional2021-09-13Recruiting
A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging [NCT03818802]48 participants (Anticipated)Interventional2019-09-16Recruiting
Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure [NCT03423342]Phase 1/Phase 230 participants (Actual)Interventional2016-05-19Completed
Efecto Del ácido nicotínico Sobre la composición de Las lipoproteínas de Alta Densidad (HDL) y la función Del Endotelio Arterial en Los Pacientes Con cardiopatía isquémica Prematura y Concentraciones Elevadas de Colesterol-HDL [NCT01450410]Phase 412 participants (Actual)Interventional2012-07-31Terminated(stopped due to Study terminated (halted prematurely) as recomended by the drug supplier and medical agencies)
Nicotinamide Riboside and Milk Production in the NICU [NCT04614714]Phase 2/Phase 332 participants (Anticipated)Interventional2024-12-31Not yet recruiting
Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid [NCT01159054]22 participants (Actual)Interventional2010-07-31Terminated(stopped due to The funding source is not going to fund this anymore. Only two subjects completed the study therefore meaningful analysis not possible.)
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Resp [NCT03578367]Phase 2104 participants (Anticipated)Interventional2018-11-22Recruiting
"Randomized, Placebo-controlled Parallel Group Clinical Trial of Nicotinamide Riboside to Evaluate NAD+ Levels in Individuals With Persistent Cognitive and Physical Symptoms After COVID-19 Illness (Long-COVID)" [NCT04809974]Phase 4100 participants (Anticipated)Interventional2021-07-22Recruiting
Measurement of NAD+ Synthesis in Human Skeletal Muscle [NCT04905446]15 participants (Actual)Interventional2021-09-10Active, not recruiting
A Worldwide, Multicenter, Double-Blind, Parallel Study to Evaluate the Tolerability of MK0524A Versus Niacin Extended-Release [NCT00378833]Phase 31,300 participants (Actual)Interventional2006-07-31Completed
"Retrospective Study of Niacin (as a Vasodilator), Combined With a Topical Steroid (for Macular Edema), For CRVO, HRVO, BRVO." [NCT00500045]Phase 2/Phase 336 participants (Actual)Interventional2007-02-28Terminated(stopped due to The PI retired/left the institution. Efforts were made to contact the PI but were unsuccessful.)
Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer [NCT01936363]Phase 265 participants (Actual)Interventional2013-09-30Completed
NAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's Ataxia [NCT04192136]72 participants (Anticipated)Interventional2020-09-03Recruiting
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia [NCT04870866]Phase 213 participants (Actual)Interventional2019-06-05Active, not recruiting
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity [NCT02812238]38 participants (Actual)Interventional2016-06-23Completed
Slow Age: a Randomized, Controlled Clinical Trial of Interventions to Slow Aging in Humans [NCT05593939]Phase 280 participants (Actual)Interventional2022-05-01Completed
Phase I Study of Nicotinamide for Early Onset Preeclampsia [NCT02213094]Phase 110 participants (Actual)Interventional2014-01-01Completed
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects [NCT03565328]Phase 22 participants (Actual)Interventional2018-09-27Terminated(stopped due to Slow/insufficient accrual and investigators have left the study.)
Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease [NCT04055818]Phase 120 participants (Anticipated)Interventional2020-01-24Recruiting
Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib [NCT02416739]Phase 2/Phase 3110 participants (Actual)Interventional2015-03-31Active, not recruiting
Randomized, Double-blind, Placebo-controlled Clinical Trial of Nicotinamide Mononucleotide on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity [NCT04664361]131 participants (Actual)Interventional2021-03-09Active, not recruiting
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients [NCT06054529]22 participants (Anticipated)Observational2023-09-11Recruiting
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally [NCT02642159]Phase 4413 participants (Actual)Interventional2016-03-15Completed
Nicotinamide and Glaucoma [NCT05916066]120 participants (Actual)Interventional2021-10-16Completed
Matching Perfusion and Metabolic Activity in HFpEF [NCT04913805]Phase 253 participants (Anticipated)Interventional2021-10-11Recruiting
Short-Term Effects of Nicotinamide and Lanthanum Carbonate on Phosphorus Homeostasis in Healthy Volunteers [NCT03136705]Phase 139 participants (Actual)Interventional2016-02-03Completed
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, Repeat-dose Study of the Safety and Efficacy of Acuroc Tablets Following Bunionectomy Surgery in Adult Patients [NCT00654069]Phase 3405 participants (Actual)Interventional2007-09-30Completed
A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy [NCT01668017]Phase 126 participants (Actual)Interventional2012-09-30Terminated(stopped due to The sponsor decided not to conduct the expansion part of trial (part 2))
Pilot Trial of Supplemental Vitamin A and Nicotinamide and Levels of Blood Vitamin A and Nicotinamide [NCT05702398]Early Phase 130 participants (Anticipated)Interventional2023-03-01Not yet recruiting
A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cance [NCT00356681]Phase 2282 participants (Actual)Interventional2006-12-31Terminated(stopped due to Sponsor decision to close study)
Frontline Asciminib Combination in Chronic Phase CML [NCT03906292]Phase 2125 participants (Actual)Interventional2019-08-19Active, not recruiting
Pilot Study of Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1 [NCT06007391]Phase 2/Phase 325 participants (Anticipated)Interventional2023-09-30Not yet recruiting
SUPREME: A 12-Week, Open-Label, Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia [NCT00465088]Phase 3199 participants (Actual)Interventional2007-04-30Completed
A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma [NCT03019666]Phase 139 participants (Actual)Interventional2017-10-18Completed
A Randomized Double-blind Placebo-controlled Clinical Trial of Nicotinamide Riboside for Restoring Mitochondrial Bioenergetics in Gulf War Illness [NCT05243290]52 participants (Anticipated)Interventional2022-04-13Recruiting
Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients: A Pilot Study [NCT04843553]Early Phase 130 participants (Actual)Interventional2016-10-14Completed
Effects of Nicotinamide Riboside on the Airway Inflammation of Older Adults With COPD: A Randomized, Double-blind, Placebo-controlled Clinical Trial (NR-COPD) [NCT04990869]60 participants (Actual)Interventional2021-07-01Completed
Randomized, Double-blinded, Placebo-controlled Study Evaluating the Efficacy of Nicotinamide Riboside (NR) - a Vitamin B3 Derivative - for Treatment of Mitochondrial Myopathy Disorder [NCT05590468]Phase 234 participants (Anticipated)Interventional2023-05-26Recruiting
Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration [NCT03912220]Phase 250 participants (Actual)Interventional2020-09-01Completed
Niacin (as a Vasodilator), and a Topical Steroid (for Macular Edema), Non-Ischemic CRVO,HRVO,BRVO [NCT00493064]Phase 2/Phase 363 participants (Actual)Interventional2006-10-31Completed
International Milk Composition (IMiC) Consortium [NCT05119166]1,000 participants (Anticipated)Observational2019-11-17Recruiting
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes and a Comparison of the Effect of Nicotinamide Riboside Supplementation on Brain NAD+ Levels [NCT02721537]30 participants (Actual)Interventional2016-09-30Completed
Early Life Interventions for Childhood Growth and Development In Tanzania [NCT03268902]Phase 2/Phase 31,188 participants (Actual)Interventional2017-09-05Completed
An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus [NCT03260166]Phase 240 participants (Anticipated)Interventional2017-08-31Active, not recruiting
Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause [NCT04841499]40 participants (Actual)Interventional2021-04-05Completed
Evaluation of the Effects of Niacin Therapy on Lipoprotein Composition and Function [NCT02322203]Phase 224 participants (Actual)Interventional2015-03-25Completed
Nutritional Supplements and Performance During Visual Field Testing [NCT03797469]32 participants (Actual)Interventional2019-04-15Completed
Cross-over Randomized Controlled Trial of Coenzyme Q10 or Nicotinamide Riboside in Chronic Kidney Disease [NCT03579693]Phase 226 participants (Actual)Interventional2018-11-14Completed
DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide. [NCT03392623]Early Phase 128 participants (Actual)Interventional2015-01-01Completed
Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia [NCT00271817]Phase 31,220 participants (Actual)Interventional2005-12-31Completed
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy [NCT05698771]6 participants (Anticipated)Interventional2023-01-29Recruiting
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant - GABRIEL [NCT05513807]Phase 3204 participants (Anticipated)Interventional2022-11-30Not yet recruiting
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease: the NOPARK Study [NCT03568968]400 participants (Anticipated)Interventional2020-05-15Recruiting
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment [NCT03482167]Phase 1/Phase 258 participants (Anticipated)Interventional2018-12-01Active, not recruiting
The Effects of Exercise Training Combined With NR Supplementation on Metabolic Health in Older Individuals [NCT04907110]30 participants (Actual)Interventional2021-08-10Completed
Evaluation of Dermatological Safety of Test Products by 24 Hours Patch Test Under Complete Occlusion or Semi Occlusion or Open Patch on Adult Healthy Human Subjects [NCT05642702]26 participants (Anticipated)Interventional2022-12-05Not yet recruiting
Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock? A Multicenter Randomized Controlled Study [NCT04589546]Phase 3310 participants (Anticipated)Interventional2020-10-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00116207 (4) [back to overview]Inflammation
NCT00116207 (4) [back to overview]Systemic Oxidative Stress
NCT00116207 (4) [back to overview]Global [11C]HED Retention Index (RI)
NCT00116207 (4) [back to overview]Global Coronary Flow Reserve as a Measure of Endothelial Function
NCT00271817 (10) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Triglycerides (TG)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Triglycerides (TG)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00271817 (10) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT00465088 (14) [back to overview]Percent Change in LDL-C:HDL-C Ratio
NCT00465088 (14) [back to overview]Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12
NCT00465088 (14) [back to overview]Percent Change in HDL-C From Baseline to Week 8
NCT00465088 (14) [back to overview]Percent Change in Non-HDL-C From Baseline to Week 12
NCT00465088 (14) [back to overview]Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12
NCT00465088 (14) [back to overview]Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12
NCT00465088 (14) [back to overview]Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12
NCT00465088 (14) [back to overview]Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12
NCT00465088 (14) [back to overview]Percent Change in Triglycerides From Baseline to Week 12
NCT00465088 (14) [back to overview]Percent Change in Total Cholesterol:HDL-C Ratio
NCT00465088 (14) [back to overview]Percent Change in Total Cholesterol From Baseline to Week 12
NCT00465088 (14) [back to overview]Percent Change in Non-HDL-C From Baseline to Week 8
NCT00465088 (14) [back to overview]Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12
NCT00465088 (14) [back to overview]Percent Change in Lipoprotein A From Baseline to Week 12
NCT00485758 (3) [back to overview]Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo
NCT00485758 (3) [back to overview]Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo
NCT00485758 (3) [back to overview]Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo
NCT00493064 (1) [back to overview]Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.
NCT00618995 (2) [back to overview]Urinary 11-Dehydrothromboxane B2 (11-dTxB2)
NCT00618995 (2) [back to overview]Prostaglandin I Metabolite (PGI-M)
NCT00630877 (9) [back to overview]Maximum Severity of Flushing Events Overall During the Study
NCT00630877 (9) [back to overview]FAST Longitudinal Construct Validity--mean Flushing Severity Score
NCT00630877 (9) [back to overview]FAST Longitudinal Construct Validity--maximum Flushing Severity Score
NCT00630877 (9) [back to overview]FAST Cross-sectional Construct Validity--mean Flushing Severity Score
NCT00630877 (9) [back to overview]FAST Cross-sectional Construct Validity--maximum Flushing Severity Score
NCT00630877 (9) [back to overview]FAST Responsiveness--mean Flushing Severity Score
NCT00630877 (9) [back to overview]FAST Responsiveness--maximum Flushing Severity Score
NCT00630877 (9) [back to overview]FAST Test-retest Reliability--maximum Flushing Severity Score
NCT00630877 (9) [back to overview]Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score
NCT00654069 (1) [back to overview]SPID48
NCT00691210 (2) [back to overview]The Greatest Number of Cycles Received in Each Treatment Group
NCT00691210 (2) [back to overview]The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide
NCT00715273 (3) [back to overview]Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI
NCT00715273 (3) [back to overview]Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI
NCT00715273 (3) [back to overview]Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions
NCT00769132 (2) [back to overview]Prostaglandin I Metabolite (PGI-M)
NCT00769132 (2) [back to overview]Urinary 11-dehydrothromboxane B2 (11-dTxB2)
NCT00943124 (8) [back to overview]Peak Plasma Concentration (Cmax) of Nicotinuric Acid
NCT00943124 (8) [back to overview]Peak Plasma Concentration (Cmax) of Simvastatin
NCT00943124 (8) [back to overview]Peak Plasma Concentration (Cmax) of Simvastatin Acid
NCT00943124 (8) [back to overview]Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin
NCT00943124 (8) [back to overview]Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid
NCT00943124 (8) [back to overview]Total Urinary Excretion of Niacin and Its Metabolites
NCT00943124 (8) [back to overview]Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant
NCT00943124 (8) [back to overview]Peak Plasma Concentration (Cmax) of Laropiprant
NCT00944645 (4) [back to overview]Maximum Plasma Concentration (Cmax) of Nicotinuric Acid
NCT00944645 (4) [back to overview]Maximum Concentration (Cmax) of Laropiprant
NCT00944645 (4) [back to overview]Area Under Curve (AUC 0-infinity) of Laropiprant
NCT00944645 (4) [back to overview]Total Amount of Urinary Excretion of Niacin and Its Metabolites
NCT00957580 (19) [back to overview]Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose
NCT00957580 (19) [back to overview]Part 1: Percentage of Subjects With Best Overall Response
NCT00957580 (19) [back to overview]Part 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation
NCT00957580 (19) [back to overview]Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose
NCT00957580 (19) [back to overview]Part 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose
NCT00957580 (19) [back to overview]Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose
NCT00957580 (19) [back to overview]Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose
NCT00957580 (19) [back to overview]Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)
NCT00957580 (19) [back to overview]Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose
NCT00957580 (19) [back to overview]Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose
NCT00957580 (19) [back to overview]Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose
NCT00957580 (19) [back to overview]Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose
NCT00957580 (19) [back to overview]Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose
NCT00957580 (19) [back to overview]Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose
NCT00957580 (19) [back to overview]Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose
NCT00957580 (19) [back to overview]Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose
NCT00957580 (19) [back to overview]Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose
NCT00957580 (19) [back to overview]Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose
NCT00957580 (19) [back to overview]Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose
NCT00961636 (2) [back to overview]Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period
NCT00961636 (2) [back to overview]Number of Participants With Maximum GFSS ≥4 During the Post-withdrawal Period
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death
NCT00982865 (69) [back to overview]Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1
NCT00982865 (69) [back to overview]Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)
NCT00982865 (69) [back to overview]Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)
NCT00982865 (69) [back to overview]Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)
NCT00982865 (69) [back to overview]Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation
NCT00982865 (69) [back to overview]Number of Subjects With Clinical Significant Laboratory Abnormalities and Vital Signs Reported as Treatment Emergent Adverse Events
NCT00982865 (69) [back to overview]Number of Subjects With Clinical Benefit (Complete Response [CR], Partial Response [PR] or Stable Disease [SD}) and Progressive Disease (PD) Based on the Best Overall Response (BOR)
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 2 (With Food Effect)
NCT00982865 (69) [back to overview]Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Twice Daily
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Once Daily
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT00982865 (69) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)
NCT01159054 (9) [back to overview]Hemodialysis Access Stenosis/Thrombosis
NCT01159054 (9) [back to overview]Hemoglobin Level
NCT01159054 (9) [back to overview]Changes in IL-6 Level
NCT01159054 (9) [back to overview]Changes in Hs-CRP Level
NCT01159054 (9) [back to overview]Albumin Level
NCT01159054 (9) [back to overview]Rate of Cardiovascular Events
NCT01159054 (9) [back to overview]Number of Completed Subjects With Significant Increase in ALT (Alanine Aminotransferase).
NCT01159054 (9) [back to overview]ESA (Erythorpoietic Stimulating Agent) Dose Requirement
NCT01159054 (9) [back to overview]Changes in FDG-PET/CT Dual Scan Score
NCT01173471 (3) [back to overview]Clinically Relevant Change in Intra-ocular Pressure After 4 Weeks of Treatment
NCT01173471 (3) [back to overview]Percentage Change in Mean Intra-ocular Pressure Compared With Baseline After 4 Weeks Treatment
NCT01173471 (3) [back to overview]Change in Mean Intra-ocular Pressure Compared With Baseline After 4 Weeks Treatment
NCT01237041 (8) [back to overview]Growth Hormone-releasing Hormone (GHRH) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours
NCT01237041 (8) [back to overview]Free Fatty Acids (FFA) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours
NCT01237041 (8) [back to overview]Somatostatin (SST) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours
NCT01237041 (8) [back to overview]Somatostatin (SST) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours
NCT01237041 (8) [back to overview]Growth Hormone-releasing Hormone (GHRH) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours
NCT01237041 (8) [back to overview]Growth Hormone Secretion Area Under the Curve in Response to Niacin and Placebo Over Time
NCT01237041 (8) [back to overview]Growth Hormone Secretion Area Under the Curve in Response to Niacin and Placebo Over Time
NCT01237041 (8) [back to overview]Free Fatty Acids (FFA) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours
NCT01275300 (1) [back to overview]Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo
NCT01294683 (10) [back to overview]Percentage of Participants With CK >=10 x ULN With Muscle Symptoms - Drug Related
NCT01294683 (10) [back to overview]Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event
NCT01294683 (10) [back to overview]Percentage of Participants With Elevations in ALT and/or AST of >=10 x ULN
NCT01294683 (10) [back to overview]Percentage of Participants With Elevations in ALT and/or AST of >=5 x ULN
NCT01294683 (10) [back to overview]Percentage of Participants With New Onset of Diabetes
NCT01294683 (10) [back to overview]Percentage of Participants With Creatine Kinase (CK) >=10 x ULN
NCT01294683 (10) [back to overview]Percentage of Participants Who Were Discontinued From the Study Due to an AE
NCT01294683 (10) [back to overview]Percentage of Participants Who Experienced at Least 1 Hepatitis-related Adverse Event (AE)
NCT01294683 (10) [back to overview]Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x Upper Limit of Normal (ULN)
NCT01294683 (10) [back to overview]Percentage of Participants Who Experienced at Least 1 AE
NCT01378377 (26) [back to overview]Volume of Distribution (Vz) of Temsirolimus
NCT01378377 (26) [back to overview]Volume of Distribution (Vz) of Temsirolimus
NCT01378377 (26) [back to overview]Maximum Plasma Concentration (Cmax) of Pimasertib
NCT01378377 (26) [back to overview]Maximum Plasma Concentration (Cmax) of Temsirolimus
NCT01378377 (26) [back to overview]Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib
NCT01378377 (26) [back to overview]Maximum Plasma Concentration (Cmax) of Temsirolimus
NCT01378377 (26) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib
NCT01378377 (26) [back to overview]Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus
NCT01378377 (26) [back to overview]Number of Subjects With Dose Limiting Toxicities (DLTs)
NCT01378377 (26) [back to overview]Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
NCT01378377 (26) [back to overview]Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib
NCT01378377 (26) [back to overview]Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus
NCT01378377 (26) [back to overview]Apparent Terminal Half-life (t1/2) of Pimasertib
NCT01378377 (26) [back to overview]Apparent Terminal Half-life (t1/2) of Pimasertib
NCT01378377 (26) [back to overview]Apparent Terminal Half-life (t1/2) of Temsirolimus
NCT01378377 (26) [back to overview]Apparent Terminal Half-life (t1/2) of Temsirolimus
NCT01378377 (26) [back to overview]Apparent Volume of Distribution (Vz/F) of Pimasertib
NCT01378377 (26) [back to overview]Apparent Volume of Distribution (Vz/F) of Pimasertib
NCT01378377 (26) [back to overview]Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib
NCT01378377 (26) [back to overview]Maximum Plasma Concentration (Cmax) of Pimasertib
NCT01378377 (26) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib
NCT01378377 (26) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus
NCT01378377 (26) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus
NCT01378377 (26) [back to overview]Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib
NCT01378377 (26) [back to overview]Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus
NCT01378377 (26) [back to overview]Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus
NCT01390818 (25) [back to overview]Number of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)
NCT01390818 (25) [back to overview]pERK Concentrations in PBMCs
NCT01390818 (25) [back to overview]pS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)
NCT01390818 (25) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)
NCT01390818 (25) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409
NCT01390818 (25) [back to overview]Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)
NCT01390818 (25) [back to overview]Total Body Clearance (CL/f) of SAR245409
NCT01390818 (25) [back to overview]Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15
NCT01390818 (25) [back to overview]Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15
NCT01390818 (25) [back to overview]Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15
NCT01390818 (25) [back to overview]Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15
NCT01390818 (25) [back to overview]Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1
NCT01390818 (25) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1
NCT01390818 (25) [back to overview]Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)
NCT01390818 (25) [back to overview]Number of Subjects With Dose Limiting Toxicities (DLT)
NCT01390818 (25) [back to overview]Apparent Terminal Half-Life (t1/2) of SAR245409
NCT01390818 (25) [back to overview]Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib
NCT01390818 (25) [back to overview]Apparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)
NCT01390818 (25) [back to overview]Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)
NCT01390818 (25) [back to overview]Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409
NCT01390818 (25) [back to overview]Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)
NCT01390818 (25) [back to overview]Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409
NCT01390818 (25) [back to overview]Half-Life (t1/2) of MSC1936369B (Pimasertib)
NCT01390818 (25) [back to overview]Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)
NCT01390818 (25) [back to overview]Maximum Observed Plasma Concentration (Cmax) for SAR245409
NCT01668017 (35) [back to overview]Apparent Clearance at Steady-state (CLss/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib of 1 Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Area Under the Concentration Over Time (AUCt) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Apparent Volume of Distribution at Terminal Phase (Vz/f) Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Apparent Volume of Distribution at Terminal Phase (Vz/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Number of Subjects Who Experienced Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEs
NCT01668017 (35) [back to overview]Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1
NCT01668017 (35) [back to overview]Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Apparent Clearance (CL/f) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Accumulation Ratio for Cmax Racc(Cmax) of Part 1: Pimasertib 30 mg In HCC Arm
NCT01668017 (35) [back to overview]Accumulation Ratio for AUC Racc(AUC) of Part 1: Pimasertib 30 mg In HCC Arm
NCT01668017 (35) [back to overview]Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Percentage of Subjects With Best Overall Response
NCT01668017 (35) [back to overview]Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib
NCT01668017 (35) [back to overview]Accumulation Ratio for AUC Racc(AUC) of Pimasertib
NCT01668017 (35) [back to overview]Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Percentage of Subjects With Objective Response
NCT01668017 (35) [back to overview]Percentage of Subjects With Disease Control
NCT01668017 (35) [back to overview]Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)
NCT01668017 (35) [back to overview]Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15
NCT01668017 (35) [back to overview]Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1
NCT01668017 (35) [back to overview]Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15
NCT01668017 (35) [back to overview]Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1
NCT01936363 (5) [back to overview]Objective Tumor Response
NCT01936363 (5) [back to overview]Overall Survival
NCT01936363 (5) [back to overview]Percentage of Participants With Disease Control
NCT01936363 (5) [back to overview]Progression-Free Survival
NCT01936363 (5) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Treatment and Death
NCT01992874 (13) [back to overview]Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01992874 (13) [back to overview]Terminal Rate Constant (λz)
NCT01992874 (13) [back to overview]Part B: Number of Subjects Who Experienced Stable Disease (SD)
NCT01992874 (13) [back to overview]Part B: Number of Subjects Who Experienced Progressive Disease (PD)
NCT01992874 (13) [back to overview]Part B: Number of Subjects Who Experienced Partial Response (PR)
NCT01992874 (13) [back to overview]Part B: Number of Subjects Who Experienced Complete Response (CR)
NCT01992874 (13) [back to overview]Maximum Observed Plasma Concentration (Cmax)
NCT01992874 (13) [back to overview]Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)
NCT01992874 (13) [back to overview]Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)
NCT01992874 (13) [back to overview]Apparent Volume of Distribution (Vz/f)
NCT01992874 (13) [back to overview]Apparent Total Body Clearance (CL/f)
NCT01992874 (13) [back to overview]Apparent Terminal Half-life (t1/2)
NCT01992874 (13) [back to overview]Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation
NCT02213094 (1) [back to overview]Number of Participants With Adverse Events
NCT02258074 (2) [back to overview]Serum Phosphate (mg/dl)
NCT02258074 (2) [back to overview]FGF23
NCT02426086 (22) [back to overview]Percentage of Participants With Clinically Meaningful Improvement in Brief Pain Inventory (BPI)
NCT02426086 (22) [back to overview]Percentage of Participants With Anemia Response Per Modified 2013 IWG-MRT Criteria
NCT02426086 (22) [back to overview]EuroQol 5 Dimension 5 Level (EQ-5D-5L): Utility Score and Visual Analog Scale (VAS)
NCT02426086 (22) [back to overview]Volume of Distribution (Vd) of Imetelstat
NCT02426086 (22) [back to overview]Total Systemic Clearance (CL) of Imetelstat
NCT02426086 (22) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC 0-24) of Imetelstat
NCT02426086 (22) [back to overview]Time to Reach Maximum Observed Plasma Concentration (Tmax) of Imetelstat
NCT02426086 (22) [back to overview]Percentage of Participants With Symptom Response
NCT02426086 (22) [back to overview]Percentage of Participants With Spleen Response
NCT02426086 (22) [back to overview]Percentage of Participants With Overall Response as Per Modified 2013 International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) Criteria
NCT02426086 (22) [back to overview]Percentage of Participants With Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-30 (QLQ-C30): Global Health Status
NCT02426086 (22) [back to overview]Percentage of Participants With Clinical Response Per Modified 2013 IWG-MRT
NCT02426086 (22) [back to overview]Percentage of Participants With Clinical Improvement (CI) Per Modified 2013 IWG-MRT Criteria
NCT02426086 (22) [back to overview]Patient's Global Impression of Change (PGIC)
NCT02426086 (22) [back to overview]Overall Survival
NCT02426086 (22) [back to overview]Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT02426086 (22) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Imetelstat
NCT02426086 (22) [back to overview]Elimination Half-Life (t1/2) of Imetelstat
NCT02426086 (22) [back to overview]Duration of Response (PR/CI/RWCI) as Per IWG-MRT Criteria
NCT02426086 (22) [back to overview]Area Under the Plasma Concentration-Time Profile From Time Zero to Infinity (AUC0-inf) of Imetelstat
NCT02426086 (22) [back to overview]Percentage of Participants With Symptoms Response Per Modified 2013 IWG-MRT Criteria
NCT02426086 (22) [back to overview]Percentage of Participants With Spleen Response Per Modified 2013 IWG-MRT Criteria
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis
NCT02642159 (23) [back to overview]Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis
NCT02642159 (23) [back to overview]Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02812238 (1) [back to overview]Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast
NCT02890992 (20) [back to overview]Percent Change From Baseline in Lipoprotein(a) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Fasting Triglyceride at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4
NCT02890992 (20) [back to overview]Percent Change From Baseline in Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Lipoprotein(a) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in HDL-C at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Fasting Triglyceride at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Apolipoprotein B at Week 8
NCT02890992 (20) [back to overview]Absolute Change From Baseline in Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8
NCT02890992 (20) [back to overview]Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8
NCT02890992 (20) [back to overview]Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8
NCT03061474 (21) [back to overview]Change in QTC
NCT03061474 (21) [back to overview]Columbia-Suicide Severity Rating Scale
NCT03061474 (21) [back to overview]QTC Abnormalities
NCT03061474 (21) [back to overview]ADASCog-13
NCT03061474 (21) [back to overview]Change in P-tau 231
NCT03061474 (21) [back to overview]Vital Signs - Weight
NCT03061474 (21) [back to overview]ECG Abnormalities
NCT03061474 (21) [back to overview]Vital Signs - Systolic Blood Pressure
NCT03061474 (21) [back to overview]Vital Signs - Pulse
NCT03061474 (21) [back to overview]Vital Signs - Diastolic Blood Pressure
NCT03061474 (21) [back to overview]Count of Adverse Events by Severity
NCT03061474 (21) [back to overview]Change in Ratio of Total Tau/ab42
NCT03061474 (21) [back to overview]Vital Signs - BMI
NCT03061474 (21) [back to overview]Change in Total Tau
NCT03061474 (21) [back to overview]Count of Treatment Emergent Adverse Events
NCT03061474 (21) [back to overview]Activities of Daily Living - Mild Cognitive Impairment
NCT03061474 (21) [back to overview]CDR Sum of Boxes
NCT03061474 (21) [back to overview]Change in ab40
NCT03061474 (21) [back to overview]Change in Ratio of Total Tau/ab40
NCT03061474 (21) [back to overview]Change in ab42
NCT03061474 (21) [back to overview]Change in P-tau 181
NCT03419364 (11) [back to overview]Percentage of Fetuses With Category III Non Stress Test Results
NCT03419364 (11) [back to overview]Change in Mean Arterial Blood Pressure (MAP)
NCT03419364 (11) [back to overview]Mean Peak Nicotinamide Level
NCT03419364 (11) [back to overview]Mean Trough Concentration Nicotinamide Administration
NCT03419364 (11) [back to overview]Number of Participants With Alanine Aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)
NCT03419364 (11) [back to overview]Number of Participants With Aspartate Aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)
NCT03419364 (11) [back to overview]Number of Participants With Maternal Side Effects
NCT03419364 (11) [back to overview]Percentage of Women With Headache Unrelieved by Oral Analgesics
NCT03419364 (11) [back to overview]Percentage of Women With Hematocrit Decrease of More Than 3%
NCT03419364 (11) [back to overview]Percentage of Women With Less Than 500 cc Urine Output in 24 Hours
NCT03419364 (11) [back to overview]Percentage of Women Maternal Abdominal Tenderness
NCT03423342 (7) [back to overview]Exploratory Endpoint: Effect of NR on Change in Left Ventricular Systolic Function
NCT03423342 (7) [back to overview]On-Trial Change in Whole Blood NAD+ Levels
NCT03423342 (7) [back to overview]Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
NCT03423342 (7) [back to overview]Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
NCT03423342 (7) [back to overview]Exploratory Endpoint: Effect of NR on Left Ventricular Diastolic Function
NCT03423342 (7) [back to overview]Exploratory Endpoint: Effect of NR on Functional Capacity
NCT03423342 (7) [back to overview]Effect of NR on Change in Mitochondrial Function (Maximal Oxygen Consumption Rate)
NCT03510715 (13) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis
NCT03510715 (13) [back to overview]Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48
NCT03510715 (13) [back to overview]Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Total Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein A1 at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Weeks 12, and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]Number of Participants With Tanner Staging at Baseline and Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 130 mg/dL (3.37 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 110 mg/dL (2.84 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved at Least 30 Percent (%) Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Achieved at Least 30% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Lipoprotein (a) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Fasting Triglycerides at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein B at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Apolipoprotein A1 at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]Change From Baseline in Cogstate Battery Test - Overall Composite Score at Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: On-treatment Estimand
NCT03510884 (44) [back to overview]OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level Lower Than (<) 130 mg/dL (3.37 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level <130 mg/dL (3.37 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Total Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Estimand
NCT03579693 (2) [back to overview]Maximal Aerobic Capacity- CoQ10
NCT03579693 (2) [back to overview]Work Efficiency
NCT03642990 (7) [back to overview]Plasma Concentration of Paclitaxel After NIAGEN Treatment Began
NCT03642990 (7) [back to overview]Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE
NCT03642990 (7) [back to overview]Number of Dose Reduction Events
NCT03642990 (7) [back to overview]Total Dose of Paclitaxel Administered
NCT03642990 (7) [back to overview]Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .
NCT03642990 (7) [back to overview]Difference in Total Neuropathy Score Between Screening and End of Treatment
NCT03642990 (7) [back to overview]Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN
NCT03789175 (2) [back to overview]Change in Time of CPET Time as a Measure of Exercise Tolerance From Baseline to 12 Weeks of NR Supplementation.
NCT03789175 (2) [back to overview]Change in PCr Recovery Tc Measurement From Baseline to 12 Week NR Supplementation Using the 31P-MRS Skeletal Muscle Submaximal Exercise.
NCT04271735 (1) [back to overview]Mean Change in the TH17 Cell Cytokine IL-17 Secretion in Response to T-cell Differentiation
NCT04818216 (6) [back to overview]Change in Area Under the Curve (AUC)
NCT04818216 (6) [back to overview]Change in Whole Blood NAD+ Level
NCT04818216 (6) [back to overview]Effect of NR on Major Adverse Kidney Events (MAKE)
NCT04818216 (6) [back to overview]Number of Participants With Adverse Events of Grade 3 or Higher
NCT04818216 (6) [back to overview]Occurrence of Thrombocytopenia
NCT04818216 (6) [back to overview]Change in Estimated Glomerular Filtration Rate (eGFR)

Inflammation

High Sensitivity CRP (nmol/L) (NCT00116207)
Timeframe: 24 months

Interventionnmol/L (Mean)
ORAL ANTIOXIDANT17.51
Placebo16.95

[back to top]

Systemic Oxidative Stress

ng of 8-epi prostaglandin F2alpha /G creatinine assessed in 24 hour urine collection (NCT00116207)
Timeframe: 24 months

Interventionng/G creatinine (Mean)
ORAL ANTIOXIDANT2.92
Placebo2.09

[back to top]

Global [11C]HED Retention Index (RI)

"Distal defects in [11C]meta-hydroxyephedrine ([11C]HED) retention involving at least 10 % of the left ventricle was used to define Cardiac Autonomic Neuropathy (CAN). The retention index (RI) is the unit of measure and is expressed as [11C]HEDblood min -1[ml tissue]-1~PET Data of Randomized Subjects at Baseline and 24-Months~The primary outcome was the change in the global [11C]HED RI = measure of cardiac innervation at 24 months in participants taking the active drug compared with those on placebo." (NCT00116207)
Timeframe: Baseline, 24 months

,
InterventionRetention index (Mean)
BASELINE24 MONTHS
ORAL ANTIOXIDANT0.0810.070
Placebo0.0730.074

[back to top]

Global Coronary Flow Reserve as a Measure of Endothelial Function

global myocardial blood flow reserve as a measure of endothelial function. Measured by PET using [13N]ammonia at rest and during adenosine stimulated coronary vasodilation. (NCT00116207)
Timeframe: Baseline, 24 months

,
Interventionratio (rest:stress) (Mean)
BASELINE24 MONTH
ORAL ANTIOXIDANT2.953.02
Placebo2.943.22

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline (NCT00271817)
Timeframe: Baseline and 24 Weeks

InterventionPercent change (Mean)
Niacin-20.1
Ezetimibe/Simvastatin + Niacin-58.5

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-53.5
Ezetimibe/Simvastatin + Niacin-58.5

[back to top]

Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin9.0
Ezetimibe/Simvastatin + Niacin30.5

[back to top]

Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin8.1
Ezetimibe/Simvastatin + Niacin30.2

[back to top]

Percent Change From Baseline in Triglycerides (TG)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Median)
Ezetimibe/Simvastatin-26.8
Ezetimibe/Simvastatin + Niacin-44.5

[back to top]

Percent Change From Baseline in Triglycerides (TG)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: baseline and 24 Weeks

InterventionPercent change (Median)
Ezetimibe/Simvastatin23.7
Ezetimibe/Simvastatin + Niacin-42.5

[back to top]

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Niacin-22.0
Ezetimibe/Simvastatin + Niacin-55.6

[back to top]

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-45.1
Ezetimibe/Simvastatin + Niacin-52.4

[back to top]

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-47.9
Ezetimibe/Simvastatin + Niacin-55.6

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-49.3
Ezetimibe/Simvastatin + Niacin-54.0

[back to top]

Percent Change in LDL-C:HDL-C Ratio

(Week 12 LDL-C:HDL-C ratio minus baseline LDL-C:HDL-C ratio) x 100/baseline LDL-C:HDL-C ratio (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin-54.5
Atorvastatin-50.5

[back to top]

Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 12

(Week 12 HDL-C minus baseline HDL-C) x 100/baseline HDL-C (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin30.1
Atorvastatin9.4

[back to top]

Percent Change in HDL-C From Baseline to Week 8

(Week 8 HDL-C minus baseline HDL-C) x 100/baseline HDL-C (NCT00465088)
Timeframe: From baseline to Week 8

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin26.7
Atorvastatin1.4

[back to top]

Percent Change in Non-HDL-C From Baseline to Week 12

(Week 12 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin-43.4
Atorvastatin-43.3

[back to top]

Percentage of Subjects With Triglycerides < 150 mg/dL at Week 12

(NCT00465088)
Timeframe: 12 weeks

InterventionPercentage of subjects (Number)
Niacin Extended-release Plus Simvastatin79
Atorvastatin70

[back to top]

Percentage of Subjects With HDL-C >/= 40 mg/dL, LDL-C Meeting NCEP ATP III Goal, and Triglycerides < 150 mg/dL at Week 12

NCEP ATP III goals for LDL-C are as follows: For high-risk patients, LDL-C < 100 mg/dL; for moderate risk patients, LDL-C < 130 mg/dL; for low-risk patients: LDL-C < 160 mg/dL. High-risk means coronary heart disease or risk equivalents; moderate risk means having at least 2 risk factors; low-risk means having no or 1 risk factor. (NCT00465088)
Timeframe: 12 weeks

InterventionPercentage of subjects (Number)
Niacin Extended-release Plus Simvastatin65
Atorvastatin34

[back to top]

Percentage of Subjects Meeting With HDL-C >/= 40 mg/dL at Week 12

(NCT00465088)
Timeframe: 12 weeks

InterventionPercentage of subjects (Number)
Niacin Extended-release Plus Simvastatin78
Atorvastatin28

[back to top]

Percentage of Subjects Meeting National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Goal for LDL-C at Week 12

For high-risk patients (coronary heart disease or equivalent), LDL-C < 100 mg/dL and non-HDL-C < 130 mg/dL; for moderate risk patients (having 2 risk factors), LDL-C < 130 mg/dL and non-HDL-C < 160 mg/dL; for low-risk patients (having 0 or 1 risk factor): LDL-C < 160 mg/dL and non-HDL-C < 190 mg/dL. (NCT00465088)
Timeframe: 12 weeks

InterventionPercentage of subjects (Number)
Niacin Extended-release Plus Simvastatin78
Atorvastatin84

[back to top]

Percent Change in Triglycerides From Baseline to Week 12

(Week 12 triglycerides minus baseline triglycerides) x 100/baseline triglycerides (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Median)
Niacin Extended-release Plus Simvastatin-44.0
Atorvastatin-37.0

[back to top]

Percent Change in Total Cholesterol:HDL-C Ratio

(Week 12 total cholesterol:HDL-C ratio minus baseline total cholesterol:HDL-C ratio) x 100/baseline total cholesterol:HDL-C ratio (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin-45.2
Atorvastatin-40.3

[back to top]

Percent Change in Total Cholesterol From Baseline to Week 12

(Week 12 total cholesterol minus baseline total cholesterol) x 100/baseline total cholesterol (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin-31.3
Atorvastatin-35.1

[back to top]

Percent Change in Non-HDL-C From Baseline to Week 8

(Week 8 non-HDL-C minus baseline non-HDL-C) x 100/baseline non-HDL-C (NCT00465088)
Timeframe: From baseline to Week 8

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin-45.0
Atorvastatin-44.3

[back to top]

Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12

(Week 12 LDL-C minus baseline LDL-C) x 100/baseline LDL-C (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Least Squares Mean)
Niacin Extended-release Plus Simvastatin-43.8
Atorvastatin-46.0

[back to top]

Percent Change in Lipoprotein A From Baseline to Week 12

(Week 12 lipoprotein A minus baseline lipoprotein A) x 100/baseline lipoprotein A (NCT00465088)
Timeframe: From baseline to Week 12

Interventionpercent change (Median)
Niacin Extended-release Plus Simvastatin-15.8
Atorvastatin16.0

[back to top]

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo

after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

InterventionPercent change at Wk 12 compared to Bl (Median)
Extended Release Niacin/Laropiprant-22.2
Placebo2.3

[back to top]

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

InterventionPercent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant-15.8
Placebo2.1

[back to top]

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

InterventionPercent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant25.4
Placebo2.2

[back to top]

Number of Participants With An Improvement in Vision, as Measured by an Increase of 15 Letters on the Early Treatment Diabetic Retinopathy Study (EDTRS) Vision Chart.

improvement with combination of niacin and topical prednisolone acetate (NCT00493064)
Timeframe: one year

InterventionParticipants (Count of Participants)
Prospective Active Treatment63

[back to top]

Urinary 11-Dehydrothromboxane B2 (11-dTxB2)

The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Interventionpg/mg creatinine (Least Squares Mean)
ER Niacin/Laropiprant525.3
ER Niacin540.8
Laropiprant585.3
Placebo625.1

[back to top]

Prostaglandin I Metabolite (PGI-M)

PGI-M in the Overall 24 Hour Collection Interval Following Administration on Day 7 (NCT00618995)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Interventionpg/mg creatinine (Least Squares Mean)
ER Niacin/Laropiprant90.1
ER Niacin95.4
Laropiprant158.5
Placebo168.1

[back to top]

Maximum Severity of Flushing Events Overall During the Study

The severity of flushing events was assessed as none, mild, moderate, severe, or very severe using the FAST. The maximum severity of flushing events overall during the study was compared among treatment groups. (NCT00630877)
Timeframe: Week 1 to Week 6

,,
InterventionPercentage of subjects (Number)
NoneMildNone/MildModerateSevereVery Severe
NER Placebo/ASA Placebo3738752220
NER/ASA26234934170
NER/ASA Placebo14163031327

[back to top]

FAST Longitudinal Construct Validity--mean Flushing Severity Score

The relationship between the change in mean flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start). (NCT00630877)
Timeframe: Week 1 to Week 2

InterventionSpearman correlation coefficient (Number)
Modified Intent-to-Treat (m-ITT) Population-0.44

[back to top]

FAST Longitudinal Construct Validity--maximum Flushing Severity Score

The relationship between the change in maximum flushing severity scores from Week 1 to Week 2, and the subject-rated overall treatment effect scale administered at Week 2, was assessed by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. The overall treatment effect was assessed on a scale of 1 (symptoms are worse since study start), 2 (symptoms are about the same since study start), or 3 (symptoms are better since study start). (NCT00630877)
Timeframe: Week 1 to Week 2

InterventionSpearman correlation coefficient (Number)
Modified Intent-to-Treat (m-ITT) Population-0.42

[back to top]

FAST Cross-sectional Construct Validity--mean Flushing Severity Score

The relationship between mean flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome. (NCT00630877)
Timeframe: Week 1

InterventionSpearman correlation coefficient (Number)
Modified Intent-to-Treat (m-ITT) Population0.64

[back to top]

FAST Cross-sectional Construct Validity--maximum Flushing Severity Score

The relationship between maximum flushing severity and overall flushing troublesomeness was evaluated by examining the Spearman rank-order correlation. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Overall flushing troublesomeness was assessed using the FAST on a scale of 1 to 10, with 10 being the most troublesome. (NCT00630877)
Timeframe: Week 1

InterventionSpearman correlation coefficient (Number)
Modified Intent-to-Treat (m-ITT) Population0.66

[back to top]

FAST Responsiveness--mean Flushing Severity Score

The change in mean flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in mean flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened. (NCT00630877)
Timeframe: Study start to Day 43

InterventionUnits on a scale (Number)
Responders-0.51
Nonresponders0.15

[back to top]

FAST Responsiveness--maximum Flushing Severity Score

The change in maximum flushing severity scores from study start to Day 43 was compared in subjects classified as responders vs. nonresponders. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. Changes in maximum flushing severity scores were negative if flushing symptoms improved and positive if flushing symptoms worsened. (NCT00630877)
Timeframe: Study start to Day 43

InterventionUnits on a scale (Number)
Responders-1.85
Nonresponders-0.18

[back to top]

FAST Test-retest Reliability--maximum Flushing Severity Score

Test-retest reliability of the maximum flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. (NCT00630877)
Timeframe: Week 1 to Week 2

InterventionIntraclass correlation coefficient (Number)
Subjects With Stable Flushing Symptoms0.40

[back to top]

Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score

Test-retest reliability of the mean flushing severity score was evaluated. The intraclass correlation coefficient comparing flushing severity scores for Week 1 and Week 2 was examined to determine test-retest reliability. Flushing severity was assessed using the FAST on a scale of 1 to 10, with 10 being the most severe. (NCT00630877)
Timeframe: Week 1 to Week 2

InterventionIntraclass correlation coefficient (Number)
Subjects With Stable Flushing Symptoms0.75

[back to top]

SPID48

"Time weighted Sum of Pain Intensity Differences over the first 48 hours (SPID48) is the sum of the Pain Intensity Difference (PID) scores observed at 0.5 , 1, 2, 3, 4, 5, 6, 12, 18, 24, 30, 36, 42, and 48 hours post-dose. Pain Intensity scores at each timepoint are based on a 100 mm visual analog scale (VAS) from 0 = no pain to 100 = worst pain imaginable. PID is calculated as the timepoint score less the baseline pre-dose score (i.e. PID.5 = PI.5 - PI0).~SPID48 = the PID for each timepoint multiplied by a time weighting factor; which is the difference (in hours) between the PID observation and prior observation. SPID48 = PID.5*.5 + PID1*.5 + PID2*1 + PID3*1 + PID4*1 + PID6*2 +PID12*6 + PID18*6 +PID24*6 + PID30*6 + PID36*6 + PID42*6 + PID48*6. The maximum SPID48 value is 4,800 (assumes PI0 of 100 and a PI of 0 at all subsequent timepoints) with a midpoint SPID48 of 2,400 (PI0=50 and PI of 0 at all subsequent readings)." (NCT00654069)
Timeframe: 48 hours

Interventionscore on a scale (Mean)
Placebo604.48
Acurox 5/30998.46
Acurox 7.5/301224.97

[back to top]

The Greatest Number of Cycles Received in Each Treatment Group

The highest number of cycles received by an individual participant in the treatment groups. Each cycle was 21 days long. (NCT00691210)
Timeframe: up to 45 weeks

Interventioncycles (Number)
Vorinostat (SAHA) and Niacinamide: Level 19
Vorinostat (SAHA) and Niacinamide: Level 212
Vorinostat (SAHA) and Niacinamide: Level 315
Vorinostat (SAHA) and Niacinamide: Level 410
Vorinostat (SAHA) and Niacinamide: Level 514
Vorinostat, Niacinamide and Etoposide: Level 13
Vorinostat, Niacinamide and Etoposide: Level 24

[back to top]

The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide

(NCT00691210)
Timeframe: 3 years

Interventionmg/kg (Number)
Vorinostat (SAHA) and Niacinamide: Level 1-5100

[back to top]

Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

,,
Interventionpercentage change/year (Mean)
LRNC changeWall Volume change
1 - Single Therapy Group-1.6-0.6
2 - Double Therapy Group-3.6-1.4
3 - Triple Therapy Group-2.8-1.2

[back to top]

Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

Interventionmm^3/year (Mean)
1 - Single Therapy Group-4.6
2 - Double Therapy Group-15.1
3 - Triple Therapy Group-9.4

[back to top]

Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions

Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5

,,
InterventionParticipants (Count of Participants)
Composite Measured at Year 3Composite Measured at Year 4 (cumulative)Composite Measured at Year 5 (cumulative)
1 - Single Therapy Group679
2 - Double Therapy Group61111
3 - Triple Therapy Group799

[back to top]

Prostaglandin I Metabolite (PGI-M)

The creatinine-normalized urine levels of PGI-M in the overall 24 hour collection interval following administration on Day 7. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Interventionpg/mg creatinine (Least Squares Mean)
ER Niacin 2 g / Laropiprant 40 mg73.5
ER Niacin 2 g70.9
Laropiprant 40 mg114.5
Placebo127.5

[back to top]

Urinary 11-dehydrothromboxane B2 (11-dTxB2)

The creatinine-normalized urine levels of 11-dTxB2 on Day 7 following a 7 day course of daily dosing in the overall 24 hour collection interval. (NCT00769132)
Timeframe: On Day 7 across the 24-hour urinary collection period.

Interventionpg/mg creatinine (Least Squares Mean)
ER Niacin 2 g / Laropiprant 40 mg414.6
ER Niacin 2 g371.6
Laropiprant 40 mg407.3
Placebo466.1

[back to top]

Peak Plasma Concentration (Cmax) of Nicotinuric Acid

Peak Plasma Concentration (Cmax) for Nicotinuric Acid, one of the active metabolites of Niacin (NCT00943124)
Timeframe: 24 Hours Post Dose

Interventionng/mL (Least Squares Mean)
MK0524B620
Simvastatin + MK0524A807

[back to top]

Peak Plasma Concentration (Cmax) of Simvastatin

(NCT00943124)
Timeframe: 48 Hours Post Dose

Interventionng/mL (Least Squares Mean)
MK0524B5.81
Simvastatin + MK0524A6.33

[back to top]

Peak Plasma Concentration (Cmax) of Simvastatin Acid

Peak Plasma Concentration (Cmax) for Simvastatin Acid, the active metabolite of simvastatin (NCT00943124)
Timeframe: 48 Hours Post Dose

Interventionng/mL (Least Squares Mean)
MK0524B1.016
Simvastatin + MK0524A0.918

[back to top]

Plasma Area Under the Curve (AUC(0 to 48 Hour)) for Simvastatin

Plasma Area Under the Curve of simvastatin (NCT00943124)
Timeframe: Through 48 Hours Post Dose

Interventionng/mL * Hour (Least Squares Mean)
MK0524B15.03
Simvastatin + MK0524A15.56

[back to top]

Plasma Area Under the Curve (AUC(0 to 48hr)) for Simvastatin Acid

Plasma Area Under the Curve of simvastatin acid, the active metabolite of simvastatin (NCT00943124)
Timeframe: Through 48 Hours Post Dose

Interventionng/mL * Hour (Least Squares Mean)
MK0524B9.19
Simvastatin + MK0524A8.03

[back to top]

Total Urinary Excretion of Niacin and Its Metabolites

(NCT00943124)
Timeframe: 96 Hours Post Dose

Interventionµmol (Least Squares Mean)
MK0524B5339
Simvastatin + MK0524A5825

[back to top]

Plasma Area Under the Curve (AUC(0 to Infinity)) for Laropiprant

Plasma Area Under the Curve of Laropiprant (NCT00943124)
Timeframe: 48 Hours Post Dose

Interventionnmol/L * hour (Least Squares Mean)
MK0524B5486
Simvastatin + MK0524A5405

[back to top]

Peak Plasma Concentration (Cmax) of Laropiprant

(NCT00943124)
Timeframe: 48 Hours Post Dose

Interventionnmol/L (Least Squares Mean)
MK0524B1030
Simvastatin + MK0524A953

[back to top]

Maximum Plasma Concentration (Cmax) of Nicotinuric Acid

Measure of rate of absorption of ER niacin (NCT00944645)
Timeframe: Predose and up to 24 hours postdose

Interventionng/mL (Median)
MK0524A New Site Tablet1190
MK0524A Phase III Tablet1260

[back to top]

Maximum Concentration (Cmax) of Laropiprant

Measure of rate of absorption of laropiprant (NCT00944645)
Timeframe: Predose and up to 48 hours postdose

Interventionmicro Molar (Median)
MK0524A New Site Tablet0.988
MK0524A Phase III Tablet0.975

[back to top]

Area Under Curve (AUC 0-infinity) of Laropiprant

Measure of extent of absorption of laropiprant (NCT00944645)
Timeframe: Predose and up to 48 hours postdose

InterventionMicro Molar times Hour (Median)
MK0524A New Site Tablet6.36
MK0524A Phase III Tablet6.37

[back to top]

Total Amount of Urinary Excretion of Niacin and Its Metabolites

Measure of extent of absorption of ER niacin (NCT00944645)
Timeframe: Predose and up to 96 hours postdose

Interventionmicro mole (Median)
MK0524A New Site Tablet5280
MK0524A Phase III Tablet5470

[back to top]

Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome. (NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])757.5
Pimasertib 15 mg (All Regimens [Part 1])524.8
Pimasertib 23 mg (All Regimens [Part 1])320.8
Pimasertib 30 mg (All Regimens [Part 1])308.8
Pimasertib 42 mg (All Regimens [Part 1])320.2
Pimasertib 45 mg (All Regimens [Part 1])260.8
Pimasertib 60 mg (All Regimens [Part 1])250.3
Pimasertib 90 mg (All Regimens [Part 1])235.2

[back to top]

Part 1: Percentage of Subjects With Best Overall Response

The best overall response was reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) >1.0x10^9 per liter (/L), platelets >100x10^9 /L, bone marrow aspirate with less than or equal to (<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC >1.0x10^9/L, platelets >100x10^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (<) 5%. (4) Progressive disease (PD) = >50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = Subjects who failed to achieve CR, CRi or PR and without criteria for PD. (NCT00957580)
Timeframe: Day 29 of every alternate 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012

,,
InterventionPercentage of Subjects (Number)
CRCRiPRSDPD
Regimen 1 (Part 1)0.00.00.060.040.0
Regimen 2 (Part 1)0.00.00.077.322.7
Regimen 3 (Part 1)0.00.00.071.428.6

[back to top]

Part 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation

An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs include both SAEs and non-SAEs. (NCT00957580)
Timeframe: Baseline up to 3 years

,,
InterventionSubjects (Number)
TEAEsSerious TEAEsTEAEs Leading to DeathTEAEs Leading to Treatment Discontinuation
Regimen 1 (Part 1)332467
Regimen 2 (Part 1)322867
Regimen 3 (Part 1)151257

[back to top]

Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. (NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionliter (Mean)
Regimen 1 (n = 0)Regimen 2 (n = 3)Regimen 3 (n = 1)
Pimasertib 75 mg (All Regimens [Part 1])NA442.2196.0

[back to top]

Part 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. (NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionliter/hour (Mean)
Regimen 1 (n=0)Regimen 2 (n=3)Regimen 3 (n=1)
Pimasertib 75 mg (All Regimens [Part 1])NA9345

[back to top]

Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose

(NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionhour (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])0.94
Pimasertib 15 mg (All Regimens [Part 1])2.25
Pimasertib 23 mg (All Regimens [Part 1])1.56
Pimasertib 30 mg (All Regimens [Part 1])1.09
Pimasertib 42 mg (All Regimens [Part 1])1.11
Pimasertib 45 mg (All Regimens [Part 1])1.12
Pimasertib 60 mg (All Regimens [Part 1])1.03
Pimasertib 75 mg (All Regimens [Part 1])2.70
Pimasertib 90 mg (All Regimens [Part 1])1.17

[back to top]

Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose

(NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

Interventionhour (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])1.44
Pimasertib 15 mg (All Regimens [Part 1])1.75
Pimasertib 23 mg (All Regimens [Part 1])2.03
Pimasertib 30 mg (All Regimens [Part 1])1.99
Pimasertib 42 mg (All Regimens [Part 1])1.64
Pimasertib 45 mg (All Regimens [Part 1])1.41
Pimasertib 60 mg (All Regimens [Part 1])1.78
Pimasertib 75 mg (All Regimens [Part 1])2.75
Pimasertib 90 mg (All Regimens [Part 1])2.00

[back to top]

Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)

The DLT was any toxicity that resulted in treatment delay for more than (>) 2 weeks due to treatment-related adverse effects, or any Grade greater than or equal to (>=) 3 non-hematological toxicity excluding Grade 4 asymptomatic increases in liver function tests reversible within 7 days in subjects with liver involvement, and Grade 3 asymptomatic increases in liver function tests reversible within 7 days for subjects without liver involvement, Grade 3 vomiting unless encountered and persistent for more than 3 days despite adequate and optimal therapy, and Grade 3 diarrhea unless encountered and persistent for more than 3 days despite adequate and optimal anti-diarrhea therapy at any DL and judged to be possibly or probably related to the trial treatment by the Investigator and/or the Sponsor. (NCT00957580)
Timeframe: Baseline Up to Day 29 of Cycle 1

Interventionsubjects (Number)
Regimen 1 (Part 1)1
Regimen 2 (Part 1)0
Regimen 3 (Part 1)5

[back to top]

Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose

(NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionnanogram/milliliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])14.8
Pimasertib 15 mg (All Regimens [Part 1])29.3
Pimasertib 23 mg (All Regimens [Part 1])59.1
Pimasertib 30 mg (All Regimens [Part 1])132.8
Pimasertib 42 mg (All Regimens [Part 1])151.6
Pimasertib 45 mg (All Regimens [Part 1])207.0
Pimasertib 60 mg (All Regimens [Part 1])269.9
Pimasertib 75 mg (All Regimens [Part 1])241.9
Pimasertib 90 mg (All Regimens [Part 1])342.6

[back to top]

Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose

(NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).

Interventionnanogram/milliliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])23.6
Pimasertib 15 mg (All Regimens [Part 1])59.3
Pimasertib 23 mg (All Regimens [Part 1])69.6
Pimasertib 30 mg (All Regimens [Part 1])150.1
Pimasertib 42 mg (All Regimens [Part 1])187.8
Pimasertib 45 mg (All Regimens [Part 1])123.2
Pimasertib 60 mg (All Regimens [Part 1])231.4
Pimasertib 75 mg (All Regimens [Part 1])383.2
Pimasertib 90 mg (All Regimens [Part 1])486.3

[back to top]

Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose

The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity. (NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionhour*nanogram/milliliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])80.5
Pimasertib 15 mg (All Regimens [Part 1])145.2
Pimasertib 23 mg (All Regimens [Part 1])315.6
Pimasertib 30 mg (All Regimens [Part 1])562.1
Pimasertib 42 mg (All Regimens [Part 1])734.9
Pimasertib 45 mg (All Regimens [Part 1])858.4
Pimasertib 60 mg (All Regimens [Part 1])1027.4
Pimasertib 75 mg (All Regimens [Part 1])1530.7
Pimasertib 90 mg (All Regimens [Part 1])1873.9

[back to top]

Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose

The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity. (NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

Interventionhour*nanogram/milliliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])226.2
Pimasertib 15 mg (All Regimens [Part 1])789.3
Pimasertib 23 mg (All Regimens [Part 1])451.2
Pimasertib 30 mg (All Regimens [Part 1])1030.2
Pimasertib 42 mg (All Regimens [Part 1])938.0
Pimasertib 45 mg (All Regimens [Part 1])786.7
Pimasertib 60 mg (All Regimens [Part 1])1270.8
Pimasertib 75 mg (All Regimens [Part 1])2712.6
Pimasertib 90 mg (All Regimens [Part 1])2830.7

[back to top]

Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose

(NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionhour*nanogram/milliliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])54.0
Pimasertib 15 mg (All Regimens [Part 1])125.4
Pimasertib 23 mg (All Regimens [Part 1])230.9
Pimasertib 30 mg (All Regimens [Part 1])456.2
Pimasertib 42 mg (All Regimens [Part 1])581.8
Pimasertib 45 mg (All Regimens [Part 1])735.2
Pimasertib 60 mg (All Regimens [Part 1])863.8
Pimasertib 75 mg (All Regimens [Part 1])905.0
Pimasertib 90 mg (All Regimens [Part 1])1268.2

[back to top]

Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose

(NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).

Interventionhour*nanogram/milliliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])131.4
Pimasertib 15 mg (All Regimens [Part 1])307.2
Pimasertib 23 mg (All Regimens [Part 1])321.9
Pimasertib 30 mg (All Regimens [Part 1])679.4
Pimasertib 42 mg (All Regimens [Part 1])761.2
Pimasertib 45 mg (All Regimens [Part 1])628.0
Pimasertib 60 mg (All Regimens [Part 1])991.6
Pimasertib 75 mg (All Regimens [Part 1])2195.2
Pimasertib 90 mg (All Regimens [Part 1])2144.7

[back to top]

Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. (NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionhour (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])5.28
Pimasertib 15 mg (All Regimens [Part 1])3.52
Pimasertib 23 mg (All Regimens [Part 1])3.05
Pimasertib 30 mg (All Regimens [Part 1])4.01
Pimasertib 42 mg (All Regimens [Part 1])3.88
Pimasertib 45 mg (All Regimens [Part 1])3.45
Pimasertib 60 mg (All Regimens [Part 1])2.97
Pimasertib 75 mg (All Regimens [Part 1])4.21
Pimasertib 90 mg (All Regimens [Part 1])3.39

[back to top]

Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. (NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).

Interventionhour (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])6.97
Pimasertib 15 mg (All Regimens [Part 1])10.91
Pimasertib 23 mg (All Regimens [Part 1])3.69
Pimasertib 30 mg (All Regimens [Part 1])3.93
Pimasertib 42 mg (All Regimens [Part 1])3.71
Pimasertib 45 mg (All Regimens [Part 1])3.96
Pimasertib 60 mg (All Regimens [Part 1])4.52
Pimasertib 75 mg (All Regimens [Part 1])8.44
Pimasertib 90 mg (All Regimens [Part 1])5.04

[back to top]

Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. (NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

Interventionliter (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])601.7
Pimasertib 15 mg (All Regimens [Part 1])863.7
Pimasertib 23 mg (All Regimens [Part 1])332.8
Pimasertib 30 mg (All Regimens [Part 1])207.8
Pimasertib 42 mg (All Regimens [Part 1])293.1
Pimasertib 45 mg (All Regimens [Part 1])395.1
Pimasertib 60 mg (All Regimens [Part 1])422.0
Pimasertib 75 mg (All Regimens [Part 1])689.9
Pimasertib 90 mg (All Regimens [Part 1])305.2

[back to top]

Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome. (NCT00957580)
Timeframe: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

Interventionliter/hour (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])99.43
Pimasertib 15 mg (All Regimens [Part 1])103.29
Pimasertib 23 mg (All Regimens [Part 1])72.88
Pimasertib 30 mg (All Regimens [Part 1])53.37
Pimasertib 42 mg (All Regimens [Part 1])57.15
Pimasertib 45 mg (All Regimens [Part 1])52.42
Pimasertib 60 mg (All Regimens [Part 1])58.40
Pimasertib 90 mg (All Regimens [Part 1])48.03

[back to top]

Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. (NCT00957580)
Timeframe: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

Interventionliter/hour (Geometric Mean)
Pimasertib 8 mg (All Regimens [Part 1])60.90
Pimasertib 15 mg (All Regimens [Part 1])46.74
Pimasertib 23 mg (All Regimens [Part 1])66.52
Pimasertib 30 mg (All Regimens [Part 1])37.95
Pimasertib 42 mg (All Regimens [Part 1])55.80
Pimasertib 45 mg (All Regimens [Part 1])69.23
Pimasertib 60 mg (All Regimens [Part 1])65.11
Pimasertib 75 mg (All Regimens [Part 1])34.44
Pimasertib 90 mg (All Regimens [Part 1])41.96

[back to top]

Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period

Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assessed the overall severity of the flushing experience, using a scale of 0 (no symptom) to 10 (extreme). The number of days/week was derived as: 7*(total number of days with GFSS ≥4 across Weeks 21-32 divided by the total number of days with nonmissing GFSS across the same period). The number of days/week with a GFSS ≥4 for each participant was listed in 1 of the following 6 categories: 0, >0 to 0.5, >0.5 to 1, >1 to 2, >2 to 3, and >3 days per week. (NCT00961636)
Timeframe: Week 21 to Week 32

,,
InterventionParticipants (Number)
0 Days per week>0 to ≤ 0.5 Days per week>0.5 to ≤1 Days per week>1.0 to ≤2 Days per week>2 to ≤3 Days per week>3 Days per week
ERN/LRPT2914338116
ERN/LRPT Then ERN1817432301720
Placebo18874314

[back to top]

Number of Participants With Maximum GFSS ≥4 During the Post-withdrawal Period

Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assesses the overall severity of the flushing experience (including redness, warmth, tingling, or itching) using a scale with response categories of None, Mild, Moderate, Severe, and Extreme. The categories were supplemented with numbers 0 to 10 to allow for greater precision within each category (None=0, Mild=1-3, Moderate=4-6, Severe=7-9, Extreme=10). The daily response was recorded in the morning, and reflected the symptoms experienced during the previous 24 hours. (NCT00961636)
Timeframe: Week 21 to Week 32

InterventionParticipants (Number)
ERN/LRPT71
ERN/LRPT Then ERN173
Placebo19

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was >20% of AUC0-inf, t1/2 derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,
InterventionHours (h) (Geometric Mean)
C1D1C1D15
MSC1936369B 7 mg2.5942.335
MSC1936369B 14 mg5.1194.443
MSC1936369B 28 mg5.1156.646
MSC1936369B 45 mg4.1875.277

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (With Food Effect)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
InterventionHour (h) (Geometric Mean)
FastedFed
MSC1936369B 150 mg4.4526.123
MSC1936369B 90 mg4.8984.534

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was >20% of AUC0-inf, t1/2 derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,
InterventionHours (h) (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 120 mg5.2473.9643.038
MSC1936369B 14 mg4.5993.2362.811
MSC1936369B 45 mg5.3894.6882.931
MSC1936369B 7 mg3.4059.2492.959
MSC1936369B 94 mg5.3515.6722.842

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was >20% of AUC0-inf, t1/2 derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,
InterventionHours (h) (Geometric Mean)
C1D1C1D12
MSC1936369B 28 mg4.7816.750
MSC1936369B 3.5 mg3.3464.985
MSC1936369B 68 mg5.3356.926

[back to top]

Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death

(NCT00982865)
Timeframe: Baseline up to 253 weeks

InterventionSubjects (Number)
MSC1936369B Regimen 110
MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)14
MSC1936369B Regimen 3 Once Daily (QD)2
MSC1936369B Regimen 3 Twice Daily2

[back to top]

Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21

DLT was defined as any of following toxicities at any dose level according to using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v3.0(CTCAE), probably or possibly related to trial medication by investigator or sponsor: a)Any Grade 3 or more non-haematological toxicity excluding: (i)Grade 3 asymptomatic increase in liver function tests (Aspartate Aminotransferase, Alanine transaminase, Alkaline Phosphatase reversible within 7 days for subjects without liver involvement, or grade 4 for subjects with liver involvement; (ii)Grade 3 vomiting if it is encountered despite adequate and optimal therapy (e.g. serotonin [5HT3] antagonists and corticosteroids); (iii)Grade 3 diarrhoea if it is encountered despite adequate and optimal anti diarrhoea therapy; b)Grade 4 neutropenia of >5 days duration or febrile neutropenia lasting for more than 1 day; c)Grade 4 thrombocytopenia >1 day or grade 3 with bleeding; d)Any treatment delay >2 weeks due to drug-related AEs. (NCT00982865)
Timeframe: Day 1 up to Day 21 of Cycle 1

InterventionSubjects (Number)
MSC1936369B Regimen 12
MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)6
MSC1936369B Regimen 3 Once Daily (QD)0
MSC1936369B Regimen 3 Twice Daily6

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

Interventionhour*ng/mL (Geometric Mean)
C1D15
MSC1936369B 1 mg15.7

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (With Food Effect)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
Interventionhour*ng/mL (Geometric Mean)
FastedFed
MSC1936369B 150 mg3344.35633.8
MSC1936369B 90 mg1580.61495.7

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,,,,,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 1 mg136.238.315.4
MSC1936369B 120 mg2773.52022.83477.6
MSC1936369B 14 mg234.1206.3134.5
MSC1936369B 2.5 mg55.543.847.6
MSC1936369B 28 mg574.2805.6489.8
MSC1936369B 3.5 mg31.447.534.4
MSC1936369B 45 mg924.2960.71072.1
MSC1936369B 7 mg61.3105.655.5
MSC1936369B 94 mg1836.42257.61056.0

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D12
MSC1936369B 1.5 mg6.29.4
MSC1936369B 68 mg1699.72108.2

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Twice Daily

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- [AUC0-t / AUC0-inf])*100. AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
InterventionPercentage of AUC 0-∞ (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg16.8211.7830.63
MSC1936369B 60 mg7.7014.1416.43
MSC1936369B 75 mg10.9019.1921.34

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- [AUC0-t / AUC0-inf])*100. %AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,,,,,,
InterventionPercentage of AUC 0-∞ (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 120 mg2.945.8216.22
MSC1936369B 150 mg2.644.8217.54
MSC1936369B 195 mg4.365.7723.45
MSC1936369B 2 mg55.7833.3433.93
MSC1936369B 255 mg3.575.2211.15
MSC1936369B 28 mg3.296.8926.32
MSC1936369B 3.5 mg31.6335.2933.77
MSC1936369B 5 mg27.2521.9317.27
MSC1936369B 68 mg2.665.0015.35
MSC1936369B 7 mg15.1019.4520.68
MSC1936369B 94 mg2.603.4018.02

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- [AUC0-t / AUC0-inf])*100. %AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
InterventionPercentage of AUC 0-∞ (Geometric Mean)
C1D1C1D15
MSC1936369B 45 mg1.462.96
MSC1936369B 14 mg12.1712.45

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- [AUC0-t / AUC0-inf])*100. %AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

InterventionPercentage of AUC 0-∞ (Geometric Mean)
C1D15
MSC1936369B 1 mg40.86

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (With Food Effect)

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- [AUC0-t / AUC0-inf])*100. AUCextra was reported in terms of percentage of AUC0-inf. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
InterventionPercentage of AUC 0-∞ (Geometric Mean)
FastedFed
MSC1936369B 150 mg1.749.96
MSC1936369B 90 mg2.542.21

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- [AUC0-t / AUC0-inf])*100. %AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,,,,,
InterventionPercentage of AUC 0-∞ (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 1 mg81.3350.6055.15
MSC1936369B 120 mg5.282.9726.05
MSC1936369B 14 mg5.317.8315.84
MSC1936369B 2.5 mg43.4540.6055.79
MSC1936369B 28 mg5.396.5728.06
MSC1936369B 3.5 mg26.8021.2732.85
MSC1936369B 45 mg3.528.1727.67
MSC1936369B 7 mg13.0819.8221.27
MSC1936369B 94 mg4.097.9416.54

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- [AUC0-t / AUC0-inf])*100. %AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,
InterventionPercentage of AUC 0-∞ (Geometric Mean)
C1D1C1D12
MSC1936369B 1.5 mg42.2333.84
MSC1936369B 68 mg4.086.56

[back to top]

Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was >20% of AUC0-inf, Vz/F derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,
InterventionLiter (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 120 mg361.99351.4316.63
MSC1936369B 14 mg396.76291.9422.04
MSC1936369B 45 mg378.56333.9348.19
MSC1936369B 7 mg561.27594.5928.91
MSC1936369B 94 mg389.49416.3438.91

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (With Food Effect)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
InterventionLiter per hour (Geometric Mean)
FastedFed
MSC1936369B 150 mg44.8526.62
MSC1936369B 90 mg56.9460.17

[back to top]

Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was >20% of AUC0-inf, Vz/F derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,
InterventionLiter (Geometric Mean)
C1D1C1D12
MSC1936369B 28 mg336.32365.1
MSC1936369B 3.5 mg640.60507.8
MSC1936369B 68 mg307.90357.8

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Twice Daily

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
InterventionLiter (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg339.51297.9571.8
MSC1936369B 60 mg292.59315.0392.9
MSC1936369B 75 mg340.43437.6362.6

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Once Daily

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
InterventionLiter (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg292.61366.5137.0
MSC1936369B 90 mg336.38507.7292.5

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was >20% of AUC0-inf, Vz/F derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,
InterventionLiter (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 120 mg361.12646.9201.39
MSC1936369B 150 mg463.92642.1212.92
MSC1936369B 195 mg440.55464.2274.24
MSC1936369B 255 mg377.28295.1144.24
MSC1936369B 68 mg366.00406.6206.07
MSC1936369B 94 mg428.99385.6244.16

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was >20% of AUC0-inf, Vz/F derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

InterventionLiter (Geometric Mean)
C1D15C3D1
MSC1936369B 5 mg252.7352.10

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was >20% of AUC0-inf, Vz/F derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,
InterventionLiter (Geometric Mean)
C1D1C1D15
MSC1936369B 14 mg473.32555.9
MSC1936369B 28 mg319.40432.5
MSC1936369B 45 mg331.36378.0
MSC1936369B 7 mg339.58454.6

[back to top]

Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (With Food Effect)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
InterventionLiter (Geometric Mean)
FastedFed
MSC1936369B 150 mg288.1235.2
MSC1936369B 90 mg402.4393.6

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Twice Daily

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
InterventionHour (h) (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg2.0502.8903.144
MSC1936369B 60 mg2.5093.2652.636
MSC1936369B 75 mg2.8143.2103.260

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Once Daily

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
InterventionHour (h) (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg4.2365.2591.780
MSC1936369B 90 mg4.0975.5992.680

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was >20% of AUC0-inf, t1/2 derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,
InterventionHours (h) (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 120 mg5.0574.8512.863
MSC1936369B 150 mg4.9045.4792.418
MSC1936369B 195 mg5.6416.0162.628
MSC1936369B 68 mg3.3056.4413.477
MSC1936369B 255 mg4.3134.8472.260
MSC1936369B 94 mg4.8265.1932.853

[back to top]

Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)

Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was >20% of AUC0-inf, t1/2 derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

InterventionHours (h) (Geometric Mean)
C1D15C3D1
MSC1936369B 5 mg2.9412.732

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Twice Daily

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
InterventionLiter per hour (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg114.8271.44126.1
MSC1936369B 60 mg80.8366.89103.3
MSC1936369B 75 mg83.8694.4877.09

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Once Daily

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
InterventionLiter per hour (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg47.8848.3153.36
MSC1936369B 90 mg56.9162.8575.63

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was >20% of AUC0-inf, CL/f derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,
InterventionLiter per hour (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 120 mg49.5092.4248.76
MSC1936369B 150 mg65.5781.2261.04
MSC1936369B 195 mg54.1353.4972.33
MSC1936369B 255 mg60.6342.2044.23
MSC1936369B 68 mg76.7743.7641.08
MSC1936369B 94 mg61.6151.4759.31

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was >20% of AUC0-inf, CL/f derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

InterventionLiter per hour (Geometric Mean)
C1D15C3D1
MSC1936369B 5 mg59.5589.34

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was >20% of AUC0-inf, CL/f derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,
InterventionLiter per hour (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 120 mg47.8261.4472.25
MSC1936369B 14 mg59.8062.53104.07
MSC1936369B 45 mg48.6949.3782.35
MSC1936369B 7 mg114.2644.55217.56
MSC1936369B 94 mg50.4550.88107.06

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was >20% of AUC0-inf, CL/f derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,
InterventionLiter per hour (Geometric Mean)
C1D1C1D12
MSC1936369B 28 mg48.7637.49
MSC1936369B 3.5 mg132.6970.60
MSC1936369B 68 mg40.0135.80

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Twice Daily

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
InterventionHours (h) (Median)
C1D1C1D15C3D1
MSC1936369B 45 mg1.5001.5001.467
MSC1936369B 60 mg1.0001.5001.183
MSC1936369B 75 mg0.6671.5001.467

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Once Daily

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
InterventionHours (h) (Median)
C1D1C1D15C3D1
MSC1936369B 60 mg1.0332.5002.000
MSC1936369B 90 mg1.5001.4921.000

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,,,,,,,
InterventionHours (h) (Median)
C1D1C1D15C3D1
MSC1936369B 1 mg1.5001.5001.250
MSC1936369B 120 mg1.2502.0001.042
MSC1936369B 150 mg1.5001.5171.333
MSC1936369B 195 mg1.2501.2501.000
MSC1936369B 2 mg1.0170.9672.000
MSC1936369B 255 mg2.0001.4581.000
MSC1936369B 28 mg1.0001.0171.50
MSC1936369B 3.5 mg1.5002.0001.258
MSC1936369B 5 mg1.0000.6671.000
MSC1936369B 68 mg1.0001.2500.500
MSC1936369B 7 mg0.5331.0082.500
MSC1936369B 94 mg1.5001.5002.000

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
InterventionHours (h) (Median)
C1D1C1D15
MSC1936369B 14 mg1.5001.500
MSC1936369B 45 mg0.5001.500

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (With Food Effect)

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
InterventionHours (h) (Median)
FastedFed
MSC1936369B 150 mg1.0006.000
MSC1936369B 90 mg1.6002.033

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,,,,,,
InterventionHours (h) (Median)
C1D1C1D12C3D1
MSC1936369B 1 mg1.5001.6331.52
MSC1936369B 1.5 mg0.7500.5330.500
MSC1936369B 120 mg1.0171.0832.000
MSC1936369B 14 mg1.0001.5001.500
MSC1936369B 2.5 mg1.5001.0001.52
MSC1936369B 28 mg1.5001.0001.000
MSC1936369B 3.5 mg1.5001.0001.000
MSC1936369B 45 mg1.0172.0001.508
MSC1936369B 7 mg1.5001.0171.517
MSC1936369B 94 mg1.4831.5001.767

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1

Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

InterventionHours (h) (Median)
C1D1C1D12
MSC1936369B 68 mg1.0001.000

[back to top]

Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)

(NCT00982865)
Timeframe: Pre-dose on C1D1, C1D2, C1D5, C1D8; 2, 4, 8 h post-dose on C1D1; pre-dose, 2, 8, 24 h post-dose on C1D12-15; pre-dose, 2, 4 h post-dose on C1D3

Interventionfold change (Mean)
C1D1, Pre-dose (pERK)C1D1, 2 h post-dose (pERK)C1D1, 4 h post-dose (pERK)C1D1, 8 h post-dose (pERK)C1D2, Pre-dose (pERK)C1D5, Pre-dose (pERK)C1D8, Pre-dose (pERK)C1D12-15, Pre-dose (pERK)C1D12-15, 2 h Post-dose (pERK)C1D12-15, 8 h Post-dose (pERK)C1D12-15, 24 h Post-dose (pERK)C3D1, Pre-dose (pERK)C3D1, 2 h Post-dose (pERK)C3D1, 4 h Post-dose (pERK)C1D1, Pre-dose (Tot ERK)C1D1, 2 h post-dose (Tot ERK)C1D1, 4 h post-dose (Tot ERK)C1D1, 8 h post-dose (Tot ERK)C1D2, Pre-dose (Tot ERK)C1D5, Pre-dose (Tot ERK)C1D8, Pre-dose (Tot ERK)C1D12-15, Pre-dose (Tot ERK)C1D12-15, 2 h Post-dose (Tot ERK)C1D12-15, 8 h Post-dose (Tot ERK)C1D12-15, 24 h Post-dose (Tot ERK)C3D1, Pre-dose (Tot ERK)C3D1, 2 h Post-dose (Tot ERK)C3D1, 4 h Post-dose (Tot ERK)
MSC1936369B Regimen 14.5241.2353.8281.4542.8532.7224.483.2571.2521.5142.7685.1791.7953.1061.11.0631.0591.0581.0751.1631.2331.2231.040.9941.0471.0741.0870.674

[back to top]

Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)

(NCT00982865)
Timeframe: Pre-dose on C1D1, C1D2, C1D5, C1D8; 2, 4, 8 h post-dose on C1D1; pre-dose, 2, 8, 24 h post-dose on C1D12-15; pre-dose, 2, 4 h post-dose on C1D3

Interventionfold change (Mean)
C1D1, Pre-dose (pERK)C1D1, 2 h post-dose (pERK)C1D1, 4 h post-dose (pERK)C1D1, 8 h post-dose (pERK)C1D2, Pre-dose (pERK)C1D8, Pre-dose (pERK)C1D12-15, Pre-dose (pERK)C1D12-15, 2 h Post-dose (pERK)C1D12-15, 8 h Post-dose (pERK)C1D12-15, 24 h Post-dose (pERK)C3D1, Pre-dose (pERK)C3D1, 2 h Post-dose (pERK)C3D1, 4 h Post-dose (pERK)C1D1, Pre-dose (Tot ERK)C1D1, 2 h post-dose (Tot ERK)C1D1, 4 h post-dose (Tot ERK)C1D1, 8 h post-dose (Tot ERK)C1D2, Pre-dose (Tot ERK)C1D8, Pre-dose (Tot ERK)C1D12-15, Pre-dose (Tot ERK)C1D12-15, 2 h Post-dose (Tot ERK)C1D12-15, 8 h Post-dose (Tot ERK)C1D12-15, 24 h Post-dose (Tot ERK)C3D1, Pre-dose (Tot ERK)C3D1, 2 h Post-dose (Tot ERK)C3D1, 4 h Post-dose (Tot ERK)
MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)3.9371.3053.4221.4542.4112.8683.2651.2931.6532.4763.7161.2882.6881.0751.0691.0121.0951.131.1081.1181.1251.0411.0451.1381.2511.052

[back to top]

Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)

(NCT00982865)
Timeframe: Pre-dose on C1D1, C1D2, C1D5, C1D8; 2, 4, 8 h post-dose on C1D1; pre-dose, 2, 8, 24 h post-dose on C1D12-15; pre-dose, 2, 4 h post-dose on C1D3

,
Interventionfold change (Mean)
C1D1, Pre-dose (pERK)C1D1, 2 h post-dose (pERK)C1D1, 8 h post-dose (pERK)C1D2, Pre-dose (pERK)C1D8, Pre-dose (pERK)C1D12-15, Pre-dose (pERK)C1D12-15, 2 h Post-dose (pERK)C1D12-15, 8 h Post-dose (pERK)C1D12-15, 24 h Post-dose (pERK)C1D1, Pre-dose (Tot ERK)C1D1, 2 h post-dose (Tot ERK)C1D1, 8 h post-dose (Tot ERK)C1D2, Pre-dose (Tot ERK)C1D8, Pre-dose (Tot ERK)C1D12-15, Pre-dose (Tot ERK)C1D12-15, 2 h Post-dose (Tot ERK)C1D12-15, 8 h Post-dose (Tot ERK)C1D12-15, 24 h Post-dose (Tot ERK)
MSC1936369B Regimen 3 Once Daily4.1211.1781.8783.0812.5413.2411.4711.9022.5981.021.0781.0781.0130.9441.3331.3351.0441.048
MSC1936369B Regimen 3 Twice Daily3.6291.2491.8212.0692.2352.161.3151.982.0431.0861.0791.0981.1081.0491.0471.0591.0261.068

[back to top]

Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation

AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 253 weeks. TEAEs include both Serious TEAEs and non-serious TEAEs. (NCT00982865)
Timeframe: Baseline up to 253 weeks

,,,
InterventionSubjects (Number)
TEAEsSerious TEAEsTEAEs leading to discontinuation
MSC1936369B Regimen 1472313
MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)824522
MSC1936369B Regimen 3 Once Daily (QD)1582
MSC1936369B Regimen 3 Twice Daily34216

[back to top]

Number of Subjects With Clinical Significant Laboratory Abnormalities and Vital Signs Reported as Treatment Emergent Adverse Events

Any clinically significant changes in laboratory evaluations and vital signs were recorded as treatment emergent adverse events. The clinical laboratory parameters that were assessed included: Hematological parameters, Blood chemistry parameters, Urinalysis and the vital signs that were assessed included: Blood pressure, Heart rate, Temperature and Weight. SAF analysis was used. (NCT00982865)
Timeframe: Baseline up to 253 weeks

,,,
InterventionSubjects (Number)
Haemoglobin decreasedAnaemiaLymphopeniaThrombocytopeniaPlatelet count decreasedNeutropeniaLeukopeniaPancytopeniaHyponatraemiaHypokalaemiaHyperkalaemiaHypocalcaemiaHypercalcaemiaHypomagnesaemiaHypophosphataemiaHepatic enzyme increasedHepatic function abnormalAlanine aminotransferase increasedAspartate aminotransferase increasedBlood alkaline phosphatase increasedHyperbilirubinaemiaBlood lactate dehydrogenase increasedBlood creatine phosphokinase increasedBlood creatinine increasedBlood 25-hydroxycholecalciferol decreasedVitamin D decreasedBlood parathyroid hormone increasedHyperglycaemiaC-reactive protein increasedProteinuriaHyperthyroidismHypoalbuminaemiaWeight increasedWeight decreasedHyperthermiaHypertensionHypotensionHeart rate increasedTachycardiaBlood potassium increased
MSC1936369B Regimen 111033000004120200001111101010000306173131
MSC1936369B Regimen 2 (Without Food Effect + With Food Effect)223761400110073321111010211111100438551000
MSC1936369B Regimen 3 Once Daily (QD)0302001002000200000000100000010004012020
MSC1936369B Regimen 3 Twice Daily0301010112010000022101500000011232140000

[back to top]

Number of Subjects With Clinical Benefit (Complete Response [CR], Partial Response [PR] or Stable Disease [SD}) and Progressive Disease (PD) Based on the Best Overall Response (BOR)

Number of subjects with clinical benefit (CR, PR, or SD) and PD according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study. (NCT00982865)
Timeframe: Baseline until disease progression (assessed up to end of treatment [253 weeks])

,,,
InterventionSubjects (Number)
CRPRSDPD
MSC1936369B Regimen 1001920
MSC1936369B Regimen 2 and Regimen 2 Food Effect043433
MSC1936369B Regimen 3 Once Daily (QD)0294
MSC1936369B Regimen 3 Twice Daily161412

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Once Daily

Cmax was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg241.27316.08473.27
MSC1936369B 90 mg402.77324.80376.62

[back to top]

Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Once Daily

AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- [AUC0-t / AUC0-inf])*100. AUCextra was reported in terms of percentage of AUC0-inf. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionpercentage of AUC 0-∞ (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg1.887.959.11
MSC1936369B 90 mg2.114.2817.56

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)

Cmax was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionng/mL (Geometric Mean)
C1D1C1D15
MSC1936369B 14 mg39.1934.87
MSC1936369B 45 mg321.85286.88

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (With Food Effect)

Cmax was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
Interventionng/mL (Geometric Mean)
FastedFed
MSC1936369B 150 mg1158.00370.70
MSC1936369B 90 mg321.14305.94

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1

Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours (h) post-dose on Cycle 1(C1) Day 1 (D1), Cycle 1 Day 12 (D12) and Cycle 3 (C3) Day 1

,,,,,,,,,
Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 1 mg2.022.922.00
MSC1936369B 1.5 mg3.202.692.90
MSC1936369B 120 mg428.85425.26652.70
MSC1936369B 14 mg62.3254.4751.30
MSC1936369B 2.5 mg4.216.295.60
MSC1936369B 28 mg126.21150.6784.70
MSC1936369B 3.5 mg6.699.758.06
MSC1936369B 45 mg212.96175.94167.75
MSC1936369B 7 mg12.6021.9310.90
MSC1936369B 94 mg325.99602.12282.44

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1

Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours (h) post-dose on Cycle 1(C1) Day 1 (D1), Cycle 1 Day 12 (D12) and Cycle 3 (C3) Day 1

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
C1D1C1D12
MSC1936369B 68 mg357.39413.58

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Twice Daily

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg407.2589.3450.0
MSC1936369B 60 mg681.4838.8577.0
MSC1936369B 75 mg791.1710.31005.0

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)

Cmax was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,,,,,,,
Interventionng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 120 mg605.11492.81568.49
MSC1936369B 150 mg539.02450.29795.86
MSC1936369B 195 mg680.87629.85773.14
MSC1936369B 2 mg2.877.774.30
MSC1936369B 255 mg990.921535.602344.91
MSC1936369B 28 mg187.98131.7196.60
MSC1936369B 3.5 mg4.554.216.56
MSC1936369B 1 mg1.652.281.25
MSC1936369B 5 mg17.2618.7814.81
MSC1936369B 68 mg306.63539.17710.94
MSC1936369B 7 mg30.9018.4716.10
MSC1936369B 94 mg373.59432.46532.80

[back to top]

Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was >20% of AUC0-inf, CL/f derived from λz was regarded as implausible & not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,
InterventionLiter per hour (Geometric Mean)
C1D1C1D15
MSC1936369B 14 mg64.0986.72
MSC1936369B 28 mg43.2845.10
MSC1936369B 45 mg54.8549.65
MSC1936369B 7 mg90.76134.9

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Once Daily

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg1229.31532.41392.3
MSC1936369B 90 mg1544.91428.81122.5

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 2 (With Food Effect)

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Summarized data over Day 1 and Day 2 was reported. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2

,
Interventionhour*ng/mL (Geometric Mean)
FastedFed
MSC1936369B 150 mg32865072.9
MSC1936369B 90 mg1509.61458.3

[back to top]

Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Twice Daily

Cmax was obtained directly from the concentration versus time curve. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
Interventionng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg132.57178.09139.60
MSC1936369B 60 mg206.46231.12157.46
MSC1936369B 75 mg263.08190.42329.28

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

,,,,,,,,,
Interventionhour*nanogram per milliliter (h*ng/mL) (Geometric Mean)
C1D1C1D12C3D1
MSC1936369B 1.5 mg5.26.02.7
MSC1936369B 120 mg2292.41682.42064.1
MSC1936369B 14 mg213.9182.0113.2
MSC1936369B 2.5 mg18.526.021.0
MSC1936369B 28 mg531.3691.9334.9
MSC1936369B 3.5 mg22.735.923.0
MSC1936369B 45 mg889.0880.0666.3
MSC1936369B 1 mg4.67.06.9
MSC1936369B 7 mg52.783.645.2
MSC1936369B 94 mg1748.11991.4876.7

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1

Interventionhour*nanogram per milliliter (h*ng/mL) (Geometric Mean)
C1D1C1D12
MSC1936369B 68 mg1624.81900.3

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,,,,,,,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 1 mg1.94.30.5
MSC1936369B 120 mg2287.01862.32053.6
MSC1936369B 150 mg2216.52086.62171.2
MSC1936369B 195 mg3415.63436.82484.5
MSC1936369B 2 mg8.222.210.2
MSC1936369B 255 mg4041.35765.94906.3
MSC1936369B 28 mg625.7621.2306.2
MSC1936369B 3.5 mg6.713.826.2
MSC1936369B 5 mg67.979.340.5
MSC1936369B 68 mg861.11553.91394.7
MSC1936369B 7 mg74.467.846.1
MSC1936369B 94 mg1484.61826.21299.3

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)

Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15
MSC1936369B 14 mg188.4161.5
MSC1936369B 45 mg808.0906.3

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Twice Daily

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1

,,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 45 mg527.6674.1696.0
MSC1936369B 60 mg742.31004.2700.8
MSC1936369B 75 mg939.9978.41285.7

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Once Daily

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 60 mg1253.11753.91597.0
MSC1936369B 90 mg1581.41517.11400.3

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,,,,,,,,,,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15C3D1
MSC1936369B 120 mg2424.22129.02461.3
MSC1936369B 195 mg3602.23900.83452.9
MSC1936369B 2 mg23.433.315.4
MSC1936369B 255 mg4300.36232.15651.1
MSC1936369B 28 mg646.9669.1415.6
MSC1936369B 3.5 mg23.621.941.2
MSC1936369B 150 mg2287.82029.92796.2
MSC1936369B 5 mg59.1102.049.5
MSC1936369B 68 mg885.81665.21655.1
MSC1936369B 7 mg90.389.758.1
MSC1936369B 94 mg1525.61893.21584.8

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT00982865)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1

,
Interventionhour*ng/mL (Geometric Mean)
C1D1C1D15
MSC1936369B 45 mg820.4933.9
MSC1936369B 14 mg218.4172.2

[back to top]

Hemodialysis Access Stenosis/Thrombosis

Comparison of the average hemodialysis access stenosis/thrombosis requiring intervention in the 3 month before and the last 3 months of the study. (NCT01159054)
Timeframe: 6 months

Intervention ()
Treatment Group (One Arm Only Study)0

[back to top]

Hemoglobin Level

Pre and Post Levels (NCT01159054)
Timeframe: 6 months

Interventiong/dL (Mean)
Average Pre-TreatmentAverage Post-Treatment
Treatment Group (One Arm Only Study)11.610.15

[back to top]

Changes in IL-6 Level

Change in IL-6 level before and after treatment in each subject (NCT01159054)
Timeframe: 6 months

Interventionpg/mL (Mean)
Average Pre-TreatmentAverage Post-Treatment
Treatment Group (One Arm Only Study)5.125414.8375

[back to top]

Changes in Hs-CRP Level

Change in hs-CRP level before and after treatment in each subject (NCT01159054)
Timeframe: 6 months

Interventionmg/L (Mean)
Average Pre-TreatmentAverage Post-Treatment
Treatment Group (One Arm Only Study)18.46526.395

[back to top]

Albumin Level

Pre and Post levels. (NCT01159054)
Timeframe: 6 months

Interventiong/dL (Mean)
Average Pre-TreatmentAverage Post-Treatment
Treatment Group (One Arm Only Study)3.94.05

[back to top]

Rate of Cardiovascular Events

Comparison of the average major cardiovascular events (myocardial infarction and/or stroke) in the 3 month before and the last 3 months of the study. (NCT01159054)
Timeframe: 6 months

Intervention ()
Treatment Group (One Arm Only Study)0

[back to top]

Number of Completed Subjects With Significant Increase in ALT (Alanine Aminotransferase).

The number of subjects with significant rise in ALT but not to the extent requiring removal from the study (rise to more than 3 times the upper limit of the normal range) (NCT01159054)
Timeframe: 6 months (checked monthly)

InterventionParticipants (Number)
Treatment Group (One Arm Only Study)0

[back to top]

ESA (Erythorpoietic Stimulating Agent) Dose Requirement

Comparison of the average ESA dose used in the 3 month before and the last 3 months of the study. (NCT01159054)
Timeframe: 6 months

Intervention ()
Treatment Group (One Arm Only Study)0

[back to top]

Changes in FDG-PET/CT Dual Scan Score

(NCT01159054)
Timeframe: 6 months

Intervention ()
Treatment Group (One Arm Only Study)0

[back to top]

Clinically Relevant Change in Intra-ocular Pressure After 4 Weeks of Treatment

(NCT01173471)
Timeframe: Baseline to 4 weeks

,,,
InterventionParticipants (Number)
>= 20% decrease in intra-ocular pressure>= 30% decrease in intra-ocular pressure
AZD4017 200 mg OD00
AZD4017 400 mg BID40
Placebo BID10
Placebo OD00

[back to top]

Percentage Change in Mean Intra-ocular Pressure Compared With Baseline After 4 Weeks Treatment

(NCT01173471)
Timeframe: Baseline to 4 weeks

InterventionPercentage change (Least Squares Mean)
Placebo OD0.8
AZD4017 200 mg OD-0.4
Placebo BID-8.1
AZD4017 400 mg BID-11.0

[back to top]

Change in Mean Intra-ocular Pressure Compared With Baseline After 4 Weeks Treatment

(NCT01173471)
Timeframe: Baseline to 4 weeks

InterventionmmHg (Least Squares Mean)
Placebo OD0.1
AZD4017 200 mg OD-0.4
Placebo BID-1.9
AZD4017 400 mg BID-2.6

[back to top]

Growth Hormone-releasing Hormone (GHRH) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours

Growth hormone-releasing hormone (GHRH) Area Under the Curve in response to Niacin and Placebo over 4 hours. For GHRH, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours

Interventionmin*pg/mL (Mean)
Niacin GHRHPlacbo GHRH
All Randomized Subjects25352283

[back to top]

Free Fatty Acids (FFA) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours

Effect of niacin vs placebo on Free Fatty Acids (FFA) Area Under the Curve in response to Niacin and Placebo over 4 hours. For FFA, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes (NCT01237041)
Timeframe: 4 hours

,,
InterventionMin*UEq/L (Mean)
Niacin FFA AUC
Dose-Establishing Study 1 Niacin 250mg164056
Dose-Establishing Study 1 Niacin 500mg94346
Dose-Establishing Study 2 Niacin 500mg48870

[back to top]

Somatostatin (SST) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours

Effect of niacin vs placebo on Somatostatin (SST) Area Under the Curve in response to Niacin and Placebo over 4 hours. For somatostatin, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours

Interventionmin*pg/mL (Mean)
Niacin SomatostatinPlacebo Somatostatin
All Randomized Subjects13291248

[back to top]

Somatostatin (SST) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours

Effect of niacin vs placebo on Somatostatin (SST) Area Under the Curve in response to Niacin and Placebo over 4 hours. For somatostatin, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours

,
Interventionmin*pg/mL (Mean)
Niacin Somatostatin
Dose-Establishing Study 1 Niacin 500mg849.8
Dose-Establishing Study 2 Niacin 500mg1578

[back to top]

Growth Hormone-releasing Hormone (GHRH) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours

Growth hormone-releasing hormone (GHRH) Area Under the Curve in response to Niacin and Placebo over 4 hours. For GHRH, samples collected at 0, 60, 120, 180, and 240 minutes. (NCT01237041)
Timeframe: 4 hours

,,
Interventionmin*pg/mL (Mean)
Niacin GHRH
Dose-Establishing Study 1 Niacin 250mg2415
Dose-Establishing Study 1 Niacin 500mg2548
Dose-Establishing Study 2 Niacin 500mg5382

[back to top]

Growth Hormone Secretion Area Under the Curve in Response to Niacin and Placebo Over Time

Growth hormone Area Under the Curve in response to niacin versus placebo over 4 hours. For growth hormone, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes. (NCT01237041)
Timeframe: 4 hours

Interventionmin*ng/mL (Mean)
NiacinPlacebo
All Randomized Subjects589.6638.5

[back to top]

Growth Hormone Secretion Area Under the Curve in Response to Niacin and Placebo Over Time

Growth hormone Area Under the Curve in response to niacin versus placebo over 4 hours. For growth hormone, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes. (NCT01237041)
Timeframe: 4 hours

,,
Interventionmin*ng/mL (Mean)
Niacin
Dose-Establishing Study 1 Niacin 250mg32.0
Dose-Establishing Study 1 Niacin 500mg84.0
Dose-Establishing Study 2 Niacin 500mg394.6

[back to top]

Free Fatty Acids (FFA) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours

Effect of niacin vs placebo on Free Fatty Acids (FFA) Area Under the Curve in response to Niacin and Placebo over 4 hours. For FFA, samples collected at 0, 30, 60, 90, 120, 150, 180, 210, and 240 minutes (NCT01237041)
Timeframe: 4 hours

InterventionMin*UEq/L (Mean)
Niacin FFA AUCPlacebo FFA AUC
All Randomized Subjects37567106047

[back to top]

Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo

Percentage change of area under the urinary prostaglandins concentration versus time curve (AUC) in response to niacin with or without pretreatment of aspirin was studied. This outcome measures whether aspirin instead of placebo will impact the subjects' response to niacin. The area was normalized by percentile. (NCT01275300)
Timeframe: -2-0, 0-2, 2-4, 4-6, 6-12 and 12-24 hours pre or post niacin

InterventionPercentage change of area under curve (Mean)
Placebo95
Aspirin43

[back to top] [back to top]

Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event

Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee a cardiovascular events were recorded. (NCT01294683)
Timeframe: up 20 weeks (12 weeks in Periods I/II and 8 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g0.2
Sequence 2: MK-0524A 2g + Simvastatin 40 mg0.2
Sequence 1: MK-0524A 2g + Simvastatin 40 mg0.0
Sequence 2: MK-0524B 2g/40g0.0

[back to top]

Percentage of Participants With Elevations in ALT and/or AST of >=10 x ULN

Participants had AST and ALT levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of either AST or ALT that was 10 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT01294683)
Timeframe: up 20 weeks (12 weeks in Periods I/II and 8 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g0.0
Sequence 2: MK-0524A 2g + Simvastatin 40 mg0.0
Sequence 1: MK-0524A 2g + Simvastatin 40 mg0.0
Sequence 2: MK-0524B 2g/40g0.0

[back to top]

Percentage of Participants With Elevations in ALT and/or AST of >=5 x ULN

Participants had AST and ALT levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of either AST or ALT that was 5 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT01294683)
Timeframe: up 20 weeks (12 weeks in Periods I/II and 8 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g0.2
Sequence 2: MK-0524A 2g + Simvastatin 40 mg0.4
Sequence 1: MK-0524A 2g + Simvastatin 40 mg0.9
Sequence 2: MK-0524B 2g/40g0.0

[back to top]

Percentage of Participants With New Onset of Diabetes

Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an AE related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults. (NCT01294683)
Timeframe: up 20 weeks (12 weeks in Periods I/II and 8 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g1.0
Sequence 2: MK-0524A 2g + Simvastatin 40 mg0.4
Sequence 1: MK-0524A 2g + Simvastatin 40 mg1.3
Sequence 2: MK-0524B 2g/40g0.9

[back to top]

Percentage of Participants With Creatine Kinase (CK) >=10 x ULN

Participants had CK levels assessed throughout the treatment periods. Participants who had any CK level that was >=10 x ULN were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT01294683)
Timeframe: up 20 weeks (12 weeks in Periods I/II and 8 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g0.0
Sequence 2: MK-0524A 2g + Simvastatin 40 mg0.0
Sequence 1: MK-0524A 2g + Simvastatin 40 mg0.9
Sequence 2: MK-0524B 2g/40g0.0

[back to top]

Percentage of Participants Who Were Discontinued From the Study Due to an AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Participants who were discontinued from the study due to an AE were recorded. (NCT01294683)
Timeframe: up 22 weeks (12 weeks in Periods I/II and 10 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g10.1
Sequence 2: MK-0524A 2g + Simvastatin 40 mg10.5
Sequence 1: MK-0524A 2g + Simvastatin 40 mg2.2
Sequence 2: MK-0524B 2g/40g2.7

[back to top] [back to top]

Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x Upper Limit of Normal (ULN)

Participants had AST and ALT levels assessed during Period I (4 weeks ) and throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of either AST or ALT that was 3 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT01294683)
Timeframe: Up 20 weeks (12 weeks in Periods I/II and 8 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g0.4
Sequence 2: MK-0524A 2g + Simvastatin 40 mg0.6
Sequence 1: MK-0524A 2g + Simvastatin 40 mg1.3
Sequence 2: MK-0524B 2g/40g0.0

[back to top]

Percentage of Participants Who Experienced at Least 1 AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. (NCT01294683)
Timeframe: up 22 weeks (12 weeks in Periods I/II and 10 weeks in Period III)

InterventionPercentage of Participants (Number)
Sequence 1: MK-0524B 2g/40g50.2
Sequence 2: MK-0524A 2g + Simvastatin 40 mg51.2
Sequence 1: MK-0524A 2g + Simvastatin 40 mg30.4
Sequence 2: MK-0524B 2g/40g29.5

[back to top]

Volume of Distribution (Vz) of Temsirolimus

The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter (Median)
DDI: Day 9DDI: Day 16
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)152189.5
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)244.5233

[back to top]

Volume of Distribution (Vz) of Temsirolimus

The Vz was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)309.7
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)172.9

[back to top]

Maximum Plasma Concentration (Cmax) of Pimasertib

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionnanogram/milliliter (Median)
DDI: Day 1DDI: Day 9
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)185.2131
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)193.5192.1

[back to top]

Maximum Plasma Concentration (Cmax) of Temsirolimus

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8

,
Interventionnanogram/milliliter (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)489.9
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)480.9

[back to top]

Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib

The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf

,
Interventionhour*nanogram/milliliter (Median)
DDI: AUCtau: Day 9DDI: AUC0-inf: Day 1
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)628573.2
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)805828.6

[back to top]

Maximum Plasma Concentration (Cmax) of Temsirolimus

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 8

,
Interventionnanogram/milliliter (Median)
DDI: Day 9DDI: Day 16
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)457.5281.1
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)505.3511.8

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)1.5
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)0.5833

[back to top]

Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus

The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter/hour (Median)
DDI: Day 9DDI: Day 16
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)5.3787.528
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)11.739.292

[back to top]

Number of Subjects With Dose Limiting Toxicities (DLTs)

DLT was defined as any of the following toxicities graded as per National Cancer Institute (NCI) common terminology criteria for adverse events (NCI CTCAE v4.0) encountered within cycle 1 of treatment at any dose level and judged not to be related to the underlying disease or concomitant medications. A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation would expose subjects to unacceptable risk; any Grade >=3 non-hematological toxicity except Grade 3 asymptomatic increases in liver function tests, diarrhea, nausea or vomiting with duration <= 48 hours and alopecia; Grade 4 neutropenia of >5 days duration or febrile neutropenia of >1 day duration; Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia; any treatment interruption >2 weeks due to adverse events; any severe, impairing daily functions or life-threatening, complication or abnormality not defined in NCI-CTCAE that is attributable to the therapy. (NCT01378377)
Timeframe: Up to 21 Days (within Cycle 1)

Interventionsubjects (Number)
Pimasertib 45 mg+Temsirolimus 12.5 mg0
Pimasertib 45 mg+Temsirolimus 25 mg7
Pimasertib 75 mg+Temsirolimus 25 mg2

[back to top]

Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. The TEAEs were those events that occur between first dose of trial treatment and up to 30 days after last dose of the trial treatment that were absent before treatment or that worsened relative to pretreatment state. (NCT01378377)
Timeframe: From the start of the trial treatment until data cut-off date (23 February 2012)

Interventionsubjects (Number)
Pimasertib 45 mg+Temsirolimus 12.5 mg4
Pimasertib 45 mg+Temsirolimus 25 mg23
Pimasertib 75 mg+Temsirolimus 25 mg6

[back to top]

Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib

Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter/hour (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)64.31
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)53.6

[back to top]

Total Body Clearance From Plasma Following Intravenous Administration (CL) of Temsirolimus

The clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter/hour (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)6.284
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)11.39

[back to top]

Apparent Terminal Half-life (t1/2) of Pimasertib

The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)7.746
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)5.712

[back to top]

Apparent Terminal Half-life (t1/2) of Pimasertib

The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
DDI: Day 1DDI: Day 9
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)5.9156.08
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)5.8865.896

[back to top]

Apparent Terminal Half-life (t1/2) of Temsirolimus

The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)29.08
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)10.42

[back to top]

Apparent Terminal Half-life (t1/2) of Temsirolimus

The t1/2 was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
DDI: Day 9DDI: Day 16
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)25.5720.62
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)13.219.14

[back to top]

Apparent Volume of Distribution (Vz/F) of Pimasertib

Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)760.6
Pimasertib 75 mg+Temsirolimus (TEM) 25 mg (Non-DDI)416.5

[back to top]

Apparent Volume of Distribution (Vz/F) of Pimasertib

Volume of distribution (Vz) was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The Vz after oral dose (Vz/F) was influenced by the fraction absorbed. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter (Median)
DDI: Day 1DDI: Day 9
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)691.3517.6
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)536.5519.5

[back to top]

Apparent Clearance From Plasma Following Oral Administration (CL/f) of Pimasertib

Clearance (CL) of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. The CL obtained after oral dose (CL/F) was influenced by the fraction of the dose absorbed (bioavailability). Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionliter/hour (Median)
DDI: Day 1DDI: Day 9
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)81.2571.99
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)54.3655.9

[back to top]

Maximum Plasma Concentration (Cmax) of Pimasertib

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: Drug-drug interaction (DDI) cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionnanogram/milliliter (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)197.6
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)308.1

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 1 and 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
DDI: Day 1DDI: Day 9
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)12.3
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)1.51.133

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)0.5
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)0.55

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Temsirolimus

Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour (Median)
DDI: Day 9DDI: Day 16
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)0.74170.9333
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)0.56670.5

[back to top]

Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) and Area Under the Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Pimasertib

The AUCtau was defined as the area under the concentration curve divided by the dosing interval. AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1 for AUCtau; DDI cohorts: Day 1 of Cycle 1 AUC0-inf

,
Interventionhour*nanogram/milliliter (Median)
Non-DDI: AUCtau: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)706
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)1402

[back to top]

Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus

The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour*nanogram/milliliter (Median)
Non-DDI: Day 8
Pimasertib 45 mg+Temsirolimus 25 mg (Non-DDI)4026
Pimasertib 75 mg+Temsirolimus 25 mg (Non-DDI)2194

[back to top]

Area Under Plasma Concentration Time Curve From Time Zero to Infinity (AUC0-inf) of Temsirolimus

The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. Pharmacokinetic parameters were reported based on DDI and non-DDI cohorts as per plan. (NCT01378377)
Timeframe: DDI cohorts: Days 9 and 16 of Cycle 1; Non-DDI cohorts: Day 8 of Cycle 1

,
Interventionhour*nanogram/milliliter (Median)
DDI: Day 9DDI: Day 16
Pimasertib 45 mg+Temsirolimus 12.5 mg (DDI)24522006
Pimasertib 45 mg+Temsirolimus 25 mg (DDI)21302743

[back to top]

Number of Subjects With Complete Tumor Response (CR), Partial Tumor Response (PR), or Stable Disease (SD)

CR=Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeter (mm). PR=At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD= At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01390818)
Timeframe: From the date of randomisation every 6 weeks up to assessed up to 4 years

,,,,,,,,,,,,,,
Interventionsubjects (Number)
Stable diseaseProgressive diseaseComplete ResponsePartial ResponseNot Evaluable
CRC: Pimasertib 60mg and SAR245409 70mg Once Daily19001
MEL: Pimasertib 60mg and SAR245409 70mg Once Daily74111
NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily106013
Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily30000
Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily21000
Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily20010
Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily31000
Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily20000
Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily21000
Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily10000
Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily11002
Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily49000
Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily02000
Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily63020
TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily78001

[back to top]

pERK Concentrations in PBMCs

"pERK Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily, Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily, Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily and Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily reporting arms." (NCT01390818)
Timeframe: DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); C1D1 and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)

,,,,,,
Interventionfluorescence intensity (Mean)
DDI Day 1: Predose (n= 1, 0, 0, 0, 0, 0, 1)DDI Day 1: 2 hr post-dose (n=1,0,0,0,0.0,1)DDI Day 1: 4 hr post-dose ((n=1,0,0,0,0,0,1)DDI Day 1: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)DDI Day 1: 24 hr post-dose (n=1,0,0,0,0,0,0)DDI Day 2: 24 hr post-dose ((n= 0,0,0,0,0,0,1)DDI Day 3: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1)DDI Day 3: 2 hr post-dose (n=1,0,0,0,0,0,1)DDI Day 3: 4 hr post-dose (n-1,0,0,0,0,0,1)DDI Day 3: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)DDI Day 3: 24 hr post-dose (n=1,0,0,0,0,0,0)DDI Day 4: 24 hr post-dose (n=0,0,0,0,0,0,1)C1D1: Pre dose (n=1,1,1,1,1,1,1)C1D1: 2hr postdose(n= 1,1,1,1,1,1,1)C1D1: 4hr postdose(n= 1,1,1,1,1,1,1)C1D1: 8hr postdose(n= 1,1,1,1,1,1,1)C1D1: 24hr postdose(n= 1,1,1,1,0,0,0)C1D2: 24hr postdose(n= 0,0,0,0,1,1,1)C1D15: pre-dose(n= 1,1,1,1,1,0,1)C1D15: 2hr postdose (n= 1,1,1,1,1,0,1)C1D15: 4hr postdose (n= 1,1,1,1,1,0,1)C1D15: 8hr postdose (n= 1,1,1,1,1,0,1)C1D15: 24hr postdose (n= 1,1,1,1,0,0,0)C1D16: 24hr postdose (n= 0,0,0,0,1,0,1)C1D19: pre-dose (n= 1,1,1,1,1,0,1)C1D19: 2hr postdose (n= 1,0,0,0,0,0,0)
Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily6.778.746.107.4210.84NA9.463.126.740.816.18NA5.562.372.850.676.23NA3.792.161.871.924.97NA6.541.60
Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyNANANANANANANANANANANANA6.962.782.913.404.59NA5.292.832.503.385.33NA4.47NA
Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyNANANANANANANANANANANANA3.451.331.370.942.15NA2.261.341.342.080.94NA2.61NA
Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyNANANANANANANANANANANANA3.251.541.241.966.26NA1.411.600.941.104.70NA5.44NA
Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyNANANANANANANANANANANANA3.351.401.961.27NA3.451.931.551.201.74NA2.362.07NA
Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyNANANANANANANANANANANANA1.970.951.111.12NA1.26NANANANANANANANA
Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily10.5510.176.509.36NA8.328.9415.820.6815.68NA1.067.421.041.010.82NA1.052.030.940.810.99NA0.995.72NA

[back to top]

pS6 Concentrations in Peripheral Blood Mononuclear Cells (PBMCs)

"pS6 Concentrations in PBMCs was measured during DDI Evaluation period and Cycle 1 for DE cohorts. DDI evaluation period is a 4-day period that was performed within 1 week prior to Day 1 Cycle 1. In DDI evaluation period, On Day 1, SAR245409 was be administered alone, and on Day 3, Pimasertib was administered alone. No data were planned to be collected for Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily, Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily, Pimasertib (MSC1936369) 30mg and SAR245409 70mg Once Daily and Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily reporting arms." (NCT01390818)
Timeframe: DDI Evaluation: Day 1 and 3 (predose, 2, 4, 8 and 24 hours (hr) postdose); Day 2 and 4 (24 hr postdose); Cycle 1 Day 1 (C1D1) and C1D15 (predose, 2, 4, 8, 24 hr postdose); C1D2 and C1D16 (24 hr postdose); C1D19 (predose, 2 hr postdose)

,,,,,,
Interventionfluorescence intensity (Mean)
DDI Day 1: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1)DDI Day 1: 2hr post-dose (n= 1,0,0,0,0,0,1)DDI Day 1: 4hr post-dose (n= 1,0,0,0,0,0,1)DDI Day 1: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)DDI Day 1: 24hr post-dose (n= 1,0,0,0,0,0,0)DDI Day 2: 24hr post-dose (n= 0,0,0,0,0,0,1)DDI Day 3: Pre-dose (n= 1, 0, 0, 0, 0, 0, 1)DDI Day 3: 2hr post-dose (n= 1,0,0,0,0,0,1)DDI Day 3: 4hr post-dose (n= 1,0,0,0,0,0,1)DDI: Day 3: 8 hr post-dose(n= 1, 0, 0, 0, 0, 0, 1)DDI:Day 3: 24hr post-dose (n= 1,0,0,0,0,0,0)DDI Day 4: 24hr post-dose (n= 0,0,0,0,0,0,1)C1D1: Pre dose (n= 1,1,1,1,1,1,1)C1D1: 2hr postdose (n= 1,1,1,1,1,1,1)C1D1: 4hr postdose (n= 1,1,1,1,1,1,1)C1D1: 8hr postdose (n= 1,1,1,1,1,1,1)C1D1: 24hr postdose(n= 1,1,1,1,0,0,0)C1D2: 24hr postdose (n= 0,0,0,0,1,1,1)C1D15: pre-dose (n= 1,1,1,1,1,0,1)C1D15: 2hr postdose (n= 1,1,1,1,1,0,1)C1D15: 4hr postdose (n= 1,1,1,1,1,0,1)C1D15: 8hr postdose (n= 1,1,1,1,1,0,1)C1D15: 24hr postdose (n= 1,1,1,1,0,0,0)C1D16: 24hr postdose (n= 0,0,0,0,1,0,1)C1D19: pre-dose (n= 1,1,1,1,1,0,1)C1D19: 2hr postdose (n= 1,0,0,0,0,0,0)
Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily61.0236.1589.1454.5488.80NA57.5155.9336.761.0887.60NA51.3231.0825.713.0246.16NA43.4826.4141.340.5369.93NA68.484.34
Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once DailyNANANANANANANANANANANANA96.9856.4150.1184.5774.15NA67.6948.2392.6777.62114.39NA125.77NA
Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once DailyNANANANANANANANANANANANA83.5224.4846.951.2872.14NA81.2943.7053.3745.970.76NA90.02NA
Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once DailyNANANANANANANANANANANANA47.0923.8929.8519.7553.47NA1.2015.020.9636.0670.46NA82.06NA
Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once DailyNANANANANANANANANANANANA50.175.7218.216.21NA24.6633.4321.1119.6830.08NA24.3630.58NA
Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once DailyNANANANANANANANANANANANA4.180.920.721.18NA1.61NANANANANANANANA
Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily33.7829.8430.2844.88NA28.8614.9034.061.0340.40NA1.0436.031.040.940.96NA1.000.981.061.030.88NA0.9849.62NA

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Pimasertib (MSC1936369B)

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhour (Median)
Day 1 (n= 6, 10, 25, 13, 4, 3, 25, 23, 18, 15 )Day 15 (n= 6, 9, 15, 9, 3, 1, 16, 17, 13, 10)
CRC: Pimasertib 60mg Once Daily1.4901.500
MEL: Pimasertib 60mg Once Daily1.0501.030
NSCLC: Pimasertib 60mg Once Daily1.5201.530
Pimasertib (MSC1936369B) 15mg1.7501.275
Pimasertib (MSC1936369B) 30mg0.7651.000
Pimasertib (MSC1936369B) 45mg Twice Daily1.4852.000
Pimasertib (MSC1936369B) 60mg2.0202.000
Pimasertib (MSC1936369B) 60mg Twice Daily1.550NA
Pimasertib (MSC1936369B) 90mg1.5001.550
TNBC: Pimasertib 60mg Once Daily1.5001.505

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of SAR245409

The time to reach maximum plasma concentration (Tmax) of SAR245409 was calculated. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhours (Median)
Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)
CRC: SAR245409 70mg Once Daily2.0001.750
MEL: SAR245409 70mg Once Daily1.5001.050
NSCLC: SAR245409 70mg Once Daily2.0001.530
SAR245409 30mg1.5101.265
SAR245409 30mg Twice Daily2.050NA
SAR245409 50mg1.1501.750
SAR245409 50mg Twice Daily1.5401.550
SAR245409 70mg1.5001.970
SAR245409 90mg1.500NA
TNBC: SAR245409 70mg Once Daily1.5002.030

[back to top]

Total Body Clearance (CL/f) of Pimasertib (MSC1936369B)

The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the Dose with area under the plasma concentration time curve from time zero to infinity (AUC0 inf)=Dose/AUC0- inf. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionlitre per hour (L/hr) (Geometric Mean)
Day 1 (n=6, 10, 26, 13, 3, 0, 22, 22, 14, 13)Day 15 (n=6, 9, 15, 9, 3, 1, 16, 17, 10, 13)
CRC: Pimasertib 60mg Once Daily30.7530.20
MEL: Pimasertib 60mg Once Daily53.9439.81
NSCLC: Pimasertib 60mg Once Daily32.7531.73
Pimasertib (MSC1936369B) 15mg33.2223.06
Pimasertib (MSC1936369B) 30mg38.9033.30
Pimasertib (MSC1936369B) 45mg Twice Daily89.4958.22
Pimasertib (MSC1936369B) 60mg37.9937.11
Pimasertib (MSC1936369B) 60mg Twice DailyNANA
Pimasertib (MSC1936369B) 90mg40.8835.28
TNBC: Pimasertib 60mg Once Daily32.1228.11

[back to top]

Total Body Clearance (CL/f) of SAR245409

The total body clearance of drug from plasma following oral administration (Cl/f) and the total body clearance of drug from plasma following intravenous administration was calculated by dividing the dose with area under the plasma concentration time curve from time zero to infinity (AUC 0-inf)=Dose/AUC 0-inf. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionlitre per hour (Geometric Mean)
Day 1 (n=5, 9, 31, 2, 1, 3, 20, 17, 12, 12)Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)
CRC: SAR245409 70mg Once Daily55.5151.24
MEL: SAR245409 70mg Once Daily61.2965.16
NSCLC: SAR245409 70mg Once Daily48.4048.69
SAR245409 30mg41.8033.78
SAR245409 30mg Twice DailyNANA
SAR245409 50mg42.9342.81
SAR245409 50mg Twice Daily151.492.90
SAR245409 70mg46.5451.38
SAR245409 90mgNANA
TNBC: SAR245409 70mg Once Daily35.4329.28

[back to top]

Accumulation Ratio (Racc) for AUCtau of Pimasertib (MSC1936369B): Day 15

Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau per Day 1 dosing interval AUCtau. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

Interventionratio (Geometric Mean)
Pimasertib (MSC1936369B) 15mg1.523
Pimasertib (MSC1936369B) 30mg1.269
Pimasertib (MSC1936369B) 60mg1.174
Pimasertib (MSC1936369B) 90mg1.364
Pimasertib (MSC1936369B) 45mg Twice Daily2.176
Pimasertib (MSC1936369B) 60mg Twice DailyNA
TNBC: Pimasertib 60mg Once Daily1.368
NSCLC: Pimasertib 60mg Once Daily1.155
CRC: Pimasertib 60mg Once Daily1.245
MEL: Pimasertib 60mg Once Daily1.283

[back to top]

Accumulation Ratio (Racc) for AUCtau of SAR245409: Day 15

Accumulation ratio (Racc) for AUCtau, calculated as Day 15 dosing interval AUCtau divided by Day 1 dosing interval AUCtau. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

Interventionratio (Geometric Mean)
SAR245409 30mg1.189
SAR245409 50mg1.004
SAR245409 70mg0.9450
SAR245409 90mgNA
SAR245409 30mg Twice DailyNA
SAR245409 50mg Twice Daily1.800
TNBC: SAR245409 70mg Once Daily1.256
NSCLC: SAR245409 70mg Once Daily0.9887
CRC: SAR245409 70mg Once Daily1.187
MEL: SAR245409 70mg Once Daily1.022

[back to top]

Accumulation Ratio (Racc) for Cmax of Pimasertib (MSC1936369B): Day 15

Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax/Day 1 Cmax. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

Interventionratio (Geometric Mean)
Pimasertib (MSC1936369B) 15mg1.525
Pimasertib (MSC1936369B) 30mg1.066
Pimasertib (MSC1936369B) 60mg1.106
Pimasertib (MSC1936369B) 90mg1.308
Pimasertib (MSC1936369B) 45mg Twice Daily1.467
Pimasertib (MSC1936369B) 60mg Twice DailyNA
TNBC: Pimasertib 60mg Once Daily1.203
NSCLC: Pimasertib 60mg Once Daily1.059
CRC: Pimasertib 60mg Once Daily1.247
MEL: Pimasertib 60mg Once Daily1.393

[back to top]

Accumulation Ratio (Racc) for Cmax of SAR245409: Day 15

Accumulation ratio (Racc) for Cmax, calculated as Day 15 Cmax divided by Day 1 Cmax. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

InterventionRatio (Geometric Mean)
SAR245409 30mg1.041
SAR245409 50mg0.8133
SAR245409 70mg0.8962
SAR245409 90mgNA
SAR245409 30mg Twice DailyNA
SAR245409 50mg Twice Daily1.336
TNBC: SAR245409 70mg Once Daily1.070
NSCLC: SAR245409 70mg Once Daily0.8950
CRC: SAR245409 70mg Once Daily0.9611
MEL: SAR245409 70mg Once Daily0.9942

[back to top]

Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (0-inf) of SAR245409: Day 1

"Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method.~Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale." (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts

Interventionhr*ng/mL (Geometric Mean)
SAR245409 30mg716.5
SAR245409 50mg1165
SAR245409 70mg1504
SAR245409 90mgNA
SAR245409 30mg Twice DailyNA
SAR245409 50mg Twice Daily331.2
TNBC: SAR245409 70mg Once Daily1974
NSCLC: SAR245409 70mg Once Daily1445
CRC: SAR245409 70mg Once Daily1261
MEL: SAR245409 70mg Once Daily1142

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-inf) of Pimasertib (MSC1936369B) at Day 1

"Area under the concentration-time curve from time 0 extrapolated to infinity, calculated as AUC0-t + last observed concentration (Clast)/terminal rate constant (λz), using the Linear up/Log down method.~Terminal rate constant (λz)." (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1 for DE cohorts

Interventionhr*ng/mL (Geometric Mean)
Pimasertib (MSC1936369B) 15mg451.6
Pimasertib (MSC1936369B) 30mg770.9
Pimasertib (MSC1936369B) 60mg1607
Pimasertib (MSC1936369B) 90mg2202
Pimasertib (MSC1936369B) 45mg Twice Daily503.1
TNBC: Pimasertib 60mg Once Daily1869
NSCLC: Pimasertib 60mg Once Daily1830
CRC: Pimasertib 60mg Once Daily1857
MEL: Pimasertib 60mg Once Daily1113

[back to top]

Number of Subjects Experiencing Any Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, which did not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were defined as those AEs that started between first dose of study drug and up to 30 days after last dose. (NCT01390818)
Timeframe: Baseline up to 30 Days after last dose; assessed up to 4 years

Interventionsubjects (Number)
Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily3
Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily3
Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily3
Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily4
Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily4
Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily3
Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily19
Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily14
Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily3
Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily3
MSC1936369B (Pimasertib) 45mg and SAR245409 50mg Twice Daily4
TNBC: Pimasertib 60mg and SAR245409 70mg Once Daily26
NSCLC: Pimasertib 60mg and SAR245409 70mg Once Daily24
CRC: Pimasertib 60mg and SAR245409 70mg Once Daily18
MEL: Pimasertib 60mg and SAR245409 70mg Once Daily15

[back to top]

Number of Subjects With Dose Limiting Toxicities (DLT)

DLT was defined as any of the following toxicities experienced during the first cycle of treatment at any dose level (DL) and judged not to be related to the underlying disease or any concomitant medication by the Investigator and/or the Sponsor: A treatment emergent adverse event (TEAE) of potential clinical significance such that further dose escalation (DE) would have exposed subjects to unacceptable risk. Any Grade greater than or equal to (>=) 3 non-hematological toxicity, except for: Grade 3 diarrhea, nausea and vomiting with a duration less than or equal to (<=) 48 hours despite adequate supportive care and Alopecia. Grade 4 neutropenia of > 5 days duration or febrile neutropenia. Grade 3 thrombocytopenia with bleeding or Grade 4 thrombocytopenia. Any treatment interruption > 2 weeks due to AEs not related to the underlying disease or concomitant medication at any dose level and any severe, life-threatening impairing daily functions complication or abnormality. (NCT01390818)
Timeframe: Day 1 up to Day 16 in cycle 1

Interventionsubjects (Number)
Pimasertib (MSC1936369B) 15mg and SAR245409 30mg Once Daily0
Pimasertib (MSC1936369B) 30mg and SAR245409 30mg Once Daily0
Pimasertib (MSC1936369B) 15mg and SAR245409 50mg Once Daily0
Pimasertib (MSC1936369B) 30mg and SAR245409 50mg Once Daily0
Pimasertib (MSC1936369B) 60mg and SAR245409 50mg Once Daily0
Pimasertib (MSC1936369B) 30mg and SAR245409 70mg Once Daily0
Pimasertib (MSC1936369B) 60mg and SAR245409 70mg Once Daily0
Pimasertib (MSC1936369B) 90mg and SAR245409 70mg Once Daily2
Pimasertib (MSC1936369B) 60mg and SAR245409 90mg Once Daily1
Pimasertib (MSC1936369B) 60mg and SAR245409 30mg Twice Daily2
Pimasertib (MSC1936369B) 45mg and SAR245409 50mg Twice Daily1

[back to top]

Apparent Terminal Half-Life (t1/2) of SAR245409

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhour (Median)
Day 1 (n=6, 9, 31, 2, 2, 3, 20, 19, 13, 14)Day 15 (n=6, 8, 22, 1, 1, 2, 10, 15, 8, 10)
CRC: SAR245409 70mg Once Daily4.0706.170
MEL: SAR245409 70mg Once Daily3.1203.065
NSCLC: SAR245409 70mg Once Daily3.3004.050
SAR245409 30mg3.0553.700
SAR245409 30mg Twice DailyNANA
SAR245409 50mg3.3004.570
SAR245409 50mg Twice Daily3.310NA
SAR245409 70mg3.3904.560
SAR245409 90mgNANA
TNBC: SAR245409 70mg Once Daily3.7552.840

[back to top]

Apparent Volume of Distribution of Total Pimasertib During the Terminal Phase Following Oral Administration (Vz/f) of Pimasertib

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale.Data was not available for 'Pimasertib (MSC1936369B) 60mg Twice Daily' arm as no subjects were considered evaluable because of limited number of samples collected to characterize the terminal phase rate constant needed for the calculation of Vz/f. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,
Interventionliter (Geometric Mean)
Day 1 (n=6, 9, 23, 13, 3, 0, 22, 22, 14, 13)Day 15 (n=6, 9, 13, 9, 0, 0, 16, 16, 9, 12)
CRC: Pimasertib 60mg Once Daily216.2230.6
MEL: Pimasertib 60mg Once Daily322.0273.8
NSCLC: Pimasertib 60mg Once Daily226.9250.9
Pimasertib (MSC1936369B) 15mg294.3188.7
Pimasertib (MSC1936369B) 30mg240.2261.8
Pimasertib (MSC1936369B) 45mg Twice Daily394.1NA
Pimasertib (MSC1936369B) 60mg282.8396.4
Pimasertib (MSC1936369B) 90mg283.0302.4
TNBC: Pimasertib 60mg Once Daily223.8226.3

[back to top]

Apparent Volume of Distribution of Total SAR245409 During the Terminal Phase Following Oral Administration (Vz/f)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Apparent volume of distribution during the terminal phase, calculated by CL/f/λz. Terminal rate constant (λz). The regression analysis (determination of λz) was to contain as many data points as possible (but excluding Cmax) and had to include concentration data from at least 3 different time points, consistent with the assessment of a straight line (the terminal elimination phase) on the log-transformed scale. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionlitre (Geometric Mean)
Day 1 (n=5, 9, 31, 2, 1, 3, 20, 17, 12, 12)Day 15 (n=6, 8, 25, 1, 1, 2, 17, 17, 10, 13 )
CRC: SAR245409 70mg Once Daily353.6475.9
MEL: SAR245409 70mg Once Daily270.3293.4
NSCLC: SAR245409 70mg Once Daily251.4247.1
SAR245409 30mg174.8165.7
SAR245409 30mg Twice DailyNANA
SAR245409 50mg223.4257.2
SAR245409 50mg Twice Daily658.0NA
SAR245409 70mg238.5355.9
SAR245409 90mgNANA
TNBC: SAR245409 70mg Once Daily175.2132.8

[back to top]

Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of Pimasertib (MSC1936369B)

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhr*ng/mL (Geometric Mean)
Day 1 (n= 6, 10, 26, 13, 3, 3, 24, 23, 17,13)Day 15 (n=6, 9, 15, 9, 3, 0, 16, 17, 10, 13)
CRC: Pimasertib 60mg Once Daily17721988
MEL: Pimasertib 60mg Once Daily10931506
NSCLC: Pimasertib 60mg Once Daily17541889
Pimasertib (MSC1936369B) 15mg426.8650.4
Pimasertib (MSC1936369B) 30mg742.1902.0
Pimasertib (MSC1936369B) 45mg Twice Daily354.9773.1
Pimasertib (MSC1936369B) 60mg15471617
Pimasertib (MSC1936369B) 60mg Twice Daily1252NA
Pimasertib (MSC1936369B) 90mg21162552
TNBC: Pimasertib 60mg Once Daily18822136

[back to top]

Area Under the Concentration-Time Curve (AUC) During a Dosing Interval (Tau) of SAR245409

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhr*ng/mL (Geometric Mean)
Day 1 (n=6, 11, 36, 3, 3, 3, 24, 23, 17, 15)Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)
CRC: SAR245409 70mg Once Daily15421365
MEL: SAR245409 70mg Once Daily948.41074
NSCLC: SAR245409 70mg Once Daily14801437
SAR245409 30mg746.9887.9
SAR245409 30mg Twice Daily634.0NA
SAR245409 50mg12651168
SAR245409 50mg Twice Daily298.6537.5
SAR245409 70mg16011362
SAR245409 90mg3032NA
TNBC: SAR245409 70mg Once Daily21152390

[back to top]

Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of Pimasertib (MSC1936369B)

Area under the concentration-time curve from time 0 to the last quantifiable concentration. (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhour*nanogram per millilitre (hr*ng/mL) (Geometric Mean)
Day 1 (n=6, 10, 25, 13, 4, 3, 25, 23, 18, 15)Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 10, 13)
CRC: Pimasertib 60mg Once Daily17091988
MEL: Pimasertib 60mg Once Daily10931506
NSCLC: Pimasertib 60mg Once Daily17541889
Pimasertib (MSC1936369B) 15mg426.8625.3
Pimasertib (MSC1936369B) 30mg734.4902.0
Pimasertib (MSC1936369B) 45mg Twice Daily326.1773.1
Pimasertib (MSC1936369B) 60mg15471617
Pimasertib (MSC1936369B) 60mg Twice Daily1252NA
Pimasertib (MSC1936369B) 90mg21162552
TNBC: Pimasertib 60mg Once Daily17812136

[back to top]

Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Last Sampling Time (0-24 Hours) of SAR245409

Area under the plasma concentration-time curve (AUC) from time zero to the last sampling time (0-24 hours) at which the concentration is at or above the lower limit of quantification. Unit of assessment was hour*nanogram per milliliter (hr*ng/mL). (NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhr*ng/mL (Geometric Mean)
Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)Day 15 (n=6, 8, 25, 1, 1, 3, 17, 17, 10, 13)
CRC: SAR245409 70mg Once Daily14791365
MEL: SAR245409 70mg Once Daily854.9968.8
NSCLC: SAR245409 70mg Once Daily14081437
SAR245409 30mg683.6861.0
SAR245409 30mg Twice Daily634.0NA
SAR245409 50mg12481125
SAR245409 50mg Twice Daily226.2537.5
SAR245409 70mg15661334
SAR245409 90mg3032NA
TNBC: SAR245409 70mg Once Daily19762232

[back to top]

Half-Life (t1/2) of MSC1936369B (Pimasertib)

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionhour (Median)
Day 1 (n=6, 9, 23, 13, 4, 3, 22, 22, 15, 13)Day 15 (n=6, 9, 14, 9, 2, 1, 16, 16, 9, 12)
CRC: Pimasertib 60mg Once Daily4.7705.210
MEL: Pimasertib 60mg Once Daily4.2404.325
NSCLC: Pimasertib 60mg Once Daily4.3705.250
Pimasertib (MSC1936369B) 15mg6.2505.855
Pimasertib (MSC1936369B) 30mg4.6705.410
Pimasertib (MSC1936369B) 45mg Twice Daily3.320NA
Pimasertib (MSC1936369B) 60mg4.8406.755
Pimasertib (MSC1936369B) 60mg Twice Daily4.640NA
Pimasertib (MSC1936369B) 90mg4.8005.590
TNBC: Pimasertib 60mg Once Daily4.8405.210

[back to top]

Maximum Observed Plasma Concentration (Cmax) for Pimasertib (MSC1936369B)

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionnanogram/millilitre (ng/mL) (Geometric Mean)
Day 1 (n=6, 10, 26, 13, 4, 3, 25, 23, 18, 15)Day 15 (n=6, 9,15,9, 3, 1, 16, 17, 13, 10)
CRC: Pimasertib 60mg Once Daily245.6307.7
MEL: Pimasertib 60mg Once Daily234.0338.9
NSCLC: Pimasertib 60mg Once Daily295.4327.6
Pimasertib (MSC1936369B) 15mg86.06131.3
Pimasertib (MSC1936369B) 30mg188.2212.8
Pimasertib (MSC1936369B) 45mg Twice Daily83.72143.1
Pimasertib (MSC1936369B) 60mg246.1234.2
Pimasertib (MSC1936369B) 60mg Twice Daily232.5NA
Pimasertib (MSC1936369B) 90mg406.9516.4
TNBC: Pimasertib 60mg Once Daily323.1320.5

[back to top]

Maximum Observed Plasma Concentration (Cmax) for SAR245409

(NCT01390818)
Timeframe: Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts

,,,,,,,,,
Interventionnanogram per millilitre (ng/mL) (Geometric Mean)
Day 1 (n=6, 11, 36, 3, 3, 4, 26, 23, 18, 15)Day 15 (n=6, 6, 25, 1, 1, 3, 17, 17, 10, 13)
CRC: SAR245409 70mg Once Daily239.6178.9
MEL: SAR245409 70mg Once Daily212.5226.6
NSCLC: SAR245409 70mg Once240.6235.5
SAR245409 30mg192.0199.8
SAR245409 30mg Twice Daily130.2NA
SAR245409 50mg295.7224.1
SAR245409 50mg Twice Daily64.22117.2
SAR245409 70mg256.9222.9
SAR245409 90mg224.5NA
TNBC: SAR245409 70mg Once Daily323.6326.0

[back to top]

Apparent Clearance at Steady-state (CLss/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

InterventionL/h (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC13.317.8

[back to top]

Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionng/mL (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC225281

[back to top]

Maximum Observed Concentration (Cmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionng/mL (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC320419

[back to top]

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib of 1 Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionh*ng/mL (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC17611431

[back to top]

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionh*ng/mL (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC22501687

[back to top]

Area Under the Concentration Over Time (AUCt) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionh*ng/mL (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC17541430

[back to top]

Apparent Volume of Distribution at Terminal Phase (Vz/f) Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionliters (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC152187

[back to top]

Apparent Volume of Distribution at Terminal Phase (Vz/f) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionliters (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC297139

[back to top]

Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionhours (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC5.685.46

[back to top]

Number of Subjects Who Experienced Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. TEAEs include both Serious TEAEs and non-serious TEAEs. (NCT01668017)
Timeframe: Baseline up to 30 days post last dose of study drug; assessed maximum up to 39.4 weeks

,,,,
Interventionsubjects (Number)
TEAEsSerious TEAEs
Part 1: Pimasertib 30 mg in HCC52
Part 1: Pimasertib 30 mg in Solid Tumor42
Part 1: Pimasertib 45 mg in HCC20
Part 1: Pimasertib 45 mg in Solid Tumor92
Part 1: Pimasertib 60 mg in Solid Tumor62

[back to top]

Area Under the Concentration Over Time (AUCt) at Cycle 1 Day 1

(NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionh*ng/mL (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor703.0
Part 1: Pimasertib 45 mg in Solid Tumor862.4
Part 1: Pimasertib 60 mg in Solid Tumor1626.9
Part 1: Pimasertib 30 mg in HCC911.4

[back to top]

Apparent Terminal Half-life (t1/2) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionhours (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC15.45.41

[back to top]

Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 30 mg in HCC Arm on Cycle 1 Day 15

The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionhours (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC0.980.95

[back to top]

Apparent Clearance (CL/f) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

InterventionL/h (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC18.523.7

[back to top]

Accumulation Ratio for Cmax Racc(Cmax) of Part 1: Pimasertib 30 mg In HCC Arm

Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax). (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

Interventionratio (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC1.502.31

[back to top]

Accumulation Ratio for AUC Racc(AUC) of Part 1: Pimasertib 30 mg In HCC Arm

Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

Interventionratio (Number)
Subject 1Subject 2
Part 1: Pimasertib 30 mg in HCC2.431.83

[back to top]

Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 15

"Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionhours (Median)
Part 1: Pimasertib 30 mg in Solid Tumor1.805
Part 1: Pimasertib 45 mg in Solid Tumor1.910
Part 1: Pimasertib 60 mg in Solid Tumor2.550

[back to top]

Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 15

"Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionliters (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor105.0
Part 1: Pimasertib 45 mg in Solid Tumor233.9
Part 1: Pimasertib 60 mg in Solid Tumor209.1

[back to top]

Apparent Volume of Distribution at Terminal Phase (Vz/f) of Pimasertib on Cycle 1 Day 1

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionliters (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor231.2
Part 1: Pimasertib 45 mg in Solid Tumor238.1
Part 1: Pimasertib 60 mg in Solid Tumor169.8
Part 1: Pimasertib 30 mg in HCC177.2

[back to top]

Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 15

"The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionhours (Median)
Part 1: Pimasertib 30 mg in Solid Tumor4.235
Part 1: Pimasertib 45 mg in Solid Tumor4.000
Part 1: Pimasertib 60 mg in Solid Tumor5.530

[back to top]

Apparent Terminal Half-life (t1/2) of Pimasertib on Cycle 1 Day 1

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionhours (Median)
Part 1: Pimasertib 30 mg in Solid Tumor3.480
Part 1: Pimasertib 45 mg in Solid Tumor3.545
Part 1: Pimasertib 60 mg in Solid Tumor3.935
Part 1: Pimasertib 30 mg in HCC4.560

[back to top]

Percentage of Subjects With Best Overall Response

Percentage of subjects with best overall response in each category (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]) according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT01668017)
Timeframe: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)

,,,,
Interventionpercentage of subjects (Number)
CRPRSDPDNot evaluable
Part 1: Pimasertib 30 mg in HCC00075.025.0
Part 1: Pimasertib 30 mg in Solid Tumor00066.733.3
Part 1: Pimasertib 45 mg in HCC00050.050.0
Part 1: Pimasertib 45 mg in Solid Tumor042.914.342.90
Part 1: Pimasertib 60 mg in Solid Tumor00075.025.0

[back to top]

Apparent Clearance (CL/f) of Pimasertib on Cycle 1 Day 1

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionliter/hour (L/h) (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor41.67
Part 1: Pimasertib 45 mg in Solid Tumor48.17
Part 1: Pimasertib 60 mg in Solid Tumor32.62
Part 1: Pimasertib 30 mg in HCC32.19

[back to top]

Accumulation Ratio for Cmax Racc(Cmax) of Pimasertib

"Racc (Cmax) was calculated as, maximum observed plasma concentration on Day 1 (Cmax) divided by maximum observed plasma concentration on Day 15 (Cmax). Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

Interventionratio (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor1.227
Part 1: Pimasertib 45 mg in Solid Tumor0.8281
Part 1: Pimasertib 60 mg in Solid Tumor1.215

[back to top]

Accumulation Ratio for AUC Racc(AUC) of Pimasertib

"Racc (AUC) was calculated as, area under the curve from time zero to end of dosing interval on Day 1 divided by area under the curve from time zero to end of dosing interval on Day 15. Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1 and Day 15

Interventionratio (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor1.782
Part 1: Pimasertib 45 mg in Solid Tumor1.382
Part 1: Pimasertib 60 mg in Solid Tumor1.311

[back to top]

Time to Reach Maximum Concentration (Tmax) of Part 1: Pimasertib 45 mg in HCC Arm on Cycle 1 Day 1

The summarized data was not available for this arm therefore individual data was presented. (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionhours (Number)
Subject 1Subject 2
Part 1: Pimasertib 45 mg in HCC1.471.92

[back to top]

Apparent Clearance at Steady-state (CLss/f) of Pimasertib on Cycle 1 Day 15

"Apparent clearance at steady state was reported. Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

InterventionL/h (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor25.24
Part 1: Pimasertib 45 mg in Solid Tumor40.00
Part 1: Pimasertib 60 mg in Solid Tumor28.02

[back to top]

Time to Reach Maximum Concentration (Tmax) on Cycle 1 Day 1

(NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionhours (Median)
Part 1: Pimasertib 30 mg in Solid Tumor2.450
Part 1: Pimasertib 45 mg in Solid Tumor1.480
Part 1: Pimasertib 60 mg in Solid Tumor1.710
Part 1: Pimasertib 30 mg in HCC1.000

[back to top]

Percentage of Subjects With Objective Response

Percentage of subjects with objective response (CR plus PR) according to RECIST Version 1.1 was reported. CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT01668017)
Timeframe: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)

Interventionpercentage of subjects (Number)
Part 1: Pimasertib 30 mg in Solid Tumor0
Part 1: Pimasertib 45 mg in Solid Tumor42.9
Part 1: Pimasertib 60 mg in Solid Tumor0
Part 1: Pimasertib 30 mg in HCC0
Part 1: Pimasertib 45 mg in HCC0

[back to top]

Percentage of Subjects With Disease Control

Percentage of subjects with disease control (CR plus PR plus greater than 12 weeks SD) according to RECIST Version 1.1 was reported CR was defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. (NCT01668017)
Timeframe: Day 1 of Cycle 3 and Day 1 of every alternate until end of treatment (up to a maximum of 35.4 weeks)

Interventionpercentage of subjects (Number)
Part 1: Pimasertib 30 mg in Solid Tumor0
Part 1: Pimasertib 45 mg in Solid Tumor57.1
Part 1: Pimasertib 60 mg in Solid Tumor0
Part 1: Pimasertib 30 mg in HCC0
Part 1: Pimasertib 45 mg in HCC0

[back to top]

Number of Subjects Who Experienced at Least One Dose Limiting Toxicity (DLT)

DLT defined using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0): any of following toxicities possibly/probably related to study drug: Any non-hematological toxicity of Grade 3 or higher (excluding Grade 3 asymptomatic rise in liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT] reversible in 7 days for subjects with solid tumor and without liver involvement, or Grade 4 for subjects with HCC or with liver involvement; Grade 3 or 4 asymptomatic rise in creatinine phosphokinase (CPK) reversible in 7 days, deniable for myocardial infarction and rhabdomyolysis; Grade 3 vomiting/diarrhea encountered without optimal therapy). Any Grade 4 neutropenia >5 days duration, any Grade 3 or above febrile neutropenia. Grade 4 thrombocytopenia >1 day or Grade 3 with bleeding. Any treatment delay >2 weeks due to drug-related adverse effects. (NCT01668017)
Timeframe: During Treatment Cycle 1 (Day 1 to 21)

Interventionsubjects (Number)
Part 1: Pimasertib 30 mg in Solid Tumor0
Part 1: Pimasertib 45 mg in Solid Tumor0
Part 1: Pimasertib 60 mg in Solid Tumor2
Part 1: Pimasertib 30 mg in HCC1
Part 1: Pimasertib 45 mg in HCC1

[back to top]

Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 15

"Data were not reported for Part 1: Pimasertib 45 mg in HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionng/mL (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor199.5
Part 1: Pimasertib 45 mg in Solid Tumor231.6
Part 1: Pimasertib 60 mg in Solid Tumor336.3

[back to top]

Maximum Observed Concentration (Cmax) of Pimasertib on Cycle 1 Day 1

(NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor162.4
Part 1: Pimasertib 45 mg in Solid Tumor222.1
Part 1: Pimasertib 60 mg in Solid Tumor288.3
Part 1: Pimasertib 30 mg in HCC167.6

[back to top]

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 15

"Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). Data were not reported for Part 1: Pimasertib 45 mg In HCC arm as there were no PK samples collected for this arm." (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 15

Interventionh*ng/mL (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor1189.3
Part 1: Pimasertib 45 mg in Solid Tumor1125.0
Part 1: Pimasertib 60 mg in Solid Tumor2140.7

[back to top]

Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-tau) of Pimasertib at Cycle 1 Day 1

Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (12 hours). (NCT01668017)
Timeframe: Cycle 1: Pre-morning dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, hours post dose, pre-evening dose (Hour 12) at Day 1

Interventionh*ng/mL (Geometric Mean)
Part 1: Pimasertib 30 mg in Solid Tumor618.3
Part 1: Pimasertib 45 mg in Solid Tumor857.4
Part 1: Pimasertib 60 mg in Solid Tumor1629.3
Part 1: Pimasertib 30 mg in HCC911.7

[back to top]

Objective Tumor Response

Objective tumor response was defined as the presence of at least one Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to more than (<) 10 millimeter (mm). Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT01936363)
Timeframe: From randomization until disease progression or death assessed every 8 weeks up to week 32, and thereafter every 12 weeks up to 52 months

Interventionpercentage of participants (Number)
Pimasertib (Once Daily) Plus SAR24540912.5
Pimasertib (Twice Daily) Plus SAR245409 Placebo12.1

[back to top]

Overall Survival

Overall survival (OS) was defined as the time (in months) from randomization to death. Data has been presented in terms of number participants who died and number of censored participants. (NCT01936363)
Timeframe: Time from randomization until death, assessed up to 52 months

,
InterventionParticipants (Count of Participants)
Number of deathsNumber for censored
Pimasertib (Once Daily) Plus SAR245409824
Pimasertib (Twice Daily) Plus SAR245409 Placebo627

[back to top]

Percentage of Participants With Disease Control

Disease control as per RECIST v.1.1 was defined as the proportion of participants with stable disease (SD), for at least 16 weeks, PR or CR according to RECIST v1.1 criteria. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters). CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. (NCT01936363)
Timeframe: Randomization until disease progression or death assessed every 8 weeks up to week 32, and thereafter every 12 weeks up to 52 months

Interventionpercentage of participants (Number)
Pimasertib (Once Daily) Plus SAR24540950.0
Pimasertib (Twice Daily) Plus SAR245409 Placebo39.4

[back to top]

Progression-Free Survival

PFS defined as time from randomization to first documentation of objective tumor progression.CR:Disappearance of all target lesions.Any pathological lymph nodes(whether target or non-target)must have reduction in short axis to<10 mm.PR:At least 30% decrease in sum of diameters of target lesions,taking as reference baseline sum diameters.PD:At least a 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study.In addition to relative increase of 20%,the sum also demonstrate absolute increase of at least 5 mm.SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,taking as reference smallest sum diameters while on study. PFS calculated as(Months)=first event date minus randomization or first dose date plus 1.Median PFS was computed using Kaplan-Meier estimates (product-limit estimates) and was presented with 95% confidence interval.The confidence intervals for median was calculated according to Brookmeyer and Crowley. (NCT01936363)
Timeframe: Time from randomization until first observation of progressive disease or death, assessed up to 52 months

Interventionmonths (Median)
Pimasertib (Once Daily) Plus SAR2454099.99
Pimasertib (Twice Daily) Plus SAR245409 Placebo12.71

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation of Treatment and Death

TEAEs, Serious TEAEs and AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0. An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A Serious Adverse Event was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to data cut-off that were absent before treatment or that worsened relative to pretreatment state. (NCT01936363)
Timeframe: First dose of study drug up to 52 months

,
InterventionParticipants (Count of Participants)
TEAESerious TEAETEAE leading to discontinuation of study treatmentDeath
Pimasertib (Once Daily) Plus SAR2454093216162
Pimasertib (Twice Daily) Plus SAR245409 Placebo3218123

[back to top]

Time to Reach Maximum Observed Plasma Concentration (Tmax)

(NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Interventionhour (Median)
Part A: Pimasertib 60 mg Capsule0.750
Part A: Pimasertib 60 mg Tablet0.517

[back to top]

Terminal Rate Constant (λz)

(NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Intervention1/h (Median)
Part A: Pimasertib 60 mg Capsule0.16
Part A: Pimasertib 60 mg Tablet0.15

[back to top]

Part B: Number of Subjects Who Experienced Stable Disease (SD)

SD as per RECIST v1.1 defined as neither shrinkage to qualify for PR nor increase to qualify for progressive disease (PD) taking the smallest sum diameters on study as reference. PR = 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters; PD = 20% increase in sum of diameters of target lesions; the appearance of >=1 new lesions. (NCT01992874)
Timeframe: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

Interventionsubjects (Number)
Part B: Pimasertib Capsule10

[back to top]

Part B: Number of Subjects Who Experienced Progressive Disease (PD)

PD as per RECIST v1.1 defined as 20% increase in sum of diameters of target lesions; the appearance of >=1 new lesions. (NCT01992874)
Timeframe: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

Interventionsubjects (Number)
Part B: Pimasertib Capsule15

[back to top]

Part B: Number of Subjects Who Experienced Partial Response (PR)

PR as per RECIST v1.1 defined as 30% decrease in sum of diameters of target lesions taking as reference the baseline sum diameters. (NCT01992874)
Timeframe: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

Interventionsubjects (Number)
Part B: Pimasertib Capsule1

[back to top]

Part B: Number of Subjects Who Experienced Complete Response (CR)

CR as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 defined as disappearance of all target lesions except lymph nodes (LN); LN must have a decrease in the short axis to less than (<)10 millimeter (mm). (NCT01992874)
Timeframe: Screening to Day 1 of each cycle (21 day in each cycle) until disease progression, intolerable toxicity, withdrawal of consent or death; assessed up to 14 Months

Interventionsubjects (Number)
Part B: Pimasertib Capsule0

[back to top]

Maximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax) was calculated for Part A Pimasertib 60 mg Capsule and tablet. (NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Part A: Pimasertib 60 mg Capsule254.6
Part A: Pimasertib 60 mg Tablet314.1

[back to top]

Area Under the Plasma Concentration-time Curve From Zero to the Last Quantifiable Concentration (AUC 0-t)

Area under the plasma concentration-time curve from time zero to the last sampling time (AUC0-t) at which the concentration was at or above the lower limit of quantification. (NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Interventionhour*nanogram per milliliter (h*ng/mL) (Geometric Mean)
Part A: Pimasertib 60 mg Capsule979.0
Part A: Pimasertib 60 mg Tablet1060.7

[back to top]

Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC0-inf)

(NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Interventionh*ng/mL (Geometric Mean)
Part A: Pimasertib 60 mg Capsule1110.3
Part A: Pimasertib 60 mg Tablet1109.2

[back to top]

Apparent Volume of Distribution (Vz/f)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. (NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

InterventionLiter (Geometric Mean)
Part A: Pimasertib 60 mg Capsule346.454
Part A: Pimasertib 60 mg Tablet334.540

[back to top]

Apparent Total Body Clearance (CL/f)

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Interventionliter per hour (L/h) (Geometric Mean)
Part A: Pimasertib 60 mg Capsule54.041
Part A: Pimasertib 60 mg Tablet54.092

[back to top]

Apparent Terminal Half-life (t1/2)

(NCT01992874)
Timeframe: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 4, 8, and 24 hours post-dose on Day 1 and 3

Interventionhour (Median)
Part A: Pimasertib 60 mg Capsule4.38
Part A: Pimasertib 60 mg Tablet4.47

[back to top]

Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug administration until 30 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pre treatment state. (NCT01992874)
Timeframe: From the first dose of study drug administration until 30 days after the last dose of study drug administration, assessed up to 14 Months

,,
Interventionsubjects (Number)
TEAEsSerious TEAEsTEAEs leading to discontinuation
Part A: Pimasertib 60 mg Capsule1910
Part A: Pimasertib 60 mg Tablet2000
Part B: Pimasertib Capsule381913

[back to top]

Number of Participants With Adverse Events

Specific adverse events were Maternal liver toxicity, defined as > 3x ULN of ALT(Alanine amniotransferase) or AST (Aspartate amniotransferase), maternal report of side effects, and fetal adverse effects. (NCT02213094)
Timeframe: Within 48 hours of dosing

Interventionparticipants (Number)
Nicotinamide 500 mg2
Nicotinamide 1000 mg0

[back to top]

Serum Phosphate (mg/dl)

Change from Baseline to 12 months in serum phosphate level (NCT02258074)
Timeframe: Baseline to 12 months

Interventionmg/dl (Mean)
Lanthanum Carbonate + Nicotinamide0.06
Lanthanum Carbonate + Nicotinamide Placebo0.06
Lanthanum Carbonate Placebo and Nicotinamide0.12
Lanthanum Carbonate Placebo and Nicotinamide Placebo0.12

[back to top]

FGF23

Change from baseline to 12 months in FGF23 level. (NCT02258074)
Timeframe: Baseline to 12 months

Interventionpg/ml (Mean)
Lanthanum Carbonate + Nicotinamide.047
Lanthanum Carbonate + Nicotinamide Placebo-.003
Lanthanum Carbonate Placebo and Nicotinamide.193
Lanthanum Carbonate Placebo and Nicotinamide Placebo.138

[back to top]

Percentage of Participants With Clinically Meaningful Improvement in Brief Pain Inventory (BPI)

The BPI rates the intensity of pain on 4 items (right now, worst, least, and average), and the interference in 7 areas (general activity, mood, walking ability, normal work, relations, sleep, enjoyment of life). Minimum value = 0; maximum value = 10. Higher scores indicate greater symptom severity/worse outcomes. Clinically meaningful improvement in BPI defined as change greater than half of the standard deviation at baseline. (NCT02426086)
Timeframe: Up to end of treatment (approximately up to 2.3 years)

,
Interventionpercentage of participants (Number)
Pain at its Worst: ImprovementPain at its Least: ImprovementPain on the Average: ImprovementPain Right Now: ImprovementRelief Pain Treatments Provided: ImprovementPain Interfered General Activity: ImprovementPain Interfered with Mood: ImprovementPain Interfered Walking Ability: ImprovementPain Interfered with Normal Work: ImprovementPain Interfered with Relations: ImprovementPain Interfered with Sleep: ImprovementPain Interfered Enjoyment of Life: Improvement
Imetelstat 4.7 mg/kg50.044.455.661.150.072.250.038.961.144.461.161.1
Imetelstat 9.4 mg/kg75.851.566.766.753.168.859.478.162.553.178.162.5

[back to top]

Percentage of Participants With Anemia Response Per Modified 2013 IWG-MRT Criteria

"Anemia response per modified 2013 IWG-MRT criteria. Anemia response is defined as participants with baseline Hb <10 g/dL but not meeting strict criteria for transfusion dependency: a ≥ 2 g/dL increase in Hb; Transfusion dependent participants at baseline: becoming transfusion independent. Transfusion independence is defined as absence of any pRBC transfusions for at least 12 rolling weeks. For response categories, benefit must last for >12 weeks to qualify as a response. Participants who achieved CI per modified IWG-MRT criteria considered as response with clinical improvement. Participants who met criteria for anemia response but had worsening cytopenias (and therefore did not meet criteria for clinical improvement) were considered to have a response without clinical improvement. The clinical improvement in IWG-MRT is defined as the achievement of anemia, spleen or symptoms response without progressive disease or increase in severity of anemia, thrombocytopenia, or neutropenia." (NCT02426086)
Timeframe: Every 12 weeks up to Week 48 then every 24 weeks (approximately up to 2.3 years)

,
Interventionpercentage of participants (Number)
Anemia response with CIAnemia response without CI
Imetelstat 4.7 mg/kg4.20
Imetelstat 9.4 mg/kg6.81.7

[back to top]

EuroQol 5 Dimension 5 Level (EQ-5D-5L): Utility Score and Visual Analog Scale (VAS)

EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of two components: a health state profile and VAS. EQ-5D health state profile comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L- VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. (NCT02426086)
Timeframe: At the end of treatment, up to approximately 2.3 years

,
Interventionscore on a scale (Mean)
EQ-5D-5L: Utility ScoreEQ-5D-5L: VAS
Imetelstat 4.7 mg/kg0.49851.28
Imetelstat 9.4 mg/kg0.62647.73

[back to top]

Volume of Distribution (Vd) of Imetelstat

(NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

InterventionL/kg (Mean)
PK: Imetelstat 4.7 mg/kg0.198
PK: Imetelstat 9.4 mg/kg0.190

[back to top]

Total Systemic Clearance (CL) of Imetelstat

(NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

InterventionL/hr/kg (Mean)
PK: Imetelstat 4.7 mg/kg0.0329
PK: Imetelstat 9.4 mg/kg0.0252

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC 0-24) of Imetelstat

(NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

Interventionμg*hr/mL (Mean)
PK: Imetelstat 4.7 mg/kg171
PK: Imetelstat 9.4 mg/kg501

[back to top]

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Imetelstat

(NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

Interventionhr (Median)
PK: Imetelstat 4.7 mg/kg2.00
PK: Imetelstat 9.4 mg/kg2.00

[back to top]

Percentage of Participants With Symptom Response

Symptom response rate is defined as percentage of participants who achieved ≥ 50% reduction in total symptom score (TSS) at Week 24 from baseline as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) version 2.0 diary. The MFSAF assessed following symptoms due to Myelofibrosis (MF): night sweats, itchiness, abdominal discomfort, pain under ribs on left side, feeling of fullness, bone or muscle pain and degree of inactivity. Each item is scored on a scale of 0 (absent) to 10 (worst imaginable) with higher scores indicating more severe symptoms and greater inactivity. The total score ranges from 0-70, where 0 indicates absent/as good as it can be and 70 indicates worst imaginable/as bad as it can be. (NCT02426086)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Imetelstat 4.7 mg/kg6.3
Imetelstat 9.4 mg/kg32.2

[back to top]

Percentage of Participants With Spleen Response

Spleen response rate is defined as the percentage of participants who achieved ≥ 35% reduction in spleen volume at Week 24 from baseline performed by the IRC using magnetic resonance imaging (MRI). (NCT02426086)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Imetelstat 4.7 mg/kg0
Imetelstat 9.4 mg/kg10.2

[back to top]

Percentage of Participants With Overall Response as Per Modified 2013 International Working Group - Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) Criteria

Overall Response Rate: % of participants with complete remission (CR) or partial remission (PR) per modified IWG-MRT.CR: bone marrow: normocellular <5% blasts, ≤Grade 1 fibrosis; immature myeloid cells in peripheral blood (PB):<2%;hemoglobin (Hb):10 g/dL-upper limit of normal (ULN); neutrophils:1*10^9/L-ULN; platelets: 100*10^9/L-ULN; spleen:not palpable and ≤350ml volume; extramedullary hematopoiesis (EMH): no non-hepato-splenic EMH; symptoms: >70% improvement in symptom score per modified MFSAF v2.0 TSS. PR: bone marrow: normocellular: <5% blasts ≤ Grade 1 fibrosis or not meeting bone marrow remission criteria; Immature myeloid cells in PB: <2%; Hb: 8.5 -<10 g/dL-ULN or 10 g/dL-ULN; neutrophils: 1*10^9/L-ULN; platelets: 50 -<100*10^9/L-ULN; spleen: ≥35% splenic volumetric reduction by MRI or not palpable; EMH: no non-hepato-splenic EMH;symptoms: >50% improvement in symptom score per modified MFSAF v2.0 TSS. All response categories, benefit must last >12 weeks to qualify as response. (NCT02426086)
Timeframe: Every 12 weeks up to Week 48 then every 24 weeks (approximately up to 2.3 years)

Interventionpercentage of participants (Number)
Imetelstat 4.7 mg/kg0
Imetelstat 9.4 mg/kg1.7

[back to top]

Percentage of Participants With Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-30 (QLQ-C30): Global Health Status

EORTC QLQ-C30 is a questionnaire to assess quality of life of cancer patients. The EORTC QLQ-C30 included 30 items resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) which are based on 4-point scale (1= Not at all to 4= Very much); and 1 global health status scale based on 7-point scale (1= Very poor to 7= Excellent). All scales and items are averaged, transformed to 0-100 scale; higher score=better level of functioning. Clinically meaningful improvement defined as change greater than half of the standard deviation at baseline in QLQ-C30 Global Health Status. (NCT02426086)
Timeframe: Up to end of the treatment (approximately up to 2.3 years)

Interventionpercentage of participants (Number)
Imetelstat 4.7 mg/kg22.2
Imetelstat 9.4 mg/kg36.4

[back to top]

Percentage of Participants With Clinical Response Per Modified 2013 IWG-MRT

Clinical response rate (CRR) was defined as percentage of participants who achieved CR, PR, or CI per modified 2013 IWG-MRT criteria. CR: bone marrow: normocellular <5% blasts, ≤Grade 1 fibrosis; immature myeloid cells in PB: <2%; Hb: 10 g/dL-ULN; neutrophils: 1*10^9/L-ULN; platelets: 100*10^9/L-ULN; spleen: not palpable and ≤350ml volume; EMH: no non-hepato-splenic EMH; symptoms: >70% improvement in symptom score per modified MFSAF v2.0 TSS. PR: bone marrow: normocellular: <5% blasts ≤ Grade 1 fibrosis or not meeting bone marrow remission criteria; Immature myeloid cells in PB: <2%; Hb: 8.5 -<10 g/dL-ULN or 10 g/dL-ULN; neutrophils: 1*10^9/L-ULN; platelets: 50 -<100*10^9/L-ULN; spleen: ≥35% splenic volumetric reduction by MRI or not palpable; EMH: no non-hepato-splenic EMH; symptoms: >50% improvement in symptom score per modified MFSAF v2.0 TSS. CI: achievement of anemia, spleen or symptoms response without PD or increase in severity of anemia, thrombocytopenia, or neutropenia. (NCT02426086)
Timeframe: Every 12 weeks up to Week 48 then every 24 weeks (approximately up to 2.3 years)

Interventionpercentage of participants (Number)
Imetelstat 4.7 mg/kg16.7
Imetelstat 9.4 mg/kg27.1

[back to top]

Percentage of Participants With Clinical Improvement (CI) Per Modified 2013 IWG-MRT Criteria

CI per the modified 2013 IWG-MRT criteria defined as the achievement of anemia, spleen or symptoms response without progressive disease or increase in severity of anemia, thrombocytopenia, or neutropenia (Increase in severity of anemia constitutes the occurrence of new transfusion dependency or a ≥ 2.0 g/dL decrease in hemoglobin level from pretreatment baseline that lasts for at least 12 weeks. Increase in severity of thrombocytopenia or neutropenia is defined as a 2-grade decline, from pretreatment baseline, in platelet count or ANC, according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. In addition, assignment to CI requires a minimum platelet count of ≥ 25,000*10^9/L and ANC of ≥ 0.5*10^9/L.) For all response categories, benefit must last for >12 weeks to qualify as a response. (NCT02426086)
Timeframe: Every 12 weeks up to Week 48 then every 24 weeks (approximately up to 2.3 years)

Interventionpercentage of participants (Number)
Imetelstat 4.7 mg/kg16.7
Imetelstat 9.4 mg/kg25.4

[back to top]

Patient's Global Impression of Change (PGIC)

The PGIC was used to capture the participant's perspective of improvement or decline in MF symptoms over time. The PGIC had a 7-point response scale ranging from 1 to 7 where, (1=very much improved, 2= somewhat improved, 3= a little improved, 4=no change, 5= a little worse, 6= somewhat worse, 7=very much worse). (NCT02426086)
Timeframe: At the end of treatment, up to approximately 2.3 years

Interventionscore on a scale (Mean)
Imetelstat 4.7 mg/kg4.82
Imetelstat 9.4 mg/kg3.97

[back to top]

Overall Survival

Overall Survival is measured from the date of Cycle 1, Day 1 to the date of the participants death. If the participant's was alive or the vital status was unknown, OS was censored at the date that the participant is last known to be alive. (NCT02426086)
Timeframe: Day 1 of Cycle 1 (each cycle was of 21 days), up to the date of the participant's death (approximately up to 4.1 years)

Interventionmonths (Median)
Imetelstat 4.7 mg/kg19.91
Imetelstat 9.4 mg/kg28.09

[back to top]

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were AEs with onset during or after the first dose of study drug, and within 30 days following the last dose of study drug. (NCT02426086)
Timeframe: Up to end of extension phase (approximately up to 4.2 years)

InterventionParticipants (Count of Participants)
Imetelstat 4.7 mg/kg47
Imetelstat 9.4 mg/kg59

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Imetelstat

(NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

Interventionμg/mL (Mean)
PK: Imetelstat 4.7 mg/kg57.0
PK: Imetelstat 9.4 mg/kg81.9

[back to top]

Elimination Half-Life (t1/2) of Imetelstat

Elimination half-life (t 1/2) is associated with the terminal slope (lambda [z]) of the semi logarithmic drug concentration-time curve, calculated as 0.693/lambda(z). (NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

Interventionhr (Mean)
PK: Imetelstat 4.7 mg/kg4.6
PK: Imetelstat 9.4 mg/kg5.5

[back to top]

Duration of Response (PR/CI/RWCI) as Per IWG-MRT Criteria

Duration of response (PR/CI/RWCI) is the duration from the date of initial documentation of a response to date of first documented evidence of PD or death, whichever occurs first. PR: BM: normocellular: <5% blasts ≤Grade 1 fibrosis/not meeting BM remission criteria; IMC in PB: <2%; Hb: 8.5 -<10 g/dL-ULN or 10 g/dL- ULN; neutrophils: 1*10^9/L-ULN; platelets: 50 -<100*10^9/L-ULN; spleen: ≥35% splenic volumetric reduction by MRI/not palpable; EMH: no non-hepato-splenic EMH; symptoms: >50% improvement in symptom score. CI: achievement of anemia, spleen or symptoms response without PD or increase in severity of anemia, thrombocytopenia, neutropenia. RWCI: Participants who met criteria for response but had worsening cytopenias. PD: Splenomegaly requires MRI showing ≥25% increase in spleen volume. (NCT02426086)
Timeframe: From date of initial documentation of a response to the date of first documented evidence of PD or death, whichever occurs first (approximately up to 2.3 years)

Interventionweeks (Median)
Imetelstat 4.7 mg/kg36.3
Imetelstat 9.4 mg/kg38.3

[back to top]

Area Under the Plasma Concentration-Time Profile From Time Zero to Infinity (AUC0-inf) of Imetelstat

(NCT02426086)
Timeframe: 0 (before start of infusion), 1, 2, 3-5, 6-10, 12-16 and 18-24 hours post dose on Day 1 of Cycle 1 (each cycle was of 21 days)

Interventionμg*h/mL (Mean)
PK: Imetelstat 4.7 mg/kg193
PK: Imetelstat 9.4 mg/kg524

[back to top]

Percentage of Participants With Symptoms Response Per Modified 2013 IWG-MRT Criteria

Symptoms response per modified 2013 IWG-MRT criteria. Symptoms Response: a ≥50% reduction in the modified MFSAF v2.0 TSS. For response category, benefit must last for >12 weeks to qualify as a response. Participants who achieved CI per modified IWG-MRT criteria considered as response with clinical improvement. Participants who met criteria for symptom response but had worsening cytopenias (and therefore did not meet criteria for clinical improvement) were considered to have a response without clinical improvement. The clinical improvement in IWG-MRT is defined as the achievement of anemia, spleen or symptoms response without progressive disease or increase in severity of anemia, thrombocytopenia, or neutropenia. (NCT02426086)
Timeframe: Every 12 weeks up to Week 48 then every 24 weeks (approximately up to 2.3 years)

,
Interventionpercentage of participants (Number)
Symptom response with CISymptom response without CI
Imetelstat 4.7 mg/kg14.64.2
Imetelstat 9.4 mg/kg22.08.5

[back to top]

Percentage of Participants With Spleen Response Per Modified 2013 IWG-MRT Criteria

Spleen response per modified 2013 IWG-MRT criteria. Spleen response: a baseline splenomegaly that is palpable at 5-10 cm, below the left costal margin (LCM), becomes not palpable or a baseline splenomegaly that is palpable at >10 cm, below the LCM, decreases by ≥50%; A spleen response requires confirmation by MRI showing >35% spleen volume reduction (SVR). For response categories, benefit must last for >12 weeks to qualify as a response. Participants who achieved CI per modified IWG-MRT criteria considered as response with clinical improvement. Participants who met criteria for spleen response but had worsening cytopenias (and therefore did not meet criteria for clinical improvement) were considered to have a response without clinical improvement. The clinical improvement in IWG-MRT is defined as the achievement of anemia, spleen or symptoms response without progressive disease or increase in severity of anemia, thrombocytopenia, or neutropenia. (NCT02426086)
Timeframe: Every 12 weeks up to Week 48 then every 24 weeks (approximately up to 2.3 years)

,
Interventionpercentage of participants (Number)
Spleen response with CISpleen response without CI
Imetelstat 4.7 mg/kg02.1
Imetelstat 9.4 mg/kg3.40

[back to top]

Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-43.3
Usual Care-0.3

[back to top]

Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-47.0
Usual Care: Intent to Prescribe Fenofibrate8.7

[back to top]

Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-41.7
Usual Care-7.0

[back to top]

Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum

Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-44.3
Usual Care: Intent to Prescribe Fenofibrate5.4

[back to top]

Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-18.9
Usual Care: Intent to Prescribe Fenofibrate3.9

[back to top]

Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis

Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were included in the imputation model. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-23.7
Usual Care3.7

[back to top]

Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis

LDL-C particle number was calculated from lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-41.6
Usual Care-3.9

[back to top]

Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

LDL-C particle number was calculated from lipid subfractions by NMR spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-45.4
Usual Care: Intent to Prescribe Fenofibrate-2.9

[back to top]

Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W13.5
Usual Care: Intent to Prescribe Fenofibrate12.3

[back to top]

Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W14.5
Usual Care8.2

[back to top]

Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-15.4
Usual Care: Intent to Prescribe Fenofibrate-24.4

[back to top]

Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-27.4
Usual Care-2.8

[back to top]

Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-33.8
Usual Care-1.6

[back to top]

Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-38.9
Usual Care: Intent to Prescribe Fenofibrate-3.8

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis

Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis). (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-37.3
Usual Care-4.7

[back to top]

Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis

Absolute change = FPG value at specified week minus FPG value at baseline. (NCT02642159)
Timeframe: Baseline, Week 12 and 24

,
Interventionmmol/L (Mean)
Change at Week 12Change at Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0.450.68
Usual Care0.210.03

[back to top]

Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis

Absolute change = HbA1c value at specified week minus HbA1c value at baseline. (NCT02642159)
Timeframe: Baseline, Week 12 and 24

,
Interventionmmol/mol (Mean)
Change at Week 12Change at Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0.592.84
Usual Care0.432.40

[back to top]

Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis

Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified week minus baseline value. (NCT02642159)
Timeframe: Baseline, Week 12 and 24

,
InterventionGlucose lowering treatments (Mean)
Change at Week 12Change at Week 24
Alirocumab 75 mg Q2W/Up to 150 mg Q2W0.040.07
Usual Care0.040.04

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-41.7
Usual Care: Intent to Prescribe Fenofibrate-8.5

[back to top]

Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis

Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-13.0
Usual Care-8.8

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-35.5
Usual Care-9.4

[back to top]

Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-30.9
Usual Care: Intent to Prescribe Fenofibrate-5.7

[back to top]

Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 8 to Week 24 regardless of status on- or off-treatment in the intent to prescribe fenofibrate stratum. The usual care here corresponds to fenofibrate. (NCT02642159)
Timeframe: From Baseline to Week 24

InterventionPercent change (Least Squares Mean)
Alirocumab 75 mg Q2W/Up to 150 mg Q2W-34.7
Usual Care: Intent to Prescribe Fenofibrate-7.3

[back to top]

Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast

The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days. (NCT02812238)
Timeframe: 4 weeks

Interventionmg/dL (Mean)
Nicotinamide Riboside582
Placebo794

[back to top]

Percent Change From Baseline in Lipoprotein(a) at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively (with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg4.5
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-26.9
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg1.5
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-25.2
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg2.2
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-7.7
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg0.1
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-7.7

[back to top]

Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg9.7
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg16.5
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg14.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg10.6
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg5.2
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg13.8
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg4.5
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg2.8

[back to top]

Percent Change From Baseline in Fasting Triglyceride at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-0.4
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-4.0
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-7.4
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg14.5
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg19.3
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-3.1
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-32.1
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-7.1

[back to top]

Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

Percent change in calculated LDL-C was defined as 100*(calculated LDL-C value at Week 8 - calculated LDL-C value at baseline)/calculated LDL-C value at baseline. All available baseline and post-baseline calculated LDL-C value during the OLDFI efficacy treatment period & within one of the analysis windows up to Week 8 were used in the model. OLDFI efficacy treatment period was defined as the period from first investigational medicinal product (IMP) injection to last OLDFI IMP injection + 21 days(for Cohorts 1 & 2) or +35 days (for Cohorts 3 & 4). Adjusted Least-squares (LS) mean & standard error (SE) at Week 8 were obtained from mixed-effect model with repeated measures (MMRM) analysis, with fixed categorical effects of alirocumab dose/dose regimen (30 mg Q2W [<50 kg], 40 mg Q2W [<50 kg], 50 mg Q2W [>=50 kg], 75 mg Q2W [>=50 kg], 75 mg Q4W [<50 kg],150 mg Q4W [>=50 kg], 150 mg Q4W [<50 kg] and 300 mg Q4W ([>=50 kg] dose), time point & dose/dose regimen-by-time point interaction. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-41.1
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-7.9
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-40.6
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-49.8
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-17.5
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg4.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-31.9
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-59.8

[back to top]

Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4

Adjusted LS means and standard error at Week 12 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. (NCT02890992)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-29.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-49.2

[back to top]

Percent Change From Baseline in Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg4.4
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg14.8
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg10.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg1.8
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg8.9
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg7.4
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg5.8
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg7.2

[back to top]

Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline value and post-baseline values in at least one of the analysis windows used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-38.4
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-9.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-36.4
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-40.1
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-12.6
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.9
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-27.2
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-51.4

[back to top]

Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-80.1
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-20.8
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-57.1
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-84.4
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-27.2
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg5.3
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-60.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-105.1

[back to top]

Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionratio (Apo B/Apo A-1) (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-0.363
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-0.262
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-0.370
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-0.402
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-0.190
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.086
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-0.282
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-0.473

[back to top]

Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-86.1
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-28.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-62.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-88.5
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-29.5
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.6
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-63.1
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-106.4

[back to top]

Absolute Change From Baseline in Lipoprotein(a) at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventiongram/Liter (g/L) (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg0.003
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-0.021
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg0.007
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-0.025
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg0.023
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.031
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-0.002
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-0.120

[back to top]

Absolute Change From Baseline in HDL-C at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg5.9
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg7.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg5.5
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg4.9
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg2.4
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg5.9
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg2.2
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg1.2

[back to top]

Absolute Change From Baseline in Fasting Triglyceride at Week 8

Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. The robust regression models included the fixed categorical effect of alirocumab dose/dose regimen. A two-step multiple imputation procedure was used to address missing values in the mITT population (in the two steps respectively; with number of imputations = 1000). In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmmol/L (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-0.121
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-0.076
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg0.168
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg0.111
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg0.117
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-0.045
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-0.402
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-0.107

[back to top]

Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8

Absolute change in LDL-C was calculated by subtracting baseline value from Week 8 value. Adjusted LS means and SE were obtained using MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmilligram per deciliter (mg/dL) (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-83.7
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-27.6
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-55.5
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-88.3
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-32.4
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg0.1
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-55.9
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-104.3

[back to top]

Absolute Change From Baseline in Apolipoprotein B at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-51.7
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-18.5
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-35.3
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-53.4
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-15.3
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg-5.4
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-34.2
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-63.5

[back to top]

Absolute Change From Baseline in Apolipoprotein A-1 at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionmg/dL (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg4.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg17.7
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg11.3
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-0.4
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg10.5
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg8.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg7.5
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg11.0

[back to top]

Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8

Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: At Week 8

Interventionpercentage of participants (Number)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg0.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg0.0
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg93.4
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg65.7
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg16.7
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg20.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg66.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg80.0

[back to top]

Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8

Combined estimate for percentage of participants was obtained by averaging out all the imputed percentage of participants reaching the level of interest. A two-step multiple imputation procedure was used to address missing values in the mITT population in the two steps respectively; with number of imputations = 1000. In the first step, the monotone missing pattern was induced in the multiply-imputed data. In the second step, the missing data at subsequent visits were imputed using the regression method for continuous variables. (NCT02890992)
Timeframe: At Week 8

Interventionpercentage of participants (Number)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg100.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg33.3
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg97.6
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg83.0
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg33.3
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg20.0
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg66.7
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg80.0

[back to top]

Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baseline values and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-29.0
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-4.1
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-28.6
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-34.2
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-10.7
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg5.2
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-24.0
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-41.8

[back to top]

Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8

Adjusted LS means and SE at Week 8 were obtained from MMRM analysis, with fixed categorical effects of alirocumab dose/dose regimen, time point and dose/dose regimen-by-time point interaction. All available baselines value and post-baseline values in at least one of the analysis windows up to Week 8 were used in the model. (NCT02890992)
Timeframe: Baseline, Week 8

Interventionpercent change (Least Squares Mean)
Cohort 1 - Alirocumab 30 mg Q2W: <50 kg-39.6
Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg-7.1
Cohort 2 - Alirocumab 40 mg Q2W: <50 kg-39.7
Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg-43.9
Cohort 3 - Alirocumab 75 mg Q4W: <50 kg-14.4
Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg3.2
Cohort 4 - Alirocumab 150 mg Q4W: <50 kg-31.5
Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg-54.6

[back to top]

Change in QTC

Average within-subject change in electrocardiogram QT interval. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionms (Mean)
Nicotinamide6.41
Placebo2.1

[back to top]

Columbia-Suicide Severity Rating Scale

"The Columbia-Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the corresponding assessment period. The scale includes suggested questions to elicit the type of information needed to determine if a suicide-related thought or behavior occurred. The number and proportion of subjects with treatment emergent Suicidal ideation or behavior during the study period of (baseline to week 48) will be reported overall and by study arm. Treatment emergent suicidal ideation or behavior is defined as a yes answer at any time during treatment to any one of the questions in the ten suicidal ideation and behavior categories (Categories 1- 10) on the C-SSRS. Self-injurious behavior without suicidal intent, while assessed on the C-SSRS, does not form part of this outcome." (NCT03061474)
Timeframe: Baseline to 48 weeks

,
Interventionevents (Number)
Baseline Number of abnormal C-SSRS eventsPost-baseline number of abnormal C-SSRS events
Nicotinamide01
Placebo33

[back to top]

QTC Abnormalities

Count of participants experiencing at least one electrocardiogram (ECG) QT interval abnormality. Abnormal defined as above 460 for men and above 470 for women. (NCT03061474)
Timeframe: Baseline to 48 weeks

InterventionParticipants (Count of Participants)
Nicotinamide2
Placebo1

[back to top]

ADASCog-13

ADAS-Cog13 is a structured scale that evaluates memory (immediate and delayed word recall; immediate word recognition), receptive and expressive language, orientation, ideational praxis (preparing a letter for mailing), constructional praxis (copying figures), and attention (number cancellation). Ratings of spoken language, language comprehension, word finding difficulty, and ability to remember test instructions also are obtained. Range: 0-85; higher scores indicate greater impairment. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionscore on a scale (Mean)
Nicotinamide3.2
Placebo5.16

[back to top]

Change in P-tau 231

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher phosphorylated tau (p-tau) is associated with a severity of Alzheimer's disease pathology. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionpg/ml (Mean)
Nicotinamide4.71
Placebo2.28

[back to top]

Vital Signs - Weight

Weight in kg was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

,
Interventionkg (Mean)
Screening VisitBaseline VisitWeek 12 VisitWeek 24 VisitWeek 48 Visit
Nicotinamide76.3976.2977.2776.8876.43
Placebo68.1170.0569.3672.2270.27

[back to top]

ECG Abnormalities

Count of participants experiencing at least one electrocardiogram (ECG) abnormality. (NCT03061474)
Timeframe: Baseline to 48 weeks

InterventionParticipants (Count of Participants)
Nicotinamide24
Placebo20

[back to top]

Vital Signs - Systolic Blood Pressure

Systolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

,
Interventionmm Hg (Mean)
Screening VisitBaseline VisitWeek 12 VisitWeek 24 VisitWeek 48 Visit
Nicotinamide134.67137.42133.36130.4129.43
Placebo126.09125.41128.05130.16129.37

[back to top]

Vital Signs - Pulse

Pulse rate was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

,
Interventionbpm (Mean)
Screening VisitBaseline VisitWeek 12 VisitWeek 24 VisitWeek 48 Visit
Nicotinamide56.4259.3358.8658.659.57
Placebo62.564.9163.4562.2664.84

[back to top]

Vital Signs - Diastolic Blood Pressure

Diastolic blood pressure was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

,
Interventionmm Hg (Mean)
Screening VisitBaseline VisitWeek 12 VisitWeek 24 VisitWeek 48 Visit
Nicotinamide75.4274.2172.4575.271.9
Placebo71.3270.4571.471.469.74

[back to top]

Count of Adverse Events by Severity

Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks). (NCT03061474)
Timeframe: Baseline to 48 weeks

,
Interventionevents (Number)
MildModerateSevereTotal
Nicotinamide4927379
Placebo3831271

[back to top]

Change in Ratio of Total Tau/ab42

Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab42/tau ratio is associated with a higher risk of dementia. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionratio (Mean)
Nicotinamide-0.46
Placebo-0.5

[back to top]

Vital Signs - BMI

Body Mass Index (BMI) was recorded at every study visit (screening, baseline, week 12, week 24, and week 48) (NCT03061474)
Timeframe: Screening through end of study (week 48)

,
Interventionkg/m^2 (Mean)
Screening VisitBaseline VisitWeek 12 VisitWeek 24 VisitWeek 48 Visit
Nicotinamide26.3526.3326.4226.5226.24
Placebo24.0924.8524.7225.0824.68

[back to top]

Change in Total Tau

Change in CSF total tau in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionpg/ml (Mean)
Nicotinamide-8.42
Placebo-60.47

[back to top]

Count of Treatment Emergent Adverse Events

Count of treatment emergent adverse events (TEAEs) over the duration of the study period (baseline to 48 weeks). (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionevents (Number)
Nicotinamide79
Placebo71

[back to top]

Activities of Daily Living - Mild Cognitive Impairment

The ADCS-ADL-MCI is a measure of patient functional performance in Alzheimer's Disease and Mild Cognitive Impairment trials. The informant-based questionnaire assesses conduct of basic and instrumental Activities of Daily Living (ADLs). A total of 24 ADLs are evaluated. Scores range from 0 to 53, with higher scores representing more maintained function. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionscore on a scale (Mean)
Nicotinamide-4.05
Placebo-1.39

[back to top]

CDR Sum of Boxes

CDR-SB is a composite rating of cognition and everyday function which incorporates both informant input and direct assessment of performance. It assesses through semi-structured interview three cognitive domains (memory, orientation, and judgement/problem solving) and three everyday functional domains (community affairs, home and hobbies, personal care). Level of impairment in each of the six domains is rated from none (score=0) to severe (score=3). The six domain scores are then summed to create the CDR-SB. Range 0-18; higher scores indicate greater impairment. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionscore on a scale (Mean)
Nicotinamide0.76
Placebo2.18

[back to top]

Change in ab40

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab40 is associated with a greater probability of fibrillar amyloid burden in the brain. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionpg/ml (Mean)
Nicotinamide2307
Placebo1961.1

[back to top]

Change in Ratio of Total Tau/ab40

Change in ratio of key peptides in cerebrospinal fluid (CSF) from baseline to 48 weeks. A lower ab40/tau ratio is associated with a higher risk of dementia. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionratio (Mean)
Nicotinamide-0.02
Placebo-0.02

[back to top]

Change in ab42

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Lower ab42 is associated with a greater probability of fibrillar amyloid burden in the brain. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionpg/ml (Mean)
Nicotinamide127.74
Placebo113.79

[back to top]

Change in P-tau 181

Change in key peptide in cerebrospinal fluid (CSF) from baseline to 48 weeks. Higher total value is associated with greater severity of Alzheimer's disease pathology. (NCT03061474)
Timeframe: Baseline to 48 weeks

Interventionpg/ml (Mean)
Nicotinamide-0.41
Placebo-10.43

[back to top]

Percentage of Fetuses With Category III Non Stress Test Results

A Non Stress Test is a determination of the current well-being of the fetus, as measured by the fetal heart rate. Category I indicates that the fetus is in a state of well-being and is tolerating the intrauterine environment. Category II indicates a fetal heart rate that is showing some signs of distress. In this instance, obstetric providers will try to improve the intrauterine environment to allow the pregnancy to continue. Category III relates to a fetus whose well-being is compromised - usually requiring rapid intervention, ie expedient delivery. (NCT03419364)
Timeframe: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

Interventionpercentage of fetuses (Number)
Nicotinamide - Pre-eclampsia0

[back to top]

Change in Mean Arterial Blood Pressure (MAP)

Blood pressure (mmHg) will be used to observe the effect of nicotinamide. The highest MAP (defined as the highest MAP within the 24 hour period prior to the administration of study agent) and the highest MAP through 24 hours after study drug administration. (NCT03419364)
Timeframe: Baseline, 48 hours

InterventionmmHg (Mean)
Nicotinamide - Pre-eclampsia0
Nicotinamide - Healthy Pregnant2
Nicotinamide - Healthy Non-Pregnant4

[back to top]

Mean Peak Nicotinamide Level

The mean was calculated for each group using blood samples drawn on Day 1 at 1 hour post 1000 mg nicotinamide administration routinely given at 8 a.m. Peak nicotinamide level expected at 1 hour post dose. (NCT03419364)
Timeframe: at 1 hour post 1000 mg nicotinamide administration on Day 1

Interventionng/mL (Mean)
Nicotinamide - Pre-eclampsia12701.7
Nicotinamide - Healthy Pregnant13279.7
Nicotinamide - Healthy Non-Pregnant16314.1

[back to top]

Mean Trough Concentration Nicotinamide Administration

The mean was calculated for each group for blood samples drawn on Day 1 8 hours post 1000 mg nicotinamide administration routinely given at 8 a.m. Trough nicotinamide level is measured immediately prior to the next dose. (NCT03419364)
Timeframe: 8 hours after the 8 a.m. 1000 mg nicotimamide administration on Day 1

Interventionng/mL (Mean)
Nicotinamide - Pre-eclampsia479.2
Nicotinamide - Healthy Pregnant1490.7
Nicotinamide - Healthy Non-Pregnant1991.2

[back to top]

Number of Participants With Alanine Aminotransferase (ALT) =/> 3x Upper Limit of Normal (ULN)

(NCT03419364)
Timeframe: Within 24 hours of any dose, up to a maximum 4 weeks

InterventionParticipants (Count of Participants)
Nicotinamide - Pre-eclampsia0

[back to top]

Number of Participants With Aspartate Aminotransferase (AST) =/> 3x Upper Limit of Normal (ULN)

(NCT03419364)
Timeframe: Within 24 hours of any dose, up to a maximum 4 weeks

InterventionParticipants (Count of Participants)
Nicotinamide - Pre-eclampsia0

[back to top]

Number of Participants With Maternal Side Effects

Maternal side effects are defined as: facial erythema, hives, sore mouth, dry hair, fatigue, flushing, headache, nausea, and heart burn. (NCT03419364)
Timeframe: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

InterventionParticipants (Count of Participants)
Nicotinamide - Pre-eclampsia0
Nicotinamide - Healthy Pregnant0
Nicotinamide - Healthy Non-Pregnant0

[back to top]

Percentage of Women With Headache Unrelieved by Oral Analgesics

(NCT03419364)
Timeframe: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

Interventionpercentage of participants (Number)
Nicotinamide - Pre-eclampsia33
Nicotinamide - Healthy Pregnant0
Nicotinamide - Healthy Non-Pregnant0

[back to top]

Percentage of Women With Hematocrit Decrease of More Than 3%

(NCT03419364)
Timeframe: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

Interventionpercentage of participants (Number)
Nicotinamide - Pre-eclampsia44

[back to top]

Percentage of Women With Less Than 500 cc Urine Output in 24 Hours

(NCT03419364)
Timeframe: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

Interventionpercentage of participants (Number)
Nicotinamide - Pre-eclampsia0

[back to top]

Percentage of Women Maternal Abdominal Tenderness

(NCT03419364)
Timeframe: From initial administration of study agent until 24 hours post last dose, up to a maximum of 4 weeks

Interventionpercentage of participants (Number)
Nicotinamide - Pre-eclampsia0
Nicotinamide - Healthy Pregnant0
Nicotinamide - Healthy Non-Pregnant0

[back to top]

Exploratory Endpoint: Effect of NR on Change in Left Ventricular Systolic Function

Change in Left Ventricular Ejection Fraction by 3D-Transthoracic Echocardiography (NCT03423342)
Timeframe: Week 12 - Week 0

Interventionpercentage of ejection fraction (Mean)
Nicotinamide Riboside0.0
Placebo0.3

[back to top]

On-Trial Change in Whole Blood NAD+ Levels

Between-group comparison of On-Trial Change in Whole Blood NAD+ Levels (NCT03423342)
Timeframe: Week 12-Week 0

InterventionuM (Mean)
Nicotinamide Riboside29.0
Placebo-0.3

[back to top] [back to top]

Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

Adverse Events (NCT03423342)
Timeframe: up to 12 weeks

Interventionevents/participant (Mean)
Nicotinamide Riboside3.1
Placebo3.2

[back to top]

Exploratory Endpoint: Effect of NR on Left Ventricular Diastolic Function

Tissue Doppler Imaging, e' (NCT03423342)
Timeframe: Week 12 - Week 0

Interventioncm/sec (Mean)
Nicotinamide Riboside0.37
Placebo-0.44

[back to top]

Exploratory Endpoint: Effect of NR on Functional Capacity

Change in Six Minute Walk Distance (NCT03423342)
Timeframe: Week 12 - Week 0

Interventionmeters (Mean)
Nicotinamide Riboside6
Placebo1

[back to top]

Effect of NR on Change in Mitochondrial Function (Maximal Oxygen Consumption Rate)

Mitochondrial Respiration in Isolated Peripheral Blood Mononuclear Cells by the Seahorse (R) Assay (NCT03423342)
Timeframe: Week 12 - Week 0

Interventionpmol/min/1,000,000 cells (Mean)
Nicotinamide Riboside21
Placebo2

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis

Adjusted least square (LS) means and standard errors were obtained from the mixed model analysis with repeated measures (MMRM) to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). (NCT03510715)
Timeframe: Baseline to Week 12

Interventionpercent change (Least Squares Mean)
Alirocumab-4.1

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline on-treatment data from Week 4 to Week 48 (on-treatment Analysis). (NCT03510715)
Timeframe: Baseline to Week 12

Interventionpercent change (Least Squares Mean)
Alirocumab-4.1

[back to top]

Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionmg/dL (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-33.4-43.0-15.0

[back to top]

Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48

Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males), and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty). (NCT03510715)
Timeframe: Baseline, Weeks 12, 24 and 48

,
InterventionParticipants (Count of Participants)
Baseline: PrepubescentBaseline: PubescentBaseline: Post-pubescentWeek 12: PrepubescentWeek 12: PubescentWeek 12: Post-pubescentWeek 24: PrepubescentWeek 24: PubescentWeek 24: Post-pubescentWeek 48: PrepubescentWeek 48: PubescentWeek 48: Post-pubescent
Alirocumab 150 mg Q2W090081081072
Alirocumab 75 mg Q2W/up to 150 mg Q2W360360260170

[back to top]

Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-4.2-11.80.9

[back to top]

Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab11.314.611.3

[back to top]

Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Mean)
Week 12Week 24Week 48
Alirocumab2.85.210.0

[back to top]

Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on-or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Mean)
Week 12Week 24Week 48
Alirocumab7.4-5.2-6.4

[back to top]

Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 24 and 48

Interventionpercent change (Least Squares Mean)
Week 24Week 48
Alirocumab-10.14.2

[back to top]

Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-3.9-9.25.7

[back to top]

Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab-1.9-6.35.5

[back to top]

Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted Percentage were obtained from a multiple imputation approach for handling of missing data including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercentage of participants (Number)
Week 12Week 24Week 48
Alirocumab50.050.039.0

[back to top]

Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis

Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided. (NCT03510715)
Timeframe: Baseline to Weeks 12, 24 and 48

Interventionpercent change (Least Squares Mean)
Week 12Week 24Week 48
Alirocumab13.08.910.1

[back to top]

DB Period: Percent Change From Baseline in Total Cholesterol at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-25.3-23.4
DB Period: Alirocumab Q4W-27.0-27.7
DB Period: Placebo Q2W7.57.4
DB Period: Placebo Q4W0.9-4.4

[back to top]

DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-33.0-31.0
Db Period: Alirocumab Q4W-34.7-35.6
DB Period: Placebo Q2W9.89.7
DB Period: Placebo Q4W2.8-3.7

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-0.1
DB Period: Alirocumab Q2W1.0
DB Period: Placebo Q4W-4.5
DB Period: Alirocumab Q4W4.4

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein A1 at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-0.1
DB Period: Alirocumab Q2W-1.7
DB Period: Placebo Q4W-0.7
DB Period: Alirocumab Q4W5.0

[back to top]

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Weeks 12, and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st investigational medicinal product (IMP) injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-34.8-33.6
DB Period: Alirocumab Q4W-39.2-38.2
DB Period: Placebo Q2W10.79.7
DB Period: Placebo Q4W2.3-4.4

[back to top]

DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W25.221.6
DB Period: Alirocumab Q4W31.932.4
DB Period: Placebo Q2W0.00.0
DB Period: Placebo Q4W0.19.1

[back to top]

Number of Participants With Tanner Staging at Baseline and Weeks 24, 68 and 104

Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males) and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty). (NCT03510884)
Timeframe: Baseline, Weeks 24, 68 and 104

,,,
InterventionParticipants (Count of Participants)
Baseline: Boys - PrepubescentBaseline: Boys - PubescentBaseline: Boys - PostpubescentBaseline: Girls - PrepubescentBaseline: Girls - PubescentBaseline: Girls - PostpubescentWeek 24: Boys - PrepubescentWeek 24: Boys - PubescentWeek 24: Boys - PostpubescentWeek 24: Girls - PrepubescentWeek 24: Girls - PubescentWeek 24: Girls - PostpubescentWeek 68: Boys - PrepubescentWeek 68: Boys - PubescentWeek 68: Boys - PostpubescentWeek 68: Girls - PrepubescentWeek 68: Girls - PubescentWeek 68: Girls - PostpubescentWeek 104: Boys - PrepubescentWeek 104: Boys - PubescentWeek 104: Boys - PostpubescentWeek 104: Girls - PrepubescentWeek 104: Girls - PubescentWeek 104: Girls - Postpubescent
Alirocumab Q2W41324161031134159196314918601011
Alirocumab Q4W01447131401252169096116908711711
Placebo/Alirocumab Q2W11331610134152074061067042
Placebo/Alirocumab Q4W543186173165153155152155

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 130 mg/dL (3.37 mmol/L) at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W70.673.3
DB Period: Alirocumab Q4W72.676.3
DB Period: Placebo Q2W16.48.0
Db Period: Placebo Q4W12.922.2

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 110 mg/dL (2.84 mmol/L) at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W61.757.2
DB Period: Alirocumab Q4W57.067.2
DB Period: Placebo Q2W0.14.0
DB Period: Placebo Q4W4.39.0

[back to top]

DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W25.221.6
DB Period: Alirocumab Q4W31.932.4
DB Period: Placebo Q2W0.00.0
DB Period: Placebo Q4W0.19.1

[back to top]

DB Period: Percentage of Participants Who Achieved at Least 30 Percent (%) Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week12Week 24
DB Period: Alirocumab Q2W65.866.7
DB Period: Alirocumab Q4W70.872.5
DB Period: Placebo Q2W0.84.0
DB Period: Placebo Q4W4.218.5

[back to top]

DB Period: Percentage of Participants Achieved at Least 30% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand

Adjusted percentages at Weeks 12 and 24 were obtained from multiple imputation approach for handling of missing data followed by logistic regression model. All available post-baseline on-treatment data up to Week 12 and Week 24 were included in the imputation model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: At Weeks 12 and 24

,,,
Interventionpercentage of participants (Number)
Week 12Week 24
DB Period: Alirocumab Q2W65.866.7
DB Period: Alirocumab Q4W70.872.5
DB Period: Placebo Q2W0.84.0
DB Period: Placebo Q4W4.218.5

[back to top]

DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-2.2
DB Period: Alirocumab Q2W3.5
DB Period: Placebo Q4W-3.5
DB Period: Alirocumab Q4W4.0

[back to top]

DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W-0.8
DB Period: Alirocumab Q2W5.6
DB Period: Placebo Q4W-1.1
DB Period: Alirocumab Q4W3.4

[back to top]

DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 24. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Mean)
DB Period: Placebo Q2W7.7
DB Period: Alirocumab Q2W11.9
DB Period: Placebo Q4W12.2
DB Period: Alirocumab Q4W-6.8

[back to top]

DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 12. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Mean)
DB Period: Placebo Q2W6.5
DB Period: Alirocumab Q2W-2.2
DB Period: Placebo Q4W7.8
Db Period: Alirocumab Q4W-0.3

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W8.9
DB Period: Alirocumab Q2W-30.0
DB Period: Placebo Q4W1.1
DB Period: Alirocumab Q4W-31.7

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W10.4
DB Period: Alirocumab Q2W-27.4
DB Period: Placebo Q4W-3.6
DB Period: Alirocumab Q4W-34.3

[back to top]

DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 8, Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. (NCT03510884)
Timeframe: Baseline to Weeks 8, 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 8Week 12Week 24
DB Period: Alirocumab Q2W-35.4-34.8-33.6
DB Period: Alirocumab Q4W-42.0-39.2-38.2
DB Period: Placebo Q2W7.110.79.7
DB Period: Placebo Q4W-3.82.3-4.4

[back to top]

DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 8, Week 12 and Week 24 were used and missing data were accounted for by the MMRM model. (NCT03510884)
Timeframe: Baseline to Weeks 8, 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 8Week 12Week 24
DB Period: Alirocumab Q2W-35.4-34.8-33.6
DB Period: Alirocumab Q4W-42.0-39.2-38.2
DB Period: Placebo Q2W7.110.79.7
DB Period: Placebo Q4W-3.82.3-4.4

[back to top]

DB Period: Percent Change From Baseline in Lipoprotein (a) at Weeks 12 and 24: On-treatment Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline on-treatment data up to Week 12 and Week 24, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-12.746-14.748
DB Period: Alirocumab Q4W-16.042-22.418
DB Period: Placebo Q2W-7.0990.492
DB Period: Placebo Q4W-2.5452.468

[back to top]

DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 day otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W3.55.6
DB Period: Alirocumab Q4W4.03.4
DB Period: Placebo Q2W-2.2-0.8
DB Period: Placebo Q4W-3.5-1.1

[back to top]

DB Period: Percent Change From Baseline in Fasting Triglycerides at Weeks 12 and 24: On-treatment Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline on-treatment data up to Week 12 and Week 24, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for those who stopped IMP before switch to Q2W regimen, + 21 days otherwise. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionpercent change (Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-2.211.9
DB Period: Alirocumab Q4W-0.3-6.8
DB Period: Placebo Q2W6.57.7
DB Period: Placebo Q4W7.812.2

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein B at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-30.0-27.4
DB Period: Alirocumab Q4W-31.7-34.3
DB Period: Placebo Q2W8.910.4
DB Period: Placebo Q4W1.1-3.6

[back to top]

DB Period: Percent Change From Baseline in Apolipoprotein A1 at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM mode, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12 and 24

,,,
Interventionpercent change (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-1.71.0
DB Period: Alirocumab Q4W5.04.4
DB Period: Placebo Q2W-0.1-0.1
DB Period: Placebo Q4W-0.7-4.5

[back to top]

DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response

Anti-drug (alirocumab) antibodies samples were analyzed using a validated non-quantitative, titer-based bridging immunoassay. Number of participants with positive ADA during 24-week treatment period is reported. Treatment-emergent positive ADA response was defined as 1) participants with no ADA positive response at baseline but with any positive response in the post-baseline period or 2) participants with a positive ADA response at baseline and at least a 4- fold increase in titer in the post-baseline period. A persistent positive response was defined as a TE ADA positive response detected in at least 2 consecutive post-baseline samples separated by at least a 12-week period. Persistent positive response was only analyzed for participants with positive TE ADA response. (NCT03510884)
Timeframe: Up to 24 weeks

InterventionParticipants (Count of Participants)
TE ADA positive responsePersistent positive response
DB Period: Alirocumab Q2W30

[back to top]

DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response

Anti-drug (alirocumab) antibodies samples were analyzed using a validated non-quantitative, titer-based bridging immunoassay. Number of participants with positive ADA during 24-week treatment period is reported. Treatment-emergent positive ADA response was defined as 1) participants with no ADA positive response at baseline but with any positive response in the post-baseline period or 2) participants with a positive ADA response at baseline and at least a 4- fold increase in titer in the post-baseline period. A persistent positive response was defined as a TE ADA positive response detected in at least 2 consecutive post-baseline samples separated by at least a 12-week period. Persistent positive response was only analyzed for participants with positive TE ADA response. (NCT03510884)
Timeframe: Up to 24 weeks

,,
InterventionParticipants (Count of Participants)
TE ADA positive response
DB Period: Alirocumab Q4W0
DB Period: Placebo Q2W0
DB Period: Placebo Q4W0

[back to top]

DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: On-treatment Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline on-treatment data available up to Week 12 and Week 24 were used for the MMRM model, i.e., for Q2W data: from 1st IMP injection up to last IMP injection + 21 days and for Q4W data: from 1st IMP injection up to last IMP injection + 35 days for who stopped IMP before switch to Q2W regimen, + 21 days otherwise. MMRM model was run on participants with a Baseline value and at one on-treatment post-baseline value for a timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionratio (Apo B/Apo A-1) (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-0.2-0.2
DB Period: Alirocumab Q4W-0.3-0.3
DB Period: Placebo Q2W0.10.1
DB Period: Placebo Q4W0.00.0

[back to top]

DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model. All post-baseline data available up to Week 12 and Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Weeks 12, and 24

,,,
Interventionratio (Apo B/Apo A-1) (Least Squares Mean)
Week 12Week 24
DB Period: Alirocumab Q2W-0.2-0.2
DB Period: Alirocumab Q4W-0.3-0.3
DB Period: Placebo Q2W0.10.1
DB Period: Placebo Q4W0.00.0

[back to top]

Change From Baseline in Cogstate Battery Test - Overall Composite Score at Weeks 24, 68 and 104

Cogstate battery test (cognitive testing system) consisted of detection test (DET), identification test (IDN), one card learning test (OCL) and Groton maze learning test (GML) to assess processing speed, attention, visual learning and executive functioning, respectively. For each test, Z-scores were computed based on participant's age at Baseline and Weeks 24, 68 and 104. Composite score: calculated as mean of Z-scores equally weighted, provided that at least 3 of 4 tests were available and if all of these domains were covered as: attention, through either DET or IDN, visual learning, through OCL and executive function, through GML. There is not minimum/maximum since values were reported as z-score but z-score of 0 means result equals to mean with negative numbers indicating values lower than mean and positive values higher. Positive change in z-score = an improvement in cognition, i.e., a better outcome; and negative change in z-score = worsening in cognition, i.e., a worse outcome. (NCT03510884)
Timeframe: Baseline, Weeks 24, 68 and 104

,,,
InterventionZ-score (Mean)
Week 24Week 68Week 104
Alirocumab Q2W-0.313-0.334-0.439
Alirocumab Q4W-0.136-0.263-0.638
Placebo/Alirocumab Q2W-0.403-0.421-0.601
Placebo/Alirocumab Q4W-0.218-0.272-0.393

[back to top]

OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: On-treatment Estimand

Percent Change in LDL-C from Baseline to Week 104 was reported in this outcome measure. (NCT03510884)
Timeframe: Baseline, Week 104

Interventionpercent change (Least Squares Mean)
OL Period: Placebo/Alirocumab Q2W-22.8
OL Period: Alirocumab Q2W-25.8
OL Period: Placebo/Alirocumab Q4W-27.6
OL Period: Alirocumab Q4W-23.4

[back to top]

OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: ITT Estimand

Percent Change in LDL-C from Baseline to Week 104 was reported in this outcome measure. (NCT03510884)
Timeframe: Baseline, Week 104

Interventionpercent change (Least Squares Mean)
OL Period: Placebo/Alirocumab Q2W-23.3
OL Period: Alirocumab Q2W-22.2
OL Period: Placebo/Alirocumab Q4W-27.1
OL Period: Alirocumab Q4W-23.7

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level Lower Than (<) 130 mg/dL (3.37 mmol/L) at Week 24: ITT Estimand

Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data up to Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Week 24

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W8.0
DB Period: Alirocumab Q2W73.3
DB Period: Placebo Q4W22.2
DB Period: Alirocumab Q4W76.3

[back to top]

DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level <130 mg/dL (3.37 mmol/L) at Week 12: ITT Estimand

Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data up to Week 12 were included in the imputation model. (NCT03510884)
Timeframe: At Week 12

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W16.4
DB Period: Alirocumab Q2W70.6
DB Period: Placebo Q4W12.9
DB Period: Alirocumab Q4W72.6

[back to top]

DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 24: ITT Estimand

Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data up to Week 24 were included in the imputation model. (NCT03510884)
Timeframe: At Week 24

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W4.0
DB Period: Alirocumab Q2W57.2
DB Period: Placebo Q4W9.0
DB Period: Alirocumab Q4W67.2

[back to top]

DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 12: ITT Estimand

Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data for Q4W. All available post-baseline data up to Week 12 were included in the imputation model. For Q2W, adjusted percentages at Week 12 were obtained from last observation carried forward approach (LOCF) to handle missing on-treatment LDL-C values as well as missing post-treatment LDL-C values in participants who discontinued treatment due to the coronavirus disease-2019 pandemic. Other post-treatment missing values were considered as failure. (NCT03510884)
Timeframe: At Week 12

Interventionpercentage of participants (Number)
DB Period: Placebo Q2W0.0
DB Period: Alirocumab Q2W61.2
DB Period: Placebo Q4W4.3
DB Period: Alirocumab Q4W57.0

[back to top]

DB Period: Percent Change From Baseline in Total Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W7.5
DB Period: Alirocumab Q2W-25.3
DB Period: Placebo Q4W0.9
DB Period: Alirocumab Q4W-27.0

[back to top]

DB Period: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W7.4
DB Period: Alirocumab Q2W-23.4
DB Period: Placebo Q4W-4.4
DB Period: Alirocumab Q4W-27.7

[back to top]

DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W9.8
DB Period: Alirocumab Q2W-33.0
DB Period: Placebo Q4W2.8
DB Period: Alirocumab Q4W-34.7

[back to top]

DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W9.7
DB Period: Alirocumab Q2W-31.0
DB Period: Placebo Q4W-3.7
DB Period: Alirocumab Q4W-35.6

[back to top]

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12: ITT Estimand

Adjusted LS means and SE were obtained from MMRM model including all available post-baseline data. All post-baseline data available up to Week 12 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W10.7
DB Period: Alirocumab Q2W-34.8
DB Period: Placebo Q4W2.3
DB Period: Alirocumab Q4W-39.2

[back to top]

DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand

Adjusted least square (LS) means and standard errors (SE) were obtained from mixed-effect model with repeated measures (MMRM) model. All post-baseline data available up to Week 24 were used and missing data were accounted for by the MMRM model. MMRM model was run on participants with a Baseline value and a post-baseline value for at least one timepoint used in the model. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Least Squares Mean)
DB Period: Placebo Q2W9.7
DB Period: Alirocumab Q2W-33.6
DB Period: Placebo Q4W-4.4
DB Period: Alirocumab Q4W-38.2

[back to top]

DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 24: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 24. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 24

Interventionpercent change (Mean)
DB Period: Placebo Q2W0.5
DB Period: Alirocumab Q2W-14.7
DB Period: Placebo Q4W2.5
DB Period: Alirocumab Q4W-22.4

[back to top]

DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Estimand

Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data up to Week 12. Combined estimates and SE were obtained by combining adjusted means and SE from robust regression model analyses of the different imputed data sets. (NCT03510884)
Timeframe: Baseline, Week 12

Interventionpercent change (Mean)
DB Period: Placebo Q2W-7.1
DB Period: Alirocumab Q2W-12.7
DB Period: Placebo Q4W-2.5
DB Period: Alirocumab Q4W-16.0

[back to top]

Maximal Aerobic Capacity- CoQ10

The maximal aerobic capacity (oxygen uptake mL/min/kg body weight) during cycle ergometry at the end of each treatment period. (NCT03579693)
Timeframe: 6 weeks

InterventionmL/min/kg (Mean)
CoQ1021.4
Nicotinamide Riboside20.7
Placebo20.7

[back to top]

Work Efficiency

The work efficiency (oxygen uptake mL/min/kg body weight at a specified constant of 60 watts work rate for 3 minutes) during cycle ergometry at the end of each treatment period. This is reported as the work performed at 60 watts divided by the energy expended at 0 watts times 100, and reported on the percent scale.. (NCT03579693)
Timeframe: 6 weeks

InterventionPercent difference (Mean)
CoQ1033.3
Nicotinamide Riboside32.5
Placebo33.1

[back to top]

Plasma Concentration of Paclitaxel After NIAGEN Treatment Began

Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks

Interventionng/ml (Median)
NIAGEN®)810

[back to top]

Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE

"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks

InterventionParticipants (Count of Participants)
NIAGEN®)3

[back to top]

Number of Dose Reduction Events

Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks

Interventionevent (Number)
NIAGEN®)0

[back to top]

Total Dose of Paclitaxel Administered

Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks

Interventionmg/M^2 (Number)
NIAGEN®)200

[back to top]

Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .

Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks

Interventionunits on a scale (Median)
NIAGEN®)7

[back to top]

Difference in Total Neuropathy Score Between Screening and End of Treatment

Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks

Interventionscore on a scale (Median)
NIAGEN®)2

[back to top]

Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN

Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks

InterventionParticipants (Count of Participants)
NIAGEN®)0

[back to top]

Change in Time of CPET Time as a Measure of Exercise Tolerance From Baseline to 12 Weeks of NR Supplementation.

Measure change in time of cardiopulmonary exercise test (CPET) to determine exercise tolerance from baseline to 12 weeks of NR supplementation. (NCT03789175)
Timeframe: Baseline to 12 weeks

InterventionMinutes (Number)
Baseline CPET Exercise Endurance Time12.1
Nicotinamide Riboside (NR) in Li-Fraumeni Syndrome11.68

[back to top]

Change in PCr Recovery Tc Measurement From Baseline to 12 Week NR Supplementation Using the 31P-MRS Skeletal Muscle Submaximal Exercise.

"The effect of nicotinamide riboside (NR) supplementation on the phosphocreatine (PCr) recovery time constant (Tc) of skeletal muscle after exercise as a marker of mitochondrial oxidative phosphorylation capacity.~The phosphocreatine level will be measured using 31P-magnetic resonance spectroscopy (MRS) during the following sequence of 3-minute rest, 2-minute exercise, and 6-minute recovery periods. The 31P spectra will be obtained during these periods and analyzed with the use of SAGE 7 (GE Healthcare) and IDL, version 6.4 (Exelis Visual Information Solutions), software. The single exponential recovery time constant (Tc) is calculated from the post-exercise recovery period data." (NCT03789175)
Timeframe: Baseline to 12 weeks

InterventionSeconds (Number)
Baseline Phosphocreatine (PCr) Recovery Tc Measurement60
Nicotinamide Riboside (NR) in Li-Fraumeni Syndrome73

[back to top]

Mean Change in the TH17 Cell Cytokine IL-17 Secretion in Response to T-cell Differentiation

Mean change in the TH17 cell cytokine IL-17 secretion in response to T-cell differentiation comparing the baseline versus NR or placebo. (NCT04271735)
Timeframe: Baseline and Day 28

Interventionpg/mL (Mean)
Participants With Mild to Moderate Psoriasis Receiving Nicotinamide Riboside-176.9
Participants With Mild to Moderate Psoriasis Receiving Placebo-7.2

[back to top]

Change in Area Under the Curve (AUC)

To determine the effect of NR on changes in AUC serum creatinine from baseline during the 10-day intervention (NCT04818216)
Timeframe: Baseline to 10 days

Interventionmg/dL x day (Median)
Placebo Group17.1
Nicotinamide Riboside Group17.9

[back to top]

Change in Whole Blood NAD+ Level

Measure of NAD+ level in whole blood from treatment beginning to end (NCT04818216)
Timeframe: Baseline to 10 days

Interventionμg/mL (Mean)
Placebo Group-0.02
Nicotinamide Riboside Group0.06

[back to top]

Effect of NR on Major Adverse Kidney Events (MAKE)

Number of occurrences of MAKE defined as doubling of serum creatinine, the initiation of long-term dialysis, or death from any cause. (NCT04818216)
Timeframe: 30 days to 90 days

InterventionNumber of MAKE events (Number)
Placebo Group6
Nicotinamide Riboside Group12

[back to top]

Number of Participants With Adverse Events of Grade 3 or Higher

Safety of NR in hospitalized patients with COVID-19 and AKI (defined as adverse event of Grade 3 or higher). Not every grade 3 event was considered to be serious. (NCT04818216)
Timeframe: Baseline to 10 days

Interventionparticipants (Number)
Placebo Group8
Nicotinamide Riboside Group12

[back to top]

Occurrence of Thrombocytopenia

Number occurrences of thrombocytopenia defined as >25% decline in blood platelet count from baseline. (NCT04818216)
Timeframe: Baseline to 10 days

Interventionparticipants (Number)
Placebo Group1
Nicotinamide Riboside Group1

[back to top]

Change in Estimated Glomerular Filtration Rate (eGFR)

Measurement of change in eGFR at 30-90 days post randomization (NCT04818216)
Timeframe: 30 days to 90 days

,
InterventionmL/min/1.73m^2 (Mean)
30-day90-day
Nicotinamide Riboside Group79.02129.91
Placebo Group86.38112.08

[back to top]